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When you set out on your journey to Ithaca, pray that the road is long, full of 
adventure, full of knowledge. The Lestrygonians and the Cyclops, the angry 
Poseidon - do not fear them: You will never find such as these on your path, if your 
thoughts remain lofty, if a fine emotion touches your spirit and your body. The 
Lestrygonians and the Cyclops, the fierce Poseidon you will never encounter, if you 
do not carry them within your soul, if your soul does not set them up before you. 
 
Pray that the road is long. That the summer mornings are many, when, with such 
pleasure, with such joy you will enter ports seen for the first time; stop at 
Phoenician markets, and purchase fine merchandise, mother-of-pearl and coral, 
amber, and ebony, and sensual perfumes of all kinds, as many sensual perfumes 
as you can; visit many Egyptian cities, to learn and learn from scholars. Always 
keep Ithaca on your mind. To arrive there is your ultimate goal. But do not hurry 
the voyage at all. It is better to let it last for many years; and to anchor at the island 
when you are old, rich with all you have gained on the way, not expecting that 
Ithaca will offer you riches. 
 
Ithaca has given you the beautiful voyage. Without her you would have never set 
out on the road. She has nothing more to give you. 
 
And if you find her poor, Ithaca has not deceived you. Wise as you have become, 
with so much experience, you must already have understood what these Ithacas 
mean. 
         by Constantine P. Cavafy 
         (1863 - 1933) 




To search gives you purpose, 
To find sets you free… 
      
 
        
 
        
    Dedicated to all the women affected by breast cancer  
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ABSTRACT  
Efforts continue to identify and validate novel risk factors / biomarkers for breast 
cancer and improve current risk prediction models in the general population due to 
ongoing issues with sensitivity and specificity. 
 
The overall goal of this PhD study is to add to this effort. Specific aims are to (1) 
examine which is the best source of getting notified for breast cancer diagnosis in 
the general population since accurate data is crucial for risk assessment studies 
(2)  investigate the association of sex steroids, gonadotrophins and novel assays 
of sex steroid hormone receptor serum bioactivity (SB) in breast cancer (3) 
examine whether they can be combined to improve breast cancer risk assessment 
and (4) identify new DNA methylation markers that might add to such a strategy in 
the future. To achieve this, a nested case-control study was undertaken within UK 
Collaborative Trial of Ovarian Cancer Screening.  
 
2629 trial participants were identified via cancer registry (CR) or self-reporting to 
have breast cancer. Diagnosis was confirmed by the treating clinician. The largest 
study was undertaken in England and Wales to examine completeness of breast 
cancer diagnosis within UKCTOCS. Analysis of complete data obtained in 1083 of 
these women showed CR to be more accurate than self-reporting but associated 
with time-delays.  
 
Serum samples from 200 eligible breast cancer cases identified through the 
process and 400 matched-controls were analysed for oestradiol, free-oestradiol, 
oestrone, androstenedione, testosterone, free-testosterone, progesterone,  
dehydroepiandrosterone sulphate (DHEAS), sex steroid hormone binding globulin 
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(SHBG), luteinising hormone (LH), follicle stimulating hormone (FSH) and 
oestrogen receptor-α and -β and androgen receptor SB. Results showed that sex 
steroid receptor SB assays could add to breast cancer risk prediction. Additionally, 
the best oestrogen for breast cancer risk prediction is oestrone and the best 
androgen is testosterone. High testosterone and FSH levels up to 5 years prior to 
diagnosis predict breast cancer with high power and may have a synergistic effect. 
 
In a separate case control study of 189 paraffin-embedded breast tissue samples, 
55 genes were investigated using MethyLight. DNA methylation alterations were 
found to be homogeneous in breast cancer with 13 genes being predictive of the 
disease, suggesting that such changes could be useful as future biomarkers.  
 
Further studies (already underway) involve using high-throughput technology to 
analyse serum DNA methylation changes and correlate these with the observed 
serum hormonal changes and build better breast cancer risk prediction models. 
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mass spectrometry   
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  MRI   Magnetic resonance imaging 
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NHS   National Health Service 
NHSCR  NHS cancer registry 
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OR   Odds ratio  
PCGT   Polycomb group target  
PCR   Polymerase chain reaction 
PMR   Percentage of methylated reference  
PPV    Positive predictive value 
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PRC   Polycomb repressor complex  
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flight mass spectrometry   
SHBG   Sex hormone-binding globulin 
SUZ12  Suppressor of zeste homologue 12 
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TBP   TATA binding protein 
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TNM Staging System: T: tumour size; N: nodes involvement; 
M: metastasis 
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UK United Kingdom 
UKCTOCS UK collaborative trial of ovarian cancer screening 
WLE Wide local excision  
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1 INTRODUCTION  
 
1.1 Overall Purpose of the Study  
Breast cancer is one of the major health problems facing the world today, being a 
significant contributor to overall morbidity and mortality. In 2008, the Breast 
Cancer Campaign Gap Analysis Meeting proposed that in order to make the 
greatest impact on breast cancer patients the following aspects need to be taken 
into account: 1) the identification of women predisposed to breast cancer by risk 
prediction markers and 2) the application of a preventive or early detection 
strategy 1. This need is further magnified by the current controversies of the 
efficacy of breast cancer screening and the concern about over diagnosis and 
unnecessary treatment 2, 3.  
 
In the last decades, a huge effort has been made to identify risk factors and 
biomarkers associated with breast cancer that can be used for risk stratification. 
The most well known to date are age, family history, previous history of benign 
breast conditions, genetic predisposition, epigenetic changes, reproductive 
factors and hormonal changes, breast density and environmental influences. 
Some of these factors have been included in risk prediction models in order to 
identify women at high risk.  At present, the only model that is in clinical use to 
assess a woman’s risk to develop breast cancer is the Gail model 4-9. However, 
the chance of correctly classifying a randomly chosen woman with this model is 
around 59%, only marginally better than chance and whilst statistically significant, 
the model lacks in sensitivity and specificity. Therefore, more studies are urgently 
needed to identify and validate risk factors / biomarkers that can effectively 
stratify women to available prevention / screening strategies 10. 
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1.2 Project overview 
The overall goal of this project is to try to improve breast cancer risk prediction in 
the general population by adding in the effort for the identification and validation 
of breast cancer biomarkers. Specific aims were: 1) a) to identify breast cancer 
cases in a large cohort – the UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) which involves 202,638 postmenopausal women aged 50-74 years 
at recruitment in 2001-5 and b) to examine the accuracy of breast cancer 
diagnosis within the cohort 2)  a) to examine the association of sex steroid and 
gonadotrophin hormonal changes in combination with novel assays of sex steroid 
hormonal receptor bioactivity and b) to investigate whether they can be combined 
to improve breast cancer risk assessment by examining their synergistic effect in 
breast carcinogenesis 3) a) to identify new epigenetic markers for breast cancer 
and b) to examine the homogeneity of these changes in the disease that might 
add to such a strategy in the future.  
 
The first objective was to identify breast cancer cases within UKCTOCS using 
two sources; cancer registry data and self-reporting (UKCTOCS follow-up 
questionnaire). Confirmation of breast cancer diagnosis and clinicopathological 
information was collected from the treating physicians in a form of questionnaire 
specifically designed for the purposes of the study. Based on the fact that 
collection of accurate cancer diagnosis information has major implications for 
research studies, especially those that include cancer risk prediction, sensitivity 
and positive predictive value (PPV) of these two sources individually and 
combined by comparing it to medical records obtained from the treating 
physicians were investigated. By the end of this procedure eligible cases for aim 
3 were identified based on the clinicopathological data collected from their 
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treating physicians. Matched controls were selected from within the UKCTOCS 
cohort. Serum samples donated by eligible participants before breast cancer 
diagnosis were identified for the cases and with the serum from the identified 
matched controls were retrieved from the trial bio-bank. 
 
As the association of sex steroid hormones with breast cancer is known for long 
time, six sex steroid hormones (oestradiol, oestrone, androstenedione, 
testosterone, dehydroepiandrosterone sulfate (DHEAS) and progesterone) were 
assayed along with sex hormone-binding globulin (SHBG) and another two sex 
steroids were calculated (free oestradiol and free testosterone) in order to 
validate their association with breast cancer risk. Earlier studies had only 
explored levels of endogenous hormones. Recently sensitive bioactivity assays 
for steroid hormones which are able to detect minimal levels of hormonal activity 
have been described. These were used to measure levels of serum bioactivity of 
oestrogen receptor (ER) -alpha and -beta (ER-α and –β) and androgen receptor 
(AR) and examine whether they are associated with breast cancer and predict 
the disease. To better understand the role of gonadotrophins in breast cancer 
risk, luteinising hormone (LH) and follicle stimulating hormone (FSH) were 
investigated. The effect of each individual hormone and the bioactivity of their 
receptors on breast cancer risk were further examined in relation to time of 
diagnosis (more and less than 2 years before diagnosis). Furthermore, as all 
previous studies had looked only at the ability of individual hormones to predict 
breast cancer risk, the markers were combined to investigate if breast cancer risk 
prediction could be improved in comparison to each individual marker’s effect and 
to identify any possible synergistic effect.  
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An attractive alternative for biomarker discovery are epigenetic modifications 
since they are known to occur early in carcinogenesis. In addition to the above 
case control study, a separate study of paraffin embedded breast tissue samples 
from a collaboration with the University of Salzburg, Austria was undertaken to 
establish whether methylation status could discriminate between non-neoplastic 
and breast cancer tissue irrespective of whether the DNA has been collected 
from the centre or the periphery of the breast tumour also addressing the issue of 
intra-tumour heterogeneity. The epigenetic field defect in breast cancer in non-
neoplastic tissue adjacent to breast tumour was also investigated to assess 
whether DNA methylation status is able to indicate the presence of breast cancer.  
 
1.3 Thesis Design 
In chapter 1 which is the introduction of this thesis the overall purpose of the 
study is described along with the general aim and the thesis design. Chapter 2 
includes the literature review. Chapter 3 covers the identification of breast cancer 
cases within UKCTOCS and completeness of the breast cancer diagnosis from 
three different sources. Chapter 4 contains the hormonal study looking into the 
association of sex steroid hormone levels, serum bioactivity of sex steroid 
hormone receptors and gonadotrophins with breast cancer risk. Chapter 5 covers 
the studies performed to investigate DNA methylation changes in breast cancer 
and their possible role as markers for risk prediction. Chapters 3, 4 and 5 contain 
a short introduction along with materials and methods, results and discussion. 




2 LITERATURE REVIEW 
 
2.1 Breast Cancer  
2.1.1 Epidemiology  
In many countries breast cancer is the most common malignancy among women. 
In UK, there were 39,681 women diagnosed with breast cancer in 2008, 
accounting for 31% of all female cancers and just over 10,000 women died from 
the disease in 2000, accounting for 16% of female deaths. A woman's lifetime 
risk to develop breast cancer is 11%. Majority of the women being diagnosed with 
breast cancer are postmenopausal. Overall, incidence rates are higher in the 
developed countries while rates in less developed countries are low but 
increasing mainly due to changes in life style 11, 12. 
 
2.1.2 Pathology 
Breast tumours are almost exclusively adenocarcinomas. Sarcomas and 
lymphomas are rare and generally excluded from studies of breast cancer. 
Morphology of the breast tumour is classified by its appearance under the 
microscope. The site of origin for most of the pathology in the breast is the ducts 
and the lobules. Historically, most invasive lobular carcinomas were thought to 
arise within the small terminal ducts of the lobules and ductal carcinomas from 
the larger or intralobular ducts. However, the distinction between lobular and 
ductal carcinoma is based more on the histological appearance than on the site 
of origin and now it is suggested that both types derive from the terminal duct 
lobuloalveolar unit 13. Invasive ductal carcinoma (IDC) is the most commonly 
histological type diagnosed accounting for up to 80% of all breast cancers, and 




that ILCs are more common in older women and their metastatic pattern is 
different but they have similar prognosis 15. There are also some distinct 
morphologic subtypes such as tubular and medullary, mucinous, papillary and 
adenoid cystic carcinomas and Paget. These histological types of breast cancer 
are not that common and have a better prognosis compared to ductal breast 
cancer 16.  
 
In addition to the invasive cancers, in situ carcinomas of the breast are also 
described including ductal and lobular carcinoma in situ (DCIS and LCIS). These 
non-invasive carcinomas used to be rather uncommon but with the introduction of 
mammography their diagnosis has increased 17. By definition, non-invasive 
breast cancers do not grow through the basement membrane. In situ carcinomas 
can be early precursors of invasive breast cancer. Models have been used to 
describe the progression from normal healthy breast tissue to atypical ductal 
hyperplasia to in situ carcinoma to breast cancer with studies also suggesting 
that LCIS can give rise to IDC 18.  
  
2.1.3 Prognosis  
Despite the huge number of discovered prognostic and predictive factors for 
breast cancer, the American Society of Clinical Oncology has concluded that 
most of them are not satisfactory yet to be recommended for general clinical use. 
The factors that are currently used include: staging (size of the tumour), lymph 
node involvement and distant metastasis, grading, ER, progesterone receptor 





Staging refers to the grouping of patients according to the extent of their disease. 
The first clinical staging system was the Columbia Clinical Classification, which 
was developed in the 1940-50's. In 2002, a new system was introduced adopted 
by the International Union against Cancer and the American Joint Committee on 
Cancer. This system is the one currently in use and is based on the principle of 
the tumour size (T), nodes involvement (N) and metastases (M) known as TNM 
21. These factors do not predict response to therapy but are only prognostic. 
Tumour size is defined as the largest diameter of the tumour and is a prognostic 
factor for breast cancer death regardless of other tumour characteristics. Lymph 
node involvement is another important independent prognostic factor. Women 
with lymph node involvement and increasing number of affected lymph nodes are 
associated with poorer prognosis 22. Finally, metastasis is a third factor of clinical 
importance. In general, women with distant metastasis have a median overall 
survival time of only 2 years 23.  
 
Tumour grade is the classification of the differentiation of the tumour into three 
groups: low, high and moderate. High grade cancers may be faster growing and 
more likely to spread. Grading was first introduced by Greenough in 1925 and 
modified by Bloom and Richardson in 1957, using three criteria; glandular 
formation, cell size and shape and proliferation. Currently the most commonly 
used grading system is the Nottingham histological grade 24. Grade is moderately 
reproducible 25 but is nevertheless a prognostic factor used after adjustment for 
tumour size and lymph node involvement.  
 
The most important predictive markers is the expression of two members of the 




associated with better survival and higher response rate to hormonal therapy. 
Women expressing both receptors have 80% better response, women expressing 
only ER have 30% and women who do not express either of the two receptors do 
not respond to oestrogen receptor modulators 26. In addition, over expression of 
HER2/neu, a member of the HER family receptor tyrosine kinases, is seen in 30% 
of breast cancer cases. Breast tumours expressing HER2/neu are associated 
with more aggressive tumour characteristics and poor survival rates. Breast 
cancer cases over-expressing HER2/neu can be treated with trastuzumab 27.  
 
The last few years a huge effort has been given to discover expression profiles 
that could eventually prove useful to predict the likelihood of breast cancer 
recurrence and response to treatment. The following four gene expression 
assays Oncotype DX (evaluates the likelihood of breast cancer recurrence and 
assesses the benefit of adjuvant chemotherapy), MammaPrint test (to predict the 
likelihood of breast cancer recurrence within five to 10 years), Rotterdam 
Signature (predict risk of breast cancer recurrence), and the Breast Cancer Gene 
Expression Ratio (to help predict recurrence of breast cancer) are under 
investigation and for the first two expression profiles trials are underway to 
confirm their clinical value 19.  
 
2.1.4 Predisposing Factors   
Epidemiological studies have suggested that sex, age, history of benign breast 
disease, breast cancer family history (particularly in a first-degree relative, such 
as mother and sister); genetic and epigenetic alterations, hormonal and 
reproductive factors, indicative of oestrogen exposure, such as age at first period, 




endogenous sex steroid hormone levels and behavioural and lifestyle factors 
such as diet, weight and alcohol intake affect breast cancer risk 28. Hormonal and 
epigenetic factors which are the main subjects of this thesis are discussed in 
more depth in sections 2.2 and 2.3. Table 2-1 summarises predisposing factors 




(Adopted from Veronesi et al, 2005 
17
 and further expanded based on the references used in 
sections 2.1-3) 
BREAST CANCER RISK FACTORS 
Parameter Low Risk High Risk RR 
Sex male female 150.0 
Age  Young Old >10 
Family history No Yes 2.6 
BRCA1 mutation  No Yes 15 
DNA methylation changes in tumour No Yes 1.4-5.3 
History of benign condition No Yes 4.0-5.0 
Age at menarche >14 <12 1.5 
Age at first birth <20 >30 1.9 - 3.5 
Age at ovarectomy <35 no 3.0 
Age at menopause <45 >55 2.0 
BMI (postmenopausal) <22.9 >30.7 1.6 
HRT never current 1.2-1.4 
Bone density 1st quintile 4th quintile 2.7-3.5 
Breast density 10% >75% 4.6 
Serum Oestradiol  1st quintile 4th quintile 1.8-2.4 
Weight gain Low High 1.2-2.3 
Height Low High 1.3-1.9 
Radiation  No Yes 1.6-5.2 
Alcohol No Yes 1.4 
Smoking No Yes 1.13-1.50 
BMI=body mass index; HRT= hormone replacement therapy 
 Table 2-1: Predisposing factors for breast cancer. 
 
 






Females are at a higher risk compared to males. Male breast cancer is very rare 
but this risk appears to be rising 11. This difference could mainly be explained 
based on the different exposure to hormones between the two sexes. 
 
Age 
Age is one of the most important risk factor for breast cancer. The risk of getting 
breast cancer increases steadily with increasing age. Before the age of 25 breast 
cancer is rare and it tends to be more aggressive when it occurs. At the age of 30 
there is a sharp increase with more than 80% of cases in women being 
diagnosed over 50 and with the greatest rate of increase prior to the menopause 
supporting an association with hormonal status 11. Increased risk due to aging 
may be partly due to genetic 29 and epigenetic changes 30. 
 
Perinatal  
Breast cancer risk has been long hypothesised to be influenced by early-life 
exposures, or intrauterine events and conditions. This field started gaining ground 
after Trichopoulos et al, published a report about the intrauterine origins of breast 
cancer 31. In two recent meta-analysis studies, it was shown that high birth weight 
as well as birth length are associated with an increased breast cancer risk. Pre-
eclampsia, eclampsia and twin membership were associated with a reduced risk 
of breast cancer for both the mother and the offspring. Being breast-fed, 
gestational age and maternal diethylstilbestrol treatment did not seem to be 
associated with breast cancer risk in the offspring. Potential underlying 
mechanisms could include high levels of maternal endogenous sex and growth 




Family history  
Breast cancer family history among first or second degree relatives is one of the 
most important risk factors 34-36. The relative risk of breast cancer is doubled for 
women who have a first-degree relative with breast cancer and risk is even 
higher if the relative is diagnosed before the age of 50 or when the woman has 
more than one relative affected by the disease 37.  
 
Genetic changes 
Breast cancer, like other tumours, develops and progresses through an 
accumulation of genetic alterations such as mutations and/or chromosomal 
alternations by activating oncogenes and/or inactivating tumour suppressor 
genes. In the 1990s, research into the genetic basis of breast cancer led to the 
identification of ‘'high risk'’ breast cancer susceptibility genes breast cancer 1 
(BRCA1) 38 and 2 (BRCA2) 39. Women carrying mutations on BRCA1 and 
BRCA2, have a life-time breast cancer risk of 45-65% 40. At present these are the 
most well described genes that increase not only breast cancer risk but also 
ovarian.  
 
Although 10% of the breast cancer cases have been shown to be due to highly 
penetrant inherited susceptibility genes, it has been suggested that 27% of the 
breast cancer risk could also be attributed to other hereditary genetic factors 41. 
Based on that hypothesis several studies have been carried out to identify novel 
hereditary genes. Genes that have been reported to be associated with breast 
cancer are ATM (Ataxia-Telengiectasia), CHEK2 (Li-Fraumeni-like Syndrome), 
STK11/LKB1 (Peutz-Jegher Syndrome), PTEN (Cowden Syndrome), TP53 (Li-




C-terminal helicase-1) and PALB2 (the partner and localizer of BRCA2 – PALB2 
protein interacts with the protein produced from the BRCA2 gene. These two 
proteins work together to mend broken strands of DNA, which prevents cells from 
accumulating genetic damage that can trigger them to divide uncontrollably). 
However, these variants combined explain less than 1% of the genetic risk 42.  
 
In the last few years a huge emphasis has been given to the identification of 
genes that appear to have a small effect on the risk (low penetrance) being either 
protective or additive, depending on the nature of the genes and the alleles 
involved 43. Based on these studies it has been reported that a certain CYP17 
genotype (A2 allele) is a risk factor for breast cancer 44  being associated with 
elevated levels of sex steroid hormones, oestrogens and androgens, in both pre- 
and post- menopausal women 45, 46. However, other studies showed conflicting 
results 47, 48.  
 
With the introduction of whole genome-wide association studies 13 novel 
susceptibility loci have been identified with a very high statistical significance in 
populations of European ancestry 49. These loci include: trinucleotide repeat 
containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), TOX 
high mobility group box family member 3 (TOX3), the 8q24, lymphocyte-specific 
protein 1 (LSP1) and fibroblast growth receptor 2 (FGFR2) 49, with the latter being 
further validated and confirmed by another study 50. In 2008, two studies by 
Garcia-Closas and her colleagues showed that some of these loci are related 
with clinically important characteristics such as ER and PR expression, grade and 
node involvement 51, 52. In addition, non genomic regions on 2q23 and 5p12 were 




More recently, a study identified five new susceptibility loci, on chromosomes 9, 
10 and 11 and in 6q25.1 and LSP1 regions that showed more significant 
association with risk than those reported previously when familial breast cancer 
cases 55 were investigated. These novel loci could eventually be useful for 
population screening 42 and for improving diagnostic methods. 
 
History of Benign Conditions  
Studies have shown that history of benign breast diseases, including proliferative 
benign diseases with or without atypia, is a significant breast cancer risk factor 56. 
Most benign conditions are non proliferative (cysts and fibroadenomas).  Women 
having such a condition are not in a high risk to develop breast cancer 57, 58. 
Women having a proliferative benign condition (hyperplasia, papilloma, radial 
scar) seem to be at 1.5-1.9 fold increased risk of breast cancer and women 
having atypical hyperplasia, either lobular or ductal types, seem to be at 4-6 fold 
increased risk to develop breast cancer. Nearly 40% of women with a family 
history and atypical hyperplasia subsequently develop breast cancer 59-61.  
 
Breast density  
Breast density reflects the breast tissue composition and is associated with 
collagen, epithelial and non-epithelial cells. A case-control screening population 
study demonstrated that women with higher breast density compared to those 
with lower were nearly five times more likely to develop breast cancer 62. Still it is 
unknown whether breast density changes over time influence breast cancer risk 
63, but it has been suggested that women leaving in urban areas have denser 
breasts compared to women leaving outside the city increasing the attention to 




2.1.5 Detection and Screening  
Currently available detection techniques for breast cancer screening include 
imaging tools (mammography, ultrasonography, magnetic resonance imaging 
(MRI) and positron emission tomography and analysis of tumour markers. 
Physical examination is also another important detection method since almost 
33% of women developing breast cancer are not identified by imaging tools.  
 
Imaging  
Mammography is one of the most important diagnostic tools in postmenopausal 
women but it is not considered a good method to detect breast cancer in dense 
breasts and recognise certain ILCs, Paget’s disease, inflammatory and small 
peripheral carcinomas 65, 66. In UK, the National Health System (NHS) by the 
Breast Screening Programme offers free mammogram to all women aged 50 to 
70. It has been shown that mortality rates have been falling after the introduction 
of mammography screening programs 67-70 but there has been a lot of 
controversy in the last few years as to its true value 2, 3, 71. Ultrasonography has 
been suggested to be an effective procedure to diagnose small tumours in 
women with dense breast 72. MRI was shown to be a highly sensitive technique 
for screening high-risk patients who are younger than 50 years 73. The UK MRI 
Breast Cancer Screening study reported that this method can detect twice the 
number of women compared to mammography 74. However, even though MRI 
has good diagnostic accuracy, the rate of false-positive cases is still high and its 
findings cannot be used as the only source of information for surgery decision 75. 
Position emission tomography is presently used to discover metastatic tumours in 
distant organs and is able to assess the status of axillary nodes in pre-operative 




Tumour Markers  
Tumour markers are certain characteristics of the tumour that differ from the 
normal tissue and can be visible and/or measurable effects of tumourigenesis 10. 
The efficacy of a biomarker is determined by its sensitivity and specificity. The 
clinical sensitivity of a biomarker refers to the proportion of subjects with 
confirmed disease who test positive, whereas its specificity refers to the 
proportion of healthy control subjects who test negative 77. In order to have an 
effective detection biomarker it needs to be: a) non-invasive or minimally 
invasive, b) be measured using a small amount of specimen c) site-specific, 
being able to rule out non-cancerous events in the same organ or tissue, d) 
highly specific in order to limit false-positive results, e) simple to perform with low 
cost and f) observer-independent 10. An example of a biomarker that could prove 
valuable for ovarian cancer screening is cancer antigen 125 (CA125). The largest 
randomised control trial (UKCTOCS) 78 coordinated by our group is underway to 
establish the biomarker’s potential in clinical setting in combination with 
sequential ultrasonography.  
 
Taking into consideration that any biological molecule can be used to distinguish 
normal from abnormal samples; different analytes have been examined as 
possible biomarkers of breast cancer. The biological molecules include: lipids, 
carbohydrates, polyamines, proteins (proteomics), RNA (genomics) and DNA 
(genetics and epigenetics) being examined in various sources, such as tissue, 
serum, plasma, nipple aspirate fluid and ductal lavage fluid 10. 
 
Proteomics detect the function of expressed genes through biochemical analysis 




genetic programme of the cell and the impact of its immediate environment. 
Therefore, given that proteomics can provide link between gene sequence and 
cellular physiology it is suggested that the proteome could complement the 
genome for biomarker discovery. Recent advances in mass spectrometry, such 
as matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOF MS) and its variant surface-enhanced laser desorption/ionisation 
(SELDI-) TOF MS, have enabled high-throughput proteome analysis 79. Several 
proteins have been identified to have significant breast cancer diagnostic, 
prognostic or predictive value. The most widely used tumour markers of the 
breast include: CA15-3 and CA27.29 79, 80. Both markers are also known as the 
extracellular mucin 1 (MUC1) protein (antigens for MUC1). MUC1 has been 
shown to be over-expressed and aberrantly glycosylated in many cancers. 
Recently, autoantibodies generated to aberrant O-glycoforms of MUC1 were 
evaluated to see whether they would serve as diagnostic biomarkers. Cancer-
associated immunoglobulin G autoantibodies in serum of breast cancer patients 
against different aberrant O-glycopeptide epitopes derived from MUC1 were 
detected representing sensitive biomarkers for early detection of breast cancer 81.  
Regardless of the voluminous data on proteins, their value as markers in large, 
prospective, clinical studies still needs to be shown. To date the only cancer 
biomarker being recognised as possibly effective for screening is the prostate-
specific antigen for prostate cancer with ongoing trials to prove its value 82.  
 
Genomics are defined as the measurement of gene expression from available 
sequence information. The expression profile represents the function and 
phenotype of a cell and is called transcriptome. Several technologies including 




(PCR) 83 have been developed to generate molecular signatures, that could 
eventually prove useful early detection biomarkers. Studies have suggested that 
mRNA in plasma as a tumour marker could facilitate the detection of cancer 
cases with high sensitivity 84. Further studies are needed though since it is still 
unclear how stable RNA is in the bloodstream especially when high levels of 
serum ribonuclease have been detected in cancer patients 10.  
 
Genetic and molecular changes causing genetic instability are early events 
occurring in carcinogenesis making them useful markers to detect breast cancer 
before the onset of symptoms and morphological changes. Such signatures have 
been studied using high throughput technologies and several markers are being 
extensively studied in animal models and in patients with established breast 
cancer. Signatures of interest include microsatellite instability, single nucleotide 
polymorphisms and epigenetic changes such as DNA methylation 
modifications. DNA methylation alterations occur at a high frequency, are 
reversible upon treatment with pharmacological agents, and arise at defined 
regions within a gene making them an attractive alternative for cancer detection 
and assessment 85. Additionally, it is evident that body fluids can carry DNA 
methylation imprints demonstrating their possible diagnostic and predictive 
importance 86. Various studies have reported the diagnostic potential of 
circulating tumour related methylated DNA in serum for cancer detection. 
Examples include the colon cancer specific methylation of septin 9 (SEPT9) 
which was shown to produce a specificity of 95% and a sensitivity of 52% when 
plasma samples were analysed and a panel of tumour suppressor genes (APC, 
RASSF1A and p14) that showed hypermethylation in bladder cancer with 87% 




2.1.6 Diagnosis  
Breast diagnosis employs cytology by means of fine-needle aspiration (FNA) or 
histology by means of core needle biopsy or excisional biopsy. FNA has a high 
diagnostic accuracy, with 10-15% false negative rate. A rare false positive rate 
has been reported in association with ductal or lobular hyperplasia. In this 
technique a needle is inserted into the mass to extract cells which are stained 
and observed under the microscope to investigate any abnormal cell morphology. 
Core needle biopsy is a less invasive method in comparison to an open biopsy 
and utilises a needle to obtain the specimen. Abnormal architecture, invasion and 
specific tumour markers such as ER, PR and HER-2/new can be evaluated in 
these tissue samples providing more information than FNA. Open biopsy which 
can be guided by image tools (mammogram or ultrasound), is rarely used and is 
only provided when inadequate sample from a core needle biopsy is obtained or 
the pathologic results are equivocal 88.  
 
2.1.7 Treatment  
The widespread adoption of effective treatments has resulted in a rise of the 5 
year mortality to 75% 11. The current breast cancer treatment involves 
multimodality therapy including: surgery, radiotherapy, chemotherapy, endocrine 
and molecular therapy, with systemic treatment being given before (neo-adjuvant) 
or after (adjuvant) surgery 89-92.  
Surgery has always been the primary treatment for breast cancer. Depending on 
the tumour size, breast conserving surgeries, such as lumpectomy and wide local 
excision (WLE), followed by breast irradiation is followed. Axillary lymph node 
clearance (ANC) is an important surgical procedure for invasive breast cancers 




Women who are at high risk of recurrence are treated with radiotherapy. In a 
meta-analysis of randomised trials it was shown that radiotherapy reduces 
mortality rates 93. The impact on mortality though has been debated as 
radiotherapy has also been shown to increase the risk of cardiovascular events 94. 
Intraoperative radiotherapy has been suggested to be the answer to the problems 
that surround conventional radiotherapy. A multinational clinical trial in UK, 
TARGIT (Targeted Intraoperative Radiotherapy Treatment), recently published a 
report suggesting targeted intra-operative radiotherapy, using conventional 
external beam, could be an attractive alternative to conventional postoperative 
radiotherapy for the treatment of early stage breast cancer 95-97.  
 
Endocrine therapy is the second key treatment of adjuvant therapy and for more 
than twenty years tamoxifen is the most commonly used drug 98. Tamoxifen is a 
member of selective ER modulators 99 and it is an anti-oestrogen that blocks the 
binding of oestrogen to its receptor. Therefore, only hormone dependent tumours 
are treated with the drug 100. Tamoxifen is effective in both pre- and post- 
menopausal women, and when it is given after chemotherapy rather than at the 
same time 90, the standard therapy duration is 5 years. The main disadvantages 
are that it has antagonistic and agonistic functions on other organs such as the 
endometrium and bone 101 and cause an increased risk of thromboembolism. 
After long administration breast cancer patients can become resistant. In the last 
few years, clinical trials have shown that aromatase inhibitors are also suitable for 
breast cancer treatment 102. These drugs inhibit the conversion of sex steroid 
hormones to oestrogens. They include the non-steroidal anastrozole and 
letrozole and the steroidal compound exemestane. They have been shown to be 




(Arimidex, Tamoxifen, Alone or in Combination trial  also known as ATAC trial) by 
improving the disease and metastatic free survival 103. Patients are given 
aromatase inhibitors after two or three years of tamoxifen, as it was shown that 
could improve the long term survival and reduce breast cancer recurrence 104. In 
addition, the value of ovarian suppressors is investigated with trials undergoing 
and alredy available data suggesting no added effect of ovarian ablation or 
suppression on the relapse-free survival or overall survival of premenopausal 
women who were treated for early-stage breast cancer. However, the role of 
ovarian ablation or suppression with ER-positive tumours requires further 
investigation 105.  
 
Chemotherapy is usually selected for women with high risk of metastatic disease 
and poor prognosis 106 given as an adjuvant treatment after surgery to increase 
the chance of long-term disease free survival and as neo-adjuvant treatment to 
reduce the size of the tumour before surgery. The most commonly used 
chemotherapeutic agents are the anthracyclines (doxorubicin and epirubicin). 
These drugs have been shown to be more effective than the traditionally used 
cyclophosphamide, methotrexate and fluorouracil chemotherapeutic agents 91. 
Furthermore, evidence indicates that addition of a newer class of 
chemotherapeutic agents, the taxanes (paclitaxel and docetaxel), may improve 
survival in high risk patients 106.  
 
In addition, in the last decade there is an increasing interest in antibody 
treatment, after it was shown that growth factor receptors are correlated with poor 
disease-free survival and resistance to endocrine therapy and chemotherapy, 




receptor antibodies and tyrosine kinase inhibitors which target the epidermal 
growth factor receptor (EGFR) and HER-2/neu. The most well know is Herceptin, 
a humanized monoclonal antibody that is directed against the external domain of 
the HER2 receptor 108. A recent study has demonstrated that yearly 
administration of Herceptin during or after chemotherapy can reduce recurrence 
risk by 50% 109. Another drug is the tyrosine kinase inhibitor lapatinib 110. The 
agent targets EGFR and HER2 receptors and prevents tumour growth by 
inhibiting intracellular tyrosine kinase activity by binding to the inactive form of the 
receptor and dissociating at a slow rate having a better effect on the target site 
111. 
 
Epigenetic therapy has also drawn attention as epigenetic changes can be 
reversed by use of small molecule inhibitors with restoration of the affected 
epigenome 112. The discovery of 5-azacytidine (5-aza-CR) (vidaza) and 5-aza-2’-
deoxycytidine (5-aza-CdR) (decitabine) agents were the first steps towards 
epigenetic treatment. These agents can incorporate into the DNA of rapidly 
dividing tumour cells and reverse the action of enzymes that are responsible for 
DNA methylation alternations (DNA methylation transferases – DNMTS) 113 
causing DNA demethylation and reactivation of methylated silenced tumour 
suppressor and other cancer-related genes 114. The use of these drugs though 
has been hindered by their cytotoxic side effects  which result from their 
incorporation into the DNA 115. An alternative approach is the use of non-
nucleoside DNMT inhibitors, such as MG98, SGI-1027 and RG108 which exert 
their effect without being incorporated into the DNA 115. In order to better 
understand the full potential of epigenetic therapy in the clinical setting, more 




2.1.8 Risk Prediction and Prevention  
The last decade there is growing interest in trying to stratify women into groups 
based on different levels of breast cancer risk. Currently, even though 
mammography screening has been suggested to decrease mortality from breast 
cancer 117 - with its true value being debated 71 - it does not reduce the number of 
women who develop the disease 118. Tools such as the Gail, Claus and Golditz 
models have been developed to calculate a woman’s absolute risk of breast 
cancer. These models help clinicians to identify women whose breast cancer risk 
is increased based on their epidemiological profile. In addition, there are models 
such as the Tyrer-Cuzick model 119 and the BRCAPRO program 120 that calculate 
the likelihood of a women with a breast cancer family history to have a BRCA 
mutation in addition to breast cancer risk. The last few years it has become 
increasingly recognised that breast cancer is not a homogeneous disease with 
the hormone-receptor status defining important clinical and aetiological 
differences. Based on that observation a model by Rosner and Colditz has been 
developed which separately estimates the risk of hormone-receptor-positive and 
hormone-receptor-negative breast cancers 121. 
 
At present, the only model that is widely used in family clinics is the Gail model 4, 
5. The model includes the following risk factors: age, race, age at menarche, age 
at first live birth, number of first degree relatives with breast cancer, number of 
previous breast biopsy examinations and presence of atypical hyperplasia. In 
recent attempts to improve Gail’s model performance breast density was included 
as an additional parameter and the test’s concordance statistics were brought up 
from 59% to 66% 7, 8. In a different study, single nucleotide polymorphisms were 




61.8% 122. When oestradiol was added in the Golditz model the test’s 
concordance statistics were brought up to 64.5% 123. A study has also been 
performed to examine performance of the Gail model for estimating invasive 
breast cancer risk by receptor status in postmenopausal women. The data 
showed that the model’s discriminatory performance was better for ER-positive 
breast cancer risk 124. Attempts to increase model’s performance is significant as 
identification of women at high risk could eventually lead to improved overall 
survival rates of breast cancer patients through prevention and more intensive 
screening. 
 
The current preventative options for breast cancer include changes in lifestyle, 
chemoprevention and secondary prevention by detection of cancer by regular 
surveillance either through palpation of the breasts and/or regular participation in 
mammography and MRI. It has been shown that prophylactic surgery, either 
bilateral mastectomy or oophorectomy, is the most cost effective means to 
reduce breast cancer risk and it is recommended to women with high risk of 
hereditary disease 125. Chemoprevention is another approach and it has been 
shown that there is a significant reduction in breast cancer incidence in women 
taking tamoxifen 126 and an even larger reduction in women taking raloxifene 127. 
The true value of such prevention strategies has been argued though with studies 
showing conflicting results 125. Moreover, tamoxifen and raloxifene have well 
known side effects such as endometrial cancer (tamoxifen) and 
thromboembolism (raloxifene) causing caution regarding their use 127. In addition, 
neither drug has been shown to be of value in preventing ER-negative breast 
cancers. Therefore their true benefit must be considered carefully before 




cancer prevention is still under investigation 128. Careful consideration between 
the risks and the benefits of the different prevention strategies is important in 
order to have the best impact in women’s life.  
 
2.2 Hormones and their Receptors  
In 1905, Ernest Starling a professor of physiology at University College London, 
UK, was the first to use the word 'hormone' in one of his lectures. Starling defined 
the word, derived from the Greek word ‘’orme’’ meaning ‘’to arouse or excite’’, as 
‘’the chemical messengers which speeding from cell to cell along the blood 
stream, may coordinate the activities and growth of different parts of the body’’. 
Later on, it was shown that cells respond to a hormone when they express a 
specific receptor for that hormone. The hormone binds to the receptor proteins 
that result in the activation of a signal transduction mechanism that ultimately 
leads to cell type-specific responses 129. Several hormones have been studied to 
examine their association with breast cancer risk. In this thesis, sex steroid 
hormones, their receptors and gonadotrophins are discussed in more depth in the 
following sections.   
 
2.2.1 Sex steroid hormones and their receptors 
Sex steroid hormones include oestrogens, androgens and progestogenes. They 
are hormones that interact with the vertebrate ER, AR or PR, respectively also 
known as nuclear receptors. Natural sex steroids are made by the gonads; in 
females by ovaries and males by testes, and in both genders by the adrenal 
glands and by conversion from other sex steroids in tissues such as liver or fat 
catalysed by specific enzymes. They are lipophilic molecules derived from 




cholesterol carried by low-density lipids can either be used immediately for 
hormone synthesis or be stored as cholesterol esters 130.  
 
The first and rate limiting step in sex steroid biosynthesis is the cleavage of 
cholesterol’s side chain to produce pregnenolone, a reaction catalysed by the 
cytochrome P450 side-chain-cleavage enzyme (P450scc). Pregnenolone is then 
converted to either 17α-OH pregnenolone by P45017 an enzyme that also 
catalyses the removal of C20-C21 side chain of 17α-OH pregnenolone converting 
it to DHEA or to progesterone by 3β-hydroxysteroid oxidoreductase-Δ4,5-
isomarase enzyme complex which then converts DHEA to androstenedione.  
Through the action of 17-oxo-reductase androstenedione is converted to 
testosterone. Through aromatisation then androstenedione is converted to 
oestrone and testosterone to oestradiol (Figure 2.1). Alternatively, DHEA is 
converted to androstenediol by 17-oxo-reductase and then to testosterone by 3β-
hydroxysteroid oxidoreductase-Δ4, 5-isomarase enzyme complex. The adrenal 
glands secrete large amounts of DHEA and its sulphate metabolite DHEA-S 
serving as precursors of both androgens and oestrogens in peripheral tissues. In 
the ovary where androgens and oestrogens are produced there are high levels of 
P45017 and upon activation of LH receptor in theca cells cholesterol is converted 
to testosterone and after stimulation by FSH oestradiol is produced in granulosa 
cells through aromatisation of testosterone 130. In blood the main fraction of 
different hormones are bound to albumin or serum SHBG and thereby 
inactivated. The unbound fractions may diffuse through cell membranes due to 
their lipophilic properties and bind to the intra-nuclear, mitochondrial or other 









   ↓ 
 Pregnenolone →        Progesterone 
 ↓     ↓ 
 17alpha-hydroxipregnenolone →   17alpha-hydroxiprogesterone 
 ↓     ↓ 
 Dehydroepiandrosterone  →   Androstenedione →    Testosterone 
 ↓       ↓ 




Sex steroid receptors belong to the nuclear receptor family. Hormone receptors 
belonging to this group have a common functional structure which is composed of 
independent domains: the NH2-terminal domain which contains the activation 
function (AF) 1, the binding domain (DBD) which contains two zinc fingers binding 
to specific sequences of DNA known as hormone response elements (HRE), the 
ligand binding domain (LBD) with the hormone dependent AF2 domain, the hinge 
domain which connects DBD with LBD and is thought to allow the receptor to 
adopt to several different conformations and the C-terminal domain. The DBD 
Figure 2.1: Summary of sex steroid biosynthesis. (Progesterone is in green, 




and LBD are highly conserved to provide specificity for the target hormones and 
genes. The NH2-terminal, the hinge and C-terminal domains are highly variable 
between the different nuclear receptors. While these are the main domains 
shared by all nuclear receptors there are sites which are responsible for the 
binding and interaction of multiple accessory proteins that assist and modulate 
the functions of the receptors 131, 132.  
 
In the absence of a ligand sex steroid hormone receptors are bound to molecular 
chaperones, such as hsp90, or interact with co-repressor proteins that repress the 
transcription of target genes. The receptors function once the ligand binds 
resulting in dissociation from the chaperone complex or the co-repressor proteins 
and interact with co-activator proteins mediating the assembly of the basal 
transcription machinery components and subsequent transcriptional activation of 
target genes. Upon that binding the activated receptor molecule, which is usually 
found in the cytoplasm of the cell, travels across the membrane into the nucleus 
where it gets homodimerised or heterodimerised with another isoform of the 
receptor or a different receptor and binds to the specific HRE. Once bound the 
receptor complex alters the transcription of the target genes either up or down 













Figure 2-2: Activation of sex steroid hormone 
receptors. Hormone (H) enters the cell by passive 
diffusion; the hormone binds to the intracellular 
receptor (HR) which is in its inactivated state located 
either in the cytoplasm or the nucleus. Upon binding, 
sex steroid hormone receptor forms a dimer which 
then binds to specific sequence of DNA known as 
Hormone Response Element (HRE) leading to 
activation of the transcription processes and synthesis 
of specific messenger RNA and protein production.  
 
Figure 2-1: Activation of sex steroid hormone 
receptors. The hormone (H) enters the cell by passive 
diffusion; the hormone binds to the intracellular 
receptor (HR) which is in its inactivated state located 
either in the cytoplasm or the nucleus. Upon binding, 
sex steroid hormone receptor forms a dimer which 






















Response element bound steroid receptors are known to additionally bind to 
chromatin remodeling complexes that cause rearrangement of the chromosome 
structure. Up-regulation of genes by the steroid receptors is usually facilitated by 
altering the chromosome structure so that the promoter and DNA polymerase 
binding sequences of the gene are exposed to the enzymes that initiate 
transcription. Steroid receptor mediated repression of gene expression is 
achieved through different mechanisms. In such events the HRE overlaps the 
TATA box, the DNA sequence that acts as a recognition site for the TATA binding 
protein (TBP) which is one of the proteins responsible for the initiation of 
transcription. When the activated steroid receptor binds to the HRE it displaces 
the bound TBP preventing the initiation of transcription. The second mechanism 
responsible for a steroid receptor gene expression switch is when the activated 
receptor is influenced by proteins bound at another site in the promoter of the 
gene. If the second binding site is bound by a homodimer or another protein then 
transcription is increased but if the site is bound by a heterodimer the 
transcription is stopped 133, 134.  
 
The direct effect of nuclear receptors on gene regulation takes hours as a 
functional effect is seen in cells after a large number of events occur between 
nuclear receptor activation and protein production. However, it has been 
observed that some effects in the presence of the sex steroid hormones occur 
within minutes in contrast to the time consuming mechanism of nuclear receptor 
action. Therefore, a different mechanism has been suggested. This is known as 
non-genomic effect of the nuclear receptors. Data has shown that sex steroid 
hormones can interact with their sex steroid receptors at the plasma membrane 




The specific effects of sex steroid hormone receptors can also be modulated by 
the binding of specific co-factors to the activated receptor, splicing of mRNA 
before translation and modification to the translated protein. The different co-
factors present within the cell can alter the effect of hormone stimulation by 
changing the affinity of the receptor for HRE binding. In addition, alternative 
splicing into different receptor isoforms is one of the major mechanisms to 
modulate the effect of hormone stimulation. The different isoforms have an 
altered affinity for the receptor’s ligand, other receptors, hormone binding 
elements and receptor co-factors. The most common change in an isoform that 
has reduced affinity to the receptor ligand, results in an altered response to 
hormonal stimulation 133.  
 
Post-translational modifications have also been shown to be responsible for 
differentiated response of the cells to hormone stimulation either directly or 
through the binding of specific co-factors to receptor complexes. A post-
translational modification is the addition of a small molecule to the protein at 
specific sites by enzymes or enzyme complexes that modify the behaviour of the 
protein. Such modifications include phosphorylation, acetylation, methylation, 
sumoylation, sulphation and ubiquitination. For example, phosphorylation is 
known to increase the activity of the ligand bound receptor in contrast to 
ubiquitination which is responsible for removing the tagged protein to the 
proteosome for degradation resulting in reduction of the hormone stimulation   133. 
 
Oestrogens 
The term oestrogenes come from the Greek word ‘‘oistros’’ which refers to the 




oestrogens are 17-β oestradiol (E2) and two metabolites oestrone (E1) and 
oestriol (E3). E2 is the predominate form in non-pregnant females, E1 is produced 
during menopause and E3 is the primary oestrogen during pregnancy. 
Oestrogens are produced primarily by developing follicles in the ovaries and the 
corpus luteum in women in reproductive phase of their life. Oestrogens are also 
produced in smaller amounts by other tissues such as the liver, adrenal glands 
and fat cells. These secondary sources of oestrogens are especially important in 
postmenopausal women in whom these are the main sources of oestrogen 
production 130.  
 
Oestrogen Receptor  
The cDNA encoding an ER protein was first cloned and described in 1973 135. 
The name was changed to ER-α when a second form of the receptor, ER-β, was 
discovered in 1996 136. ER-α is slighter bigger than ER-β encoding a protein that 
is 595 amino acids in comparison to ER-β which encodes a protein that is 530 
amino acids long. The two different forms of ER are known to be each encoded 
by two separate genes, ESR1 and ESR2 for ER-α and ER-β, respectively. ESR1 
is located at chromosome 6q25.1 and ESR2 is located in chromosome 14q22-24 
137, 138. ESR1 and ESR2 genes show significant overall sequence homology. In 
the DBD there is only one base pair difference with 97% homology and 59% 
amino acid identity in the LBD. This homology is lost at the end of the genes, in 
the trans-activation factor domains, modulating their receptor functions that 
results in different effects 139, 140. In summary, despite the differences in structure 
between the two receptors their expression is regulated by the same factors and 
have similar binding affinity to free oestradiol but their molecular and 




expressed in endometrium, ovarian stromal cells, hypothalamus and breast 
cancer cells, ER- β is expressed in kidney, brain, heart, lungs, intestinal mucosa 
and endothelial cells 141.  
 
Androgens  
Androgens, including testosterone and 5α-dihydrotestosterone (DHT) control the 
development, differentiation and function of male reproductive and accessory sex 
tissues such as prostate. In females, androgens are mainly the precursors of all 
oestrogens. There are also the adrenal androgens produced by the adrenal 
cortex that function as weak steroids or steroid precursors including DHEA, 
DHEAS, and androstenedione. Testosterone is the most important circulating 
androgen in both men and women. Its effect is mediated directly via AR binding 
or after peripheral aromatisation to oestradiol via the ER or through 5-a reduction 
in the form of DHT 130.  
 
Androgen Receptor  
The AR gene is located at Xq11-12 and is 90kb long with eight exons. There are 
two characterised forms of AR -A and -B. The second form, which is also the 
most predominant one, is a 110-114 kDa protein of 910-919 amino acids. The 
first is a smaller protein, 87 kDa, of 720-729 amino acids in length that makes up 
only about 4-26% of the detectible androgen receptors located in varying tissues 
and it is believed to be inert with its exact function being unknown 142-144.  
 
Progestogenes 
Progesterone is the naturally occurring progestogen also known as hormone of 




the placenta. It serves as a precursor for the production of oestrogens, 
androgens and adrenocortical steroids. It is responsible for the preparation of the 
endometrium for implantation, keeping the myometrium quiescent until parturition 
and affecting the female immune system to accept the foetus 130.  
 
Progesterone Receptor  
PR gene is located at 11q22-23 chromosome and contains eight exons and is 
about 90kb 145. There are two forms of the receptor PR-α and PR-β both of them 
deriving from the same gene but being activated by different promoters. PR-α is 
a 98 kDa protein and PR-β is larger than the alpha isoform at 116 kDa 146. Both 
isoforms have different effects on different tissues because of their different 
structure and accessory molecules helping to initiate or block transcription 147.  
 
2.2.2 Gonadotrophins and their receptors 
Gonadotrophins are protein hormones that are secreted by gonadotrope cells 
from the pituitary gland. The two principal gonadotrophins are LH and FSH. 
Chorionic gonadotrophin (hCG) belongs also in the group and is produced by the 
placenta during pregnancy.  
 
Luteinising hormone and Follicle stimulating hormone 
LH and FSH are heterodimers consisting of two peptide chains, alpha and beta. 
LH and FSH share nearly identical alpha chains (LH and FSH - 92 amino acids) 
whereas the beta chain is different (LH-121 amino acids; FSH-118 amino acids). 
The beta chain is the one responsible for providing specificity for receptor 
interaction. Their release is controlled by gonadotrophin-releasing hormone from 




Luteinising hormone receptor and Follicle stimulating hormone receptor 
The luteinising hormone receptor (LHR) and follicle stimulating hormone receptor 
(FSHR) are transmembrane G protein-coupled receptors. They are found in the 
ovary and the uterus. LHR interacts with LH and hCG and FSHR interacts with 
FSH. The gene of both receptors is located on chromosome 2p21. LHR consists 
of 70 kilo base pair (bp) and FSHR consists of 2,080 nucleotides. LH is 674 
amino acids long and has a molecular mass of about 85-95 kDA and FSH is a 
695 amino acids protein and has a molecular mass of about 76 kDa. Both 
receptors have the same structure consisting of an extracellular domain, a 
transmembrane domain and a C-terminal domain. Upon binding of the hormone 
a transduction signal takes place that activates the G protein. After attachment of 
the hormone on the receptor the cAMP system gets activated and shifts 
hormone’s state from inactive to active 148.  
 
2.2.3 Hormone detection methods 
Hormones are generally measured with immunoassays. However other 
techniques and in particular bioassays could also play a significant role. Both 
assays relay on a comparison between responses produced in the assay system 
by the sample and those produced by the different concentrations of a reference 
sample. A calibration curve is generated with the reference preparation and the 
unknown concentration or bioactivity of the hormone in the sample can then be 
extrapolated from this. Immunoassays are based on the interaction between an 
antibody and its antigen and there are two different forms; competitive-binding 
assay and sandwich assay. In competitive-binding assay the antigen in the 
unknown sample competes with the labelled antigen to bind with antibodies and 




response is inversely proportional to the concentration of antigen in the unknown 
sample because the greater the response the less antigen in the unknown 
sample is available to compete with the labelled antigen. In sandwich assay the 
antigen in the unknown sample is bound to the antibody site and then labelled 
antibody is bound to the antigen and the amount of labelled antibody on the site 
is measured. The response is directly proportional to the concentration of the 
antigen, in contrast to the competitive method because the labelled antibody 
cannot bind if the antigen is not present in the unknown sample 130.  
 
Bioassays are an attractive alternative for hormone measurement. They are 
conducted to measure the effects of substances on a living organism and involve 
estimation of the concentration or potency of the substances by measurement of 
the biological response that produce. Receptor bioactivity assays have been of 
great interest as they allow evaluation of the overall hormonal effect instead of 
measuring single hormone compounds; therefore, it can be used to estimate 
circulating hormonal bioactivity. Their advantage is that they are based on a 
direct interaction between the binding ligand and the relevant bioactive site on the 
structure of a hormone and are characterised by all the positive features of the 
immunoassays in terms of sensitivity, precision and high sample capacity 130.  
 
Another method to measure hormones is by mass spectrometry (MS). MS is an 
analytical technique that determines the elemental composition of a sample or 
molecule. Its principle consists of ionising chemical compounds to generate 
charged molecules or molecule fragments and measurement of their mass-to-
charge ratio. Even though MS is a very sensitive technique, there are still some 




and requires a large amount of starting material making difficult to implement in 
clinical settings 150 and widely used 149.  
 
During the last few years concerns have been raised regarding the reliability and 
validity of steroid sex hormone measurements in biologic specimens using 
immunoassays. Studies performed to evaluate the reproducibility of these assays 
have shown that there is considerable variation in results from different 
laboratories but measurements from a single laboratory are satisfactorily 
reproducible 151. Comparison of immunoassays to MS has shown that both 
techniques yield similar estimates of most sex steroid hormones 151, 152.  
 
2.2.4 Sex steroid hormonal changes and their receptors during normal 
development 
The main role of sex steroid hormones is the induction of the primary and 
secondary sex characteristics and skeletal maturation. The last few years they 
have also drawn attention due to their profound regulatory effects on 
differentiation and growth and their function in a variety of tissues including brain, 
cardiovascular and adipose tissue.   
 
Sex steroid hormones are responsible for signalling the development of the 
glandular breast tissue. All women throughout their life cycle experience changes 
in their breasts due to fluctuating sex steroid hormone levels during the menstrual 
cycle. The most obvious changes occur during foetal development, puberty, 
pregnancy and menopause. Human breast tissue fast develops in the sixth week 
of foetal life. After birth there is little development till puberty when in women, 




fibrous breast tissue becomes more elastic, the breast ducts begin to grow and 
this growth continues until menstruation begins. During pregnancy, a variety of 
breast changes occur. The blood vessels within the breast enlarge as surges of 
oestrogen stimulate the growth of the ducts and surges of progesterone cause 
the glandular tissue to expand. During menopause there is a huge decline of 
oestrogen and progesterone production affecting the structure of the breast. The 
breast shrinks, the glandular tissue gets replaced with fatty tissue and the fibrous-
connective tissue loses its strength. Changes in circulating androgen levels with 
age have not been well documented due to lack of longitudinal studies 153 but is 
well known that testosterone levels are mainly maintained after menopause 154.  
 
The members of the sex steroid receptor family have numerous functions and are 
associated with the control of cellular growth and differentiation in many tissues. 
In the human breast, ER-β is the predominant ER expressed in the luminal 
epithelial cells and the stromal compartment, in contrast to ER-α which is 
expressed in low levels only within the luminal cells. ER-α is the receptor which 
functions primarily as a mitogenic factor in the breast tissue while ER-β has been 
suggested to antagonise the functions of ER-α 155. AR is important on the breast 
mainly due to the effects of androgens on the breast tissue.  PR has two main 
actions in normal breast tissue; interferes with ER and slows the growth of breast 
epithelial tissue 147. Since the physiology of breast is different before and after 
menopause, it is important to be taken into account in study designs. Therefore, 
studies that are affected by the different structure and biochemistry of the breast 
should separate women based on their menopausal status. For the purposes of 





2.2.5 Gonadotrophins during normal development 
LH and FSH are very important hormones during reproduction exerting their 
effects through their receptors. LH initiates steroidogenesis in the ovarian follicle, 
induces ovulation and maintains secretory functions of the corpus luteum. FSH 
stimulates the development of ovarian follicles and secretion of oestradiol. After 
menopause due to low oestrogen production LH and FSH levels rise 130.  
 
2.2.6 Sex steroid hormones and their receptors in breast cancer  
Sex steroid hormones have been long hypothesised to increase breast cancer 
risk. The connection between sex steroid hormones, and in particular oestrogens, 
with breast cancer was established more than 100 years ago by George 
Beatson, when he observed a drastic clinical response for breast cancer cases 
after removal of the ovaries suggesting that the ovaries have a control over the 
proliferation of the breast epithelium 156. Later on, in the 1960s and 1970s, 
reproductive risk factors, which regulate sex steroid hormone availability in 
women, such as ages at menarche, first birth, parity and menopause were shown 
to be associated with breast cancer risk and based on these factors Malcolm Pike 
suggested an age-incidence model for breast cancer 157.  
 
Further epidemiological studies supported the relationship that surrogates for 
lifetime sex steroid hormone exposure and exogenous sex steroid hormones 
being associated with breast cancer risk. Reports have shown high levels of 
oestrogens to be related with increased breast cancer risk. Oestrogens are 
associated with both the initiation and progression of breast cancer through two 
pathways; one that involves the binding of oestradiol to ER-α stimulating cell 




increased number of replication errors and the second one which is a result from 
the formation of genotoxic metabolites of oestradiol, which can bind to DNA 
causing depurination that eventually leads to mutations 158, 159. While the majority 
of breast tumours respond to oestrogens, some lose expression of the ERs either 
because the gene becomes disabled or because the receptors are spliced or 
mutated. These tumours are not responsive to hormonal treatment.  
 
In breast cancer the predominant receptor is ER-α being expressed in 70% of 
breast cancer cases. After the discovery of ER-β the complexity of oestrogen 
signalling in the breast was noted. ER-β has been shown to be expressed only in 
advanced breast cancer and in low levels 160 and has been suggested to act as a 
negative modulator of ER-α, changing its transcriptional activation by altering the 
recruitment of c-Fos and c-Jun to oestrogen-responsive promoters 161. Even 
though, ER-α is a well known and used as a prognostic and hormonal treatment 
predictive factor, only the last few years studies supported the hypothesis that 
increased expression of ER-β is associated with an increased likelihood of 
response to endocrine therapy 160. Recently, our group was the first to provide 
evidence that serum ER-α and -β bioactivity are independently associated with 
breast cancer 162. It was further shown that sex steroids through their receptors 
can modify methylation patterns in the DNA of cells that are not directly related to 
the target organ and this can be used to assess breast cancer risk 163.  
 
Although oestrogens and ER in breast cancer have been extensively studied the 
role of androgens and AR in breast cancer have been less investigated and 
remain poorly understood. There is evidence through retrospective and 




associated with higher breast cancer risk. In vitro studies have shown that 
testosterone and other androgens may have two different effects. Under 
oestrogen deprived conditions androgens after aromatase conversion may 
stimulate tumour growth via ER-α and this effect can be blocked by anti-
oestrogens. In the presence of oestrogens, androgens inhibit the growth 
stimulatory effect of oestrogens and this antagonistic affect mediated via the 
androgen receptor can be blocked by anti-androgens 164. AR is expressed in a 
significant subset of both ER-positive (89%) and ER-negative (49%) breast 
cancers 160 and its expression has been associated with a good prognosis in ER-
negative/PR-negative breast tumours. Loss of AR expression, on the other hand, 
has been associated with poor prognosis in ER-negative/PR-negative/HER2-
negative lymph node positive breast tumours 160.  
 
Progesterone has been hypothesised based on in vitro studies and animal work 
to both decrease and increase breast cancer risk 165. Epidemiological studies 
though have shown that progesterone in combination with oestrogens increases 
breast cancer risk 166. Clinically, PR-A and PR-B are routinely assessed along 
with ER-α expression and overall it has been suggested that PR expression is 
positively associated with ER-α expression 160.  
 
Regarding gonadotrophins there are not that many studies investigating their 
association with breast cancer. It has been shown though that gonadotrophins 
can act on breast cancer cells and accelerate conversion of DHEA into 





Exogenous Sex Steroid Hormones  
OCs: OCs were first introduced in the 1960s and since then different formulations 
have been used. Most of them contain ethinyl oestradiol with new generation 
OCs containing lower concentration of oestrogen and new types of progestins. 
For a long time, it was hypothesised that OCs increase breast cancer risk but 
studies failed to show an association 168, 169.  A meta-analysis combining 54 
epidemiologic studies provided the first convincing evidence that current OC use 
was associated with a 25% increase in breast cancer risk 170. Studies looking into 
different doses and regimens of OCs to investigate whether they have a different 
effect on breast cancer showed that lower doses of newer regimens of OCs are 
associated with a lower breast cancer risk among young women 171.  
 
HRT: Hormone replacement therapy was first introduced in the 1930s to manage 
menopause symptoms 172. Early reports indicated that oestrogen alone was 
associated with an increased risk of endometrial cancer and this led to the 
addition of a progestagen. Increases in venous thromboembolic events were 
reported, but presumed beneficial effects for cardiovascular disease and 
osteoporosis and general well-being led to the continuation of its use 172, 173. The 
first reports of an increased breast cancer risk came in 1976 from Hoover and 
colleagues 172. Since then, several studies were carried out with two meta-
analyses showing increased breast cancer risk among users of HRT 174, 175. 
When the Collaborative group on breast cancer presented data showing an 
association between breast cancer and HRT, recommendation of hormonal 
therapy was taken more seriously 176 and the report published from the Women’s 
Health Initiative Study caused HRT administration to drop quickly 177, 178. A larger 




previous studies showing that oestrogen in combination with progestin to be 
associated with higher breast cancer risk than oestrogen alone. The risks were 
also similar irrespective of formulation and sequential or continuous use of 
oestrogen or progestin 179.   
 
Endogenous Sex Steroid Hormones  
Reproductive Factors: Long duration of lactation and breastfeeding are 
associated with reduced risk of breast cancer and older age at first birth, 
decreased parity and late menopause are all well-established factors suggested 
to increase breast cancer risk 56, 180. Breast cancer risk increases by almost 3% 
for each year delay to menopausal status (natural or surgical) 176 due to 
increased number of menstrual cycles 181. Breastfeeding has a protective role, 
reducing breast cancer risk by 4% for every 12 months of breastfeeding 182. 
There is 7% reduction in risk with each full term pregnancy, and overall women 
with children have 30% lower risk than nulliparous women 182. Data has shown 
that reduction in breast cancer risk with childbirth and higher risk with later age at 
first full time birth may only be associated with ER-positive breast tumours 183. 
Induced abortion and recognised spontaneous abortion were not associated with 
breast cancer 184. 
 
Surrogates for lifetime sex steroid hormone exposure: Surrogates for long 
term sex steroid hormone exposure have also been suggested to be associated 
with breast cancer risk. Several anthropometric factors including height, weight, 
weight changes, body mass index (BMI), fat deposition and breast size 185 have 
been investigated in order to examine their association with breast cancer. 




especially among postmenopausal women. Weight gain or BMI are factors that 
have been shown to have a different impact on risk depending on menopausal 
status. In premenopausal women increased weight decreases the risk but in 
postmenopausal women increased weight increases breast cancer risk 185, 186. 
Weight gain during adult life increases postmenopausal breast cancer risk with 
the greater risk being observed when it occurs in the upper part of the body 185. 
Fat adiposity which is measured by waist circumference and waist-hip ratio has 
been shown to be associated with the breast cancer risk in postmenopausal 
women but not in premenopausal. Weight-loss after menopause and physical 
activity has been shown to reduce breast cancer risk 180, 185. Finally, breast size 
has also been investigated with conflicting results. The biological mechanisms 
behind the association of the above anthropometric measures and breast cancer 
risk include the nutritional lifestyle during childhood and adult periods, genetic 
predisposition, prenatal factors, IGF levels 185 and endogenous sex steroid 
hormones 187. In a recent study these factors were shown to have an impact on 
tumour biology and pathology, confirming previously described associations 
between weight and increased risk of postmenopausal breast cancer and high 
BMI being associated with tumours expressing several markers corresponding 
with less aggressive cancers 188. 
 
Another parameter could affect a woman’s exposure to sex steroid hormones is 
diet. Meta-analysis of prospective studies investigating whether specific types of 
food consumption are associated with breast cancer risk showed a small 
increase or no associations 189, 190. Phytoestrogens which are known to affect the 
hormone metabolism and bind to ER have been hypothesised to increase breast 




established diet related risk factor is alcohol consumption which is known to 
increase bioavailable oestrogen and ethanol and may stimulate carcinogenesis 
by inhibiting DNA methylation 192. Data from six prospective studies showed that 
alcohol intake is correlated with breast cancer incidence in women who drink 
alcohol regularly and reduction of consumption could lower the risk 193. The 
relationship between smoking and breast cancer still remains controversial and 
for some studies it is considered to be a risk 194, whereas for others seems to 
have a protective effect lowering breast cancer risk 195 . 
 
Circulating sex steroid hormones: Endogenous, exogenous sex steroid 
hormones and surrogates for long term sex steroid exposure have been shown to 
be associated with breast cancer as discussed above. Based on these 
observations it was hypothesised that circulating sex steroid levels may be a 
good measure of risk prediction for the total hormonal exposure that influences a 
woman’s risk. In a study investigating the association of sex steroid hormones 
along with several epidemiological factors and breast cancer risk it was shown 
that oestradiol increased and SHBG decreased with increasing body mass index 
and the latter decreased with increasing waist-hip ratio. No associations were 
observed between sex hormones and age at menarche, parity, age at 
menopause, and previous use of oral contraceptives. Based on these 
observations it was suggested that obesity and perhaps waist-hip ratio may 
mediate their effects on breast cancer risk by changing circulating concentrations 
of sex hormones 196. 
 
Table 2-2 summarises previous studies that have been carried out in order to 




in postmenopausal women. A meta-analysis by Key et al, 2002 investigated the 
association of sex steroid hormones with postmenopausal breast cancer risk, 
combining 9 prospective studies, showed that women who have sex steroid 
hormone serum levels in the highest quintiles to have a two-fold increased risk of 
developing breast cancer 197. One of the largest studies examining 663 cases 
and 1765 controls found total oestradiol, free oestradiol, oestrone, and oestrone 
sulphate to be associated with breast cancer risk 197. Similar data was reported in 
EPIC study among 677 cases and 1309 controls 198. Additionally, in the New York 
University Women’s Health Study, two samples from one woman were analysed - 
one within 5 years of diagnosis and the second at least 5 years post diagnosis - 
to assess any changes in the hormone levels over time. The changes observed 
between the serial samples were not statistically significant different suggesting 
that circulating sex steroid hormones are a marker rather than a tumour related 
hormonal effect 199. The same group also examined whether increased risk for 
DCIS is associated with high levels of sex steroid hormones but no significant 
trend was observed for any of the hormones examined 200. In a more recent study 
it was shown that only oestrone and oestrone sulphate and not oestradiol and 
bioavailable oestradiol were associated with statistically significant increases in 
breast cancer risk 201. 
 
There are conflicting data on endogenous levels of androgens and breast cancer 
risk 201. In the largest case-control study high androgen levels were associated 
with higher breast cancer risk in postmenopausal women 197 which was 
supported by the EPIC study 198.  In general, it has been thought that the causal 
relationship of androgens in breast cancer is difficult to establish since increased 




increased capacity to convert testosterone to oestradiol may be both the major 
factors. After adjustment for oestradiol the association of the androgens with 
breast cancer risk remained indicating that androgens have an effect 
independent of the oestrogens 197, 198, 202.  
 
Interestingly, despite the association of exogenous progesterone and breast 
cancer risk, the association of endogenous progesterone and breast cancer risk 
is not clear. There is only one large study among postmenopausal women by 
Missmer et al, which has not shown any association of the circulating 
progesterone and breast cancer risk 202.  
 
The last few years there has been an interest in assessing the association of sex 
steroid hormones and breast cancer risk by oestrogen and progesterone receptor 
status of the tumour. The first report was that by Helzlsouer et al, demonstrating 
that in postmenopausal women the association of endogenous oestrogens with 
breast cancer risk was independent of the ER status of the tumour 203. Almost 
10 years later, another study reported that circulating levels of sex steroid 
hormones were most strongly associated with risk of ER-positive/PR-positive 
breast tumours 202. In a recent larger study positive association was observed 
for oestradiol and testosterone for ER-positive/PR-positive tumours and weak 
and no association for ER-positive/PR-negative and ER-negative/PR-negative 
tumours 202. A recent study confirmed these results providing further evidence 
that the developing tumours are mainly oestrogen receptor positive and showed 
that although HER2-positive and HER2-negative breast cancers were both 
associated with high total testosterone, they showed opposing associations with 




reporting that the associations of endogenous hormones with postmenopausal 
breast cancer risk are independent of tumour grade, and hormone receptor status 
but that might increase in strength with age 205. 
 
Studies have also looked into whether there is an association between sex 
steroid hormones and breast cancer in women at varying levels of breast cancer 
risk. No association was observed between reduced risk in tamoxifen treated 
women in the high risk population of the National Surgical Adjuvant Breast and 
Bowel Project Cancer Prevention trial with both androgens and oestrogens levels 
206. In the Nurses’s Health Study cohort women with high levels of endogenous 
oestrogens and testosterone were at increased breast cancer risk regardless of 
predicted risk or family history of breast. Therefore, it was suggest that sex 
steroid hormones are predictive of risk irrespective whether a woman has an 
increased predicted breast cancer risk 207.  
 
All the above described studies have included only women who were not using 
HRT treatment. In order to investigate associations between sex steroid 
hormones and breast cancer risk among women using hormonal treatment and 
those who do not a prospective study was carried out. The data suggested that 
higher sex steroid hormone levels are associated with breast cancer among the 
hormonal users 208. 
 
Studies have also been carried to investigate premenopausal breast cancer risk 
in association with sex steroid hormones. That relationship still is not clear as 
these studies are difficult to be carried out due to large intra-individual variation 




European Prospective Investigation into Cancer and Nutrition (EPIC) study 
demonstrating only androgens to be associated with premenopausal breast 
cancer risk 209 and the Nurse’s Health Study reporting both oestrogens and 
androgens to be associated with premenopausal breast cancer risk 210. For the 
purposes of this thesis, the literature review presented is focused on 
postmenopausal women.  
 
2.2.7 Gonadotrophins and breast cancer  
Oestrogen synthesis is under the control of LH and FSH. LH through its receptor 
stimulates the production of ovarian androgens and FSH the aromatisation of 
androgens to oestrogens. Therefore, it is of great interest to investigate whether 
LH and FSH are associated with breast cancer risk. To date, studies measuring 
the actual LH and FSH levels have failed to demonstrate an association with 
breast cancer risk 211, 212 in contrast to mouse model work demonstrating that 
over expression of LH is responsible for the development of spontaneous 
mammary tumours that lack PR expression 213. High levels of FSH and LH have 
been shown to stimulate both normal and malignant human ovarian surface 
epithelial cell growth 214 and FSH has been reported to be associated with 
ovarian cancer risk 215. Further studies are needed to better understand the role 
of FSH and LH in breast cancer. It would be of great interest to investigate the 
association of gonadotrophins with HRT use since previous studies have 
suggested that HRT stimulates the growth of only the clinically significant breast 
cancers and is known to increase breast density (risk factor) reducing the 
sensitivity on the other hand of mammography 216.    
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Study Design and Assays and Hormones 
Analysed 
General Findings 





Nested Case-Control Study            
130 cases and 260 controls 
Free E2 assay: ultra filtration 
method, Total E2 and E1: RIA, 
FSH: radiometric assay 
Association of endogenous oestrogens with breast cancer 
risk is independent of the ER status of the tumour.  




Nested Case-Control study               
130 cases and 260 controls 
(Mean age of cases 58.9 yrs) 
Invasive breast cancer, no comment on 
histology 
Free E2: ultrafiltration method, 
total E2 and E1: RIA, FSH: 
standard radiometric assay 
First confirmation in a large prospective epidemiologic study 
of a link between circulating oestrogens and breast cancer 
risk. Higher levels of oestrone, total oestradiol, and free 
oestradiol, and a lower percent of oestradiol bound to SHBG 
for women who developed breast cancer than women who 
remained free of cancer. 
Key et al, 1996 
217
 
Case Control Study                        
69 developed breast cancer after joining 
the study  
(Mean age of cases 58.3 yrs) 
No comment on histology 
RIA assays: oestrone, 
oestradiol, oestriol-urine 
samples  
High levels of endogenous oestrogens in postmenopausal 
women are associated with increased breast cancer risk but 
that the relationship of oestrogens in premenopausal women 
with risk unclear. 




Prospective Nested Case Control Study                                            
72 postmenopausal women and 144 
controls (matched: on age and on date 
and time of day)  




E1S: RIA after extraction, 
SHBG: immunoradiometric 
assay 
Further evidence in support of the already established 
association between elevated oestrogen levels and breast 
cancer. New evidence that high serum testosterone levels 
precede breast cancer occurrence. 




Case Control Study                                
24 cases and 88 controls                 
(Mean age cases: 59.4 yrs and controls: 
54.9yrs)  
E1 and Total testosterone: a 
non-extraction RIA, free 
testosterone: coated-tube RIA, 
SHBG: immunoradiometric. 
Further evidence in support of the already established 
association between elevated oestrogen levels and breast 
cancer. Evidence that high serum testosterone levels 
precede breast cancer occurrence. 




Nested Case Control Study                    
72 cases and 144 controls            
(Median age cases:61 yrs and controls: 
62 yrs)  
No comment on histology 
RIA: E2, testosterone, E1, 
androstenedione and DHEAS  
Risk of breast cancer was positively and significantly 
associated with serum levels of oestrogens and androgens. 
The results lend considerable support to the hypothesis that 
serum concentrations of oestrogens and androgens are 
related to the subsequent diagnosis of breast cancer in 
postmenopausal women. 
Table 2-2: Summary of studies investigating association between endogenous sex steroid hormones and postmenopausal breast cancer risk.  
 
Table 2-2: Summary of studies investigating association between endogenous sex steroid hormones and postmenopausal breast cancer risk.  
DHEAS=dehydroepiandrosterone sulphate; E2=oestradiol; E1=oestrone; E1S=oestrone sulphate; FSH=follicle stimulating hormone; RIA=radioimmunoassay; 
SHBG=sex hormone-binding globulin 
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Prospective Nested Case  
Control Study                                                 
72 cases and 144 controls 
(Median age cases:61 yrs and controls: 
62 yrs)  
No comment on histology 
DHEA and DHEAS: RIA with 
extraction  
Increasing risk of breast cancer for increasing 
concentrations of DHEA. The relationship of DHEAS to 
breast cancer was less consistent, but women whose serum 
DHEAS concentration was in the highest quartile also 
exhibited a significantly elevated risk ratio.  





Case Control Study                                
61 cases and 179 controls  
No comment on histology 
RIA High concentration of E2 associated with breast cancer. 
Adjustment with testosterone and SHBG concentrations did 
not change the odds ratio for E2. Testosterone and SHBG 
concentrations were associated with breast cancer risk but 
the associations were not statistically significant after 
adjusting for E2. Evidence that serum oestradiol 
concentrations in postmenopausal women may have a 






Nested Case Control Study within the 
New York University Women's Health 
Study                           
130 cases and 260 controls  
(Mean age cases: 59.2 yrs and controls: 
59.1 yrs) 
Total testosterone: solid-phase 
RIA: DHEAS directly in diluted 
serum, total E2: standard RIA 
and % E2 bound to SHBG and 
% E2 free: concanavalin A-
sepharose binding and an ultra 
filtration method respectively 
Testosterone associated with breast cancer risk but after 
adjustment with E2 bound to SHBG and total E2 no longer 
significant. Breast cancer risk remained associated with total 
E2 levels and negatively associated with E2 bound to SHBG 
after adjustment for serum testosterone levels. No evidence 
was found of an association between DHEAS and risk of 





Nested Case Control Study within the 
Nurses' Health Study           
156 cases and  312 control (matched with 
respect to age, menopausal status, 
month and time of day of blood collection, 
and fasting status at the time of blood 
collection)  
RIA Strong evidence for a causal relationship between 
postmenopausal oestrogen levels and the risk of breast 
cancer. 
DHEA=dehydroepiandrosterone; DHEAS=dehydroepiandrosterone sulphate; E2=oestradiol; RIA=radioimmunoassay; SHBG=sex hormone-binding globulin 
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Prospective Case Cohort Study. 97 
cases and 244 controls; not receiving 
oestrogen therapy 
(Mean age cases:70.9 yrs and 
controls:71.8 yrs) 
Total E2, E1, E1S, 
androstenedione, DHEA: RIA 
after extraction and 
chromatography, free E2: 
equilibrium dialysis and calculated 
by the % of dialyzable oestradiol, 
total E2, % of non-SHBG-bound 
E2 or bioavailable E2: monium 
sulphate precipitation of SHBG-
bound steroids, total testosterone: 
RIA with chromatographic 
purification, free testosterone: 
equilibrium dialysis, SHBG: direct 
RIA 
Oestradiol and testosterone levels may play important roles 
in the development of breast cancer. A single measurement 
of bioavailable oestradiol and free testosterone may be used 
to estimate a woman's risk for breast cancer. Women 
identified as being at high risk for breast cancer as 
determined by these hormone levels may benefit from 
antioestrogen treatment for primary prevention. 




Case Control Study from the Life Span 
Study, Japan                        
72 cases and 150 control (matched on 
age, date of blood collection, 
exposure, radiation dose) 
(Mean age cases: 60.7 yrs) 
E2, prolactin, SHBG and 
progesterone: RIA,  levels of 
bioavailable E2: calculated, 
DHEAS: RIA for 11-deoxy-17 
ketosteroid 
Further prospective support for the hypothesis that a high 
level of biologically available E2 is a risk factor for the 
subsequent development of breast cancer. 
Key et al, 2002 
197
 
Meta-analysis of 9 studies                               
663 cases and 1765 controls 
Different assays applied within 
the different studies; oestradiol, 
free oestradiol, bioavailable 




All hormones statistically significant associated with an 
increased breast cancer risk. 
DHEA= dehydroepiandrosterone; DHEAS=dehydroepiandrosterone-sulphate; E2=oestradiol; E1=oestrone; E1S=oestrone sulphate; RIA=radioimmunoassay; 
SHBG=sex hormone-binding globulin 
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Two populations based prospective 
cohort studies in Sweden. Blood 
samples were collected in about 65,000 
women/Follow-up yielded  
173 postmenopausal breast cancer 
cases who had not been exposed to 
HRT (Mean age cases: 61.6 yrs and 
controls: 60.5 yrs)  
Testosterone, androstenedione: 
competitive RIA, DHEAS, E1, E2: 
direct RIA, FSH, prolactin: 
sandwich magnetic separation 
assay, SHBG: immuno 
fluorometry 
High levels of E1, E2, testosterone, and possibly 
androstenedione and DHEAs, in postmenopausal women 
are associated with a high risk of subsequent breast cancer. 
Onland-Moret 
et al, 2003 
227
 
A nested case-cohort study was 
conducted within a large cohort (the 
DOM cohort) in the Netherlands 
(n=9,349)                                    
Women using hormones were excluded 
leaving 364 breast cancer cases and 
382 women in the cohort for the 
analyses (Mean age cases: 61.6 yrs 
and controls 60.5 yrs) 
E1, E2, testosterone and 5a-
androstane-3a, and 17b-diol 
(3aD): RIA after extraction and 
chromatography 
Women with higher excretion levels of both oestrogens and 
androgens have an increased risk of breast cancer. 




A cross-sectional study            
133 women  
(Mean age cases: 61 yrs and controls: 
62 yrs)           
 
E2, testosterone, 
androstenedione, DHEAS,  E1S: 
RIA after extraction and 
chromatography, SHBG: 
immunoradiometnic assay, % of 
unbound and albumin-bound E2: 
centrifugal ultra filtration 
Higher oestrogens and possibly testosterone mediate the 
increased breast cancer risk associated with obesity. Higher 
testosterone levels could potentially contribute to the 
increased risk of breast cancer among nulliparous 
postmenopausal women. The results did not support a role 
for changes in serum oestrogen, androgen and SHBG levels 
in explaining the age-related increase in breast cancer 
incidence.  
DHEAS=dehydroepiandrosterone-sulphate; E2=oestradiol; E1=oestrone; E1S=oestrone sulphate; FSH=follicle stimulating hormone; RIA=radioimmunoassay; 
SHBG=sex hormone-binding globulin 
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Nested Case Control Study           
264 invasive, 41 in situ,153 ER+/PR+, 
39 ER-/PR- cases and 643 controls 
Mean age of cases: 62 yrs 
E1, E2, testosterone, SHBG, 
DHEAS, progesterone: RIA and 
free and percent free E2: 
calculated by the law of mass 
action 
Circulating levels of sex hormones strongly associated with 
risk of ER+/PR+ breast tumours. 
Zeleniuch-




Nested Case Control Study           
297 cases and 563 controls 
Mean age of cases: 60 yrs 
E1, E2, androstenedione, FSH, 
testosterone and DHEAS: direct 
RIA, SHBG: direct ‘sandwich’ 
immunoradiometric assay 
Associations of circulating oestrogen with breast cancer risk 
are more likely due to an effect of circulating hormones on 
the development of cancer than to elevations induced by the 
tumour. Contribution of androgens to risk is largely through 
their role as substrates for oestrogen production. 




Nested Case Control Study           
446 cases and 459 controls 
Mean age of cases: 59.9 yrs and 
controls: 59.8 yrs 
E2 and testosterone: RIA after 
extraction and chromatography, 
SHBG: immunoassay, free E2 
and free testosterone: calculated 
by the law of mass action 
Although women using hormonal treatment have a different 
hormonal profile than those not using hormonal treatment 
plasma sex hormone concentrations are associated with 
breast cancer among those who were treated with 
hormones.  




Nested Case Control Study          
677 cases and 1309 controls Mean 
age of cases: 60.4 yrs and controls 
60.3 yrs 
Testosterone and DHEAS: RIA, 
androstenedione, E1 and E2: RIA 
with a double-antibody system for 
the separation of free and bound 
antigen 
Elevated serum oestrogens and androgens associated with 
increased breast cancer risk. Since DHEAS and 
androstenedione are largely of adrenal origin in 
postmenopausal women, the results indicated that elevated 
adrenal androgen synthesis is a risk factor for breast cancer. 
Caution against the use of DHEA(S) or other androgens for 
postmenopausal androgen replacement therapy. 
Zeleniuch-




Nested Case Control Study                
69 DCIS and 134 matched controls 
Mean age of cases: 58 yrs and controls 
58 yrs 
E2, E1 and androstenedione: 
direct double-antibody RIA, 
testosterone and DHEAS: direct 
RIA, SHBG: direct sandwich 
immunoradiometric assay, FSH: 
immunometric assay 
No statistically significant trend of increasing risk with 
increasing level of any hormone was observed. 
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Case Control Study – samples taken at 
diagnosis                     
179 cases (invasive breast cancer and 152 
controls (benign conditions of breast) 
Mean age of cases: 67.1 yrs and controls  
 
E2, E1, E1S  testosterone, DHEA 
and androstenedione: RIA after 
extraction and chromatography 
Higher serum concentrations of oestrogens were 





A prospective nested case-control study 
within the Nurses' Health Study  
418 cases  817 age matched controls 
Low/Moderate/High Risk of cases based on 
Gail Rosner and Colditz models 
RIA following extraction and celite 
chromatography 
Higher levels of endogenous oestrogens and testosterone 
are associated with increased breast cancer risk 
regardless of predicted risk or family history of breast 
cancer. 




Case-Cohort Design                          
135 cases and 275 controls Women had 
enrolled in the National Surgical Adjuvant 
Breast and Bowel Project Cancer 
Prevention Trial and who had been treated 
with tamoxifen or placebo for 69 months 
RIA: oestradiol, testosterone, 
SHBG 
Reduced risk of invasive breast cancer in tamoxifen-
treated women compared with placebo treated women was 
not associated with sex steroid hormone levels. The data 
did not support the use of endogenous sex hormone levels 
to identify women who are at particularly high risk of breast 
cancer and who are most likely to benefit from 
chemoprevention with tamoxifen. 




Case-Control Study                                       
165 who developed breast cancer after 
being followed up for 13.5 years ER+, ER-, 
PR+, PR- 
Mean age cases: 58.02 yrs and controls 
58.10 yrs 
RIA: testosterone and oestradiol  
and immunoassay: SHBG 
High levels of circulating testosterone increase the risk of 
postmenopausal women to develop breast cancer. The 






Case Study                                             
197 postmenopausal women with breast 
cancer and 857 random chosen women  
Testosterone and E2: 
electrochemiluminescence 
immunoassay, E1S and 
androstenedione: RIA, DHEAS: 
competitive immunoassay, 
SHBG: immunometric assay 
Associations of endogenous hormones with 
postmenopausal breast cancer risk are independent of 
tumor grade and hormone receptor status and may 
increase with age. 
DHEAS=dehydroepiandrosterone-sulphate; E2=oestradiol; E1=oestrone; E1S=oestrone sulphate; FSH=follicular stimulating hormone; RIA=radioimmunoassay; 
SHBG=sex hormone-binding globulin 




Epigenetics have been defined as modifications of DNA or associated factors with 
information content other than the DNA sequence itself that are maintained during 
cell division, mitosis and/or meiosis 229. The Greek ‘epi’- prefix of the word 
‘epigenetics’ implies features that are ‘on top of’ or ‘in addition to’ genetics. 
Therefore, the term epigenetics encompasses events that influence gene 
function, but it is on top of or in addition to the traditional molecular basis for 
inheritance. The term was first introduced in 1940s describing the interaction 
between genes and environment in the development of specific phenotypical 
traits, which cannot be explained by genetic principles. There are four main, inter-
related types of epigenetic inheritance which are all linked together acting in a 
synergistic way: DNA methylation, histone modifications, nucleosome positioning 
and non-coding RNAs, specifically microRNA expression. Epigenetic 
modifications are known to be an early event in carcinogenesis and to precede 
major genetic changes leading to cancer 115.  Several reports have demonstrated 
an association between DNA methylation changes and breast cancer (discussed 
in section 2.4.3). Women with gene specific DNA methylation changes are at an 
increased risk to develop the disease with odds ratio (OR) ranging from 1.4 to 
5.28 163, 230.  
 
2.3.1 DNA methylation  
DNA methylation refers specifically to the covalent addition of a methyl group 
from the methyl group S-adenosyl-L-methionine (SAM) to the carbon-5 position of 
the cytosine ring to form the called fifth base, 5-methylcytosine  231. The reaction 
is catalysed by a family of enzymes which are transferring the methyl group from 
the donor molecule, SAM, to the cytosine ring known as DNMTs 232, 233 (Figure 2-
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3). Several distinct physiologically active members have been cloned and 
characterised including DNMT1 which is responsible for maintaining methylation 
after DNA replication and DNMT3a and DNMT3b which are responsible for de 
novo methylation during early embryogenesis. Studies have shown though that 
DNMT1 is not sufficient in maintaining methylation with de novo activities of 
DNMT3a and b being necessary for the establishment of methylation patterns in 










But how DNMTs are targeted in particular sites within the genome causing DNA 
methylation? One of the suggested mechanisms is by the recognition of specific 
chromatin structures. Chromatin is known to consist of 146 base pairs of DNA 
wrapped around an octamer of four core histone proteins: H3, H4, H2A and H2B. 
It is found in two states either in an active euchromatic state or an inactive 
heterochromatic state. Euchromatin is defined by di- and trimethylation of lysine 4 
on histone H3 and acetylation of histones H3 and H4. Heterochromatin is 
characterised by either trimethylation of lysine 27 and 9 on histone H3 or 
methylation of lysine 20 on histone H4 235. These modifications are known to be 
regulated by enzymes that add and remove covalent modifications to histone 
Figure 2-3: DNA methylation reaction catalysed by DNA 
methyltransferases.  
 
Figure 2-2: DNA methylation reaction catalysed by DNA 
methyltransferases.  
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proteins. Based on the modifications the proteins are divided into: histone 
acetylases (HATs), methyltransferases (HMTs), deacetylases (HDACs), 
demethylases (HDMs). Studies have suggested that DNA methylation occurs at 
heterochromatic regions, these histone modifications either individually or in 
combination make possible targets for the DNMTs. DNMTs have also been 
shown to interact with HMTs such as G9a, protein arginine methyltransferase 5 
and SUV39 115. SUV39 is responsible for methylation of lysine 9 on histone 3 and 
the enhancer of zeste homologue 2 (EZH2) which is one of the proteins contained 
in the Polycomb Repressor Complex (PRC) 2 also containing the embryonic 
ectoderm development (EED) and suppressor of zeste homologue 12 (SUZ12), 
which catalyses the methylation of lysine 23 on histone H3. PRC1 and PRC2 
complexes are known to regulate gene expression of embryonic stem (ES) cells 
which contain coexisting active trimethylated lysine 4 on histone H3 and 
repressive trimethylated lysine 27 on histone H3 marks at the promoters of genes 
that are important in developmental processes 236. Recently it has been 
suggested that the occurrence of methylation and dimethylation of lysine 9 on 
histone H3 and trimethylation of lysine 27 on histone H3 within the same region of 
the genome can serve as a signal to recruit DNMTs 237. DNMTs are also known 
to interact with heterochromatin protein I, a protein that is known to specifically 
bind to methylated lysine 9 on histone 3 115, 236. Other suggestions include the 
recruitment of DNMTs by repressors and RNAi with conflicting data being 
presented and further studies needed to show that this mechanism is important in 
mammals 236.  
 
Methylation occurs predominantly in cytosines located 5′ of guanines and known 
as CpG dinucleotides, where p refers to phosphate link between the two 
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nucleosides. CpGs are unequally distributed and they are greatly 
underrepresented in the mammalian genome through evolutionary loss of 5-
methylcytosines through deamination to thymine 238. However, clusters of CpGs 
known as CpG islands (CGIs) are present in 1–2% of the genome (approximately 
30,000 CGIs have been suggested to be present in the genome) and their length 
ranges from 200 bp to 2 kilo bases. CGIs are frequently contained within and 
around the promoter regions, in the first and second exons and the first intron, of 
the mammalian gene and it has been estimated that around 40% of all genes 
contain a CGI 239. The fact that CGIs are localised in the promoter region of a 
gene makes them critical in gene regulation, usually with an inverse relationship 
between the degree of methylation of a regulatory CGI and the extent of gene 
transcription 240.  
 
The regulation of gene expression by DNA methylation modifications is based on 
the suggestion that DNA methylation is able to physically prevent the binding of 
transcription factors to their binding sites in the promoter of the genes, therefore 
inhibiting the transcription process. Another mechanism is based on the theory 
that DNA methylation can prevent transcription by interfering with the propagation 
of active chromatin marks. Studies provided evidence that methylated DNA is 
able to recruit a family of proteins known as methyl-CpG binding proteins (MBDs) 
consisting of five well-characterised members: MeCP2, MBD1, MBD2 MBD3 and 
MBD4. These proteins are important mediators between DNA methylation and 
histone modifier genes establishing a transcriptionally inactive chromatin through 
their association with protein complexes that involve the action of HDCA1 and 
HDCA2 and chromatin remodelling proteins such as sin3a and mi-2. This protein 
association is responsible for deacetylation of the histones that leads to a tighter 
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binding between the positively charged lysine residues of histones and the 
negatively charged phosphodeoxyribose backbone of the DNA reducing 
accessibility of DNA for transcription factors 115, 236. Even though there are a lot of 
studies trying to better understand the molecular interplay between these 
epigenetic modifications, still the mechanisms which underlie the link between 
DNA methylation and histone modifications remain under intense scrutiny. The 
hierarchy and chronology of DNA methylation, histone modifications and altered 
gene transcription are yet to be established.  
 
2.3.2 DNA methylation detection methods  
Detection of DNA methylation changes is based on the ability to differentiate 
between cytosine and 5-methylcytosine in the DNA sequence. Nowadays, there 
are a variety of methods which can be used to obtain DNA methylation data. 
These methylation techniques can be categorised according to the following DNA 
treatments: 1) methylation sensitive restriction digestion, 2) immunoprecipitation 
and 3) sodium bisulphite modification (BM). 
 
Methylation sensitive restriction digestion analysis using specific restriction 
enzymes is a technique that has been used for many years to confirm the 
methylation status of CpG dinucleotides 241, 242. Due to increased interest in 
developing methods which can examine genome-wide epigenetic alterations 
restriction landmark genomic scanning was introduced in 1991 243 allowing single 
base resolution via sequencing. More recent developments such as differential 
methylation hybridisation via CpG-island microarrays provide an attractive 
alternative 244. The drawback of these techniques is that they are significantly 
labour intensive and require high concentrations of DNA. 
Literature Review                                                 
 
2-85 
Immunoprecipitation is another approach. Main advantage of the technique is the 
lack of requirement for restriction digestion that reduces sequence bias. It 
involves two approaches: 1) Methylated-CpG Island Recovery Assay (MIRA) 
which uses antibodies against the MBD family of proteins that preferentially binds 
to methylated DNA. MIRA has been developed in conjunction with CpG island 
arrays, and very recently, was used to demonstrate increased methylation of 
homeobox genes in breast cancer 245, 246, 2) MeDIP which involves the use of a 
monoclonal antibody directly against methylated cytosines 247.  
 
The most widely used techniques and those that have been at the forefront of 
DNA methylation analysis are those that involve the use of chemically treated 
DNA with sodium bisulphite. Sodium BM relies on the differential deamination of 
cytosine to uracil without affecting the 5-methylcytosine content 248. The 
conversion produces differences in the DNA sequence which are dependant on 
the original methylation status of the genome. These differences can be used to 
design PCR primers which will either amplify a region depending on its 
methylation status or amplify a pool of unmethylated and methylated products. 
The most well known method is methylation specific PCR (MSP) which was 
introduced in 1996 249. Several techniques since then have been developed 
including MethyLight 250, combined bisulphite restriction analysis (COBRA) 251 
and pyrosequencing 252.  
 
MethyLight has an increased level of sensitivity as a result of the incorporation of 
a probe with the primers; however, this can complicate assay design. 
Quantification of methylation by MethyLight is represented by the ‘percentage of 
fully methylated reference or ‘‘PMR’’ which compares the fluorescence intensities 
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of the target gene in the sample with those of a theoretically fully methylated 
reference DNA 250. COBRA and pyrosequencing provide quantitative information 
using PCR-primers that do not cover any potentially methylated CpG sites. 
COBRA relies on a methylation sensitive restriction enzyme digest to provide 
quantitative assessment of the methylation status of individual CpG sites 251. 
Pyrosequencing which is an improved method of bisulphite genomic sequencing 
provides assessment at single CpG dinucleotide level 252. Recently, 
pyrosequencing was re-introduced as the ‘Next-generation’ sequencing involving 
PCR amplification of target DNA and use of fluorophores, a method during which 
incorporation of each nucleotide is accompanied by an enzymatically driven 
emission of light. This process was recently used to perform massively parallel 
bisulphite sequencing from serum and breast tissue 253.  
 
Until now, the majority of studies have relied on a candidate gene approach 
allowing the analysis of a limited number of genes. Very recently, epigenome 
wide analyses came into the scene with Illumina introducing their universal bead 
array technology in the form of the Goldengate and Human Methylation 27 
(Methyl 27K) platforms 254, 255. Both of them generate quantitative data expressed 
as beta (β) which are continuous variables between 0 and 1, representing the 
ratio of the intensity of the methylated bead type to the combined locus intensity. 
The beadchip technology allows detection of methylation levels down to as little 
as 2.5% 255 and the Illumina Methyl 27K platform has a capacity for the 
simultaneous analysis of approximately 14,000 genes. As described there are 
limitations in any of the methods available and no single technique can be 
considered better than the other one. Validation of the data is important either by 
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using a second set of samples. The application of these tools in clinical research 
is critical in breast cancer as it will allow not only to identify novel methylation 
targets but it will also enable the identification of patients that could eventually 
benefit from treatment.  
 
2.3.3 DNA methylation during normal development and disease 
In humans DNA methylation patterns are established during defined phases in 
embryonic development. After fertilisation dramatic waves of methylation changes 
occur. Gamete methylation patterns are erased by a genome-wide demethylation 
event at around the eight-cell stage of blastocyst formation 256. During 
implantation, DNA methylation patterns are re-established via de novo 
methylation and are maintained through subsequent cell divisions 257. During 
adulthood, the primary role of DNA methylation is the maintenance of 
transcriptionally silent repetitive DNA elements which are scattered all over the 
human genome preventing chromosomal instability 258. In contrast, most CGIs are 
unmethylated under normal circumstances in normal tissue 259, with the exception 
of those associated with imprinted genes with promoter methylation of either the 
paternal or maternal allele 260 and genes subjected to X chromosome inactivation 
in females 247. There are also studies showing methylated non-imprinted 
autosomal CGIs in normal cells playing an important role in the establishment and 
control of cell type specific gene expression e.g. Homeobox A5 (HOXA5) 261.  
 
Disruption of these pre-set patterns of DNA methylation during adult life have 
been linked to aging and disease. Several congenital malignancies such as 
immunodeficiency, centromeric region instability, facial anomalies syndrome 
which have a mutation in DNMT3B enzyme have been shown to be associated 
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with hypomethylation 262. Methylation changes have also been linked to Beckwith-
Wiedemann and Prader-Willi syndromes which are imprinting disorders 263. 
Furthermore, dysregulation of developmental programming by maternal and/or 
environmental factors is thought to induce abnormal DNA methylation of specific 
genes and thence their faulty expression, leading to disease 264. Such 
observations have been made by studying epigenetic differences between 
monozygotic twins. In early age monozygotic twins it is not possible to distinguish 
any epigenetic differences but as they grow older several differences in their 
epigenome are seen suggesting that the influence of the environment is an 
important parameter that needs to be taken into account 265. Age dependent 
methylation alterations are also observed in normal tissues 266 but the most 
significant and frequently studied changes are those detected in many cancer 
types including breast cancer.  
 
2.3.4 DNA methylation and cancer  
During carcinogenesis normal cells undergo an extensive epigenetic 
transformation. The cancer epigenome is characterised by global changes in 
DNA methylation and histone modification patterns and altered expression of 
chromatin modifying enzymes. Segregation of the epigenome into unmethylated 
and methylated regions is responsible for the formation of a rigid repressive 
chromatin which leads to reduced cellular plasticity. These changes result in 
dysregulation of gene expression profiles and along with genetic alterations play 
an important role in cancer initiation and progression of cancer. When gene 
expression is altered due to DNA methylation, it is usually characterised as due to 
hypomethylation or hypermethylation 115.  
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It was first shown that the genome of cancer cells is hypomethylated in 
comparison to normal tissue 267. The genome-wide hypomethylation observed in 
cancer is mostly due to loss of methylation from repetitive elements in the 
genome resulting in genomic instability by promoting chromosomal 
rearrangements 268. It is also responsible for the activation of oncogenes (growth-
promoting genes) such as c-myc (C-myelocytic leukaemia) and loss of imprinting 
in colorectal cancer 269.  
 
The most well characterised epigenetic modification though during 
carcinogenesis is the de novo methylation of CGIs around the promoter region of 
genes correlating with transcriptional repression. CGI methylation and 
subsequent transcriptional silencing occurs at least as often as genetic alterations 
in tumour suppressor genes in cancer 270. Various tumour suppressor genes 
have been identified to undergo tumour-specific silencing by hypermethylation. 
These genes are involved in cell cycle regulation, apoptosis, transformation, 
signal transduction and adhesion, angiogenesis and metastasis 85. Moreover, 
indirect silence of genes by silencing transcription factors and DNA repair genes 
has also been shown.  
 
Despite the fact that we know a great deal regarding these hypo- and hyper- 
methylation changes in cancer still the events that lead to their initiation and the 
mechanism by which CGIs in normal cells are protected against methylation but 
lose this protective barrier in cancer and become hypermethylated are not fully 
understood.  Epigenetic alterations have been suggested to be initiating events in 
the expansion of cells in preneoplastic lesions but the influences of these 
alterations as initiation events have been difficult to study. It is known that 
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methylation of specific genes alongside coordinated genetic hits potentially drive 
the development of a cancer, with multiple epigenetic hits being shown to be 
potential early events in precancerous cells prior to genetic alterations 
predisposing cancer cells to further mutations and increasing the likelihood of 
tumour progression 271. Further to this, methylation in premalignant breast and 
colorectal tissue has been suggested to represent a field defect, perpetuating 
further neoplastic changes 272, 273. There is also the recent suggestion that 
epimutations of stem cells may be the initiating progenitor event in 
tumourigenesis 264. In addition, as epigenetic modifications are mitotically 
heritable they provide a growth advantage to rapidly growing cancer cells that 
result in their proliferation 115. In addition, it has also been shown that epigenetic 
modifications are affected by age 30, 274 environment 275, chronic inflammation 276 
and endocrine exposure 163.  
 
Tumour-specific CpG island methylation has been suggested to occur through a 
sequence specific instructive mechanism during which DNMTs are targeted at 
specific genes through an association with oncogenic transcription factors 115. 
Additionly, it has been shown that de novo methylation may start in exonic CGIs 
and subsequently spread into the promoter region of genes 277. Alterations in 
methylation have been believed to locally silence discrete genes during 
carcinogenesis but recent work has challenged this concept by showing that long 
range epigenetic silencing may exist hypermethylating neighbouring genes and 
causing global gene silencing through chromatin remodelling activities 278.  
 
Recent evidence has also shown that genes which are methylated in cancers 
may be vulnerable to aberrant DNA hypermethylation and epigenetic silencing 
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during tumour initiation and progression because of alterations in chromatin 
structure in stem or progenitor cells, including dimethylated and trimethylated 
lysine 9 on histone H3 279, 280. This finding supports the cancer stem cell 
hypothesis which is based on the observation that tumourigenic tissue contains a 
heterogeneous population of cells that are characterised by tumourigenic 
properties. As epigenetic modifications are key for the maintenance of stem cell 
identity it has been hypothesised that their disruption could give rise to a high risk 
aberrant progenitor cell population which is capable of undergoing 
transformations leading to the subsequent production of mutations. This 
phenomenon can lead to an overall increase in the number of progenitor cells 
and an increase in their ability to keep their stem cell state, forming a high risk 
population which can finally become neoplastic through additional genetic 
mutations 115.  
 
Based on these suggestions a new model of carcinogenesis has been suggested.  
The predisposition of stem cell PRC2, which contains EZH2, EED and SUZ12 as 
mentioned before, targets to cancer-specific DNA hypermethylation suggesting a 
‘crosstalk’ between PRC2 and de novo DNA methyltransferases in precursor 
cancer cells with a PRC2 target gene distribution similar to that of stem cells. This 
‘crosstalk’ may be initiated and/or facilitated by various environmental exposures, 
transgenerational inheritance, endocrine exposure, inflammation and by age. A 
stem cell whose potential to differentiate has been irreversibly blocked by CpG 
methylation would then be predisposed to carcinogenesis via the acquisition of 
further genetic events, such as mutations and deletions (Figure 2-4) 280. Better 
understanding of how specific genomic regions are targeted for DNA 
hypermethylation and how these DNA modifications are initiated in cancer will 










































































































potentially lead to therapeutic strategies and identification of biomarkers for early 









2.3.5 DNA Methylation biomarkers and breast cancer 
Hypermethylation or hypomethylation of CGIs is a potentially attractive marker for 
detecting the neoplasm and detection of these changes have been proposed as 
a potential early diagnostic tool in cancer. Beside the presence of epigenetic 
alternations in the tumour tissue, DNA methylation changes in cancers can 
frequently be assayed in various sources of body fluids, serum and plasma, and 
may serve as a potential target to early detect cancer or to detect minimal 
residual disease after primary treatment has been completed. The precise 
mechanism by which DNA is released into the bloodstream still remains uncertain 
but evidence is accumulating that in areas of high cell turnover and cell lysis, 
DNA from necrotic and apoptotic cells can be transported from the intercellular 
space via lymph vessels into the blood stream 86. It has already been shown by 
several groups that CGI methylation can be detected in plasma with the same 
characteristic changes as those found in the corresponding tumour and 
Figure 2-4: Fixation of a stem cell signature by means of DNA methylation as a 
prerequisite for carcinogenesis. 
 
Figure 2-3: Fixation of a stem cell signature by means of DNA methylation as a 
prerequisite for carcinogenesis. 
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cancerous tissues are methylated in contrast to CGIs in normal tissue making 
DNA methylation signature a promising biomarker 10. Amongst the methylated 
genes are tumour suppressor genes such as p16, damage response genes such 
as BRCA1, mismatch repair genes e.g. hMLH1 and HMSH2, steroid receptor 
gene family members such as ER, PR and retinoic acid, cell adhesion and cell 
surface molecules and DNMT inhibitors 85. Several reviews have summarised 
breast cancer biomarkers 85, 281, 282 with a recent review specifically focusing on 
the presentation of markers discovered by examining breast tumour tissue 283. 
Another review summarised studies that have revealed various genes to be 
either hypo- or hyper- methylated in breast cancer 284. Recent diagnostic and risk 
prediction DNA methylation breast cancer markers are shown in Table 2-3 116. 
Markers were analysed in a variety of tissue sources including, tumour tissue, 
serum/plasma, peripheral blood cell DNA, nipple aspirate/duct fluid and fine 
needle aspirate washings.  
 
DNA methylation analysis for the early detection of breast cancer was pioneered 
by Evron et al, 2001 by comparing methylation of cyclin D, RAR-β and TWIST 
promoters using cells extracted from ductal lavage fluid. In this study apart from 
detecting methylation changes in women with DCIS, they also found abnormal 
methylation in asymptomatic healthy women who later developed breast cancer 
285. This was the first report to indicate the value of DNA methylation as a 
possible marker for the early detection of breast cancer and these data was 
further confirmed and expanded 286-288. Our group recently was the first to 
perform a large-scale epigenotyping study showing ZNF217 plasma methylation 
to be associated with breast cancer risk 163. Prognostic DNA methylation 
markers have also been suggested by examining both serum and breast cancer 
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tissue. PITX2, RASSF1A and APC were the most frequently detected genes. 
Single gene loci as well as gene panels showed an association of methylation 
status with disease free and overall survival/mortality as well as early distant 
recurrence and lymph node metastasis. Finally, only a limited number of DNA 
methylation markers for breast cancer predicting and monitoring adjuvant 
treatment have been identified 116.  
 
Regardless of the several studies no single identified marker has made the 
transition to the clinic. In order to improve early diagnostic and risk prediction 
strategies better models are needed to investigate early stage disease. In 
addition, more specific and sensitive markers need to be identified with studies 
stratifying their analysis based on the different types of breast cancer, e. g. based 
on the hormone sensitivity of the tumour as it has been done with genetic 
analysis 51. Finally, the issue of intra-tumour heterogeneity when tumour tissues 







Genes Identified Tissue Analyzed No of samples Significant Findings Ref. 
ZNF217 Peripheral blood cell DNA 1083 Association with breast cancer risk 
163
 
TMS1, BRCA1, ERα,PRB 
Tumour tissue, normal 
tissue, serum 







, Cyclin D2, Slit2 Serum 36 Potential diagnostic markers 
290
 
RASSF1A, APC, DAPK 
Tumour tissue and paired 
preoperative serum DNA 
34 
Potential diagnostic markers being 









; RASSF1A, DAPK 
Tumour tissue, normal 
breast tissue, nipple 
aspirate fluid 
22 
Potential diagnostic markers being 
associated with the disease 
288
 
CCND2, RASSF1A, APC, HIN1 Needle aspirate washings 
training set:109  test 
set:78 validation set: 45 
Potential diagnostic markers being 
associated with the disease 
292
 
APC,RASSF1A Serum 122 




ESR1, APC, HSD17B4, HIC1, RASSF1A  Serum 
training set: 24 
test set: 62 
Association with overall survival ion 




Histone modifications (including methylation changes): 
H3K4me2, H4K20me3, H4R3me2 (lysine methylation) 
Tumour tissue 880 




Kallikrein 10 (KLK 10), Cystatin M (CST6) 
Tumour tissue 
test set: 35 
validation set: 93 
Association with disease-free interval 




Table 2-3: Diagnostic, prognostic and risk prediction DNA methylation biomarkers for breast cancer in different types of tissue.  
 







Genes Identified Tissue Analyzed No of samples Significant Findings Ref. 
RASSF1A Tumour tissue 
test set:35 
validation set: 93 
Association with disease-free interval 
297
 








BRCA1, p16 Serum 122 Association with overall survival 
299
 
SFRP5 Tumour tissue 133 Association with overall survival 
300
 
PITX2 Tumour tissue 412 
Association with early distant 






test set: 109 
validation set: 236 




ID4 Tumour tissue 170 
Association with recurrence free 
survival and lymph node metastasis 
303
 
RASSF1A Serum 148 
Marker for monitoring of efficacy of 
adjuvant tamoxifen treatment 
304
 
NEUROD1 Tumour tissue and serum 
74 (tumour tissue) 
 44 (pre-treatment core 
biopsies), 
107 (serum) 
Marker for monitoring adjuvant 





















response and disease free survival 
307
 
Adopted from Jones et al, 2010 
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3 IDENTIFICATION OF BREAST CANCER CASES - CANCER REGISTRY 
VS SELF-REPORTING  
  
In this thesis breast cancer cases were identified from among 189,046 women 
from England and Wales participating in a national screening study (UKCTOCS). 
Data on breast cancer diagnosis was available for two data sources – cancer 
registry follow-up and from self-reporting on the UKCTOCS follow-up 
questionnaire. 
 
National cancer registries are found in many countries and collect comprehensive 
cancer information for the whole population which enables documentation of 
historical trends in cancer incidence / survival over long periods of time. The 
information is used for research, education and for planning national strategies to 
deliver the best cancer care to the whole population. The cancer registries work 
on a country-specific policy and therefore the availability of cancer data differs 
between countries. In the UK, the registries are divided between England and 
Wales, Scotland and Northern Ireland. In England and Wales, the NHS 
Information Centre for Health and Social Care (formerly the Office of National 
Statistics, ONS) provides data on cancer registrations through the NHS Cancer 
Registry (NHSCR) and data on death and cause of death through the Death 
Certification process (Medical Certificate of Cause of Death). In Scotland, this is 
through the Scottish Cancer Registry and the General Registry Office for death 
certificates, while in Northern Ireland Cancer Registry and the Central Services 
Agency (CSA) provide data on cancers and deaths, respectively.  
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All cancer registries collect information on every new diagnosis of cancer 
occurring in their populations. The information is acquired from a variety of 
sources including hospitals, cancer and treatment centres, hospices and private 
hospitals, cancer screening programmes, other cancer registers and death 
certificates, general practices and nursing homes. Processing of data involves 
checking the validity and completeness of the data and a complex process of 
clinical data linkage and consolidation. Overall, the data on cancer registrations 
has been shown for the most part to be reliable 308. Major errors in International 
Classification of Diseases (ICD) coding are few 309 with data regarding cancer 
stage, grade and date of treatment being less consistent and delays occurring in 
the recording of the data. This suggests that even though the quality of the data 
may be good, improvements are needed in standardising the recording of 
information by clinicians 310.  
 
Cancer registries are also often used for tracking participants in research studies 
where cancer diagnosis and mortality are key outcome measures. In such 
circumstances, completeness of information and timely notification is crucial. To 
compensate for possible delays in recording cancer data by cancer registries, 
researchers often use additional sources such as self-reporting through follow-up 
questionnaires or medical notes. Follow-up questionnaires are regarded as the 
most cost-effective way in obtaining these data 311. However, the validity of this 
form of reporting is dependent on the site of cancer, with self-reported breast 
cancer being most accurately identified in comparison to other type of cancers 
such as endometrial, cervical 312 and ovarian cancer 313. Reported sensitivity for 
breast cancer classification ranged between 79-98% in comparison to colon 
cancer, ranging from 58-89% 312, 314-320. In addition, in situ cancers have been 
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shown to have much higher rates of misclassification by individuals than invasive 
cancers regardless of the site 312. Sensitivity of self-reporting is dependent on a 
variety of factors such as age at diagnosis, education, previous family history and 
race 311, 316. Abstraction of clinical information from medical reports obtained 
directly from the clinicians treating the patient are considered to be the most 
accurate means of collecting cancer data 321. However this can be extremely 
time-consuming and expensive especially when different centers are involved 322. 
 
The accuracy of the cancer data has major implications for research studies, 
especially those that include cancer risk prediction 7 and screening. Most previous 
studies reporting on accuracy of cancer data have used two of the three possible 
information sources (self-reported data on questionnaires, cancer registry records 
or medical notes). Only two have looked at all three sources of cancer data but 
analysis was limited to small subgroups within the study populations 311, 316.  
 
The initial goal of the work in this thesis therefore was the identification of women 
with breast cancer via the two data sources available in the trial and further 
investigation through contact with the treating clinician to confirm breast cancer 
diagnosis and collection of histopathological information. This also provided an 
opportunity for breast cancer diagnosis to: 1) explore the apparent sensitivity and 
positive predictive value (PPV) of the data sources (self-reported cancer data and 
cancer registry records versus confirmation from the treating clinician) 2) 
elucidate causes of errors and discrepancies 3) investigate the effect of time on 
cancer registration delays and 4) examine the association between self-reporting 
and age, education and family breast cancer history. 
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3.1 Materials and Methods  
3.1.1 Ethical Approval 
The thesis protocol was developed and submitted for ethical approval. During the 
process, the Joint UCL/UCLH Committees on the Ethics of Human Research 
meeting was attended and all questions that were raised were answered. No 
major amendments were required. The study was approved on 22nd February 
2007 (06/Q0505/102).  
 
3.1.2 Subjects in UKCTOCS   
The subjects were participants in UKCTOCS; the largest multi-centre randomised 
controlled trial for ovarian cancer that involves a cohort of 202,638 
postmenopausal women from the general population recruited from 2001-2005. 
Details of the study design and screening interventions are available from Menon 
et al 78 and the trial website (www.ukctocs.org.uk) (screening continues until the 
end of 2011 and the primary endpoint of mortality reduction through screening will 
then be documented until 2014). Briefly, the trial was set up at 13 NHS trusts in 
England, Wales and Northern Ireland and is co-ordinated by the Gynaecological 
Cancer Research Centre at UCL. Women aged 50-74 were randomly invited 
from age/sex registers of the 27 participating Primary Care Trusts. Women who 
accepted the invitation were provided with written and verbal information about 
the trial. In addition, they viewed an information video at the recruitment interview. 
Written consent was obtained which included access to their medical records and 
use of their data/samples in future studies. Each woman filled in a baseline 
questionnaire regarding medical and family history (Appendix I). This included 
questions on previous history of any cancer (ovarian, breast, bowel, and lung), 
HRT use, and data on parity, hysterectomy, sterilisation operation, treatment for 
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infertility, contraceptive pill use. All the data was entered onto a sophisticated 
custom-built Trial Management System which confirmed their eligibility to 
participate in the trial.  
 
3.1.3 Identification of breast cancer cases in UKCTOCS  
The subjects for the purposes of this study were women residing in England and 
Wales identified by the cancer registries or self-reporting (through UKCTOCS 
FUQ) to have developed breast cancer by 2nd of February 2009 following 
randomisation to UKCTOCS. For these women who were initially identified 
through cancer registry and self-reported information was not available the 
UKCTOCS FUQ was sent to obtain information on cancer reporting. Women with 
benign conditions or in situ carcinomas of the breast were not included in the 
study subjects. Women recruited from Northern Ireland were excluded as data 
from the Northern Ireland cancer registry became available only in 2008 after the 
project had already started.  
 
Cancer Registry (CR)  
All women participating in the trial are ‘’flagged’’ using the NHS number for 
cancers and deaths through the NHSCR. As a result the computerised entry of 
each subject at the registry is ‘’flagged’’ so that the UKCTOCS coordinating 
centre at UCL can be notified of any deaths or new diagnosis/recurrence of 
cancer. The information is sent using the ICD and Health Related Problems 
Codes, 9th and 10th revision (ICD-9 and -10 Codes – two different editions of the 
cancer registry coding) and includes cancer site, morphology and date of 
diagnosis. For the purposes of this project the CR data was examined to identify 
breast cancer using ICD codes as listed in Table 3-1. Regular downloads from 
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the relevant cancer registries are received every 6 months in the trial centre. For 
women with in situ carcinoma of breast the following ICD codes are used: DO5* 














UKCTOCS Follow-Up Questionnaire (FUQ) 
The UKCTOCS protocol included a follow-up questionnaire 3.5 years after 
randomisation (Appendix II). The 11-item FUQ included items on cancer 
diagnosis since randomisation and a specific question related to breast cancer, 
education, alcohol consumption, smoking status, skirt size, HRT use. Women 
who reported breast cancer were asked to provide the name of the treating 
physician (consultant), the hospital where they were treated and the year when 
surgery/biopsy was undertaken.  
Invasive malignant neoplasm of breast                                                                  
C50 (ICD-10) and C174 (ICD-9) 
Includes: connective tissue of breast 
Excludes: skin of breast ( C43.5 , C44.5 ) 
C50.0 and C174.0      -      Nipple and areola 
C50.1 and C174.1      -      Central portion of breast 
C50.2 and C174.2      -      Upper-inner quadrant of breast 
C50.3 and C174.3      -      Lower-inner quadrant of breast 
C50.4 and C174.4      -       Upper-outer quadrant of breast 
C50.5 and C174.5      -       Lower-outer quadrant of breast 
C50.6 and C174.6      -       Axillary tail of breast 
C50.8 and C174.8      -       Overlapping lesion of breast 
C50.9 and C174.9      -       Breast, unspecified 
Table 3-1: International classification of breast cancer, ICD -9, -10 codes for breast cancer 
(invasive malignant neoplasm of breast).  
 
ICD=International classification of diseases 
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3.1.4 Confirmation of breast cancer diagnosis through the collection of 
clinicopathological data in a form of questionnaire 
For all women who were identified to have developed breast cancer after 
randomisation, the diagnosis was confirmed by sending a Breast Cancer 
Questionnaire (BCQ) (Appendix III) specifically designed for the purposes of the 
study to the consultants treating the women. The 15-item BCQ included questions 
on site of tumour, grade, stage, histology, receptor status (ER, PR and 
HER2/neu), diagnosis date and treatment. The consultants had the option to 
provide a histopathology report if they were unwilling to complete the 
questionnaire. Some of the consultants provided both the questionnaire and the 
histopathology report. Individualised letters were sent to consultants where there 
was missing data on the returned BCQ (A-BCQ). Those who did not return the 
BCQ within four months were sent a second questionnaire (R-BCQ). A copy of 
the consent form was not routinely sent but was provided to consultants on 
request. In some cases, it was not possible to post a BCQ to the treating 
physician as the contact details were missing or incomplete or the only source of 
information was a death certificate with a breast cancer diagnosis. In such cases, 
the UKCTOCS research nurse at the regional centre where the woman was 
registered was asked to search the medical notes for a histopathology report.  
 
3.1.5 Socio-demographic characteristics of study subjects 
From the baseline recruitment questionnaire and FUQ socio-demographic 
characteristics were collected as mentioned above. The following factors were 
analysed to investigate whether self-reporting is dependent on them: (1) race 
(white/non white) (2) breast cancer family history (no and yes, including first and 
second degree relatives such as mother, sister, grandmother, granddaughter and 
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aunt) as recorded by the women in the baseline recruitment questionnaire (3) 
Education (high: university/university college, low: college: A – and O- level, 
qualifications such as clerical and commercial e.g. hairdressing, and none: either 
not reporting anything or reporting that they did not have any of the above 
education, as recorded in the FUQ.  
 
3.1.6 Database development and data storage 
As part of the work undertaken in the course of this thesis, an ACCESS database 
was built to enter the study data. It had two main tables - one holding general 
information on women identified to have breast cancer (Breast Cancer Table) 
and the second with all the data collected from the BCQs/histopathology reports 
(Clinical Data Table).  
 
3.1.7 Data analysis 
When data collection was complete, a flow diagram along the lines of CONSORT 
flow chart was prepared which included the outcome in each of the women 
initially identified to have breast cancer. All women for whom it was possible to 
obtain data from the three sources (CR, FUQ and BCQ/histopathology report) 
were included in the final study subjects in order to investigate the sensitivity and 
PPV of CR and self-reporting and to identify the eligible cases for the study 
described in chapter 4. Baseline characteristics and histopathological information 
were calculated using descriptive statistics. If both breast cancer and in situ 
carcinoma of breast was reported in the same woman, the breast cancer 
diagnosis was used for comparisons.  
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For the secondary objectives, analysis was undertaken comparing CR and FUQ 
with the gold standard - BCQ/histopathology report. Misclassifications were 
identified for CR and FUQ individually. The true positive (TP), false positive (FP), 
false negative (FN) and true negative (TN) were assessed and the apparent 
sensitivity and positive predictive value (PPV) of each data source was calculated 
as shown in Figure 3-1. Apparent sensitivity was used as it was not possible in 
this study plan to identify women with breast cancer who did not self-report breast 
cancer or had cancer registration (true negatives TN) since their physicians were 


















Apparent Sensitivity = TP / TP + FN 
Positive Predictive Value = TP / TP + FP 
 
 
Apparent Sensitivity = TP / TP + FN 
Positive Predictive Value = TP / TP + FP 
 
 
Figure 3-1: Description of performance characteristics used for data analysis. 
Calculation of apparent sensitivity and positive predictive value (PPV) for cancer 
registry (CR) and follow-up questionnaire (FUQ) data using the breast cancer 
questionnaire (BCQ)/ histopathology report as the gold standard.  
 
BCQ=breast cancer questionnaire; CR=cancer registry; FN=false negative; FP=false 









Gold Standard  
BCQ/histopathology report 
CR/FUQ 
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In most situations where large numbers of women with breast cancer need to be 
identified, it is not possible to obtain confirmation through the physician. To 
address this issue, combining CR and FUQ data was explored using the following 
rules - a. breast cancer case is correctly reported if both sources concurred for 
breast cancer diagnosis and b. breast cancer case is correctly reported if either 
source (CR or FUQ) reported breast cancer diagnosis. Fisher’s test was used to 
compare sensitivities and PPVs of CR and FUQ.  
 
The effect of time on cancer registration delays was assessed by looking at the 
completeness of relevant cancer registrations according to year of diagnosis and 
time from diagnosis to CR notification. The effect on apparent sensitivity and PPV 
of age at FUQ, race, education and family history was investigated. Apparent 
sensitivity was modelled using logistic regression with the above characteristics 
as the independent variables, and using only those cases where the 
BCQ/histopathology report confirmed breast cancer. All four variables were 
suitably categorised before modelling and from the regression, the respective 
odds ratio and significance levels were estimated, given the other variables' 
presence in the equation. PPV was also modelled in exactly the same way, using 
only those cases where women self-reported positively. Analysis was carried out 
using a computer assisted program-SPSS version 12.0.1, Chicago, IL. 
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3.2 Results  
3.2.1 Identification of breast cancer cases in UKCTOCS  
Of 189,046 women recruited into the trial from England and Wales between 2001 
and 2005, 2629 women were identified as having breast cancer post 
randomisation by 2nd February 2009 either by cancer registry or self-reporting. It 
is to be noted that this was heavily skewed towards initial identification through 
CR (total number of women identified through CR were 2475) as UKCTOCS 
FUQ had not been sent to most women when this study commenced (for 460 
women who reported breast cancer and there was also a cancer registration – 
these number of women only were used for the purposes of the analysis since 
our aim was to obtain information from all three sources for as many women 
within the UKCTOCS cohort). In addition to the three sources, in 10 women 
breast cancer was identified as a result of ovarian cancer screening in UKCTOCS 









The 2015 women identified through CR and the 10 cases identified during 
screening, were sent a UKCTOCS FUQ as shown in Figure 3-2. It was not 
possible to send FUQ to the 154 women for whom breast cancer was first 
identified through the death certificate. The response rate for FUQs sent during 
CR   
ONS 2015 
Death certificates 154 
CR and Self-Reporting    
FUQ 460* 
*10 women identified during screening 
Total No of women                                                                                2629 
Primary source of notification for breast cancer  
 
Primary source of notification for breast cancer  
CR=Cancer registry; FUQ=follow-up questionnaire; ONS=Office of national 
statistics 
 
Table 3-2: Primary source of breast cancer notification in UKCTOCS  
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this study was 84.9% (1719 of 2025). The overall FUQ response rate for 
UKCTOCS at the time of this study was 74.6% (115396/154590) for England and 
Wales. BCQ was sent to 1557 women (Figure 3-2) with a response rate at 63.1% 
and R-BCQs were sent to 574 with a response rate at 18.5%. The overall 
response rate was therefore 70% (1089 of 1557). To obtain missing data the A-
BCQs were sent to 192 consultants, with a response rate of 50%. BCQs could 
not be sent to the physicians for 622 women who did not provide contact details 
of their consultant. The UKCTOCS trial nurses were contacted in order to obtain 
the histopathology reports for these women. 104 reports were obtained giving a 
response rate at 16.7%.   
 
For 1089 women data from all three sources was obtained. 32 women had to be 
excluded from the analysis as complete histological information was missing in 
28 and 4 women were diagnosed after completion of the FUQ. Therefore, the 
final number of eligible women in this study was 1057. In 23 women where CR 
gave notification of both breast cancer and in situ carcinoma of breast, the breast 
cancer registration was used in the analysis. In an additional 95 women CR 
reported a cancer other than breast which was not taken into consideration for 
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 Figure 3-2: Diagram showing how the study subjects were identified. 
(Collection of three sources; cancer registry, self-report through UKCTOCS follow-up questionnaire and breast cancer questionnaire).  
 
Figure 3-2: Diagram showing how the study subjects were identified. 
(Collection of three sources; cancer registry, self-report through UKCTOCS follow-up questionnaire and breast cancer questionnaire).  
A-BCQ= additional breast cancer questionnaire; BCQ= breast cancer questionnaire; CR=cancer registry; FUQ= follow-up questionnaire; R-BCQ= reminder 
breast cancer questionnaire 
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3.2.2 Distribution and frequency of socio-demographic characteristics of 
the study subjects 
Women were reported with breast cancer between 2001 and 2008 with nearly 
30% being identified in 2005. The median age of the women at breast cancer 
diagnosis was 62 years (range 50-78 years). The median age of the women at 
self-reporting (FUQ) was 64 years (range 52-80 years). 97.9% of the women 
were white, 33.1% were university graduates, and 27.6% had at least one 1st / 2nd 




 Characteristics No of Women % 
Age at diagnosis     
50-64 665 62.9 
65-80 392 36.9 
Age at FUQ      
50-64 557 52.5 
65-80 500 47.1 
Race     
White 1039 97.9 
Non-White 14 1.3 
Unknown 4 0.4 
Education     
None  331 31.2 
Low 372 35.1 
High 354 33.1 
Year of breast cancer diagnosis   
2001 3 0.3 
2002 37 3.5 
2003 117 11 
2004 250 23.6 
2005 313 29.5 
2006 257 24.2 
2007 79 7.4 
2008 1 0.1 
Breast cancer family history      
Yes 293 27.6 
No 764 72 
Table 3-3: Distribution and frequency of sociodemographic characteristics of the study 
subjects. (N=1057)  
 
Table 3-3: Distribution and frequency of sociodemographic characteristics of the study 
subjects. (N=1057)  
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3.2.3 Performance characteristics for CR and self-reporting through the 
FUQ 
On comparing CR with the BCQ/histopathology report (gold standard), 30 (3.2%) 
FP cases were identified having a breast cancer registration code despite not 
having breast cancer according to their physician (BCQ/histopathology report). 29 
had DCIS on BCQ/histopathology report and 6 of these women had a breast 
registration code of carcinoma in situ in addition to their breast cancer registration 
code. The remaining one FP had atypical ductal hyperplasia. There were 47 FN 
cases; this included one woman who had a neck cancer registration 2 years and 
3 months prior to breast cancer diagnosis. Seven (0.7%) of the 47 FN had an in 
situ carcinoma of breast registration code instead of a breast cancer registration 
code and 2 of these had DCIS as well as breast cancer on BCQ/histopathology 
report. Forty (4.3%) of the 47 FN cases were not registered since the last CR 
follow-up (2nd February 2009) (Figure 3-3 A and Table 3-4) and all of them were 
diagnosed with an invasive breast cancer according to their physician 
(BCQ/histopathology record). Overall, on BCQ/histopathology report, 112 women 
had DCIS and 1 LCIS and 3 had benign conditions of which 74 of the DCIS and 2 
of the benign breast conditions had a corresponding in situ carcinoma registration 
code. The apparent sensitivity of CR was 95.0% (93.4 to 96.2) and PPV was 
96.8% (95.3 to 97.8) (Figure 3-3 C).  
 
On comparing the FUQ with BCQ/histopathology report (gold standard), there 
were 116 (12.3%) women (FP) who self-reported breast cancer despite having an 
in situ carcinoma or benign conditions (112 women had a diagnosis of DCIS, 1 
LCIS, and 3 benign breast conditions; atypical ductal hyperplasia, fibrocystic 
changes and non invasive papillary lesion) as confirmed by their physicians on 
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the BCQ/histopathology report. Moreover, 35 (3.3%) women (FN) did not self-
report breast cancer on the FUQ which was completed a median 4 months 
(range 53 days up to 4.7 years, Interquartile range: 1.4 years) after breast cancer 
diagnosis (Figure 3-3 B and Table 3-4). The apparent sensitivity of self-reporting 
on the FUQ was 96.3% (94.9 to 97.3) and PPV was 88.7% (86.5 to 90.5) (Figure 
3-3 C).  
 
Table 3-4 summarises the discrepancies/errors identified by comparing the two 
sources (CR and self-reporting through the FUQ) to BCQ/histopathology report 
(gold standard). Out of 941 (89.0%) women with confirmed breast cancer 
diagnosis on histopathology, both CR and self-reporting concurred in 859 
(69.5%) women diagnosed with breast cancer. 77 (8.2%) women would have 
been missed if CR alone was used and 151 (16.0%) women would have been 
missed if FUQ alone was used.  When the rule that both sources (CR and FUQ) 
need to concur for breast cancer diagnosis was applied, there were 30 (3.2%) 
women who would have been falsely identified as breast cancer cases. When the 
rule that breast cancer case is correctly reported if either source (CR or FUQ) 
reported breast cancer diagnosis was applied, there were 168 women (17.9%) 
who would have been misclassified or not reported/registered. The lowest rate of 
misclassifications (3.2%) was observed when breast cancer diagnosis was 
confirmed by both sources; CR and self-reporting through FUQ.   
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Performance Characteristics  
CR  FUQ 
p-value 
BCQ (Gold Standard) 
% Apparent Sensitivity (95% CI)  95.0 (93.4 to 96.2) 96.3 (94.9 to 97.3)  0.2140 







Figure 3-3: Performance characteristics for cancer registry and UKCTOCS follow-up 
questionnaire.  
Numbers of true positives (TP), false positives (FP), false negatives (FN) and true positives 
(TP) for breast cancer cases identified within UKCTOCS. Comparison with gold standard 
(BQC/histopathology) of (A) CR and (B) self-reporting through FUQ. C) Calculation of 
sensitivity and positive predictive value (PPV).  
  
 
Figure 3-3: Performance characteristics for cancer registry and UKCTOCS follow-up 
questionnaire.  
Numbers of true positives (TP), false positives (FP), false negatives (FN) and true positives 
(TP) for breast cancer cases identified within UKCTOCS. Comparison with gold standard 
(BQC/histopathology) of (A) CR and (B) self-reporting through FUQ. C) Calculation of 




BCQ=breast cancer questionnaire; CR=cancer registry; FUQ=follow-up questionnaire; 
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Cause of misclassification 
                                                     Data source and interpretation 
FUQ  CR               
 CR and FUQ                                                                                                                     
(both need to concur 
for BC diagnosis)            
 CR and FUQ
(BC diagnosis if either 
report BC diagnosis)            
DCIS or benign condition misclassified as BC 116 (12.3%) 30 (3.2%) 30 (3.2%) 86 (9.1%) 
BC misclassified as DCIS or benign condition  0 (0%) 7 (0.7%) 0 (0%) 7 (0.7%) 
BC not reported/registered 35 (3.7%) 40 (4.3%) 0 (0%) 75 (8.0%) 
Total No (%) of missed study subjects 
(either misclassified or not reported/registered)  
151 (16.0%) 77 (8.2%) 30 (3.2%) 168 (17.9%) 
Table 3-4: Identified misclassifications/errors by comparing all three different sources and their causes. The error is dependent on the data source and how it 
is interpreted. % of misclassifications were calculated based on the total number of women confirmed with breast cancer diagnosis (N=941).  
 
 
BC=breast cancer; CR=cancer registry; DCIS=ductal carcinoma in situ; FUQ=follow-up questionnaire 
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3.2.4 Distribution and frequency of the clinicopathological characteristics 
of the confirmed breast cancer cases within UKCTOCS 
Histopathological data and treatment information of the confirmed breast cancer 
cases (N=941) is provided in Table 3-5. Majority of the women had breast cancer 
on their left breast. 44.7% of the women were diagnosed with Grade II and 41.2% 
had a Stage 1 tumour. Most of the women (74%) did not have a lymph node 
metastasis and 1.8% of women had a metastasis in a distant organ. The highest 
percentage of women was diagnosed with IDC (70.1%). 73% of the women were 
diagnosed with ER positive breast cancer, 38% with PR positive and 11% with 
HER2 positive. Regarding treatment, 61.1% of the women had radiotherapy, 
50.4% of the women had WLE, and 48.9% had ANC. The most common 




Clinicopathological Data  
No of 
women % 
Primary tumour site  
Left 473 50.3 
Right 413 43.9 
Bilateral 31 3.3 
Missing  24 2.6 
Grade  
I 210 22.3 
II 421 44.7 
III 234 24.9 
Other 32 3.4 
Missing 44 4.7 
Stage 
1 388 41.2 
2 207 22.0 
3 30 3.2 
4 or 5 3 0.3 
Combination of 1/2/3 36 3.8 
Missing 279 29.6 
Lymph node involvement  
Yes 245 26.0 
No 696 74.0 
Metastasis to distant organ 
Yes 17 1.8 
No 924 98.2 
Table 3-5: Clinicopathological characteristics of the confirmed breast cancer cases within 
the UKCTOCS cohort. (N=941)  
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IDC 602 64.0 
IDC&DCIS 57 6.1 
ILC 110 11.7 
ITC 3 0.3 
IDC&ILC (Mixed) 32 3.4 
Other 137 14.6 
ER 
Positive 687 73.0 
Negative 143 15.2 
Not done 5 0.5 
Borderline 2 0.2 
Missing 106 11.3 
PR 
Positive 360 38.3 
Negative 196 20.8 
Not done 11 1.2 
Borderline 8 0.9 
Missing 366 38.9 
HER2 
Positive 104 11.1 
Negative 296 31.5 
Not done 47 5 
Missing 498 52.9 
Radiotherapy 
Yes 575 61.1 
No 366 38.9 
Surgery-Breast 
WLE 474 50.4 
Simple Mastectomy 297 31.6 
Radical Mastectomy 29 3.1 
Lumpectomy 41 4.4 
None 4 0.4 
Combination of the above 49 5.2 
Missing 47 5.0 
Surgery-Nodes 
SLN 185 19.7 
ANC 460 48.9 
ANS 145 15.4 
No dissection 16 1.7 
SLN and ANC 24 2.6 
SLN and ANS 35 3.7 
Missing 76 8.1 
Systemic Therapy 
Tamoxifen 318 33.8 
Aromatase Inhibitors 130 13.8 
Anthracyclines 37 3.9 
Non Anthracyclines 6 0.6 
Herceptin 6 0.6 
Combination of the above 231 30 
Missing 163 17.3 
ANC=axillary node clearance; DCIS=ductal carcinoma in situ; ER=oestrogen receptor; 
IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; ITC=invasive tubular carcinoma; 
PR=progesterone receptor; WLE=wide local excision 
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3.2.5 Cancer registration delays 
As in some instances, there are delays in CRs, it was important to investigate 
whether this might account for the lack of cancer registration in the 47 women 
who were confirmed on BCQ to have breast cancer but did not have a breast 
cancer registration on 2nd February 2009. The year of diagnosis of breast cancer 
in these 47 women were 2003 in 3 (2.6%), 2004 in 6 (2.4%), 2005 in 7 (2.2%), 
2006 in 8 (3.1%) and 2007 in 23 (29.1%) (Figure 3-4). Between 2001-2002, there 
were no women diagnosed with breast cancer not having breast cancer 
registration code. The highest percentage of women (29.1%) being missed on 
CR were those diagnosed within the year 2007.   
 
Figure 3-5 which examines time for diagnosis shows that the majority of women 
without a cancer registration were those diagnosed 1 to 2 years prior to the date 
of last CR follow-up (2nd February 2009). For all women with breast cancer in the 
study subjects who were identified from the two data sources (CR and FUQ) 
between 2001-2008 and compared to BCQ/histopathology report, 7, 18, 8, 6, 7 










Identification of breast cancer cases – cancer registry versus self-reporting 




























Figure 3-4: % of women without a breast cancer registration code based on the last cancer 
registry follow-up (2
nd
 February 2009) in relation to the number of years prior to diagnosis. 
 
Figure 3-5: % of women without a breast cancer registration code based on the last cancer 
registry follow-up (2
nd
 February 2009) in relation to the number of years prior to diagnosis. 
Figure 3-5: % of women without a breast cancer registration code per year based on the 
last cancer registry follow-up (2
nd
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3.2.6 Apparent sensitivity and PPV of self-reporting based on 
characteristics of the study subjects 
In order to investigate whether self-reporting is affected by factors such as age, 
race, education and breast cancer family history, we calculated the apparent 
sensitivity and PPV in relation to the above mentioned study characteristics 
(Table 3-6). Education was the most significant determinant of apparent 
sensitivity and borderline significant for PPV, with more educated women 
correctly reporting their breast cancer diagnosis in comparison to women with no 
education. Breast cancer family history was a significant determinant of apparent 
sensitivity but not for PPV, with women having a relative with breast cancer 
compared to respondents who did not have any relatives with breast cancer 
under-reporting their breast cancer diagnosis.  Age was a significant determinant 
for PPV but not for apparent sensitivity, with women <65 in comparison to women 
>65 over-reporting their breast cancer diagnosis. Both apparent sensitivity and 
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OR 95%CI p-value PPV OR 95%CI p-value 
Race         
White  96.38 1.00   87.55 1.00   
Non-White 100.00 (not measurable) 0.00 - 92.85 1.64 0.21 to 12.82 0.637 
Unknown         
Age at FUQ         
50-64 96.65 1.00   85.55 1.00   
65-80 96.22 0.72 0.33 to 1.53 0.394 90.02 1.57 1.10 to 2.32 0.022 
Family Breast Cancer History         
No 97.01 1.00   87.5 1.00   
Yes 94.98 0.35 0.16 to 0.74 0.006 88.1 0.87 0.56 to 1.35 0.534 
Education         
None 90.17 1.00   84.81 1.00   
Low 99.10 10.85 3.72 to 31.63 0.000 90.24 1.64 0.99 to 2.72 0.057 
High 99.34 24.42 
3.25 to 
183.20 
0.002 87.42 1.53 0.99 to 2.34 0.055 
Total 96.3    88.7    
Table 3-6: Characteristics of the study women as determinants of apparent sensitivity and positive predictive value. The respective odds ratio and 
significance levels were estimated.  
 
 
Table 3-6: Characteristics of the study women as determinants of apparent sensitivity and positive predictive value. The respective odds ratio and 
significance levels were estimated.  
 
CI=confidence interval; FUQ=follow-up questionnaire, OR=odds ratio; PPV=positive predictive value 
 
CI=confidence interval; FUQ=follow-up questionnaire, OR=odds ratio; PPV=positive predictive value 
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3.3 Discussion 
As a result of this study, 2629 women were identified on either CR or FUQ 
update on 2nd February 2009 to have breast cancer following recruitment to 
UKCTOCS. Using the BCQ, invasive breast cancer diagnosis was confirmed in 
941 women. These women formed the cohort used for the identification of eligible 
cases in Chapter 4.  
 
The distribution of Stage (TNM), histology and treatment was similar to that 
reported for women diagnosed with breast cancer in cohorts described in 
England, in 2007 and 2009 323, 324 and to be representative of any breast cancer 
cohort in Europe compared to a recent publication by ONCOPOOL – a European 
database that includes 16,944 breast cancer cases 325. In general, it has been 
shown that on average 80% of breast cancers are IDC and 5-15% are ILC, 70% 
are ER positive, 25% are HER2 positive and 5% of the breast cancers will 
metastasize in a distant organ and almost 30% will have a nodal status positive 
11, 14. Regarding treatment, majority of the study women had radiotherapy, WLE 
and hormonal therapy. This observation comes in agreement with previous 
cohorts studied in England 323, 324.   
 
Based on the data collected the apparent sensitivity and PPV of CR and FUQ 
were calculated making this study the first in England and Wales to examine the 
performance characteristics of both self-reporting and CR for breast cancer 
diagnosis in comparison to a report from the treating physician. A high 
sensitivity was observed for both FUQ and CR but  PPV was significantly lower 
for FUQ compared to CR. For breast cancer, using national CR data for 
England and Wales would result in an error rate of 8.2%. However half (4.3%) 
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of this is related to the two year time delay in registration so that allowing for 
this, error rates could be reduced to 3.9%. Self-reported data is not associated 
with time delays but is dependent on age, family history and education. 
Misclassifications would be in the range of 16% (3.7% of women may not report 
breast cancer and 12.3% may self-report breast cancer despite having only in 
situ carcinoma or benign condition). If confirmation from the physician is not 
available then the most accurate source of information would involve combining 
CR and self-reporting data using the rule that both must concur if breast cancer 
diagnosis is to be confirmed. This is associated with the lowest rate (3.2%) of 
misclassifications.  
 
One of the main advantages of this study is that the consultants responsible for 
treating the women were contacted to obtain data regarding breast cancer 
diagnosis which could be used as the gold standard. Physicians were contacted 
on multiple occasions to obtain as complete data as possible. Another is the size 
of the study. Except for eight women who refused consent to CR ‘flagging’, we 
were able to ‘flag’ all 189,038 women taking part in UKCTOCS from England and 
Wales. This was due to having accurate NHS numbers of all women prior to 
invitation to the trial as a result of electronic transfer from Primary Care age-sex 
registers 78. In addition, by the time, this study was undertaken, 154,590 of the 
189,038 women had been sent questionnaires to gather data on self-reporting.  
Moreover, as the trial invited over 1.2 million women, aged 50 to 74, randomly 
selected from England and Wales, it possible to extrapolate the findings to 
women from the general population belonging to this age group. The high 
response rates of FUQ (85%) and BCQ (70%) add to the strength of the study. 
The latter is especially notable as busy consultants who were not trial 
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collaborators completed the questionnaire. The response rate of second requests 
for information (18.5%) was low and suggests that there is little to be gained by 
contacting consultants who did not provide information initially. For future studies, 
it would be also useful coming in contact with the consultants through telephone 
and investigate whether such approach could improve the response rates.  
 
One limitation of the study was that the treating physicians of every woman in the 
cohort were not contacted to identify women with breast cancer due to the 
significant resource issues related to contacting making it only possible to 
determine apparent sensitivity and PPV of self-reporting (FUQ) and CR. Other 
parameters such as specificity and negative predictive value could not be 
accurately estimated. An earlier study suggested that individuals usually tend to 
under-report rather than over-report breast cancer history 319. In this study 
though, there were more women over-reporting their diagnosis (self-reporting in 
situ or benign condition as breast cancer).  
 
For future studies, it would be possible to also come in contact with General 
Practitioners (GPs) in order to investigate how accurate these data could be in 
relation to the other sources. Previous studies have shown conflicting results 
about the validity of information being obtained from GPs. A study comparing the 
Northern and Yorkshire CR and Information Service with GP data, obtained by 5 
practices, on cancer diagnosis, reported that GP responses were not able to 
identify the majority of patients diagnosed with a cancer. There was a poor level 
of completeness (29.4%) and correctness (65.6%) when compared with CR 326. 
However, this is in contrast to a comparison of GP Research Database to ONS in 
England 327.  
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The national CR data failed to identify 5% (47/941) of women with a confirmed 
breast cancer diagnosis. 40 (4.3%) women had no cancer registration and 7 
(0.7%) had in situ carcinoma of breast registration. The latter 7 women would 
have been classified as over-reporting in studies using only CR and FUQ. 
Confirmation of diagnosis in our study eliminated this bias. Brewster et al 
investigating the Scottish CR versus data from 5 independent clinical trial 
databases reported 0.3% of women being incorrectly classified as breast cancer 
when they had carcinoma in situ of the breast 320. When delays in national cancer 
registration were investigated, it was seen that 18.9% (7/40) of women who did 
not have a cancer registration were within 1-2 years of their diagnosis. Sensitivity 
of CR has improved over the last decades (from 72% in 1987 to 95% in this 
report) and it is likely that further improvements in the recording of cancer data by 
the regional cancer registries will result in complete data as that seen in the 
Scandinavian countries 328 (Table 3-7). In order to meet the growing demand for 
timely and accurate data about cancer registration, it has been suggested that 
CRs should be provided with additional support so that there would be an 
enhancement in their capability to rapidly ascertain cancer cases 329. 
 
The apparent sensitivity of 95.0% of CR in England and Wales reported in this 
study is comparable to the most recent report of 98.0% by Brewster et al 
investigating the Scottish CR. 320. The rates are also similar to Gathani and his 
colleagues who reported a sensitivity of 96% for breast cancer diagnosis when 
CR and the National Health Service Breast Screening Program were compared 
in the largest study so far in England including more than 5,000 breast cancer 
cases 330. In general though there are not many studies in England on validation 
of CR data and most of them include only a small number of breast cancer cases 
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(Table 3-7). When countries are compared on data regarding breast cancer 
diagnosis, Denmark has the highest rates (99%) of  complete CR records 328.   
 
In our study, the apparent sensitivity and PPV of self-reported breast cancer 
diagnosis through the UKCTOCS FUQ was 96.8%. This is comparable to the 
high sensitivity reported by Parikh-Patel et al, 2003 (96.0% for both invasive and 
in situ, 98.1% for invasive and 87.8% for in situ carcinoma) 312 and that by 
Abraham et al, 2009 who reported a sensitivity of 96.9% for breast cancer 
diagnosis and 90.2% for DCIS 311 (Table 3-7). It is not possible in our study to 
comment on DCIS as the primary aim was to identify breast cancer cases. What 
needs to be pointed though is that 12.3% of women over-reported their diagnosis 
with a PPV value for the FUQ at 88.2%.  
 
Previously, it has been shown that a variety of factors affect self-reporting 
including age, sex, education level and family history of the investigated disease 
311, 316. In this study, we examined race, age at completion of FUQ, education and 
family history of breast cancer. Even though analysis was performed for race, 
real conclusions cannot be withdrawn as the majority of the volunteer women in 
UKCTOCS and our study participants were White.  
 
Age at completion of FUQ did not make any difference in the apparent sensitivity 
of reporting but it did significantly correlate with PPV. Younger women were more 
likely to give a false positive history than the older respondents. Previous studies 
have shown age to have an effect on under-reporting but also over-reporting 312, 
315, 316, 318, 319 . It is to be noted that in majority of the cases the FUQ was sent 2 
years following diagnosis and the two ages (at diagnosis and at completion FUQ) 
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highly correlated and therefore only the latter was included in the regression 
analysis model. As reported by others 311, 315-317, women who are less educated 
have a greater possibility to falsely self-report cancer diagnosis. Our observation 
was similar with women who had been to college or university having less false 
positive when self-reporting breast cancer diagnosis in comparison to women 
who did not report anything on the FUQ regarding their education or reported no 
education. It has been suggested that women with a family history of the disease 
are better responders when they are asked about their breast cancer diagnosis 
311. In this study, though, the opposite observation was made as women having 
relatives with breast cancer history significantly under-reported their diagnosis. It 
is unclear as to what the explanation for this might be.  
 
Furthermore, it is worth mentioning that in general on self-reporting, the sensitivity 
for breast cancer is better in comparison to other cancers with breast cancer 
having highest percentage agreement, followed by bowel and then lung cancer 
319. In 1993, a US study showed that best rates of confirmation were for breast, 
bladder, prostate and uterine cancer but that the rates decreased in the closely 
related sites, such as colon and rectum 314 indicating that use of self-reporting for 
more diagnostically complex diseases may require  additional confirmation. 
 
In conclusion, the data in this study informs researchers who plan 
epidemiological studies or trials to rely on CR as in general; the percentage of 
misclassification is low especially if time delays are taken into consideration. 
While self-reporting using postal questionnaires is another good source of cancer 
data, several factors such as education, age and family history need to be taken 
into account. Confirmation of the data by checking medical notes would be ideal 
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as misclassifications by both sources may occur. In the absence of the latter, the 
most accurate source of information involves combining CR and self-reporting 
data using the rule that both must concur if breast cancer is to be confirmed. This 
would result in around 3% misclassifications but this need to be balanced against 
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Self-Report vs CR 
Dominguez 
319
 2007 1980-1981 United States  2624 92.1 
Manjer 
318
 2004 1991-1996 Sweden  170 97 
Parikh-Patel 
312
 2003 1995-1996 United States  2596 98.1 
Desai 
317
 2001 1981-1982 United States  64 79.2 
Bergmann 
316
 1998 1992-1993 United States  995 91 
Schrijvers 
315
 1994 1991 United States  85 84 





1983 United States  271 90 
1985 United States  148 45 
CR vs Medical Record 
Brewster 
320
 2008 1978-2000 Scotland  2621 98.2 
Stotter 
331
 2000 1997 England  599 89 
Villard-Mackintosh 
332
 1988 1968-1985 England  150 92 
Hunt and Coleman 
333
 1987 1985 England  50 72 
Jensen 
328
 2002 1983-1989 Denmark  2062 99 




 2005 1996-2000 England  5684 96 




 2009 1996-2006 United States  24631 96.9 
CR=cancer registry  
 
 
CR=cancer registry  
 
Table 3-7: Summary of previous studies indicating the percentage agreement/sensitivity of different sources for breast cancer cases 
identification.  
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4 HORMONAL EFFECT IN BREAST CANCER  
 
4.1 Introduction 
Sex steroid hormones are known to be crucially involved in breast 
carcinogenesis and are known to increase breast cancer risk. As discussed in 
the literature review it has become apparent that factors which are surrogates 
for long term sex steroid exposure such as reproductive factors (age at 
menarche, first birth, parity and menopause) and breast size are associated with 
breast cancer risk 334 as well as several anthropometric factors such as height, 
weight, weight changes, BMI, fat deposition, all of which contribute to changes 
in sex steroid levels 185. This has led to the hypothesis that circulating sex steroid 
levels can predict breast cancer risk. A number of studies have been carried out 
in order to identify the association of serum sex steroid hormones with breast 
cancer 198-202, 204-208, 211, 227, 228. The largest meta-analysis combining nine 
prospective studies demonstrated that postmenopausal women with serum sex 
steroid hormone levels in the highest quintiles have a two-fold increased risk of 
breast cancer 197. In women who develop the disease, hormonal therapy plays an 
increasingly significant role in treatment. It is therefore imperative that we 
increase our understanding of how hormones interact to increase a woman’s 
breast cancer risk.  
 
Sex steroids exert their effects through binding to sex steroid hormone receptors. 
Upon binding, the receptor travels from the cytoplasm where is located in its 
inactive form to the nucleus where it gets dimerized and binds to HRE. This leads 
to activation of transcription processes and synthesis of specific messenger RNA 
and protein production. All of the published studies on associations of sex steroid 
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hormones with breast cancer risk have used conventional immunoassays to 
measure hormonal levels. However, in the past few years, bioactivity assays for 
steroid hormones have been described, enabling quantification of total sex steroid 
hormonal action. As a result, our group was able to provide the first evidence that 
ER-α and ER-β serum bioactivity (SB) are independently associated with breast 
cancer using samples collected at diagnosis. Women with the highest quintile of 
ER-α had a 2.70 fold increase in oestrogen receptor positive breast cancer risk 
and women with ER-β SB had a 2.31 fold increase in oestrogen receptor positive 
breast cancer risk 162. Therefore, we have hypothesised that sex steroid receptor 
SB could predict breast cancer risk before diagnosis and provide further 
information on their effect in breast carcinogenesis.  
 
To better understand the long term effect of sex steroids and bioactivity of their 
receptors on breast cancer risk, it is crucial to examine levels many years prior to 
diagnosis. In the meta-analysis high oestrogen and androgen levels more than 
two years before breast cancer diagnosis were found to be associated with 
higher breast cancer risk in comparison to levels within two years of diagnosis. 
This suggests that the positive associations between sex steroid hormone levels 
and breast cancer prior to diagnosis are more likely to be due to the effect of 
hormones on the development of breast cancer rather than an effect of the pre-
clinical tumour on hormone metabolism 197. Additionally, even though the 
association of sex steroid hormones with breast cancer risk is well studied and 
their association with gonadotrophins in menopausal transition has been well 
described, interaction of sex steroids and gonadotrophins in breast cancer is not 
known. Moreover, there are not any studies investigating whether combination of 
hormones could improve risk prediction further investigating their possible 
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synergistic effects in breast carcinogenesis. The only study that has reported 
data on combinational effect of endogenous oestrogens and androgens on breast 
cancer risk was by Adly et al, showing a higher increased risk for women having 
oestrone sulphate and androstenediol in top quintiles compared to each single 
hormone 201. It needs to be pointed though that the samples used for the 
purposes of this study were taken at the point of diagnosis and not years before 
diagnosis as the samples used in this study. Therefore, we hypothesised that by 
investigating different combinations of sex steroid hormones, gonadotrophins and 
SB of sex steroid receptors could prove to have a better breast cancer risk 
prediction power in comparison to each individual measurement and provide 
information on their synergistic effect in breast carcinogenesis.  
 
Using the UKCTOCS biobank we were able to explore all the above issues to 
better understand breast carcinogenesis. Women recruited to the trial between 
2001-2005 provided blood samples for secondary studies and continue to be 
followed up by cancer registration and self-reporting 78, 335. A nested case control 
study was undertaken using serum samples donated between 6 months and 5 
years before diagnosis by women who developed breast cancer after joining the 
trial and healthy women who had not developed the disease examining: 1) Five 
sex steroid hormones (oestradiol, oestrone, androstenedione, testosterone, 
DHEAS), free oestradiol and free testosterone (calculated by the mass action 
law), two gonadotrophins (LH and FSH) and SHBG in association with ER-
positive breast cancer risk. Since all earlier studies have only explored levels of 
endogenous hormones with regard to breast cancer risk and with the relatively 
new discovery of very sensitive bioactivity assays for steroid hormones being 
able to detect very low hormone levels, we investigated 2) SB of ER-α and -β and 
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AR in breast cancer and examined whether they are associated and predict the 
disease. 3). Since previous studies have looked at the effect of each individual 
hormone in breast cancer risk, joint associations of sex steroids, gonadotrophins 
and steroid receptor bioactivity were examined hypothesising that they may have 
better risk prediction and further examined their synergistic effect in breast 
cancer. Moreover, 4) association of hormones and serum bioactivity of the 
receptors in relation to time of breast cancer diagnosis was also investigated. 
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4.2 Methods and Materials 
4.2.1 Eligible cases and samples 
Breast Cancer Cases were women identified in chapter 3, who fulfilled the 
eligibility criteria stated below: 
(1)  ER-positive invasive breast cancer diagnosis 
(2)  not having HRT treatment at recruitment and  
(3) having a serum sample given at least 6 months up to 5 years prior to 
diagnosis following randomisation into the trial 
 
Controls were women who had: 
(1)  no history of breast cancer and any other cancer 
(2)  had a serum sample collected on the same day and in the same clinic as the 
cases 
Two controls were selected for each case and were age matched to breast 
cancer cases. 
 
Blood samples were collected in Greiner gel tubes (Cat no: 455071) at the 
centres and couriered overnight to the central UKCTOCS laboratory. The 
samples were centrifuged at 2000 g for 10 minutes and the serum was removed 
from the cells within 56 hours of sample collection. A novel semi automated 
system aliquoted serum in 500 micro liter straws which were then heat sealed bar 
coded and stored in special containers in liquid nitrogen tanks. Two straws were 
retrieved, one for the measurement of hormonal levels and one for the bioactivity 
assays. The samples were only thawed before use. 
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4.2.2 Collection of epidemiological factors 
As mentioned in methods and materials in chapter 3, there were two large-scale 
questionnaire surveys covering demographics, health behaviour, medical history 
and epidemiological factors were conducted during UKCTOCS trial. One was 
based at the time of recruitment and one after 3.5 years of participation into the 
trial.  From the questionnaires the following (potential) breast cancer risk factors 
were obtained: ethnicity, height input, weight input, height, BMI calculated as 
weight (in kilograms) divided by height (in metres) squared, age at first period, 
age at menopause, skirt size difference (increase/decrease), ovarian cancer 
family history, breast cancer family history, HRT use, hysterectomy, pill use, 
pregnancies less than 6 months, pregnancies more than 6 months, sterilisation, 
infertility.  
 
4.2.3 Sex steroid hormonal levels using immunoassay systems  
Enzyme-Linked ImmunoSorbent Assay (ELISA) is the most popular 
immunological assay because of its versatility, sensitivity, specificity and ease of 
automation.  It is a biochemical technique used to detect the presence of an 
antibody or an antigen in a sample. In simple terms, in ELISA an unknown 
amount of antigen is affixed to a surface, and then a specific antibody is washed 
over the surface so that it can bind to the antigen. This antibody is linked to an 
enzyme, and in the final step a substance is added that the enzyme can convert 
to some detectable signal. For the purposes of this study two different types of 
ELISA assays were used; the sandwich and competitive assay. A standard curve 
with known concentrations of the antigen of interest is plotted in order to 
determine the unknown antigen in experimental samples.  
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Kits for SHBG, LH and FSH (electrochemiluminescence sandwich 
immunoassays), oestradiol, testosterone, DHEAS and progesterone 
(electrochemiluminescence competitive immunoassays) were obtained from 
Roche Diagnostics and the samples assayed on an Elecsys 2010 analyzer 
(Roche Diagnostics GmbH, Mannheim, Germany). Androstenedione was 
analysed by competitive chemiluminescent immunoassay on DPC IMMULITE 
2500 analyzer (SIEMENS Medical Solutions Diagnostics, Germany). For 
oestrone, ELISA kits (solid phase competitive enzyme immunoassay on microtitre 
plates) were obtained from DRG (DRG, Instruments GmbH, Germany). 
Information regarding the kits and how the assays were performed in detail are 
provided in Appendix IV, specifications of the ELISA kits are provided in Table 4-
1. The samples were analysed blind in randomly mixed batches of cases and 
controls using a single lot number of reagent and calibrator. All measurements 
were done by me.  
 
Briefly the principles of the different assays used were: Competitive assay - 
Elecsys 2010 analyser, samples were incubated with biotinylated monoclonal 
specific antibody and a monoclonal specific antibody labelled with ruthenium. The 
binding sites of the labelled antibody became occupied partially by the sample 
analyte (depending on its concentration) and partly by the ruthenium-labelled 
hapten forming the respective immunocomplexes. Sandwich assay - the samples 
were incubated with biotinylated monoclonal specific antibody and a monoclonal 
specific antibody labelled with ruthenium forming a sandwich complex. After the 
addition of the streptavidin coated microparticles the complex became bound to 
the solid phase. The reaction mixture was aspirated into the measuring cell 
where the microparticles were magnetically captured into the surface of the 
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electrode. For DPC IMMULITE 2500 analyser, the antigen in the sample 
competed with a fixed amount of alkaline phosphatase-conjugated label to bind 







For all assays used the unbound substances were then removed with Procell 
(Elecsys 2010 analyser) or L2KPM (DPC IMMULITE 2500 analyser). Application 
of a voltage to the electrode then induced chemiluminescent emission which was 
measured by photomultiplier. The results were determined via a calibration curve 
which was instrument specifically generated by 2-point calibration and a master 
curve that was provided via the reagent barcode. The calibration procedure was 
performed before running the samples in the analysers. For the method the 
stored master curve adjusted by running the low and high adjusters was carried 
each in replicates.  
 
Competitive assay was used to measure oestrone levels. The antigen of the 
sample competed with oestrone horseradish peroxidase conjugate for binding to 







Oestradiol 35 18.4-15,781 pmol/L 1.6-5.7 2.3-6.2 
Oestrone 25 15-2000pg/ml 4.5-9.3 7.4-12.9 
Androstenedione 25 1-35 nmol/L 3.5-11.3 4.4-13.2 
Testosterone 50 0.0695-52 nmol/L 0.9-4.6 1.6-7.4 
DHEAS 15 0.003-27 ulmol/L 0.8-1.8 1.9-5.2 
SHBG 10 0.350-200 nmol/L 2.1-2.7 2.6-5.6 
Progesterone 30 0.095-191 nmol/L 1.5-2.7 3.7-5.4 
LH 20 0.100-200 mIU/mL 1.7-2.8 2.4-4.7 
FSH 40 0.100-200 mIU/mL 1.4-2.0 2.9-5.1 
Table 4-1: Specifications of ELISA kits.  
DHEAS=dehydroepiandrosterone sulphate; ELISA=enzyme-linked immunosorbent assay; 
FSH=follicular stimulating hormone; LH=luteinising hormone; SHBG=sex hormone-binding 
globulin 
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the coated antibody. The amount of bound peroxidase conjugate was reverse 
proportional to the concentration of the oestrone in the sample. Therefore, after 
adding the substrate solution the intensity of the colour developed was reverse 
proportional to the concentration of oestrone in the sample. The samples, 
controls and standards (for standard curve) were run in duplicates. In order to 
construct the standard curve the mean absorbance obtained from each standard 
(on the vertical (Y)) was plotted against its concentration (concentrations 0-15-50-
200-800-2000 pg/ml) (on the horizontal (X)). The best fitted curve was obtained 
by using a 4 parameter logistics curve fit (Excelstat). The concentrations of the 
samples were read directly from this standard curve.  
 
Quality controls were run on each day for the samples that were done in the 
analysers and they were included in each plate for the samples that were done 
manually. Details regarding the quality controls are provided in Appendix V. For 
the samples run in Elecsys 2010 analyser, PreciControl Universal PC1 and PC2 
were used, for the samples run in DPC IMMULITE 2500 analyser, CO6 was used 
and for the samples run manually to measure oestrone levels controls were 
provided within the kit. 
 
4.2.4 Calculation of free oestradiol and testosterone 
For the calculation of free oestradiol (fE2) and free testorenone (fT) the equation 
based on mass of action law by Vermeulen 336 was used. The equation relies on 
the assumption that the concentration of fE2 and fT in blood is determined mainly 
by the interaction between SHBG and albumin, and that other hormones present 
in the blood do not influence this equilibrium much.  
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Equations:     
     
     
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where [E2] and [T] are total oestradiol and testosterone concentrations; KSE2 and 
KST are the affinity constants for SHBG for E2 and T; N1= KaE2Ca + 1 and N2= 
KaTCa + 1, where Ca is the albumin concentration and KaE2 and KaT are the 
affinity constants of albumin for E2 and T.  
 
KSE2 = 3.14 X 10
8 liters/mol   KST = 1 X 10
9 liters/mol 
KaE2 = 4.21 X 10
4 liters/mol   KaT =  4.06 X 10
4 liters/mol 
Ca = 6.5 X 10
-4 mol/litre 
 
4.2.5 Sex steroid hormonal receptor bioactivity assay 
The test used to measure sex steroidal hormonal receptor bioactivity is a yeast 
based reporter gene assay which not only determines whether a chemical binds 
to the receptor, but also if oestrogen or androgen-dependent gene expression is 
stimulated. The recombinant yeast was provided from our collaborators from 
University of Bonn, Germany where all the experimental work was carried out 
after being trained. The group run by Professor Hella Lichtenberg-Fraté has 
published results based on the assay 337, 338. The assay utilises the yeast 
Saccharomyces cerevisiae, an eukaryotic organism, as the biological component 
since it has been proven to be a good model for studying more complex 
eukaryotic processes, such as steroid receptor function. Yeast is an attractive 
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and widely used model because the cellular structure is that of eukaryotes, like 
mammals. It exhibits a eukaryotic architecture with internal organelles and similar 
chromosome structure and DNA repair and metabolic processes. Therefore, by 
using such an assay it allows the combination of a eukaryotic test system with the 
advantages connected to prokaryotic systems like the short incubation time, 
reproducible growth rates, simple optical read outs and the ability to use well 
defined culture conditions.  
 
The test was developed by preparing different strains of genetically modified 
yeasts integrating the DNA sequence for the human ER-α or ER-β or AR-b into 
the main chromosome of Saccharomyces cerevisiae. The recombinant yeast 
cells contain HRE where the ligand binds and a plasmid that possesses the 
Aquorea victoria green fluorescence protein (GFP) as reporter gene. This method 
is applicable to complex samples (blood serum) which are soluble under the 
conditions of the test. The endpoint is the determination of fluorescence 
development. Upon exposure of the genetically modified Saccharomyces 
cerevisiae cells the production of GFP which, upon excitation by 485 nm emits 
green fluorescence whose emission at 535 nm can be detected using 
photodetectors. Results are obtained in arbitrary fluorescence units versus 
increasing 17β-E2 concentrations for the ER-α and ER-β bioactivity assay and 
DHT for the AR-b bioactivity assay (calibration curve).  
 
Briefly, the genetically modified yeast cells are incubated in a defined test 
medium with the reference substance 17β-E2 or DHT and different test samples. 
At the end of the incubation period the developed green fluorescence is 
determined and corrected for cell density, optical density (OD) of the cell 
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suspension and blanks. The measurements were performed in microplate reader 
(TECAN). The cell growth was determined by measuring the light absorption at 
600 nm and GFP-fluorescence was determined by measuring GFP at 535 nm, 
specific OD and fluorescence at t = 0 and t = 16,5 h for ER-α and ER- β and t = 
24h for AR-b was measured in each of the 96-wells. Tests were considered as 
valid if the turbidity of the negative control culture increased five times during the 
incubation period. The control culture should expose no fluorescence 
development. The bioactivity was determined by comparison of the fluorescence 
development in test cultures versus the 17β-E2 or DHT calibration curve. The 
dose-response curves of the reference values were fitted using the Hill equation 
fit and the R function (The R Foundation for Statistical Computing, http://www.r-
project.org/) 337, 338. Analysis was performed blind and cases and controls were 
randomly mixed. Tests were carried out with two replicates at a time on two 
different days (thus four readings in total. No temporal effects were detected. By 
the nature of the assay, minor daily performance differences may occur, but were 
accounted by including a daily reference curve, comprising 10 different 
concentrations. Order effects were not detected since, as mentioned above, all 
samples were randomised before numerical coding. 
 
Media preparation 
Amino Acid-Drop-out-Mix: L-Arginine (100 mg), L-Methionine (100 mg), L-
Tyrosine (100 mg), L-Lysine (150 mg), L-Valine (300 mg), L-Threonine (500 mg), 
L-Serine (500 mg), L-Phenylalanine (250 mg), L-Asparagin (100 mg), L-Glutamic 
acid (100 mg), Adenine (250 mg), L-Histidine (100 mg). All the components were 
added in a glass container and mixed thoroughly.  
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5x-concentrated liquid nutrient medium-Yeast Nitrogen Base (YNB) medium with 
0.5% glucose, pH 6.4: Components for 1000 ml medium were mixed. Yeast 
Nitrogen Base (YNB) (DIFCO) w/o amino acids and w/o ammonium sulfate (8.5 
g), Amino Acid Drop-Out-Mix (2.6 g), Ammonium-nitrate (25 g), Citrate-buffer (50 
mM final concentration, 52.5 g). Sterilised water was added to 850 ml. The pH 
was adjusted to 6.4 by adding 25-30 g sodium hydroxide pellets and 
subsequently 5 M sodium hydroxide-solution. Sterilised water was added to 
937.5 ml and the medium was autoclaved (20 minutes at 121°C). The addition of 
autoclaved stock solution of 62.5 ml 40% glucose (in sterilised water) was 
conducted under a clean-bench.  
 
Charcoal stripped serum preparation 
The protocol was taken from Miller et al, 1999 339. A mixture of 0.5% charcoal and 
0.05% dextran in 50 mM HEPES (buffering agent), ph 8.0 was smoothly agitated 
for 30 minutes at 37 °C. The slurry was centrifuged at 3000 rpm, 4 °C, for 30 
minutes and the supernatant was removed and replaced with foetal bovine serum 
that had been heat-inactivated for 30 minutes at 56 °C. The mixture was then 
smoothly agitated for 3 h at 37 °C and finally centrifuged at 3000 rpm, 4 °C for 60 
minutes. After centrifugation the serum was carefully pipetted away from the 
formed charcoal pellet and filter sterilised. The serum was stored at -20 °C until 
used. 
 
Preparation of 17β-E2 and DHT stock solutions 
Water soluble 17β-E2 (Sigma E4389) was dissolved in stripped serum to a final 
concentration of 1mg/ml. Solution was stored at -20 °C. From this solution a 
dilution series was prepared with 1:50 steps. From the dilution series 17β-E2 
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stock solutions were prepared by adding stripped serum to give final 
concentrations in the test of [17βE2] = 0, 1, 3, 10, 30, 100, 300, 1000, 3000, 
10000 pg/ml. The 5 x 17β-E2 stock solutions were directly in a volume of 20µl 
(according 20 %) to the test culture of overall 100µl. Dilution series and 5x17β-E2 
stock solutions were stored at 4 °C for 4 weeks. The same procedure was 
followed for DHT (Sigma A8380).  
 
Yeast starter and pre-culture cultivation 
Vials containing the recombinant yeast strains with sterile glycerol were obtained 
from our collaborators which were kept frozen at -80 °C. From all yeast strains, 
20 µl of the glycerol stock were spread out on YNB nutrient medium agar plates 
(prepared by our collaborators). The lid of the agar plate was sealed with parafilm 
and incubated at 30 ° C until yeast colonies were observed.  
 
For the liquid pre-cultures, cell material from one selected single colony was 
taken with a sterile toothpick and inoculated in 20 ml YNB-medium in a sterile 
100ml flask with cellulose stopper or metal tight-lock cap. The flask was 
incubated on a rotary shaker at 30 °C and 220 rpm until the cells entered the 
stationary phase (overnight, 16 h). The cell density was above 4.5 x 10E7 cell/ml 
and the visual inspection (microscope, 600x) of the cells resulted in a low 
percentage (<20%) of budding cells. Such a yeast culture was stored at 4 °C and 
was used as pre-culture for subsequent tests for up to 5 days maximum.   
 
Conduction of the assay 
The prepared liquid pre-culture was centrifuged (3000 rpm for 3 min) and the 
supernatant was removed and the cells were resuspended in 1 ml sterile water 
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and centrifuged again. The supernatant was removed again and the cells were 
resuspended in 1 ml 5x YNB-medium. The cell density was determined by means 
of OD 600 measured in a photometer.  The final cell density was adjusted with 
the 5 x YNB-medium of 4 x 10E7 cells/ml. The serum samples were 
homogenised by vigorous shaking immediate before usage. 80 µl of the cell 
suspension were pipetted in each (culture) well. 20 µl of testing serum or internal 
standard curve serum to the (culture) wells were added. Negative controls were 
added in the plate consisting of 80 µl cell suspension of the cells and 20 µl of 
water. The OD and fluorescence at time zero (t = 0) was measured in the reader 
and the plate was sealed with lid and with parafilm. Finally, the plate was placed 
on a rotary shaker with 950 rpm for 16, 5 hours (ER-α and ER-β) or 20 hours 
(AR-b). Incubation temperature was 30 °C. Measurement of the OD at 600 nm 
and of the GFP-specific fluorescence emission at 535 nm of all wells was 
conducted after the incubation period. 
 
Data evaluation 
After 16.5 hours or 20 hours incubation depending on the assay, the obtained 
end point fluorescence (FL) values (corrected for blanks) were divided by growth 
determined as OD (corrected for blanks) for each replica well to normalise 
fluorescence for cell number (FL/OD).  
 
To increase the reproducibility of results, the FL/OD values obtained for a test 
compound at a given concentration were expressed as fractional values of the 
maximal response of a saturating concentration of the reference compound E2 or 
DHT (internal standard curve).  
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The top and bottom values were obtained by Hill equation fit using the R function:
  
    hillslopex)-(LEC50101
bottom-top




with y(x) = FL/OD at the actual compound concentration, x = the decadical 
logarithm of compound concentration, LEC50 = decadical logarithm of EC50, top 
= fitted maximal FL/OD at saturating concentrations, bottom = fitted maximal 
FL/OD of negative control and hill_slope as the hill steepness parameter to the 
FL/OD values for each E2 or DHT concentration.  
 
4.2.6 Statistics 
Mean and median levels of sex steroid hormones, ER-α and ER-β and AR SB 
were calculated for all breast cancer samples and for controls. Differences in the 
medians between groups were tested for statistical significance using the 
Kruskal–Wallis test. Correlations between sex steroid hormones and, ER-α and 
ER-β and AR SB among cases and controls were assessed by the Spearman's 
rank correlation coefficient. Statistical analysis was carried out using a computer 
assisted program-SPSS version 12.0.1, Chicago, IL. The associations between 
hormones/SB of sex steroid receptors and risk of breast cancer was determined 
by logistic regression to estimate OR and compute 95% confidence intervals (CI). 
Subjects were classified according to quintiles of the respective marker among 
controls. Cut-off points of the top quintiles for the different hormones and SBs are 
provided in table 4-2. Hormones and sex steroid receptor SB levels were entered 
and controlled in regression models to estimate their independent and combined 
associations with breast cancer risk. All regression analyses were adjusted for 
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age. Therefore, we present ORs not adjusted (only age adjustment) and adjusted 


















Further analysis was carried out to investigate the effect of paired hormones/SB 
on breast cancer risk prediction. Subjects were identified with different pairs of 
hormone/SB levels in the highest quintile and compared to those that did not 
have at least one variable in the highest quintile (the predictor variable 
construction is presented in Formula (1). For some of the investigated pairs not 
enough points were found in the highest quintiles for both hormones/SB. 
Therefore, for these pairs instead of the OR and CIs values the description ‘‘not 
Hormone Cut-off point 
Oestradiol (pg/ml) 22.66 
Free Oestradiol (pmol/l) 1.191 
Oestrone (pg/ml) 115.532 
Androstenedione (nmol/l) 4.614 
Testosterone (nmol/l) 0.382 
Free Testosterone (ng/dl) 0.164 
DHEAS (ug/dl) 162.04 
SHBG (nmol/l) 80.134 
Progesterone (ng/ml) 0.387 
LH (mIU/ml) 42.978 
FSH (mIU/ml) 98.32 
ER-α (pg/ml) 104.359 
ER-β (pg/ml) 98.955 
AR (ng/ml) 2.867 
Table 4-2: Cut-off points of the top quintiles for sex steroids, sex hormone-binding 
globulin, gonadotrophins and serum bioactivity of sex steroid hormone receptors. 
AR=androgen receptor; DHEAS=dehydroepiandrosterone sulphate; ER=oestrogen receptor; 
FSH=follicular stimulating hormone; LH=luteinising hormone; SHBG=sex hormone-binding 
globulin 
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enough points’’ is given. All regression analyses were adjusted for age. Further 
investigation was undertaken by adjusting for each individual hormone/SB. 
Therefore, the data is presented as ORs unadjusted (only age adjustment) and 
adjusted for other serum hormones/SB. To validate the results on the best pairs 
identified through the above described analysis 1000 experiments were run, 
where 10% of the data was removed from cases and 10% of controls. The 
quintiles were re-calculated and ORs were re-evaluated. Mean, median and 
variance were calculated to examine the distribution of the data.  
 
Next the synergistic effect of the different pairs (hormones/SB) was investigated. 
The ratio of observed versus expected was computed quantifying the hidden 
synergistic effect of hormones/SB pairs. Initially, the expected value of the OR for 
the different pairs was calculated based on the value of the single observed OR 
and the corresponding regression coefficients. This was computed using the 
algorithm to construct the predictor variable (Formula 1) and under the 
assumption that hormones/SB are independent. The expression that defined the 
expected OR as a function of the single OR is demonstrated in Equation 1. To 
compute the CIs of the expected ORs and the CIs of ratio of observed versus 
expected ORs, Monte Carlo stimulation was used. For analysis the R Foundation 
for Statistical Computing program was used. Description of the models created 
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Encoding the predictor variable: 
Pair of hormones/SB 
For pair of hormones the predictor variable Xij, i=1 N the predictor variable Xi is 
constructed as follows:  
 
Xij 
 1, if H i and H j are in 5th Quantile





  Formula (1) 
Quintile values are chosen on the base of the control set only. 
 
Calculation of the OR for the pair hormones/SB: 
Correspondingly, for the predictor variable Xij describing the joint action of two 
















 0  1Xi  2X j  3A.as OR  exp(1) If adjustment was carried out 
by another hormone/SB predictor Xj and age predictor variable A.  
 
Calculation of the expected OR: 
Suppose that for the two hormones the following two probability tables.  
 
To calculate the expected OR when the two ORs when the single hormones/SB 
OR1 and OR2 and the corresponding interceptors R1 and R2, defined as Ri=exp 
(βi0) are known and since the coefficients of the logistic regression are known, 
the probability to be in Case category for any value of the predictor variable can 
be found.  
Quintile 
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Where N’=Ncases/N, the table probabilities can be found  
p01
1  



















Using these table probabilities the probability of the predictor variable to be equal 








( N  N R1  R1)OR1
OR1 1
 







( N  N R1  R1)
R1(1 N OR1  N OR1)
. 









( N  N R2  R2 )OR2
OR2 1
 







( N  N R2  R2 )
R2 (1 N OR2  N OR2 )
.  
 
Using the same methods of the introduction of the predictor variable for the 
hormone/SB pairs, the probabilities of the joint predictor variable was estimated.  
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pc3  pc1pc2 pk3  pk1pk2. 













, N  p11
3  p01









3 .  








 and to obtainOR3 OR1OR2
T
B
,  where; 







2R1R2  N R1  2OR1OR2R1 N R2  N R2  2OR2R1 N R2 
2OR1R1 N R2 OR2R1R2 OR1OR2R1R2 OR1R1R2 )
   Equation (1) 
And  









To summarise, joint OR for two hormones/SB as a function of their single OR 
(OR1,OR2 ) and their interceptor coefficients ( R1,R2 ) and proportion of cases 
N  Ncases / N was found. For analysis the R Foundation for Statistical Computing 
program was used. 
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4.3 Results 
4.3.1 Clinicopathological characteristics of the eligible cases  
Clinicopathological characteristics of the breast cancer cases are provided in 
Table 4-3. Cases included 200 women with invasive breast carcinoma. Most of 
the tumours were ductal (81%), 48% were early stage (stage 1) at diagnosis and 
only 5% were advanced, with 27.5% being un-staged. Regarding hormone 
status, all of the cases were ER-positive, 50% were PR-positive and 39.5% were 
HER2-negative, with the majority of the cases having an unknown HER2 status 




Histology Classification No  % 
IDC 162 81 
ILC 25 12.5 
ITC 1 0.5 
Other 12 6 
Stage (TNM) 
1 96 48 
2 39 19.5 
3 10 5 
Unknown 55 27.5 
Grade     
I 32 16 
II 111 55.5 
III 53 26.5 
Unknown 4 2 
Oestrogen Receptor 
ER positive 200 100 
Progesterone Receptor 
PR negative 32 16 
PR positive 100 50 
Unknown  68 34 
HER2 
HER2 negative 79 39.5 
HER2 positive 16 8 
Unknown 105 52.5 
Nodal Status 
Positive 50 25 
Negative 150 75 
Table 4-3: Clinicopathological details of cases.  
HER2=human epidermal growth factor receptor 2; IDC=invasive ductal carcinoma; ILC=invasive 
lobular carcinoma; ITC=invasive tubular carcinoma 
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4.3.2 Epidemiological risk factor profile of the study women 
The median age of the 200 women with breast cancer (cases) was 61.33 (inter-
quartile range IQR 11.32) and 62.33, (IQR 9.57) in the 400 healthy women 
(matched controls). None of the traditional risk factors (family history, age at 
menarche, menopause, number of pregnancies, contraceptive pill use, 
hysterectomy, infertility, BMI, height) were significantly different between cases 
and controls except for fallopian tube ligation (OR for breast cancer 0.57; 95% 
confidence interval (CI): 0.35-0.94; p=0.029) (Table 4-4). 
  

















OR* L95%CI U95%CI p-value 
N N N 
Ethnicity 
Non-white 5 2.5% 11 2.7% 16 1.00    
White 194 97.5% 392 97.3% 586 1.09 0.37 3.18 0.876 
Breast cancer family history 
No 148 74.4% 291 76.6% 439 1.00    
Yes 51 25.6% 89 23.4% 140 1.13 0.76 1.68 0.556 
Ovarian cancer family history 
No 189 95.0% 363 95.5% 552 1.00    
Yes 10 5.0% 17 4.5% 27 1.13 0.51 2.52 0.765 
Age at menopause 
<50 85 42.7% 187 46.4% 272 1.00    
50+ 114 57.3% 216 53.6% 330 1.16 0.82 1.64 0.392 
Age 1st period 
<12 47 23.6% 79 19.8% 126 1.00    
12+ 152 76.4% 319 80.2% 471 0.80 0.53 1.21 0.288 
Pregnancies <6 months 
None 31 15.6% 50 12.5% 81 1.00    
1+ 168 84.4% 349 87.5% 517 0.78 0.48 1.26 0.306 
Pregnancies >6 months 
None 146 73.4% 273 69.1% 419 1.00    
1+ 53 26.6% 122 30.9% 175 0.81 0.56 1.19 0.284 
HRT use 
No          
Yes 200 100% 400 100%      
Pill use 
No 98 49.2% 180 44.7% 278 1.00    
Yes 101 50.8% 223 55.3% 324 0.83 0.59 1.17 0.289 
Hysterectomy 
No 162 81.4% 322 79.9% 484 1.00    
Yes 37 18.6% 81 20.1% 118 0.91 0.59 1.40 0.661 
Infertility 
No 195 98.0% 393 97.5% 588 1.00    
Yes 4 2.0% 10 2.5% 14 0.81 0.25 2.60 0.719 
Sterilization 
No 176 88.4% 328 81.4% 504 1.00    
Yes 23 11.6% 75 18.6% 98 0.57 0.35 0.94 0.029 
BMI 
<24.0 54 27.1% 132 33.2% 186 1.00    
24.0+ 145 72.9% 266 66.8% 411 1.33 0.92 1.94 0.134 
Height 
1.6m 89 44.7% 191 48.0% 280 1.00    
1.6m+ 110 55.3% 207 52.0% 317 1.14 0.81 1.61 0.451 
Table 4-4: Traditional risk factors in cases and controls. (numbers of cases and controls do not always add up to totals due to missing values in 
some participants; cases N=200 and controls N=400) 
 
BMI= body mass index; HRT=hormone replacement therapy; OR=odds ratio  
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4.3.3 Association of hormones and serum bioactivity with breast cancer  
Amongst the nine hormones analysed difference between cases and controls 
was observed for serum androstenedione, testosterone and free testosterone 
levels. (Table 4-5 and Table 4-6). Women were then stratified into groups based 
on whether the sample was obtained 6 months to ≤2 or >2 to 5 years prior to 
breast cancer diagnosis. For those women who had given samples ≤2 years 
before diagnosis, SHBG and serum free testosterone showed significant 
differences between cases and controls (Table 4-5 and Table 4-6). For those 
women who had given a sample >2 years before diagnosis, androstenedione, 
testosterone and free testosterone showed significant differences between cases 
and controls (Table 4-5 and Table 4-6). The other hormones did not show 
statistically significant differences between cases and controls (Table 4-5 and 
Table 4-6). 
 
A significant difference for both ER-α and ER-β SB was shown between cases 
and controls for those samples that were taken >2 years before diagnosis but not 
when all cases were investigated or for those women that gave samples ≤2 years 
before breast cancer diagnosis. AR SB did not show any statistically significant 
difference between cases and controls (Table 4-7).  
















Controls 379 18.44 16.03 13.81   
All Cases 194 18.57 16.51 10.59 0.47 
≤2 years 93 17.93 16.24 11.19 0.93 




Controls 362 0.91 0.79 0.62   
All Cases 193 0.98 0.84 0.51 0.07 
≤2 years 93 0.93 0.84 0.44 0.17 




Controls 384 99.74 80.93 80.63   
All Cases 198 112.42 81.79 125.44 0.11 
≤2 years 95 116.56 83.14 132.79 0.09 




Controls 386 3.38 3.13 1.76   
All Cases 195 4.07 3.59 2.30 0.01 
≤2 years 95 3.95 3.37 2.27 0.19 




Controls 382 0.28 0.25 0.16   
All Cases 193 0.35 0.28 0.28 0.04 
≤2 years 94 0.31 0.27 0.18 0.08 




Controls 365 0.12 0.09 0.20   
All Cases 193 0.15 0.11 0.13 0.00 
≤2 years 93 0.13 0.11 0.10 0.03 




Controls 385 111.83 100.60 61.15   
All Cases 195 118.87 97.95 72.92 0.58 
≤2 years 95 121.30 103.00 70.78 0.25 




Control 385 56.62 53.25 26.09  
Case 195 50.67 47.55 20.98 0.12 
≤2 years 95 48.54 47.40 20.49 0.02 




Control 382 0.29 0.25 0.26   
Case 139 0.38 0.24 1.07 0.60 
≤2 years 195 0.42 0.24 1.29 0.32 
>2 years 95 0.29 0.24 0.21 0.63 
Table 4-5: Oestrogens and androgens levels in serum samples from 200 cases and 400 
controls. (The numbers do not always add up due to some missing values) 
*Kruskal-Wallis for difference in median value among cases and controls.    
DHEAS=dehydroepiandrosterone sulphate; SHBG=sex hormone-binding globulin  



















Controls 387 33.11 30.84 13.72  
All Cases 195 31.64 30.53 11.16 0.39 
≤2 years 100 32.07 31.37 10.58 0.95 
>2 years 95 30.50 29.12 11.10 0.10 
FSH (mIU/ml) 
  
Controls 387 78.18 76.95 28.52   
All Cases 195 75.58 74.27 27.58 0.64 
≤2 years 100 75.49 74.43 22.34 0.69 











Controls 390 70.74 62.09 60.45   
All Cases 198 80.24 64.17 68.54 0.30 
≤2 years 95 74.86 57.60 69.81 0.78 
>2 years 103 85.60 74.85 67.19 0.05 
ER-β (pg/ml) 
  
Controls 391 59.95 43.87 67.63   
All Cases 198 71.69 48.22 83.79 0.41 
≤2 years 95 61.10 37.56 85.81 0.26 
>2 years 103 82.26 59.64 80.79 0.01 
AR (ng/ml) 
  
Controls 391 2.33 2.32 1.01   
All Cases 197 2.36 2.29 0.86 0.97 
≤2 years 94 2.28 2.26 0.85 0.20 
>2 years 103 2.44 2.38 0.88 0.19 
Table 4-6: Gonadotrophin levels in serum samples from 200 cases and 400 controls. 
(The numbers do not always add up due to some missing values) 
Table 4-7: Serum bioactivity of oestrogen receptor-α and -β and androgen receptor in 
serum samples from 200 cases and 400 controls. (The numbers do not always add up due 
to some missing values) 
*Kruskal-Wallis for difference in median value among cases and controls. 
FSH=follicular stimulating hormone; LH=luteinising hormone 
 
*Kruskal-Wallis for difference in median value among cases and controls.  
AR=androgen receptor; ER=oestrogen receptor; SB=serum bioactivity 
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4.3.4 Association of hormones and serum bioactivity with breast cancer 
risk 
Further analysis was carried out of the data based on top-bottom classification, 
using top quintile versus bottom 4 quintiles, according to top-bottom classification 
among controls. When all cases were used for the analysis significant association 
with serum androstenedione (≥4.614 nmol/L), testosterone (≥0.382 nmol/L), free 
testosterone (≥ 0.164 ng/dl) and SHBG (≥ 80.134 nmol/L) was observed in breast 
cancer samples. Women who had serum levels in the top quintile of 
androstenedione, testosterone and free testosterone had 1.854 (95% CI: 1.240-
2761), 2.238 (95% CI: 1.512-3.317), 1.637 (95% CI: 1.090-2.543) fold breast 
cancer risk. In order to test whether these hormones were independently 
associated with breast cancer risk, a logistic regression analysis was performed 
adjusting for the other hormones and SB of steroid receptors. The association of 
testosterone and SHBG with breast cancer remained significant throughout all 
adjustments. However, the association of androstenedione with breast cancer 
risk was not statistically significant after adjustment for testosterone and for free 
testosterone after adjustment for oestradiol and androstenedione, respectively. 
DHEAS was only significantly associated with breast cancer risk after adjustment 
for testosterone. Oestrogens – oestradiol, free oestradiol and oestrone did not 
show any significant association with breast cancer risk (Table 4-8, Table 4-9, 
Table 4-10). LH levels were associated with reduced breast cancer risk after 
adjustment for androstenedione and FSH did not show any significant association 
with breast cancer risk (Table 4-11). Neither ER-α, ER-β nor AR SB showed any 
significant association with breast cancer risk (Table 4-12).  
 











Hormones Oestradiol Free oestradiol  Oestrone 
    OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.080 (0.700-1.650) 1.207 (0.791-1.827) 1.438 (0.956-2.154) 
p=0.723 p=0.378 p=0.079 
Hormones  Oestradiol Free oestradiol  Oestrone 









  1.467(0.785-2.753) 1.390 (0.919-2.093) 
 p=0.229 p=0.116 
Free oestradiol  
0.808 (0.420-1.525)  1.437 (0.951-2.161) 
p=0.515  p=0.083 
Oestrone  
1.066 (0.689-1.631) 1.259 (0.824-1.909)  
p=0.772 p=0.281  
Androstenedione 
0.971 (0.619-1.505) 1.133 (0.731-1.740) 1.451 (0.957-2.189) 
p=0.898 p=0.572 p=0.077 
Testosterone 
0.808 (0.506-1.272) 0.927 (0.58-1.446) 1.316 (0.865-1.991) 
p=0.364 p=0.741 p=0.196 
Free testosterone  
0.915 (0.557-1.432) 0.989 (0.616-1.568) 1.375 (0.908-2.072) 
p=0.703 p=0.962 p=0.129 
DHEAS 
1.075 (0.694-1.647) 1.205 (0.786-1.831) 1.435 (0.954-2.150) 
p=0.743 p=0.387 p=0.080 
SHBG 
1.060 (0.684-1.625) 1.096 (0.714-1.669) 1.437 (0.951-2.162) 
p=0.790 p=0.670 p=0.082 
Progesterone 
1.055 (0.680-1.619) 1.231 (0.804-1.871) 1.435 (0.953-2.152) 
p=0.809 p=0.333 p=0.082 
LH 
1.056 (0.683-1.615) 1.158 (0.756-1.759) 1.425 (0.946-2.135) 
p=0.804 p=0.494 p=0.088 
FSH 
1.091 (0.704-1.673) 1.224 (0.797-1.866) 1.446 (0.960-2.166) 
p=0.693 p=0.351 p=0.075 
ER-α SB 
1.031 (0.665-1.580) 1.205 (0.787-1.829) 1.405 (0.930-2.111) 
p=0.889 p=0.385 p=0.102 
ER-β SB 
1.047 (0.676-1.604) 1.224 (0.800-1.857) 1.427 (0.944-2.147) 
p=0.833 p=0.345 p=0.089 
AR SB 
1.013 (0.651-1.557) 1.218 (0.794-1.852) 1.429 (0.947-2.147) 
p=0.954 p=0.361 p=0.087 
Table 4-8: Association of oestrogens with risk of breast cancer - all cases. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones 
not adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones 
adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 





Hormones Androstenedione Testosterone Free testosterone  DHEAS 
    OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.854 (1.24-2.761) 2.238 (1.512-3.317) 1.637 (1.090-2.453) 1.048 (0.665-1.636) 
p=0.002 p<0.0001 p=0.017 p=0.837 
Hormones Androstenedione Testosterone Free testosterone  DHEAS 









1.802 (1.193-2.718) 2.367 (1.565-3.591) 1.682 (1.095-2.578) 1.044 (0.658-1.640) 
p=0.005 p<0.0001 p=0.703 p=0.852 
Free oestradiol  
1.751 (1.157-2.646) 2.289 (1.513-3.472) 1.653 (1.054-2.590) 1.015 (0.639-1.594) 
p=0.008 p<0.0001 p=0.028 p=0.950 
Oestrone  
1.826 (1.220-2.731) 2.194 (1.478-3.260) 1.663 (1.104-1.844) 1.069 (0.678-1.671) 
p=0.003 p≤0.0001 p=0.015 p=0.770 
Androstenedione 
 1.906 (1.189-3.057) 1.300 (0.826-2.033) 0.785 (0.473-1.283) 
 p=0.007 p=0.253 p=0.340 
Testosterone 
1.259 (0.776-2.028)  0.946 (0.550-1.600) 0.589 (0.340-0.997) 
p=0.346  p=0.837 p=0.050 
Free testosterone  
1.661 (1.071-2.571) 2.338 (1.409-3.910)  0.837 (0.507-1.366) 
p=0.022 p=0.001  p=0.483 
DHEAS 
2.006 (1.304-3.090) 2.819 (1.785-4.499) 1.743 (1.120-2.714)  
p=0.001 p<0.0001 p=0.013  
SHBG 
1.814 (1.212-2.710) 2.165 (1.457-3.120) 1.462 (0.967-2.204) 1.022 (0.645-1.603) 
p=0.003 p<0.0001 p=0.070 p=0.924 
Progesterone 
1.923 (1.239-2.988) 2.612 (1.666-4.128) 1.699  (1.099-2.624) 0.941  (0.516-1.693) 
p=0.004 p<0.0001 p=0.017 p=0.840 
LH 
1.910 (1.277-2.855) 2.298 (1.548-3.417) 1.636  (1.088-2.454) 1.089 (0.688-1.706) 
p=0.002 p<0.0001 p=0.018 p=0.713 
FSH 
1.860 (1.246-2.166) 2.243 (1.513-3.329) 1.637 (1.085-2.463) 1.047 (0.662-1.637) 
p=0.002 p<0.0001 p=0.018 p=0.843 
ER-α SB 
1.769 (1.181-2.65) 2.193 (1.477-3.260) 1.578 (1.408-2.371) 1.070 (0.677-1.674) 
p=0.005 p<0.0001 p=0.028 p=0.768 
ER-β SB 
1.846 (1.234-2.577) 2.194 (1.479-3.259) 1.594 (1.058-2.394) 1.085 (0.689-1.691) 
p=0.003 p<0.0001 p=0.025 p=0.721 
AR SB 
1.808 (1.207-2.703) 2.148 (1.446-3.191) 1.592 (1.056-2.390) 1.003 (0.634-1.571) 
p=0.004 p<0.0001 p=0.025 p=0.988 
Table 4-9: Association of androgens with risk of breast cancer - all cases. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not adjusted in 
relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted for other hormones or SB 
treated as categorical variable, using top bottom classification and age adjusted. OR with p-values ≤0.05 marked 
with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; ER=oestrogen 
receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds ratio; SB=serum bioactivity; 
SHBG=sex hormone-binding globulin 
 






















Hormones SHBG Progesterone 
    OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.430 (0.245-0.720) 1.124 (0.720-1.739) 
p=0.002 p=0.602 
Hormones  SHBG Progesterone 









0.464 (0.267-0.772) 1.077 (0.683-1.681) 
p=0.004 p=0.748 
Free oestradiol  
0.464 (0.267-0.776) 1.053 (0.667-1.643) 
p=0.005 p=0.823 
Oestrone  
0.401 (0.226-0.679) 1.198 (0.773-1.844) 
p=0.001 p=0.413 
Androstenedione 
0.422 (0.236-0.716) 0.841 (0.509-1.368) 
p=0.002 p=0.491 
Testosterone 




0.414 (0.229-0.713) 0.890 (0.548-1.429) 
p=0.002 p=0.635 
DHEAS 
0.430 (0.245-0.720) 1.168 (0.653-2.081) 
p=0.002 p=0.597 
SHBG 
 1.115 (0.712-1.732) 
 p=0.630 
Progesterone 
0.456 (0.263-0.758)  
p=0.003  
LH 
0.432 (0.246-0.724) 1.146 (0.732-1.776) 
p=0.002 p=0.547 
FSH 
0.428 (0.244-0.718) 1.114 (0.711-1.728 
p=0.002 p=0.633 
ER-α SB 
0.445 (0.254-0.747) 1.215 (0.781-1.875) 
p=0.003 p=0.383 
ER-β SB 
0.425 (0.241-0.715) 1.068 (0.683-1.654) 
p=0.001 p=0.771 
AR SB 
0.409 (0.231-0.692) 1.137 (0.730-1.753) 
p=0.001 p=0.566 
Table 4-10: Association of sex hormone-binding globulin and progesterone with risk of 
breast cancer - all cases. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Hormonal effect in breast cancer  
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 Hormones LH FSH 
    OR* (95% CI) OR* (95% CI) 
Not adjusted  
0.652 (0.395-1.051) 0.981 (0.630-1.509) 
p=0.086 p=0.932 
Hormones LH FSH 









0.660 (0.399-1.066) 1.075 (0.690-1.657) 
p=0.097 p=0.745 
Free oestradiol  
0.662 (0.399-1.071) 1.088 (0.697-1.680) 
p=0.100 p=0.707 
Oestrone  
0.658 (0.398-1.063) 1.104 (0.712-1.695) 
p=0.094 p=0.654 
Androstenedione 
0.556 (0.327-0.916) 1.053 (0.672-1.631) 
p=0.025 p=0.820 
Testosterone 
0.616 (0.327-1.003) 1.030 (0.654-1.603) 
p=0.057 p=0.896 
Free testosterone  
0.663 (0.400-1.071) 0.990 (0.633-1.557) 
p=0.100 p=0.998 
DHEAS 
0.647 (0.391-1.045) 0.985 (0.631-1.519) 
p=0.081 p=0.948 
SHBG 
0.659 (0.398-1.066) 1.041 (0.665-1.613) 
p=0.096 p=0.858 
Progesterone 
0.646 (0.391-1.042) 0.926 (0.588-1.438) 
p=0.079 p=0.737 
LH 
 1.203 (0.737-1.951) 
 p=0.456 
FSH 
0.598 (0.344-1.02)  
p=0.062  
ER-α SB 
0.659 (0.399-1.063) 0.947 (0.602-1.468) 
p=0.095 p=0.809 
ER-β SB 
0.652 (0.395-1.050) 0.917 (0.584-1.418) 
p=0.085 p=0.700 
AR SB 
0.656 (0.396-1.058) 0.923 (0.588-1.429) 
p=0.091 p=0.723 
Table 4-11: Association of gonadotrophins with risk of breast cancer - all cases. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 




SB ER-α ER-β AR 
    OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.371 (0.905-2.603) 1.028 (0.665-1.570) 1.125 (0.733-1.711) 
p=0.133 p=0.900 p=0.584 
SB ER-α ER-β AR 









1.332 (0.876-2.011) 1.047 (0.676-1.604) 1.138 (0.737-1.739) 
p=0.175 p=0.833 p=0.554 
Free oestradiol  
1.326 (0.872-2.003) 1.038 (0.670-1.592) 1.115 (0.720-1.708) 
p=0.183 p=0.345 p=0.361 
Oestrone  
1.305 (0.858-1.971) 0.999 (0.643-1.534) 1.115 (0.724-1.701) 
p=0.209 p=0.995 p=0.616 
Androstenedione 
1.291 0.858-1.971) 0.995 (0.637-1.534) 1.162 (0.753-1.777) 
p=0.233 p=0.980 p=0.491 
Testosterone 
1.295 (0.847-1.967) 0.998 (0.641-1.537) 1.109 (0.715-1.701) 
p=0.228 p=0.995 p=0.640 
Free testosterone  
1.316 (0.865-1.988) 1.016 (0.655-1.558) 1.099 (0.711-1.681) 
p=0.195 p=0.944 p=0.668 
DHEAS 
1.372 (0.906-2.066) 1.029 (0.666-1.571) 1.125 (0.733-1.711) 
p=0.131 p=0.897 p=0.584 
SHBG 
1.309 (0.862-1.977) 0.936 (0.602-1.437) 1.092 (0.709-1.666) 
p=0.202 p=0.765 p=0.685 
Progesterone 
1.343 (0.884-2.028) 1.030 (0.666-1.575) 1.146 (0.746-1.744) 
p=0.163 p=0.894 p=0.529 
LH 
1.376 (0.908-2.073) 1.028 (0.665-1.573) 1.092 (0.710-1.663) 
p=0.129 p=0.899 p=0.684 
FSH 
1.366 (0.902-2.058) 1.025 (0.663-1.567) 1.122 (0.731-1.706) 
p=0.137 p=0.909 p=0.594 
ER-α SB 
 0.880 (0.536-1.426) 1.021 (0.642-1.607) 
 p=0.608 p=0.928 
ER-β SB 
1.407 (0.879-2.246)  1.161 (0.739-1.808) 
p=0.152  p=0.514 
AR SB 
1.325 (0.845-2.065) 1.000 (0.631-1.565)  
p=0.216 p=0.999   
Table 4-12: Association of serum bioactivity of steroid receptors with risk of breast cancer 
- all cases. 
OR values for top-bottom classification are based on controls only. *OR - for single SB of steroid 
receptors not adjusted in relation to other hormones or SB, only age adjusted. **OR - for single SB 
of steroid receptors adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Hormonal effect in breast cancer  
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For those women who had given a sample ≤2 years before diagnosis serum 
levels in the top quintile of androstenedione, testosterone, free testosterone and 
oestrone were significantly associated with a 1.823 (95% CI: 1.095-2.933), 2.240 
(95% CI: 1.368-3.639), 1.705 (95% CI: 1.018-2.814) and 1.777 (95% CI: 1.076-
2.893) fold risk for breast cancer, respectively. Testosterone remained significant 
after adjustment for all other hormones. However, the association of 
androstenedione and oestrone with breast cancer risk was not statistically 
significant after adjustment for testosterone (Table 4-13, Table 4-14). In addition, 
women who had serum levels in the top quintile of SHBG had a reduced risk of 
breast cancer (0.347; 95% CI: 0.150-0.705; P0.007) which remained significant 
after all adjustments (Table 4-15). Progesterone (Table 4-15), FSH and LH 
(Table 4-16), ER-α, ER-β and AR SB (Table 4-17) did not show any significant 
association with breast cancer risk.  




Hormones Oestradiol Free oestradiol  Oestrone 
    OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.891 (0.492-1.548) 1.134 (0.652-1.916) 1.777 (1.076-2.893) 
p=0.692 p=0.645 p=0.022 
Hormones Oestradiol Free oestradiol  Oestrone 









 1.551 (0.713-3.311) 1.738 (1.045-2.847) 
 p=0.260 p=0.030 
Free oestradiol  
0.645 (0.281-1.427)  1.754 (1.032-2.938) 
p=0.288  p=0.035 
Oestrone  
0.869 (0.477-1.515) 1.152 (0.659-1.954)  
p=0.631 p=0.609  
Androstenedione 
0.825 (0.448-1.458) 1.056 (0.563-1.826) 1.785 (1.068-2.941) 
p=0.522 p=0.849 p=0.024 
Testosterone 
0.674 (0.60-1.208) 0.862 (0.476-1.511) 1.616 (0.966-2.661) 
p=0.199 p=0.614 p=0.063 
Free testosterone  
0.755 (0.406-1.345) 0.916 (0.149-1.633) 1.727 (1.040-2.879) 
p=0.200 p=0.722 p=0.032 
DHEAS 
0.878 (0.483-1.531) 1.122 (0.641-1.905) 1.767 (1.070-2.879) 
p=0.658 p=0.678 p=0.024 
SHBG 
0.875 (0.481-1.526) 1.017 (0.581-1.727) 1.789 (1.077-2.932) 
p=0.648 p=0.951 p=0.022 
Progesterone 
0.845 (0.463-1.479 1.095 (0.624-1.865) 1.771 (1.072-2.887) 
p=0.569 p=0.744 p=0.023 
LH 
0.881 (0.486-1.531) 1.106 (0.634-1.875) 1.766 (1.070-2.877) 
p=0.663 p=0.714 p=0.024 
FSH 
0.904 (0.498-1.575) 1.161 (0.663-1.974) 1.791 (1.084-2.920) 
p=0.730 p=0.591 p=0.021 
ER-α SB 
0.835 (0.455-1.464) 1.092 (0.621-1.858) 1.737 (1.046-2.843) 
p=0.543 p=0.753 p=0.030 
ER-β SB 
0.843 (0.459-1.480) 1.122 (0.637-1.914) 1.816 (1.089-2.986) 
p=0.566 p=0.680 p=0.020 
AR SB 
0.835 (0.455-1.464) 1.090 (0.618-1.860) 1.739 (1.048-2.844) 
p=0.543 p=0.759 p=0.029 
Table 4-13: Association of oestrogens with risk of breast cancer - cases that gave a 
sample less than 2 years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted for 
other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 










Hormones Androstenedione Testosterone Free testosterone  DHEAS 
    OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.823 (1.095-2.933) 2.240 (1.368-3.639) 1.705 (1.018-2.814) 1.103 (0.614-1.924) 
p=0.019 p=0.001 p=0.039 p=0.737 
Hormones Androstenedione Testosterone Free testosterone  DHEAS 









1.827 (1.081-3.046) 2.457 (1.469-4.069) 1.842 (1.077-3.111) 1.137 (0.630-1.999) 
p=0.022 p<0.0001 p=0.024 p=0.660 
Free oestradiol  
1.754 (1.032-2.938) 2.338 (1.390-3.912) 1.786 (1.017-3.099) 1.089 (0.601-1.917) 
p=0.035 p=0.001 p=0.041 p=0.773 
Oestrone  
1.811 (1.083-2.989) 2.150 (1.306-3.511) 1.733 (1.031-2.872) 1.145 (0.639-1.999) 
p=0.021 p=0.002 p=0.035 p=0.641 
Androstenedione 
 1.831 (1.009-3.287) 1.328 (0.71-2.333) 0.858 (0.448-1.586) 
 p=0.044 p=0.331 p=0.632 
Testosterone 
1.284 (0.698-2.319)  1.018 (0.517-1.960) 0.650 (0.329-1.246) 
p=0.413  p=0.959 p=0.204 
Free testosterone  
1.655 (0.951-2.873) 2.259 (1.194-4.256)  0.886 (0.467-1.632) 
p=0.070 p=0.001  p=0.704 
DHEAS 
1.912 (1.109-3.260) 2.690 (1.528-4.729) 1.779 (1.017-3.072)  
p=0.018 p<0.0001 p=0.041  
SHBG 
1.771 (1.059-2.922) 2.122 (1.290-3.463) 1.473 (0.874-2.448) 1.047 (0.580-1.837) 
p=0.027 p=0.003 p=0.139 p=0.875 
Progesterone 
1.843 (1.055-3.185) 2.463 (1.412-4.282) 1.682 (0.967-2.886) 0.901 (0.419-1.886) 
p=0.030 p=0.001 p=0.061 p=0.786 
LH 
1.847 (1.108-3.038) 2.263 (1.381-3.682) 1.705 (1.017-2.816) 1.128 (0.627-1.975) 
p=0.017 p=0.001 p=0.039 p=0.679 
FSH 
1.838 (1.102-3.024) 2.264 (1.379-3.692) 1.713 (1.017-2.844) 1.111 (1.017-2.844) 
p=0.018 p=0.001 p=0.039 p=0.717 
ER-α SB 
1.781 (1.063-2.939) 2.199 (1.336-3.591) 1.629 (0.967-2.777) 1.124 (0.626-1.964) 
p=0.026 p=0.002 p=0.062 p=0.687 
ER-β SB 
1.825 (1.087-3.019) 2.194 (1.332-3.585) 1.672 (0.991-2.777) 1.174 (0.658-2.041) 
p=0.021 p=0.002 p=0.050 p=0.577 
AR SB 
1.782 (1.064-2.940) 2.156 (1.312-3.514) 1.630 (0.967-2.702) 1.102 (0.614-1.920) 
p=0.025 p=0.002 p=0.061 p=0.738 
Table 4-14: Association of androgens with risk of breast cancer - cases that gave a sample less than 2 
years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not adjusted in 
relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted for other hormones or SB 
treated as categorical variable, using top bottom classification and age adjusted. OR with p-values ≤0.05 marked 
with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; ER=oestrogen 
receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds ratio; SB=serum bioactivity; 
SHBG=sex hormone-binding globulin 
 












Hormones SHBG Progesterone 
    OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.347 (0.150-0.705) 1.258 (0.715-2.159) 
p=0.007 p=0.413 
Hormones SHBG Progesterone 









0.352 (0.152-0.715) 1.296 (0.731-2.242) 
p=0.007 p=0.363 
Free oestradiol  
0.349 (0.150-0.714) 1.245 (0.702-2.156) 
p=0.007 p=0.443 
Oestrone  
0.296 (0.121-0.625) 1.212 (0.688-2.084) 
p=0.003 p=0.495 
Androstenedione 
0.321 (0.130-0.677) 0.967 (0.511-1.777) 
p=0.006 p=0.915 
Testosterone 
0.324 (0.131-0.685) 0.801 (0.420-1.485) 
p=0.006 p=0.490 
Free testosterone  
0.279 (0.105-0.617) 1.039 (0.565-1.864) 
p=0.004 p=0.899 
DHEAS 
0.348 (0.150-0.708) 1.343 (0.643-2.750) 
p=0.006 p=0.425 
SHBG 
 1.244 (0.704-2.148) 
 p=0.441 
Progesterone 
0.348 (0.150-0.708)  
p=0.007  
LH 
0.348 (0.150-0.708) 1.278 (0.725-2.2197) 
p=0.007 p=0.384 
FSH 
0.343 (0.148-0.699) 1.253 (0.710-2.158) 
p=0.006 p=0.425 
ER-α SB 
0.351 (0.151-0.716) 1.183 (0.667-2.044) 
p=0.008 p=0.554 
ER-β SB 
0.316 (0.136-0.647) 1.164 (0.657-2.006) 
p=0.003 p=0.593 
AR SB 
0.347 (0.149-0.705) 1.162 (0.657-2.000) 
p=0.007 p=0.595 
Table 4-15: Association of sex hormone-binding globulin and progesterone with risk of 
breast cancer - cases that gave a sample less than 2 years before diagnosis. 
 
OR values for top-bottom classification are based on controls only. *OR - for single hormones 
not adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones 
adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
























Hormones LH FSH 
    OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.768 (0.408-1.376) 1.067 (0.608-1.813) 
p=0.391 p=0.814 
Hormones LH FSH 









0.775 (0.411-1.391) 1.143 (0.654-1.934) 
p=0.409 p=0.629 
Free oestradiol  
0.780 (0.413-1.404) 1.165 (0.665-1.985) 
p=0.423 p=0.582 
Oestrone  
0.780 (0.413-1.402) 1.230 (0.709-2.078 
p=0.422 p=0.448 
Androstenedione 
0.617 (0.308-1.155) 1.113 (0.624-1.920) 
p=0.148 p=0.709 
Testosterone 
0.749 (0.395-1.395) 1.118 (0.626-1.934) 
p=0.355 p=0.697 
Free testosterone  
0.785 (0.417-1.410) 1.036 (0.575-1.801) 
p=0.435 p=0.903 
DHEAS 
0.760 (0.403-1.363) 1.078 (0.613-1.837) 
p=0.374 p=0.787 
SHBG 
0.777 (0.412-1.398) 1.140 (0.645-1.952) 
p=0.417 p=0.642 
Progesterone 
0.754 (0.400-1.352) 0.964 (0.537-1.668) 
p=0.360 p=0.899 
LH 
 1.231 (0.664-2.221) 
 p=0.498 
FSH 
0.698 (0.349-1.333)  
p=0.290  
ER-α SB 
0.781 (0.415-1.400) 0.959 (0.535-1.653) 
p=0.423 p=0.883 
ER-β SB 
0.773 (0.410-1.387) 0.931 (0.519-1.606) 
p=0.404 p=0.804 
AR SB 
0.768 (0.408-1.378) 0.945 (0.528-1.628) 
p=0.392 p=0.844 
Table 4-16: Association of gonadotrophins with risk of breast cancer - cases that gave a 
sample less than 2 years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones 
not adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones 
adjusted for the other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 











SB ER-α ER-β AR 
    OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.021 (0.576-1.746) 0.651 (0.339-1.176) 0.995 (0.561-1.704) 
p=0.941 p=0.173 p=0.986 
SB ER-α ER-β AR 









0.965 (0.538-1.665) 0.665 (0.345-1.205) 1.044 (0.588-1.792) 
p=0.900 p=0.198 p=0.878 
Free oestradiol  
0.959 (0.538-1.665) 0.660 (0.342-1.196) 1.044 (0.588-1.792) 
p=0.884 p=0.198 p=0.921 
Oestrone  
0.928 (0.516-1.606) 0.612 (0.316-1.116) 0.989 (0.556-1.700) 
p=0.796 p=0.125 p=0.970 
Androstenedione 
0.906 (0.497-1.584) 0.607 (0.307-1.121) 1.070 (0.600-1.845) 
p=0.736  p=0.128 p=0.812 
Testosterone 
0.914 (0.506-1.589) 0.636 (0.329-1.159) 1.019 (0.571-1.757) 
p=0.757 p=0.156 p=0.946 
Free testosterone  
0.947 (0.527-1.636) 0.638 (0.339-1.180) 1.007 (0.566-1.730) 
p=0.849 p=0.157 p=0.980 
DHEAS 
1.022 (0.577-1.748) 0.653 (.0339-0.180) 0.994 (0.560-1.701) 
p=0.938 p=0.177 p=0.983 
SHBG 
0.938 (0.527-1.612) 0.556 (0.288-1.012) 0.932 (0.523-1.603) 
p=0.821 p=0.065 p=0.805 
Progesterone 
0.963 (0.537-1.661) 0.652 (0.339-1.179) 1.017 (0.573-1.743) 
p=0.895 p=0.176 p=0.951 
LH 
1.030 (0.581-1.763) 0.652 (0.339-1.179) 0.978 (0.551-1.677) 
p=0.917 p=0.176 p=0.938 
FSH 
1.019 (0.574-1.744) 0.649 (0.337-1.173) 0.995 (0.561-1.703) 
p=0.948 p=0.171 p=0.985 
ER-α SB  
 0.611 (0.298-1.83) 1.024 (0.558-1.820) 
 p=0.159 p=0.936 
ER-β SB 
1.170 (0.616-2.153)  1.142 (0.632-1.998) 
p=0.621  p=0.649 
AR SB 
0.946 (0.510-1.691) 0.637 (0.325-1.174)  
p=0.855 p=0.165   
Table 4-17: Association of serum bioactivity of sex steroid receptors with risk of breast 
cancer - cases that gave a sample less than 2 years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for single SB of sex 
steroid receptors not adjusted in relation to other hormones or SB, only age adjusted. **OR - for SB 
sex steroid receptors adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Hormonal effect in breast cancer  
4-168 
For those women who had given a sample >2 years before diagnosis serum 
levels in the top quintile of oestradiol, free oestradiol and oestrone did not show 
any significant association with breast cancer risk. Serum levels in the top quintile 
androstenedione and testosterone were significantly associated with 1.868 (95% 
CI: 1.120-3.073) and 2.218 (95% CI: 1.341-3.634) fold risk for breast cancer, 
respectively. Whereas testosterone remained significant after adjustment for all 
other hormones, androstenedione did not retain significance after adjustment for 
testosterone (Table 4-19). In addition women with serum ER-α bioactivity 
(≥104.359 pg/ml) in the top quintile had a 1.791 (95% CI: 1.070-2.951; P<0.05) 
fold breast cancer risk. This association remained statistically significant after 
adjustment for other hormones and AR SB. No association was shown between 
breast cancer risk and ER-β and AR SB (Table 4-22). Other hormones tested did 
not show any significant association with breast cancer risk. 
 
 




Hormones Oestradiol Free oestradiol  Oestrone 
   OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.294 (0.747-2.184) 1.284 (0.742-2.165) 1.116 (0.634-1.901) 
p=0.343 p=0.358 p=0.695 
Hormones Oestradiol Free oestradiol  Oestrone 








Oestradiol   1.331 (0.594-2.923) 1.076 
 p=0.480 p=0.796 
Free oestradiol  1.045 (0.461-2.313)  1.161 (0.658-1.985) 
p=0.914  p=0.695 
Oestrone  1.290 (0.744-2.178) 1.380 (0.801-2.322)  
p=0.351 p=0.233  
Androstenedione 1.148 (0.652-1.966) 1.206 (0.687-2.061) 1.129 (0.639-1.932) 
p=0.622 p=0.503 p=0.666 
Testosterone 
0.993 (0.552-1.734) 1.008 (0.561-1.758) 1.038 (0.580-1.793) 
p=0.981 p=0.978 p=0.897 
Free testosterone  1.137 (0.637-1.975) 1.089 (0.591-1.950) 1.049 (0.589-1.805) 
p=0.654 p=0.780 p=0.866 
DHEAS 1.304 (0.748-2.213) 1.296 (0.744-2.201) 1.117 (0.634-1.904) 
p=0.336 p=0.346 p=0.693 
SHBG 1.276 (0.735-2.158) 1.192 (0.684-2.205) 1.118 (0.634-1.910) 
p=0.373 p=0.524 p=0.691 
Progesterone 1.300 (0.746-2.208) 1.379 (0.798-2.329) 1.115  (0.633-1.903) 
p=0.342 p=0.238 p=0.696 
LH 1.249 (0.719-2.113) 1.198 (0.689-2.031) 1.099 (0.624-1.876) 
p=0.416 p=0.510 p=0.736 
FSH 1.295 (0.743-2.201) 1.285 (0.735-2.193) 1.113 (0.63201.899) 
p=0.348 p=0.366 p=0.701 
ER-α SB 1.252 (0.720-2.120) 1.316 (0.761-2.218) 1.085 (0.614-1.858) 
p=0.413 p=0.313 p=0.771 
ER-β SB 1.268 (0.731-2.144) 1.325 (0.767-2.232) 1.073 (0.606-1.840) 
p=0.384 p=0.300 p=0.803 
AR SB 
1.216 (0.695-2.067) 1.363 (0.790-2.298) 1.139 (0.646-1.945) 








Table 4-18: Association of oestrogens with risk of breast cancer - cases that gave a 
sample more than 2 years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 









Hormones Androstenedione Testosterone Free testosterone  DHEAS 
    OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.868 (1.120-3.073) 2.218 (1.341-3.634) 1.558 (0.916-2.599) 0.990 (0.535-1.762) 
p=0.015 p=0.001 p=0.095 p=0.972 
Hormones Androstenedione Testosterone Free testosterone  DHEAS 









1.756 (1.036-2.932) 2.215 (1.304-3.733) 1.490 (0.82-2.555) 0.947 (0.508-1.700) 
p=0.033 p=0.003 p=0.153 p=0.859 
Free oestradiol  
1.735 (1.020-2.909) 2.213 (1.333-3.622) 1.499 (0.832-2.652) 0.935 (0.500-1.680) 
p=0.039 p=0.002 p=0.169 0.826 
Oestrone  
1.801 (1.074-2.977) 2.207 (1.333-3.622) 1.574 (0.923-2.632) 0.983 (0.531-1.752) 
p=0.023 p=0.001 p=0.089 p=0.954 
Androstenedione 
 1.959 (1.086-3.505) 1.282 (0.719-2.236) 0.748 (0.385-1.393) 
 p=0.024 p=0.389 p=0.372 
Testosterone 
1.262 (0.684-2.281)  0.906 (0.458-1.745) 0.539 (0.263-0.972) 
p=0.448  p=0.770 p=0.082 
Free testosterone  
1.645 (0.941-2.832) 2.350 (1.245-4.414)  0.781 (0.397-1.479) 
p=0.076 p=0.008  p=0.461 
DHEAS 
2.038 (1.182-3.478) 2.895 (1.618-5.173) 1.705 (0.954-3.001)  
p=0.010 p≤0.0001 p-=0.067  
SHBG 
1.849 (1.106-3.050) 2.161 (1.305-3.549) 1.439 (0.840-2.418) 0.969 (0.522-1.732) 
p=0.017 p=0.002 p=0.176 p=0.917 
Progesterone 
1.963 (1.123-3.395) 2.675 (1.514-4.711) 1.714 (0.971-2.977) 0.984 (0.457-2.047) 
p=0.016 p<0.0001 p=0.058 p=0.966 
LH 
1.891 (1.132-3.119) 2.220 (1.340-3.645) 1.532 (0.898-2.561) 1.030 (0.555-1.841) 
p=0.013 p=0.002 p=0.109 p=0.923 
FSH 
1.867 (1.118-3.075) 2.218 (1.336-3.652) 1.551 (0.905-2.606) 0.977 (0.527-1.745) 
p=0.015 p=0.002 p=0.103 p=0.938 
ER-α SB 
1.751 (1.042-2.900) 2.178 (1.312-3.582) 1.527 (0.894-2.555) 1.000 (0.538-1.789) 
p=0.031 p=0.002 p=0.113 p=1.000 
ER-β SB 
1.858 (1.111-3.065) 2.165 (1.306-3.557) 1.520 (0.891-2.540) 0.983 (0.530-1.753) 
p=0.016 p=0.002 p=0.166 p=0.954 
AR SB 
1.819 (1.084-3.008) 2.125 (1.279-3.495) 1.543 (0.905-2.578) 0.898 (0.479-1.614) 
p=0.021 p=0.003 p=0.103 p=0.726 
Table 4-19: Association of androgens with risk of breast cancer - cases that gave a sample more than 2 
years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not adjusted in 
relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted for other hormones or SB 
treated as categorical variable, using top bottom classification and age adjusted. OR with p-values ≤0.05 marked 
with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; ER=oestrogen 
receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds ratio; SB=serum bioactivity; 
SHBG=sex hormone-binding globulin 
 











Hormones SHBG Progesterone 
    OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.518 (0.250-0.982) 0.992 (0.539-1.753) 
p=0.057 p=0.978 
Hormones SHBG Progesterone 








Oestradiol  0.589 (0.292-1.101) 0.876 (0.466-1.577) 
p=0.115 p=0.668 
Free oestradiol  0.596 (0.294-1.121) 0.870 (0.463-1.566) 
p=0.126 p=0.652 
Oestrone  0.513 (0.248-0.973) 1.183 (0.664-2.047) 
p=0.054 p=0.556 
Androstenedione 0.522 (0.251-0.994) 0.741 (0.380-1.384) 
p=0.061 p=0.361 
Testosterone 0.551 (0.265-1.052) 0.550 (0.271-1.066) 
p=0.087 p=0.085 
Free testosterone  0.563 (0.270-1.080) 0.741 (0.379-1.385) 
p=0.101 p=0.362 
DHEAS 0.517 (0.250-0.981) 1.001 (0.469-2.067) 
p=0.056 p=0.997 
SHBG  0.987 (0.536-1.650) 
 p=0.966 
Progesterone 0.573 (0.284-1.068)  
p=0.096  
LH 0.525 (0.253-0.997) 1.003 (0.544-1.779) 
p=0.063 p=0.993 
FSH 
0.521 (0.252-0.990) 0.977 (0.529-1.735) 
p=0.060 p=0.938 
ER-α SB 0.547 (0.264-1.043) 1.253 (0.700-2.181) 
p=0.082 p=0.436 
ER-β SB 0.543 (0.261-1.037) 0.972 (0.528-1.719) 
p=0.080 p=0.924 
AR SB 0.474 (0.222-0.918) 1.108 (0.616-1.930) 
p=0.037 p=0.723 
Table 4-20: Association of sex hormone-binding globulin and progesterone with risk of 
breast cancer - cases that gave a sample more than 2 years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 








Hormones LH FSH 
    OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.535 (0.256-1.029) 0.889 (0.483-1.565) 
p=0.075 p=0.694 
Hormones LH FSH 








Oestradiol  0.545 (0.260-1.051) 1.005 (0.549-1.772) 
p=0.085 p=0.985 
Free oestradiol  
0.544 (0.259-1.053) 1.005 (0.546-1.781) 
p=0.086 p=0.987 
Oestrone  
0.535 (0.256-1.032) 0.964 (0.528-1.691) 
p=0.077 p=0.902 
Androstenedione 
0.523 (0.249-1.011) 0.992 (0.543-1.742) 
p=0.067 p=0.979 
Testosterone 
0.534 (0.254-1.035) 1.001 (0.539-1.784) 
p=0.078 p=0.996 
Free testosterone  
0.548 (0.262-1.055) 0.967 (0.521-1.720) 
p=0.087 p=0.912 
DHEAS 
0.534 (0.255-1.028) 0.887 (0.480-1.566) 
p=0.074 p=0.689 
SHBG 
0.543 (0.259-1.046) 0.932 (0.504-1.648) 
p=0.083 p=0.814 
Progesterone 
0.533 (0.255-1.025) 0.884 (0.478-1.564) 
p=0.074 p=0.683 
LH 
 1.155 (0.594-2.165) 
 p=0.660 
FSH 
0.500 (0.226-1.029)  
p=0.072  
ER-α SB 
0.537 (0.256-1.037) 0.931 (0.504-1.647) 
p=0.079 p=0.813 
ER-β SB 
0.531 (0.254-1.022) 0.905 (0.491-1.596) 
p=0.072 p=0.738 
AR SB 
0.541 (0.258-1.044) 0.904 (0.490-1.595) 
p=0.082 p=0.737 
Table 4-21: Association of gonadotrophins with risk of breast cancer - cases that gave a 
sample more than 2 years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for single hormones 
not adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones 
adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 











SB ER-α ER-β AR 
    OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted  
1.791 (1.070-2.951) 1.495 (0.882-2.482) 1.271 (0.734-2.143) 
p=0.023 p=0.126 p=0.378 
SB ER-α ER-β AR 









1.775 (1.059-2.931) 1.513 (0.890-2.521) 1.237 (0.707-2.105) 
p=0.026 p=0.117 p=0.442 
Free oestradiol  
1.766 (1.052-2.918) 1.494 (0.877-2.494) 1.218 (0.694-2.076) 
p=0.028 p=0.130 p=0.479 
Oestrone  
1.773 (1.058-2.928) 1.496 (0.878-2.500) 1.280 (0.738-2.161) 
p=0.027 p=0.130 p=0.366 
Androstenedione 
1.746 (1.039-2.890) 1.464 (0.858-2.455) 1.281 (0.737-2.171) 
p=0.032 p=0.152 p=0.366 
Testosterone 
1.745 (1.035-2.898) 1.450 (0.848-2.428) 1.235 (0.703-2.108) 
p=0.033 p=0.164 p=0.449 
Free testosterone  
1.776 (1.059-2.933) 1.493 (0.878-2.489) 1.209 (0.737-2.156) 
p=0.027 p=0.130 p=0.494 
DHEAS 
1.791 (1.070-2.951) 1.496 (0.878-2.484) 1.278 (0.737-2.156) 
p=0.023 p=0.126 p=0.369 
SHBG 
1.726 (1.029-2.851) 1.392 (0.816-2.325) 1.240 (0.714-2.097) 
p=0.035 p=0.214 p=0.431 
Progesterone 
1.810 (1.079-2.989) 1.496 (0.882-2.487) 1.296 (0.748-2.187) 
p=0.022 p=0.127 p=0.342 
LH 
1.795 (1.071-2.965) 1.500 (0.883-2.496) 1.218 (0.702-2.060) 
p=0.024 p=0.125 p=0.471 
FSH 
1.784 (1.065-2.943) 1.480 (0.877-2.474) 1.263 (0.729-2.133) 
p=0.025 p=0.132 p=0.392 
ER-α SB 
 1.197 (0.657-2.133) 1.017 (0.558-1.801) 
 p=0.548 p=0.954 
ER-β SB 
1.646 (0.920-2.901)  1.161 (0.650-2.019) 
p=0.080  p=0.604 
AR SB 
1.795 (1.206-3.096) 1.468 (0.841-2.513)  
p=0.037 p=0.167   
Table 4-22: Association of serum bioactivity of sex steroid receptors with risk of breast 
cancer - cases that gave a sample more than 2 years before diagnosis. 
OR values for top-bottom classification are based on controls only. *OR - for SB of sex steroid 
receptors not adjusted in relation to other hormones or SB, only age adjusted. **OR - for SB of 
sex steroid hormones adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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4.3.5 Correlation among hormones and serum bioactivity  
Using all samples, correlations among sex steroid hormones, SHBG, 
gonadotrophins and SB of the sex steroid receptors were investigated. A positive 
statistically significant correlation was demonstrated for free oestradiol and free 
testosterone with SB of ER-α, ER-β and AR. A negative statistically significant 
correlation was shown among SHBG with ER-α, ER-β and AR SB. All three 
different sex steroid hormone receptors investigated were shown to be correlated 
amongst them (Table 4-23). Serum concentration of free oestradiol was positively 
and significantly correlated with all other hormones, with correlation ranging from 
0.100 to 0.897. Oestrone serum level was correlated with all other oestrogens 
and with testosterone. Serum concentrations of androstenedione (r ranged from 
0.093 for oestrone to 0.708 for testosterone) and free testosterone (r ranged from 
0.105 for oestrone to 0.875 for testosterone) were correlated with all oestrogens 
and androgens. Testosterone and DHEAS serum levels were correlated with 
serum levels of all other androgens and with oestradiol and free oestradiol. 
SHBG was significantly negative correlated with free oestradiol (r=-0.524, 
p≤0.0001) and free testosterone (r=-0.453, p≤0.0001) (Table 4-24). LH and FSH 
were demonstrated to be negatively correlated with oestrogens and SB of the sex 
steroid receptors. LH was shown to be negatively and FSH to be positively 
correlated with androgens and progesterone. A positive correlation was observed 
amongst FSH and LH with SHBG and between them (Table 4-25).  
























Correlation coefficients  








0.059 0.062 0.055 
p=0.181 p=0.160 p=0.214 
Free oestradiol (pmol/l) 
0.124 0.148 0.109 
p=0.005 p=0.001 p=0.013 
Oestrone (pg/ml) 
0.025 0.066 0.080 
p=0.565 p=0.132 p=0.067 
Androstenedione (nmol/l) 
0.058 0.081 0.002 
p=0.186 p=0.064 p=0.963 
Testosterone (nmol/l) 
0.024 0.051 0.034 
p=0.592 p=0.244 p=0.443 
Free Testosterone (ng/dl) 
0.102 0.139 0.090 
p=0.021 p=0.002 p=0.041 
DHEAS (ug/dl) 
0.020 0.010 0.012 
p=0.647 p=0.814 p=0.785 
SHBG (nmol/l) 
-0.220 -0.242 -0.128 
p=0.005 p<0.0001 p=0.004 
Progesterone (ng/ml) 
0.015 0.014 -0.007 
p=0.727 p=0.751 p=0.873 
ER-α SB (pg/ml) 
 0.507 0.307 
 p<0.0001 p<0.0001 
 
ER-β SB (pg/ml) 
  
  0.330 
    
p<0.0001 
Table 4-23: Spearman correlation coefficients between sex steroid hormones and sex 
hormone-binding globulin and serum bioactivity of oestrogen and androgen receptors. 
AR=androgen receptor; DHEAS=dehydroepiandrosterone sulphate; ER=oestrogen receptor; 
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Free oestradiol (pmol/l) 
0.897        
p<0.0001        
Oestrone (pg/ml) 
0.097 0.100       
p=0.029 p=0.024       
Androstenedione (nmol/l) 
0.239 0.252 0.093      
p<0.0001 p<0.0001 p=0.034      
Testosterone (nmol/l) 
0.395 0.356 0.075 0.708     
p<0.0001 p<0.0001 p=0.091 p<0.0001     
Free Testosterone (ng/dl) 
0.425 0.554 0.105 0.651 0.875    
p<0.0001 p<0.0001 p=0.018 p<0.0001 p<0.0001    
DHEAS (ug/dl) 
0.155 0.176 0.052 0.593 0.663 0.601   
p<0.0001 p<0.0001 p=0.238 p<0.0001 p<0.0001 p<0.0001   
SHBG (nmol/l) 
-0.177 -0.524 -0.042 -0.083 -0.048 -0.453 -0.078  
p=0.062 p<0.0001 p=0.346 p=0.062 p=0.279 p<0.0001 p=0.075  
Progesterone (ng/ml) 
  
0.266 0.253 0.045 0.629 0.704 0.625 0.855 -0.023 
p<0.0001 p<0.0001 p=0.307 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p=0.595 
Table 4-24: Spearman correlation coefficients among sex steroid hormones along with sex steroid hormone binding globulin. 
AR=androgen receptor; ER=oestrogen receptor; DHEAS=dehydroepiandrosterone sulphate; SHBG=sex hormone-binding globulin 
 




























Correlation coefficients  































ER-α SB (pg/ml) 
-0.024 -0.103 
p=0.588 p=0.019 
ER-β SB (pg/ml) 
-0.028 -0.121 
p=0.521 p=0.006 
AR SB (ng/ml) 
-0.074 -0.106 
p=0.090 p=0.016 
Table 4-25: Spearman correlation coefficients between gonadotrophins and oestrogens 
or androgens or sex hormone-binding globulin along with serum bioactivity of 
oestrogen and androgen receptors. 
AR=androgen receptor; DHEAS=dehydroepiandrosterone sulphate; ER=oestrogen receptor; 
FSH=follicular stimulating hormone; LH=luteinising hormone; SB=serum bioactivity; SHBG=sex 
hormone-binding globulin 
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4.3.6 Combination of hormones and serum bioactivity and their joint 
association with breast cancer risk 
Further investigation was undertaken to examine whether joint association of 
hormones, hormones and steroid receptor SB and joint association of steroid 
receptors has a better predictive power. Additionally, analysis was carried out in 
relation to time of diagnosis (less and more than 2 years before diagnosis). Within 
the following section different pairs of hormones/SB that were significantly 
associated with breast cancer risk are presented and those that were not found to 
have significant results are included in the appendices. 
 
Initially, joint associations between the different hormones were examined 
analysing all cases. When high levels (top quintiles) of the joint association of 
oestrogens and androgens were investigated it was shown that women with 
oestrone and testosterone in the top quintiles had 2.507 (95% CI: 1.495-5.738; 
p≤0.05) fold breast cancer risk which remained statistically significant after 
adjustment for other hormones and SB. Women with high levels of oestradiol and 
androstenedione or testosterone had 1.899 (95% CI: 1.032-3.561, p≤0.05) or 
1.958 (95% CI: 1.182-3.604, p≤0.05) fold risk which did not remain statistically 
significant after adjustment for testosterone and androstenedione respectively 
(Table 4-26). After applying Bonferroni correction the significance was lost. Joint 
associations of androgens demonstrated that women having androstenedione 
and testosterone (this significance remained after bonferonni correction) or 
androstenedione and DHEAS levels (this significance was lost after bonferonni 
correction) in the top quintile had 2.567 (95% CI: 1.703-4.678; p<0.0001), 1.972 
(95% CI: 1.106-3.483; p≤0.05) fold breast cancer risk with the latter association 
not remaining statistically significant after adjustment for testosterone (Table 4-
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27). Women with high levels of androstenedione or testosterone with 
progesterone were at 1.731 (95% CI: 0.989-2.866; p≤0.05) or 1.824 (95% CI: 
1.092-2.972; p≤0.05) fold risk of breast cancer which did not remain statistically 
significant after adjustment for testosterone and androstenedione respectively 
and the significance of these joint associations were lost after bonferonni 
correction (Table 4-28). Analysis on the joint association of androgens with 
gonadotrophins showed women with high levels of androstenedione and FSH 
(significance that remained after bonferonni correction) or testosterone and LH 
(significance that was lost after bonferonni correction) having 1.731 (95% CI: 
0.935-4.174, p≤0.05) or 3.029 (95% CI: 1.284-5.555; p≤0.05) fold breast cancer 
risk. FSH and testosterone was the pair with the highest statistically significant 
OR that remained after adjustment for other hormones/SB. Women having these 
two hormones in top quintile had 5.924 (95% CI: 2.337-16.152; p<0.0001) fold 
breast cancer risk (Table 4-29). All other combinations were not shown to be 
statistically significant associated with risk of breast cancer (Appendix VI). 
 
When women who gave samples ≤2 before diagnosis were analysed, joint 
association of oestrogens was shown to be statistically significant associated with 
breast cancer risk (OR: 2.578; 95% CI: 1.044-6.120; p≤0.05) which was lost after 
adjustment for testosterone and for sex steroid receptors SB (Table 4-30).  When 
high levels (top quintiles) of the joint association of oestrogens and androgens 
were investigated it was shown for those women who had given samples ≤2 
before diagnosis with oestrone and testosterone levels in the top quintiles to have 
had 3.390 (95% CI: 1.818-8.384; p≤0.05) fold risk of breast cancer (Table 4-31). 
High levels of androstenedione and oestrone were also shown also to be 
statistically significant associated with breast cancer risk but after adjustment for 
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ER-α and AR this significance was lost (Table 4-31). When all the above joint 
associations were corrected with bonferonni correction, they lost significance. 
Joint associations of androgens demonstrated that the only pair of hormones that 
remained statistically significant associated with breast cancer risk after adjust for 
all hormones and SB was androstenedione and testosterone (OR: 2.555; 95%CI: 
1.426-4.580; p≤0.05) (Table 4-32), which also remained significantly associated 
with breast cancer risk after bonferonni correction. Women with high levels of 
androstenedione or testosterone and progesterone were at 1.928 (95%CI: 0.978-
3.590; p≤0.05) or 2.025 (95%CI: 1.094-3.705; p≤0.05) fold risk of breast cancer 
which did not remain statistically significant after adjustment for oestrone, 
testosterone, SB of all steroid receptors and androstenedione respectively (Table 
4-33). Finally, analysis on the joint association of androgens with gonadotrophins 
showed that women with high levels of testosterone and LH had 3.816 (95% CI: 
1.527-7.891; p≤0.05) fold breast cancer risk (significance that was lost after 
bonferonni correction). The best breast cancer risk predictive pair was FSH and 
testosterone with women having these two hormones in the top quintile having 
6.404 (95% CI: 2.620-21.648; p<0.0001) fold increased breast cancer risk 
(significance that remained after bonferonni correction) (Table 4-34). All other 
combinations were not shown to be statistically significant associated with breast 
cancer risk (Appendix VI).  
 
When analysis was undertaken for those women who gave a sample >2 before 
diagnosis it was demonstrated that high levels (top quintiles) of the joint 
association of oestradiol and androstenedione were associated with 2.101 (95% 
CI: 1.114-5.069; p≤0.05) fold increased breast cancer risk which was not 
significant after adjustment for testosterone and AR SB. A significant association 
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with breast cancer risk was also shown for high levels of testosterone with 
oestradiol that remained significant after adjustment for other hormones and SB 
(Table 4-35). All the above joint associations though lost significance after 
bonferonni correction. Analysis of the joint associations of androgens 
demonstrated androstenedione and testosterone (OR: 2.555; 95%CI: 1.426-
4.580; p≤0.05) to be the only pair of androgens that remained statistically 
significant associated with breast cancer risk after adjust for all hormones and 
SB, and after bonferonni correction (Table 4-36). Finally, analysis on the joint 
association of androgens with gonadotrophins demonstrated that women with 
testosterone and FSH levels in the top quintile to have 5.330 (95% CI: 1.456-
15.174; p≤0.05) fold breast cancer risk (Table 4-37). All other combinations were 
not shown to be statistically significant associated with breast cancer risk 
(Appendix VI).   








Joint association of oestrogens and androgens 
Oestradiol  Oestrone 
Androstenedione Testosterone Testosterone 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.899 (1.010-3.567) 1.958 (1.182-3.604) 2.507 (1.495-5.738) 
p=0.039 p=0.016 p=0.006 









    2.613 (1.332-5.200) 
  p=0.005 
Oestrone 
1.865 (1.009-3.435) 1.903 (1.095-3.303)  
p=0.045 p=0.022  
Androstenedione 
 1.583 (0.876-2.850) 2.131 (1.062-4.311) 
 p=0.125 p=0.033 
Testosterone 
1.196 (0.607-2.341)   
p=0.601   
DHEAS 
1.930 (1.029-3.611) 2.014 (1.140-3.559) 2.576 (1.309-5.133) 
p=0.039 p=0.015 p=0.006 
SHBG 
1.863 (1.004-3.444) 1.961 (1.124-3.415) 2.257 (1.161-4.434) 
p=0.047 p=0.017 p=0.017 
Progesterone  
2.011 (1.057-3.826) 1.965 (1.115-3.460) 2.465 (1.260-4.876) 
p=0.032 p=0.019 p=0.009 
LH 
1.859 (1.005-3.427) 1.922 (1.106-3.335) 2.511 (1.294-4.992) 
p=0.046 p=0.020 p=0.007 
FSH 
1.909 (1.030-3.524) 2.003 (1.148-3.491) 2.524 (1.302-4.993) 
p=0.038 p=0.014 p=0.006 
ER-α SB 
1.898 (1.013-3.539) 1.851 (1.059-3.223) 2.371 (1.212-4.673) 
p=0.043 p=0.029 p=0.012 
ER-β SB 
1.810 (0.972-3.350) 1.882 (1.077-3.275) 2.378 (1.216-4.685) 
p=0.059 p=0.025 p=0.011 
AR SB 
1.724 (0.917-3.210) 1.804 (1.027-3.152) 2.357 (1.206-4.644) 
p=0.086 p=0.038 p=0.012 
Table 4-26: Joint association of oestrogens and androgens (top quintiles) with risk of 
breast cancer – all cases.    
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values ≤ 
0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Hormones 
Joint association of androgens 
Androstenedione  
Testosterone  DHEAS 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
2.567 (1.703-4.678) 1.972 (1.106-3.483) 
p<0.0001 p=0.015 









2.703 (1.663-4.417) 2.047 (1.170-3.576) 
p<0.0001 p=0.012 
Oestrone 






 1.213 (0.632-2.319) 
 p=0.559 
DHEAS 
3.354 (1.945-5.903)  
p<0.0001  
SHBG 
2.458 (1.538-3.941) 1.995 (1.193-3.337) 
p<0.0001 p=0.008 
Progesterone  
3.827 (2.168-6.940) 2.586 (1.288-5.306) 
p<0.0001 p=0.008 
LH 
2.665 (1.667-4.281) 2.125 (1.218-3.704) 
p<0.0001 p=0.008 
FSH 
2.577 (1.617-4.121) 1.982 (1.143-3.425) 
p<0.0001 p=0.014 
ER-α SB 
2.603 (1.620-4.198) 2.039 (1.175-3.531) 
p<0.0001 p=0.003 
ER-β SB 
2.586 (1.614-4.158) 2.052 (1.180-3.560) 
p<0.0001 p=0.003 
AR SB 
2.491 (1.553-4.010) 1.885 (1.081-3.270) 
p<0.0001 p=0.004 
Table 4-27: Joint association of androgens (top quintiles) with risk of breast cancer – all 
cases.    
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values ≤ 
0.0007 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 




Joint association of androgens and progesterone 
Progesterone 
  Androstenedione Testosterone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.731 (0.989-2.866) 1.824 (1.092-2.972) 
p=0.043 p=0.019 









1.741 (0.532-2.996) 1.847 (1.104-3.080) 
p=0.046 p=0.019 
Oestrone 
1.740 (1.006-2.960) 2.016 (1.209-3.357) 
p=0.041 p=0.007 
Androstenedione 
 1.330 (0.731-2.404) 
 p=0.346 
Testosterone 
1.031 (1.018-2.146)  
p=0.924  
DHEAS 
2.175 (0.547-2.575) 2.635 (1.345-5.315) 
p=0.022 p=0.005 
SHBG 






1.770 (0.995-3.024) 1.883 (1.132-3.123) 
p=0.037 p=0.014 
FSH 
1.708 (1.123-2.912) 1.820 (1.095-3.015) 
p=0.050 p=0.020 
ER-α SB 
1.678 (0.981-2.848) 1.806  (1.082-3.003) 
p=0.056 p=0.023 
ER-β SB 
1.661 (0.965-2.839) 1.808 (1.084-3.004) 
p=0.064 p=0.022 
AR SB 
1.653 (0.959-2.829) 1.863 (1.112-3.111) 
p=0.068 p=0.017 
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Table 4-28: Joint association of androgens and progesterone (top quintiles) with risk of 
breast cancer – all cases.    
















Joint association of androgens and gonadotrophins  
Androstenedione Testosterone 
LH LH FSH 
 OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.731 (0.935-4.174) 3.029 (1.284-5.555) 5.924 (2.337-16.152) 
p=0.033 p=0.003 p<0.0001 









1.741 (1.099-5.154) 2.964 (1.445-6.222) 6.261 (2.535-17.712) 
p=0.027 p=0.003 p<0.0001 
Oestrone 
1.740 (1.253-6.111) 3.532 (1.672-7.748) 7.518 (2.893-23.355) 
p=0.012 p=0.001 p<0.0001 
Androstenedione 
 2.033 (0.932-4.472) 4.350 (1.671-12.703) 
 p=0.074 p=0.004 
Testosterone 
1.031 (0.790-3.931)   
p=0.164   
DHEAS 
2.175 (1.069-5.147) 3.277 (1.542-7.150) 5.979 (2.385-17.077) 
p=0.032 p=0.002 p<0.0001 
SHBG 
1.711 (1.011-4.675) 2.987 (1.447-6.318) 6.351 (2.509-18.325) 
p=0.045 p=0.003 p<0.0001 
Progesterone  
2.664 (1.084-5.207) 2.879 (1.360-6.224) 4.978 (1.047-14.347) 
p=0.030 p=0.006 p<0.0001 
LH 
  9.117 (3.425-27.654) 
  p<0.0001 
FSH 
1.708 (1.066-4.939) 3.153 (1.523-6.689)  
p=0.032 p=0.002  
ER-α SB 
2.455 (1.137-5.339) 3.085 (1.502-6.488) 5.816 (2.296-16.703) 
p=0.022 p=0.002 p<0.0001 
ER-β SB 
2.272 (1.062-4.866) 3.026 (1.476-6.353) 5.495 (2.179-15.718) 
p=0.033 p=0.002 p<0.0001 
AR SB 
2.293 (1.072-4.914) 3.058 (1.490-6.424) 5.594 (2.216-16.017) 
p=0.031 p=0.002 p<0.0001 
OR values for top-bottom classification are based on controls only. *OR - for single hormones 
not adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones 
adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with italic and after bonferonni 
correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Table 4-29: Joint association of androgens and gonadotrophins (top quintiles) with 
risk of breast cancer – all cases.    





























Joint association of oestrogens 
Oestradiol 
Oestrone 


















Androstenedione 2.413 (0.962-5.770) 
p=0.051 
Testosterone 2.101 (0.830-5.061) 
p=0.103 
DHEAS 2.562 (0.885-6.058) 
p=0.035 




















Table 4-30: Joint association of oestrogens (top quintiles) with risk of breast cancer – cases 
that gave a sample less than 2 years before diagnosis.   
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values ≤ 
0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 



























Joint association of oestrogens and androgens  
Oestrone 
Androstenedione Testosterone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
2.496 (1.255-6.725) 3.390 (1.818-8.384) 
p=0.029 p=0.001 














Androstenedione  2.883 (1.276-6.388) 
 p=0.009 
Testosterone 
1.792 (0.698-4.377)  
p=0.208  
DHEAS 
2.510 (1.045-5.778) 3.478 (1.593-7.511) 
p=0.033 p=0.001 
Progesterone  
2.730 (1.100-6.569) 3.275 (1.509-7.009) 
p=0.026 p=0.002 
SHBG 
2.307 (0.976-5.206) 2.996 (1.394-6.344) 
p=0.048  p=0.004 
LH 2.406 (1.023-5.401) 3.393 (1.585-7.149) 
p=0.037 p=0.001 
FSH 
2.494 (1.063-5.585) 3.438 (1.605-2.427) 
p=0.029 p=0.001 
ER-α SB 
2.229 (0.918-5.094) 3.128 (1.435-6.668) 
p=0.064 p=0.003 
ER-β SB 
2.396 (0.979-5.541) 3.274 (1.495-7.028) 
p=0.045 p=0.002 
AR SB 
2.229 (0.917-5.099) 3.135 (1.435-6.700) 
p=0.064 p=0.003 
Table 4-31: Joint association of oestrogens and androgens (top quintiles) with risk of 
breast cancer – cases that gave a sample less than 2 years before diagnosis.   
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values ≤ 
0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 























Joint association of androgens  
Androstenedione  
Testosterone  DHEAS 
 OR* (95% CI) OR* (95% CI) 
Not adjusted  
2.555 (1.426-4.580) 2.046 (0.959-3.655) 
p=0.001 p=0.038 









2.818 (1.531-5.132) 2.211 (1.086-4.362) 
p<0.0001 p=0.024 
Oestrone 






 1.349 (0.597-2.993) 
 p=0.465 
DHEAS 
3.090 (1.581-6.058)  
p=0.001  
SHBG 
2.360 (1.308-4.194) 1.948 (0.962-1.052) 
p=0.004 p=0.056 
Progesterone  
3.346 (1.658-6.822) 2.324 (0.978-5.593) 
p=0.001 p=0.056 
LH 
2.607 (1.449-4.620) 2.187 (1.079-4.297) 
p=0.001 p=0.025 
FSH 
2.572 (1.430-4.554) 2.064 (1.024-4.022) 
p=0.001 p=0.037 
ER-α SB 
2.614 (1.433-4.692) 2.120 (1.052-4.133) 
p=0.001 p=0.030 
ER-β SB 
2.619 (1.437-4.699) 2.203 (1.087-4.326) 
p=0.001 p=0.024 
AR SB 
2.490 (1.374-4.435) 2.049 (1.018-3.895) 
p=0.002 p=0.038 
Table 4-32: Joint association of androgens (top quintiles) with risk of breast cancer – 
cases that gave a sample less than 2 years before diagnosis.   
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values ≤ 
0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 





























Joint association of androgens and progesterone  
Progesterone  
Androstenedione Testosterone  
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.928 (0.978-3.590) 2.025 (1.094-3.705) 
p=0.048 p=0.023 








Oestradiol 2.046 (1.030-3.943) 2.137 (1.131-3.945) 
p=0.035 p=0.017 
Oestrone 1.789 (0.907-3.408) 2.121 (1.122-3.913) 
p=0.083 p=0.018 
Androstenedione 
 1.560 (0.739-3.223) 
 p=0.235 
Testosterone 1.239 (0.568-2.641)  
p=0.583  
DHEAS 2.340 (1.045-5.251) 2.883 (1.263-6.788) 
p=0.038 p=0.013 
SHBG 
1.868 (0.947-3.565) 1.971 (1.047-3.618) 
p=0.063 p=0.031 
Progesterone    
  
LH 
1.971 (1.004-3.743) 2.078 (1.109-3.801) 
p=0.042 p=0.019 
FSH 
1.893 (0.965-3.591) 2.030 (1.082-3.715) 
p=0.056 p=0.024 
ER-α SB 
1.728 (0.872-3.292) 1.952 (1.031-3.593) 
p=0.104 p=0.035 
ER-β SB 
1.819 (0.914-3.486) 1.975 (1.042-3.640) 
p=0.078 p=0.032 
AR SB 
1.782 (0.897-3.404) 2.011 (1.060-3.711) 
p=0.088 p=0.028 
Table 4-33: Joint association of androgens and progesterone (top quintiles) with risk of 
breast cancer – cases that gave a sample less than 2 years before diagnosis.   
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted for 
other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values ≤ 
0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 













Joint association of androgens and gonadotrophins  
Testosterone 
LH FSH 
  OR* (95% CI) OR* (95% CI) 
Not adjusted 
3.816 (1.527-7.891) 6.404 (2.620-21.648) 
p=0.001 p=0.001 









3.799 (1.649-8.663) 7.068 (2.546-21.342) 
p=0.001 p<0.0001 
Oestrone 
4.386 (1.846-10.462) 8.322 (2.844-27.583) 
p=0.0001 p<0.0001 
Androstenedione 






4.231 (1.737-10.337) 6.406 (2.224-19.798) 
p=0.001 p<0.0001 
SHBG 
3.690 (1.590-8.501) 6.496 (2.231-20.388) 
p=0.002 p<0.0001 
Progesterone  
3.792 (1.581-9.057) 5.368 (1.807-16.804) 
p=0.003 p=0.003 
LH 
 9.227 (2.981-31.158) 
 p<0.0001 
FSH 
3.916 (1.686-9.014)  
p=0.001  
ER-α SB 
3.828 (1.664-8.709) 5.633 (1.901-17.607) 
p=0.001 p=0.002 
ER-β SB 
3.866 (1.677-8.823) 5.756 (1.941-18.012) 
p=0.001 p=0.002 
AR SB 
3.843 (1.669-8.759) 5.675 (1.916-17.736) 
p=0.001 p=0.002 
Table 4-34: Joint association of androgens and gonadotrophins (top quintiles) with risk of 
breast cancer – cases that gave a sample less than 2 years before diagnosis.   
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values 
≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 





























Joint association of oestrogens and androgens  
Oestradiol 
Androstenedione Testosterone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
2.101 (1.114-5.069) 2.362 (1.250-4.786) 
p=0.047 p=0.010 












2.079 (0.968-4.261) 2.328 (1.185-4.438) 
p=0.050 p=0.012 
Androstenedione 
 1.907 (0.924-3.827) 
 p=0.073 
Testosterone 
1.328 (0.573-2.959)  
p=0.496  
DHEAS 
2.201 (1.004-4.624) 2.559 (1.256-5.056) 
p=0.041 p=0.007 
SHBG 
2.089 (0.971-4.291) 2.388 (1.213-4.566) 
p=0.050 p=0.010 
Progesterone  
2.424 (1.087-5.222) 2.541 (1.265-4.981) 
p=0.026 p=0.007 
LH 
2.027 (0.942-4.162) 2.296 (1.166-4.383) 
p=0.060 p=0.013 
FSH 
2.108 (0.978-4.343) 2.388 (1.207-4.589) 
p=0.048 p=0.010 
ER-α SB 
2.240 (1.034-4.646) 2.307 (1.169-4.414) 
p=0.033 p=0.013 
ER-β SB 
2.101 (0.976-4.315) 2.344 (1.191-4.476) 
p=0.048 p=0.011 
AR SB 
1.927 (0.875-4.011) 2.211 (1.108-4.257) 
p=0.088 p=0.020 
Table 4-35: Joint association of oestrogens and androgens (top quintiles) with risk of 
breast cancer – cases that gave a sample more than 2 years before diagnosis.   
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted 
for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 





























Joint association of androgens 
Androstenedione  
Testosterone  
 OR* (95% CI) 
Not adjusted  
2.558 (1.450-4.666) 
p=0.001 












































Table 4-36: Joint association of androgens (top quintiles) with risk of breast cancer – cases 
that gave a sample more than 2 years before diagnosis.   
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted for 
other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values ≤ 
0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
















Joint association of androgens and gonadotrophins  
Testosterone 
FSH 
















































Table 4-37: Joint association of androgens and gonadotrophins (top quintiles) with risk of 
breast cancer – cases that gave a sample more than 2 years before diagnosis.   
OR values for top-bottom classification are based on controls only. *OR - for single hormones not 
adjusted in relation to other hormones or SB, only age adjusted. **OR - for hormones adjusted for 
other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with italic and after bonferonni correction p-values ≤ 
0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint associations of SB between sex steroid receptors were also investigated. 
Women who gave a sample >2 years before diagnosis with ER-α and ER-β SB or 
ER-α and AR SB or ER-β and AR SB in the top quintile had 1.950 (95% CI: 
1.072-3.963; P≤0.05) or 1.981 (95% CI: 1.093-3.779; P≤0.05) or 2.482 (95% CI: 
1.072-3.963; P≤0.05) fold breast cancer risk. These joint associations though lost 
significance after bonferonni correction (Table 4-38). Statistically significant 
association of the joint effect of steroid receptor SB was not seen when all cases 
and these who gave a sample less than two years before breast cancer diagnosis 
were investigated (Appendix VII). 
 
Further analysis was carried out to investigate joint association of each receptor’s 
SB with each hormone. When all cases were analysed, women with ER-α and 
testosterone in top quintiles had 1.999 (95% CI: 1.224-4.836; p≤0.05) fold breast 
cancer which did not remain statistically significant after adjustment with 
androstenedione (Table 4-39). Women with AR SB and oestrone or testosterone 
in the top quintiles had 2.480 (95% CI: 1.177-5.179; p≤0.05) and 2.558 (95% CI: 
1.389-6.163; p≤0.05) fold breast cancer respectively (Table 4-40 and 4-41). Joint 
association between AR SB and androstenedione also showed to increase 
breast cancer (OR: 2.410; 95% CI: 1.124-5.170; p≤0.05) but did not remain 
significant after adjustment with testosterone (Tables 4-41). All the above joint 
associations with breast cancer risk were lost though after bonferonni correction. 
Any association between SB of the sex steroid receptors and progesterone and 
gonadotrophins did not show significant association with breast cancer risk 
(Appendix VIII).  
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For those women who had given a sample ≤2 years before diagnosis joint 
association of AR SB and oestrone referred to 2.575 (95%CI: 1.054-6.168; 
p≤0.05) fold breast cancer risk (Table 4-42). All other pair combinations were 
shown to be statistically insignificant associated with breast cancer risk (Appendix 
VIII). For those women who had given a sample >2 years before diagnosis, 
women with ER-α or ER-β SB in the top quintile along with testosterone were at a 
2.304 (95%CI: 1.330-7.031; p≤0.05) and 2.754 (95%CI: 1.436-7.313; p≤0.05) fold 
breast cancer risk which did not remain statistically significant after adjustment 
with androstenedione respectively (Table 4-43 and 4-44). Women with ER-β SB 
and SHBG in the top quintile were at 7.306 (95%CI: 1.436-7.313; p≤0.05) fold 
breast cancer risk which remained after all adjustments (Table 4-45). Women 
with AR SB and testosterone in top quintile had 2.807 (95%CI: 1.321-7.882; 
p≤0.05) fold breast cancer risk which remained statistically significant after 
adjustments apart for androstenedione (Table 4-46). In addition, joint association 
of AR SB and androstenedione referred to 2.961 (95%CI: 1.124-7.311; p≤0.05) 
fold breast cancer which did not remain statistically significant after adjustment 
with testosterone (Table 4-46). Significance of all the above joint association with 
breast cancer risk though was lost after bonferonni correction. All the other joint 
associations were not shown to be statistically significant associated with breast 
cancer risk (Appendix VIII).  






Joint association of high SB of steroid receptors – 
more than 2 years before diagnosis 
SB 
ER-α and ER-β ER-α and AR ER-β and AR 
OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.950 (1.072-3.963) 1.981 (1.093-3.779) 2.482 (1.072-3.963) 
p=0.031 p=0.036 p=0.007 









1.987 (1.059-3.452) 1.924 (0.990-3.604) 2.445 (1.241-4.676) 
p=0.028 p=0.046 p=0.008 
Oestrone 
1.897 (1.010-3.483) 1.991 (1.024-3.738) 2.407 (1.217-4.622) 
p=0.040 p=0.036 p=0.009 
Androstenedione 
1.897 (1.010-3.483) 1.932 (0.990-3.640) 2.305 (1.163-4.429) 
p=0.050 p=0.046 p=0.014 
Testosterone  
1.904 (1.009-3.358) 1.872 (0.957-3.528) 2.428 (1.218-4.703) 
p=0.040 p=0.058 p=0.009 
DHEAS 
1.950 (1.042-3.403) 1.991 (1.027-3.724) 2.524 (1.278-4.845) 
p=0.031 p=0.035 p=0.006 
SHBG 
1.844 (0.982-3.513) 1.956 (1.006-3.670) 2.384 (1.207-4.571) 
p=0.050 p=0.041 p=0.010 
Progesterone  
1.935 (1.033-3.513) 1.944 (1.003-3.635) 2.532 (1.282-4.861)  
p=0.034 p=0.042 p=0.006 
LH 
1.917 (1.022-3.486) 1.901 (0.979-3.563) 2.401 (1.217-4.599) 
p=0.037 p=0.050 p=0.009 
FSH 
1.938 (1.034-3.523) 1.970 (1.014-3.694) 2.472 (1.255-4.727) 
p=0.033 p=0.039 p=0.007 
ER-α SB 
  1.801 (0.836-3.802) 
  p=0.126 
ER-β SB 
 1.735 (0.825-3.551)  
 p=0.137  
AR SB 
1.891 (0.951-3.552)   
p=0.060     
Table 4-38: Joint association of high steroid receptor serum bioactivity (top quintiles) with 
risk of breast cancer - cases that gave a sample more than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with italic and after 
bonferonni correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 





Joint association of SB and androgens 
ER-α SB 
Testosterone 
















































Table 4-39: Joint association of high ER-α serum bioactivity and androgens (top quintiles) 
with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with italic and after 
bonferonni correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 




SB - Hormones 
Joint association of SB and oestrogens  
AR SB 
Oestrone 
 OR* (95% CI) 
Not adjusted  
2.480 (1.177-5.179) 
p=0.015 












































Table 4-40: Joint association of high AR serum bioactivity and oestrogens (top quintiles) 
with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with italic and after 
bonferonni correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 




SB - Hormones 
Joint association of SB and androgens 
AR SB 
Androstenedione Testosterone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
2.410 (1.124-5.170) 2.558 (1.389-6.163) 
p=0.024 p=0.012 









2.380 (0.790-5.197) 2.554 (0.985-5.246) 
p=0.027 p=0.013 
Oestrone 
2.356 (1.093-5.146) 2.440 (1.173-5.156) 
p=0.029 p=0.017 
Androstenedione 
  2.104 (0.686-4.550) 
  p=0.050 
Testosterone 
1.709 (1.068-3.847)   
p=0.189   
DHEAS 
2.466 (1.110-5.459) 2.663 (1.225-5.279) 
p=0.023 p=0.011 
SHBG 
2.254 (1.042-4.939) 2.531 (1.210-5.385) 
p=0.039 p=0.014 
Progesterone  
2.333 (1.130-5.146) 2.599 (1.260-5.584) 
p=0.033 p=0.013 
LH 
2.336 (0.997-5.106) 2.501 (1.099-5.280) 
p=0.030 p=0.014 
FSH 
2.398 (1.145-5.246) 2.548 (1.244-5.387) 
p=0.026 p=0.012 
ER-α SB 
2.207 (0.997-4.941) 2.347 (1.098-5.086) 
p=0.050 p=0.028 
ER-β SB 
2.548 (1.115-5.757) 2.650 (1.244-5.741) 
p=0.020 p=0.012 
AR SB 
    
    
Table 4-41: Joint association of high AR serum bioactivity and androgens (top quintiles) 
with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with italic and after 
bonferonni correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 





SB - Hormones 
Joint association of SB and oestrogens 
AR SB 
Oestrone 
















































Table 4-42: Joint association of high AR serum bioctivity and oestrogens (top quintiles) 
with risk of breast cancer – cases that gave a sample less than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with italic and after 
bonferonni correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 




SB - Hormones 
Joint association of SB and androgens 
ER-α SB 
Testosterone 
















































Table 4-43: Joint association of high ER-α serum bioctivity and andoregens (top quintiles) 
with risk of breast cancer – cases that gave a sample more than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with italic and after 
bonferonni correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 









SB - Hormones 
Joint association of SB and androgens 
ER-β SB 
Testosterone 
















































Table 4-44: Joint association of high ER-β serum bioactivity and androgens (top quintiles) 
with risk of breast cancer - cases that gave a sample more than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with italic and after 
bonferonni correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
























Joint association of SB and SHBG 
ER-β  SB 
SHBG 
  OR* (95% CI) 
 Not adjusted  
7.306 (1.769-36.412) 
p=0.007 












































Table 4-45: Joint association of high ER-β serum bioactivity and sex hormone bidning 
globulin (top quintiles) with risk of breast cancer - cases that gave a sample more than 2 
years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 




SB - Hormones 
Joint association of SB and androgens 
AR SB 
Androstenedione Testosterone 
  OR* (95% CI) OR* (95% CI) 
  
2.961 (1.234-7.310) 2.807 (01.321-7.882) 
p=0.016 p=0.020 









2.872 (1.147-6.901) 2.693 (1.081-6.404) 
p=0.020 p=0.027 
Oestrone 
2.949 (1.180-7.083) 2.766 (1.117-6.538) 
p=0.017 p=0.022 
Androstenedione 
 2.229 (0.865-5.487) 
 p=0.086 
Testosterone 
2.122 (0.813-5.311)  
p=0.112  
DHEAS 
3.180 (1.247-7.841) 3.174 (1.235-7.892) 
p=0.012 p=0.013 
SHBG 2.939 (1.127-6.789) 2.830 (1.136-6.739) 
p=0.022 p=0.020 
Progesterone  
2.939 (1.151-7.237) 3.141 (1.222-7.805) 
p=0.020 p=0.014 
LH 
2.900 (1.157-6.980) 2.719 (1.094-6.448) 
p=0.019 p=0.025 
FSH 
2.941 (1.173-7.083) 2.786 (1.120-6.619) 
p=0.017 p=0.022 
ER-α SB 
2.371 (0.917-5.885) 2.213 (0.860-5.434) 
p=0.066 p=0.088 
ER-β SB 




    
 
 
Table 4-46: Joint association of high AR serum bioactivity and androgens (top quintiles) 
with risk of breast cancer - cases that gave a sample more than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with italic and after 
bonferonni correction p-values ≤ 0.0007 marked with bold. 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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The following figures (Figure 4-1, 4-2, 4-3) summarise all different pairs 
investigated indicating FSH and testosterone to have the best predictive power in 
comparison to all other pairs examined independently of time to diagnosis. ER-β 
and SHBG pair also has high breast cancer predictive power but this time only 
more than two years before diagnosis.  
 















 FSH=follicle stimulating hormone; OR=odds ratio; SB=serum bioactivity 
 




FSH and testosterone 
Figure 4-1: Odds ratio of all possible combination pairs of hormones/serum bioactivity- all cases.  
 

















FSH and testosterone 
Number of combination pairs  
 
Number of combination pairs  
Figure 4-2: Odds ratio of all possible combination pairs of hormones/serum bioactivity- cases that gave a sample 









FSH=follicle stimulating hormone; OR=odds ratio; SB=serum bioactivity 
 
 
FSH=follicle stimulating hormone; OR=odds ratio; SB=serum bioactivity 
 








Figure 4-3: Odds ratio of all possible combination pairs of hormones/serum bioactivity- cases that gave a sample 
more than two years before breast cancer diangnosis.  
 
 
Figure 4-3: Odds ratio of all possible combination pairs of hormones/serum bioactivity- cases that gave a sample 
more than two years before breast cancer diangnosis.  
 
Number of combination pairs  
 








FSH and testosterone 
 
FSH and testosterone 
ER-β and SHBG 
 
ER-β and SHBG 
ER=oestrogen receptor; FSH=follicle stimulating hormone; OR=odds ratio; SB=serum bioactivity, SHBG=sex hormones binding globulin 
 
 
ER=oestrogen receptor; FSH=follicle stimulating hormone; OR=odds ratio; SB=serum bioactivity, SHBG=sex hormones binding globulin 
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4.3.7 Validation of the predictive power of testosterone and FSH in breast 
cancer risk 
To further validate the predictive power of testosterone and FSH, 1000 
experiments were run, where 10% of the data was removed from cases and 10% 
of controls and OR was re-evaluated. The quintiles were also re-calculated after 
removing 10% of the data. Distribution (Gaussian distribution) of the OR values 
obtained with a mean of 5.637; p-value=0.002, median of 5.443; p-value=0.001 
and variance of 1.824; p-value=2.77E-05. 
 
4.3.8 Examination of the synergistic effect of the different pairs 
investigated 
From the analyses undertaken in section 4.3.6, possible synergistic interplays 
between sex steroids, gonadotrophins and sex steroid receptor SB among 
postmenopausal women were found to be associated with increased breast 
cancer. Further investigation, was carried out by computing the observed versus 
expected OR ratio to quantify whether a hidden synergistic effect is possible. 
Initially the eexpected OR was estimated under the assumption that two 
hormones are independent (Table 4-47). Then based on the observed and the 
expected OR the ratio was calculated (Table 4-48). As indicated in Table 4-48, a 
significant hidden synergistic effect was confirmed for FSH and testosterone 
(p=0.048) and for ER-β and SHBG (p=0.022).  
 








Hormone / SB Hormone / SB 
Expected Lower Upper p-
value OR CI CI 
Oestradiol  Oestrone  1.47 0.87 2.58 0.152 
Oestradiol  Androstenedione  1.69 0.97 3.05 0.062 
Oestradiol  Testosterone 1.92 1.10 3.51 0.021 
Oestradiol  DHEAS 1.09 0.61 1.89 0.782 
Oestradiol  Progesterone 1.17 0.66 2.05 0.590 
Oestradiol  SHBG 0.53 0.26 1.03 0.062 
Oestradiol  LH 0.75 0.40 1.31 0.315 
Oestradiol  FSH 1.06 0.58 1.83 0.855 
Oestradiol  ER-α 1.38 0.84 2.46 0.205 
Oestradiol  ER-β 1.11 0.63 1.96 0.715 
Oestradiol  AR 1.20 0.72 2.15 0.493 
Oestrone  Androstenedione  2.19 1.40 3.80 0.001 
Oestrone  Testosterone 2.50 1.57 4.36 0.000 
Oestrone  DHEAS 1.55 0.79 2.38 0.204 
Oestrone  SHBG 0.65 0.33 1.31 0.233 
Oestrone  Progesterone 1.46 0.86 2.57 0.158 
Oestrone  LH 0.94 0.51 1.66 0.827 
Oestrone  FSH 1.35 0.76 2.29 0.308 
Oestrone  ER-α 1.76 1.20 3.06 0.004 
Oestrone  ER-β 1.39 0.82 2.45 0.222 
Oestrone  AR 1.52 0.95 2.69 0.079 
Androstenedione  Testosterone 2.97 1.80 5.18 0.000 
Androstenedione  DHEAS 2.25 0.88 2.83 0.090 
Androstenedione  Progesterone 1.68 0.97 3.04 0.065 
Androstenedione  SHBG 0.76 0.37 1.57 0.451 
Androstenedione  LH 1.09 0.57 2.01 0.799 
Androstenedione  FSH 1.59 0.85 2.73 0.150 
Androstenedione  ER-α 2.07 1.35 3.64 0.001 
Androstenedione  ER-β 1.61 0.92 2.93 0.096 
Androstenedione  AR 1.78 1.09 3.19 0.022 
Testosterone  DHEAS 2.95 0.99 3.25 0.053 
Testosterone  Progesterone 1.90 1.09 3.49 0.023 
Testosterone  SHBG 0.86 0.42 1.81 0.691 
Testosterone  LH 1.24 0.63 2.33 0.529 
Testosterone  FSH 1.82 0.95 3.15 0.072 
Testosterone  ER-α 2.36 1.51 4.16 0.000 
Testosterone  ER-β 1.83 1.03 3.36 0.039 
Testosterone  AR 2.04 1.22 3.66 0.006 
Table 4-47: Expected odds ratio of the different combinations of hormones/SB to 
investigate their synergistic effect in breast cancer.  
 
Table 4-47: Expected odds ratio of the different combinations of hormones/SB to 
investigate their synergistic effect in breast cancer.  
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Hormone / SB Hormone / SB 
Expected Lower Upper p-
value OR CI CI 
DHEAS SHBG 0.38 0.24 0.94 0.037 
DHEAS Progesterone  1.08 0.60 1.88 0.796 
DHEAS LH 0.59 0.36 1.21 0.149 
DHEAS FSH 0.95 0.53 1.69 0.859 
DHEAS ER-α 1.46 0.76 2.26 0.252 
DHEAS ER-β 1.03 0.58 1.81 0.916 
DHEAS AR 1.18 0.65 1.98 0.587 
SHBG Progesterone 0.53 0.26 1.03 0.060 
SHBG LH 0.33 0.16 0.61 0.000 
SHBG FSH 0.46 0.23 0.90 0.023 
SHBG ER-α 0.61 0.32 1.25 0.178 
SHBG ER-β 0.50 0.25 0.98 0.043 
SHBG AR 0.53 0.28 1.09 0.083 
Progesterone  LH 0.75 0.39 1.30 0.310 
Progesterone  FSH 1.06 0.58 1.82 0.858 
Progesterone  ER-α 1.38 0.83 2.44 0.211 
Progesterone  ER-β 1.11 0.63 1.95 0.716 
Progesterone  AR 1.19 0.71 2.14 0.505 
LH FSH 0.66 0.35 1.16 0.147 
LH ER-α 0.88 0.49 1.58 0.674 
LH ER-β 0.71 0.38 1.25 0.239 
LH AR 0.76 0.43 1.37 0.361 
FSH ER-α 1.27 0.73 2.19 0.396 
FSH ER-β 1.00 0.56 1.75 0.989 
FSH AR 1.09 0.63 1.91 0.765 
ER-α ER-β 1.31 0.79 2.35 0.288 
ER-α AR 1.43 0.91 2.56 0.117 




AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicle stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone 
sulphate; ER=oestrogen receptor; FSH=follicle stimulating hormone; LH=luteinising 
hormone; OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 










Hormone / SB Hormone / SB 
Observed/Expected Lower Upper p-
value OR CI CI 
Oestradiol  Oestrone  1.35 0.51 3.37 0.541 
Androstenedione  Oestradiol 1.12 0.47 2.47 0.799 
Oestradiol  Testosterone 1.01 0.44 2.16 0.973 
Oestradiol  DHEAS 0.98 0.39 2.52 0.971 
Oestradiol  Progesterone 0.94 0.38 2.33 0.887 
Oestradiol  SHBG 0.77 0.18 3.48 0.738 
Oestradiol  LH 0.94 0.26 3.67 0.924 
Oestradiol  FSH 0.69 0.16 3.18 0.631 
Oestradiol  ER-α 1.01 0.38 2.45 0.983 
Oestradiol  ER-β 0.67 0.23 1.95 0.466 
Oestradiol  AR 1.28 0.48 3.09 0.619 
Androstenedione  Oestrone  0.81 0.33 1.89 0.628 
Oestrone  Testosterone 0.96 0.40 2.15 0.923 
Oestrone  DHEAS 0.77 0.33 2.24 0.634 
Oestrone  SHBG 0.72 0.19 2.73 0.631 
Oestrone  Progesterone 1.09 0.42 2.68 0.865 
Oestrone  LH 1.11 0.37 3.47 0.852 
Oestrone  FSH 1.09 0.39 3.20 0.865 
Oestrone  ER-α 0.87 0.35 1.96 0.743 
Oestrone  ER-β 0.83 0.33 1.99 0.671 
Oestrone  AR 1.64 0.63 3.77 0.311 
Androstenedione  Testosterone 0.83 0.40 1.64 0.588 
Androstenedione  DHEAS 0.80 0.52 2.49 0.704 
Androstenedione  Progesterone 0.96 0.43 2.01 0.920 
Androstenedione  SHBG 0.73 0.19 2.85 0.655 
Androstenedione  LH 1.89 0.72 5.12 0.198 
Androstenedione  FSH 1.28 0.46 3.76 0.633 
Androstenedione  ER-α 0.88 0.35 1.98 0.756 
Androstenedione  ER-β 0.98 0.37 2.40 0.964 
Androstenedione  AR 1.35 0.50 3.24 0.555 
Testosterone  DHEAS 0.52 0.39 1.82 0.306 
Testosterone  Progesterone 0.91 0.41 1.88 0.808 
Testosterone  SHBG 1.25 0.35 4.39 0.733 
Testosterone  LH 2.29 0.88 6.12 0.091 
Testosterone  FSH 3.08 1.01 9.98 0.048 
Testosterone  ER-α 0.82 0.34 1.82 0.630 
Testosterone  ER-β 0.99 0.38 2.38 0.986 
Testosterone  AR 1.24 0.47 2.94 0.658 
Table 4-48: Observed versus expected odds ratio of the different combinations of 
hormones/SB to quantify their possible synergistic effect in breast cancer.  
 
Table 4-48: Observed versus expected odds ratio of the different combinations of 
hormones/SB to quantify their possible synergistic effect in breast cancer.  





Hormone / SB Hormone / SB 
Observed/Expected Lower Upper p-
value OR CI CI 
DHEAS SHBG 2.36 0.52 6.85 0.265 
DHEAS Progesterone  1.12 0.53 2.40 0.766 
DHEAS LH 1.60 0.55 3.70 0.392 
DHEAS FSH 1.47 0.46 4.71 0.515 
DHEAS ER-α 0.63 0.25 1.96 0.424 
DHEAS ER-β 1.02 0.36 3.01 0.971 
DHEAS AR 0.95 0.35 2.68 0.922 
SHBG Progesterone 1.03 0.28 4.08 0.965 
SHBG LH 0.68 0.13 3.78 0.660 
SHBG FSH 1.26 0.40 4.09 0.692 
SHBG ER-α 2.42 0.65 8.62 0.186 
SHBG ER-β 6.67 1.31 35.49 0.022 
SHBG AR 2.26 0.62 7.58 0.215 
Progesterone  LH 1.15 0.44 3.32 0.771 
Progesterone  FSH 1.02 0.30 3.80 0.970 
Progesterone  ER-α 0.99 0.34 2.66 0.978 
Progesterone  ER-β 0.65 0.21 2.00 0.450 
Progesterone  AR 1.42 0.50 3.66 0.510 
LH FSH 1.25 0.57 3.00 0.576 
LH ER-α 0.73 0.24 2.24 0.582 
LH ER-β 0.85 0.27 2.93 0.796 
LH AR 0.77 0.18 3.33 0.731 
FSH ER-α 0.91 0.30 2.75 0.865 
FSH ER-β 1.63 0.57 4.98 0.363 
FSH AR 0.84 0.26 2.58 0.759 
ER-α ER-β 1.06 0.48 2.14 0.882 
ER-α AR 0.99 0.44 1.92 0.983 
ER-β AR 1.52 0.66 3.22 0.330 
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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4.4 Discussion 
The role of sex steroid hormones in breast cancer has been known for a long 
time and has been the subject of many studies. In this study, we report for the 
first time on sex steroid hormone bioactivity. Serum ER-α and ER-β bioactivity 
using a yeast-based assay was significantly higher in postmenopausal women 
prior to diagnosis of invasive ER-positive breast cancer compared to controls. 
Women with ER-α SB in the top quintile more than two 2 years before diagnosis 
had a two-fold breast cancer risk increase. We further validated the role of sex 
steroid hormones in breast cancer risk. Less than 2 years before diagnosis, 
oestrone was associated with increased breast cancer risk. Testosterone and 
androstenedione levels were shown to be significantly associated with increased 
cancer risk irrespective of time (>6months and <5 years) before invasive ER-
positive breast cancer, with the first being independent of other hormones and 
the latter being dependent on testosterone.  
 
For the first time joint associations of sex steroid hormones, gonadotrophins and 
sex steroid receptor SB were examined. Joint association of FSH and 
testosterone was shown to be highly associated with breast cancer risk with 
women with both hormones in top quintiles having almost six fold increased 
breast cancer risk independent of time to diagnosis with further analysis 
confirming a possible synergistic effect. Interestingly, SHBG and ER-β were also 
shown to be associated with high breast cancer risk with women with both in the 
top quintiles more than two years before diagnosis having a six fold increased 
breast cancer risk  
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The strengths of this study are (1) use of standardised protocol for serum sample 
collection with protocol adherence confirmed by the lack of any difference in 
mean hormone or steroid receptor SB levels between the different trial centres 
(data not shown) (2) prospective nested case-control design which ensured the 
selection controls from the same population (trial participants) as that in which the 
breast cancer cases occurred (3) confirmation of breast cancer diagnosis and 
receptor status from the treating physicians which eliminated possible 
misidentification of cases from use of cancer registry data or self reporting alone 
(4) use of women not on HRT with ER positive invasive breast cancer which 
ensured that a homogenous case mix (5) measurement of all sex steroid 
hormones of ovarian origin with only DHEA and oestrone sulphate not being 
analysed (6) analysis of the joint association of hormones, hormones and SB and 
SBs provided robust results. Ideally cases should have been a random selection 
from all women with fully characterised ER positive breast cancer within the trial. 
However the need to start experimental work meant that the first 200 fully 
characterized cases that fulfilled eligibility criteria were used.   
 
Our findings are in keeping with our previous findings of elevated ER-α and ER-β 
SB in women with breast cancer at the time of clinical diagnosis 162 and with the 
meta-analysis by Key et al. that showed sex steroid hormone levels more than 2 
years prior to diagnosis to be more significantly associated with breast cancer risk 
197. Free oestradiol has the highest known affinity for ER-α and ER-β receptors 340 
and a statistically significant correlation between free oestradiol and receptor SB 
was found in our study. Phosphorylation of the receptors is probably modulated 
by other surrogates as well. Thus, we found increased breast cancer risk in 
women with ER-α SB in the highest quintile more than two years before 
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diagnosis in the absence of a correlation with individual oestrogens. In our 
previous study, receptor SB was also 2-3 folds higher than the actual oestradiol 
concentration 162. Other factors such as insulin growth factor-1 (IGF-1) which 
have been shown to bind to the ER 341 could contribute to the higher bioactivity. 
IGF-1 has been shown to stimulate ER-mediated trans-activation and ER-
phosphorylation 341. Recently elevated IGF-1 levels have been associated with 
ER-positive breast-cancer risk 342. We hope to investigate IGF-1 levels in relation 
to ER SB within our study cohort where appropriate samples (spun within 24 
hours 343) are available. Additionally, other serum steroid independent co-
activators may have an impact on breast carcinogenesis through ER-α and ER-β 
SB activation, such as cAMP and cytokines 344. Generally, the advantage of using 
SB assays for steroid receptors is that their levels reflect the sum of all the factors 
in the serum that trans-activate the two different ERs. Given the significant 
reduction in breast cancer incidence in women taking anti-oestrogens such as 
tamoxifen 126, raloxifene 127 and aromatase inhibitors 128, it is likely that ER SB 
may prove to be beneficial in individualising and monitoring breast cancer 
chemopreventive strategies. Studies are urgently needed to assess this further. 
 
The role of ER-α in breast carcinogenesis has been extensively studied and it is 
one of the main tumour markers used in the clinical setting. However, the role of 
ER-β still remains to be determined. Cell-based assays have shown ER-β to be 
less active on gene transcription than ER-α 345. This could be the explanation for 
our findings of that while ER-β SB is different among cases and controls more 
than 2 years before diagnosis, levels in the top quintile are not associated with an 
increased breast cancer risk. Expression of both receptors favours a positive 
response to endocrine therapy 345 but it is unclear whether the addition of ER-β to 
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ER-α as a tumour marker would be clinically beneficial. Recently, our group 
showed that women whose levels of ER-α and ER-β SB in the top quintiles at the 
time of diagnosis had a 10 fold increased risk for ER positive breast cancer 162.  
In this study, joint association of SB of ERs was shown to be associated with 
breast cancer risk in those women who gave a sample more than two years 
before diagnosis indicating that SB of sex steroid receptors could prove useful for 
breast cancer risk assessment. Women with SB in the top quintiles had a breast 
cancer risk ranging between 2-2.5 fold. This reinforces the possibility that SB may 
prove to be a useful tool in individualising and monitoring breast cancer 
chemopreventive strategies. 
 
Oestrone is the main circulating oestrogen after menopause in postmenopausal 
women 346. We found oestrone in the top quintile less than two years before 
breast cancer diagnosis to be associated with increased risk. Our findings 
support previous studies which showed only oestrone and not oestradiol or bio-
available oestradiol to be significantly associated with increased breast cancer 
risk 212, 218, 224, 225. Studies that have not been able to find a significant association 
of oestrone with breast cancer risk are on the whole based on small number of 
cases 203, 217, 347. There are conflicting results in the literature on the role of 
oestradiol. There have been three reports in postmenopausal women that similar 
to our study did not find any differences between oestradiol levels in cases and 
controls 226, 347 but there are conflicting reports as well 212, 217, 222-225 that 
demonstrate an increased risk 203, 218, 219. While earlier publications from the 
European Prospective Investigation into Cancer and Nutrition (EPIC) study 198 
found total oestradiol, oestradiol and oestrone to be associated with breast 
cancer risk independent of time to diagnosis, a recent study by Zeleniuch-
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Jacquotte et al found that oestrone close to diagnosis had the strongest 
association with increased breast cancer risk 199.  
 
In general, some of these differences observed in studies between the hormones 
and their association with breast cancer may be a result of the variety of assays 
used to measure oestrogens, direct or indirect radioimmunoassay (RIA) and 
immunoassays. The reliability and validity of steroid sex hormone measurements 
in biologic specimens using immunoassays has been recently evaluated. While 
considerable variation was found in results from different laboratories, the 
measurements from a single laboratory was reproducible 151. The most sensitive 
method is mass spectrometry which does not lend itself to use in clinical settings 
150 149. Immunoassays have been shown that to yield similar estimates of most 
sex steroid hormones in comparison to mass spectrometry 151, 152. We have in 
addition used calculated free oestradiol and testosterone levels as these were 
highly correlated with the actual hormone levels measured on equilibrium dialysis 
348.  
 
Oestrone levels did not correlate significantly with ER SB, raising the question of 
how this oestrogen might exert its effect on breast carcinogenesis. Oestrone is a 
weak oestrogen which preferentially binds to the alpha receptor but with low 
affinity 349. Studies have shown that oestrogens also exert their effects through 
their binding to the oestrogen G protein-coupled receptor GPR30 (GPER), which 
is independent of ER-α and ER-β 350. This has led to the suggestion that oestrone 
may be capable of inducing ERK phosphorylation via GPR30 without the 
requirement of ER receptors, as oestradiol has been shown previously 350. In 
addition, other oestrogen metabolites independent of ER mediation has been 
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shown to contribute to breast carcinogenesis 351. If this is confirmed, then there 
could be implications for hormonal therapy in prevention and treatment of breast 
cancer in postmenopausal women.  
 
Androstenedione and testosterone were associated with a two-fold increase in 
breast cancer risk independent of time from diagnosis. Overall, there is conflicting 
data on endogenous levels of androgens and breast cancer risk 201. In the meta-
analysis high testosterone levels were associated with breast cancer risk in 
postmenopausal women 197 with six out of nine studies included in the pooled 
study showing an increased risk of breast cancer in women having testosterone 
in the highest quintiles 218, 219, 222-225. This observation was also seen in the EPIC 
study 198, confirming no difference in the effect of testosterone in relation to time 
of diagnosis. Our observation that androstenedione was significantly associated 
with breast cancer risk is also in line with most of the previous prospective studies 
203, 218, 224, 225. But in contrast to other studies 203, 218, 221, 224, 225, our results showed 
DHEAS to be associated with breast cancer risk only after adjustment with 
androstenedione. Since, both DHEAS and androstenedione are largely of 
adrenal origin in postmenopausal women, our data suggests that adrenal 
androgens may play a role in breast carcinogenesis.  
 
The role of endogenous androgens in breast cancer development has been 
debated. One of the possible pathways is through increased aromatase activity in 
the setting of oestrogen depletion after menopause and increased capacity to 
convert testosterone to oestradiol and androstenedione to oestrone may be the 
major factor. After adjustment for oestradiol and oestrone levels, the association 
of the androgens with breast cancer risk was shown to remain in the main, 
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indicating that androgens may have oestrogen-independent effects on breast 
cancer, an observation that has been reported by other authors 197, 198, 202. It is 
possible that androgens may influence breast cancer risk by directly binding to 
AR to stimulate or inhibit breast cell growth 352, 353 but we were unable to 
demonstrate any association between AR SB and breast cancer. Joint 
association of AR though with testosterone when all cases were analysed, 
demonstrated that women with AR SB and testosterone in top quintiles have a 
2.5 fold increased risk which remained significant after all adjustments. 
Additionally, joint association of AR SB and oestrone in samples taken less than 
two years before breast cancer diagnosis, showed that women with AR SB and 
oestrone in the top quintiles had a 2.5 fold increased risk which remained 
significant after all adjustments. A second possible explanation for the direct 
association of androgens with breast cancer risk is conversion of high circulatory 
levels of these hormones to oestrogen either locally in the breast or peripherally 
in adipose tissue with the oestrogens then being responsible for tumour 
development 198. A statistically significant correlation between free testosterone 
and both ER receptors was observed. While free testosterone is the best ligand 
of AR, androgens have also been shown to bind and activate ERs 353, favouring 
the view that a third pathway may exist through binding to ER and directly 
promoting breast cell proliferation. 
 
Joint association of high levels of oestrone and testosterone was shown to 
increase breast cancer risk up to 3.5 folds independent of time to diagnosis. 
During the last few years exogenous oestrogens and testosterone have been 
extensively used to manage post-menopausal symptoms. Recently, it was 
demonstrated by the Nurses’ Health Study that women using combination of 
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oestrogen and testosterone therapy rather than oestrogen alone had a higher 
breast cancer risk 354. In addition, in a recent trial in women undergoing adjuvant 
treatment for breast cancer, use of tibolone, a drug which is a synthetic steroid 
with oestrogenic, progestational and androgenic properties to prevent side-effects 
of vasomotor symptoms and bone loss was shown to be associated with breast 
cancer recurrence 355. The increasing number of studies showing association of 
oestrogens and testosterone with breast cancer risk including the results of the 
current study suggests that use of such combinations in postmenopausal women 
should be carefully considered.  
 
Progesterone has been shown in in-vitro studies and animal work to both 
decrease and increase breast cancer risk 165. Controversy surrounds the true 
effect of progesterone on breast proliferation with various progestins being shown 
to block, stimulate or have no effect on cell growth 356. The only reported large 
study investigating endogenous levels of progesterone did not show any 
association of the circulating progesterone with breast cancer risk 202 in 
agreement with these data. Epidemiological studies, however, have consistently 
shown an increase in breast cancer risk when exogenous progesterone is used in 
combination with oestradiol 177, 179 causing decline in HRT use among 
postmenopausal women 357. Joint association of progesterone with testosterone 
or androstenedione was shown to increase breast cancer risk by almost 2 fold 
but this significance was lost after adjustments. Combination of high endogenous 
levels of progesterone and oestrogens was not shown to be associated with 
increased risk of breast cancer although, exogenous administration of oestrogen 
in combination with progestin is responsible for a higher breast cancer risk than 
oestrogen alone 179. 
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Our results on breast cancer risk reduction with increasing levels of SHBG are 
similar to meta-analysis 197 with only one study demonstrating no reduction in risk 
with high levels of SHBG 358. Conflicting data has been shown with regards to 
SHBG levels in samples that were collected at different time intervals in relation 
to time of diagnosis. Similar to the meta-analysis elevated SHBG levels less than 
two years before diagnosis were shown to have a stronger association with 
reduced breast cancer risk 197. This was in contrast to Kaaks et al who reported 
no difference 198. Given that SHBG binds to both oestradiol and testosterone 
prohibiting binding of the hormones to their receptors, it is expected that high 
levels of SHBG are associated with lower risk. 
 
Interestingly though, joint association of SHBG with ER-β was shown to increase 
breast cancer risk by six fold more than two years before diagnosis. Previous 
studies have demonstrated that high SHBG levels were associated with higher 
mammographic density, indicating a positive relationship between them 359, 360 
with mammographic density shown to be a strong independent predisposing 
factor for breast cancer 62. SHBG has also been suggested to promote the effects 
of oestradiol by interacting with plasma membrane binding sites in target cells 
within the breast 359. ER-β is the main ER expressed in epithelial cells in normal 
human breast. Therefore, it could be hypothesised that the observed increased 
breast cancer risk in our study associated with high levels of SHBG and ER-β SB 
may be due to high breast proliferation caused through ER-β possibly promoted 
by SHBG which also associates with high breast density. Further studies though 
are needed before any suggestions can be made.  
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There are not that many studies investigating LH and FSH levels and breast 
cancer risk. The only study identified was by Wang et al, who reported in 1976 
that breast cancer patients with low LH and FSH levels measured at the point of 
diagnosis had a faster recurrence, even though the data did not reach statistical 
significance 361. In this study, it was shown for the first time that high level of LH 
was associated with a decreased breast cancer risk after adjustment for 
androstenedione. On the other hand, FSH was not shown to be association with 
breast cancer.  
 
Joint association of the gonadotrophins or in combination with oestrogens were 
not shown to be associated with breast cancer risk, but a significantly increased 
risk was observed for FSH and testosterone up to 5 years prior to breast cancer 
diagnosis, with the risk ranging 5-6 folds. This is an interesting finding as it is for 
the first time shown androgens in combination with gonadotrophins to be 
associated with such an increased breast cancer risk. Validation of these 
observations is required in independent studies. It is difficult to explain in 
postmenopausal women with inactive ovaries since the known action of FSH is in 
the ovaries where it stimulates granulosa cells to produce oestradiol through 
aromatisation of testosterone 362 and increases  production of androgens in 
response to LH by stimulating secretion of paracrine factors, such as inhibin B 363.  
One explanation may be related to the action of FSH on the breast. FSHR mRNA 
is expressed in the normal breast and has been also detected in breast cancer 
cell lines and breast cancer core biopsies 364. Therefore, an attractive model in 
postmenopausal women would be that FSH through its binding to FSHR in the 
breast tissue modulates aromatase activity triggering the conversion of 
androgens, in particular testosterone, into oestrogens that in turn are responsible 
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for breast proliferation. Additionally, it could also be speculated that FSH could be 
a surrogate marker of IGF1 since previous studies have shown a positive 
correlation between the two hormones 360. Previous work on bovine granulosa 
cells demonstrated that IGF1 with FSH act synergistically to up-regulate sex 
steroid synthesis 365. Animal work has indicated a synergism of sex steroid 
hormones and FSH in bovine granulosa cells. DHT was shown to synergise with 
FSH inducing FSHR 366. Based on our hypothesis, we have set up collaboration 
with Professor Louis Dubeau to further investigate the possible synergistic effect 
of FSH and testosterone in breast carcinogenesis in a mouse model. Two 
transgenic mouse lines expressing Cre recombinase under the control of a 
truncated form of the FSHR will be crossed with a ROSA26R Cre reporter mouse 
367. Expression of FSHR in the breast will be examined (stroma, epithelium and 
fat). If FSHR mRNA is confirmed then mouse mammary cells will be treated with 
FSH and IGF1 alone and in combination to investigate whether increased 
aromatization occurs by measuring CYP11A1, HSD3B1 and CYP19A1 (genes 
known to encode aromatase enzymes) mRNA and oestradiol, oestrone levels 
and compare to non treated cells. Finally, the relationship of FSH levels and HRT 
use would be interesting. HRT is known to increase breast cancer risk and 
possibly decrease FSH levels. In this study women with high levels of FSH and 
testosterone have increased risk to develop breast cancer – therefore, it could be 
hypothesised that an altered pathway could be responsible for the development 
of breast cancer between the action of FSH and sex steroid hormones under the 
administration of HRT.  
 
Sex steroid hormones and their receptors along with gonadotrophins could prove 
a useful tool for the early detection and prevention of breast cancer. Currently, 
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even though mammography screening has been suggested to decrease mortality 
from breast cancer 117, its true value has been the subject of much debate 118. 
Tools such as the Gail, Claus and Golditz models using family history and 
lifestyle data have been developed to calculate a woman’s absolute risk of breast 
cancer and triage women to screening or risk reducing mastectomy. When 
oestradiol was added in the Golditz model the test’s concordance statistics were 
slightly increased 123. It is possible that addition of oestrone, testosterone and 
FSH, or the bioactivity of ER receptors may improve the performance of these 
scores. The significance of the attempts to increase the models performance is in 
identification of those women at high risk, eventually leading to improved overall 
survival rates of breast cancer patients through prevention strategies.  
 
In summary, in postmenopausal women with ER-positive breast cancer, 
testosterone and androstenedione independent of time to diagnosis, ER-α SB 
more than 2 years prior to diagnosis and oestrone levels less than 2 years before 
diagnosis were associated with increased risk. Sex steroid receptor SB assays 
may be a new tool for breast cancer risk assessment and warrant further 
research. Combination of the different hormones/SB of the sex steroid hormone 
receptors has been shown to have a better prediction power in relation to single 
hormones or SB. Testosterone with FSH independent of time to diagnosis and 
SHBG with ER-β more than two years before breast cancer diagnosis were 
shown to be highly significant associated with breast cancer risk indicating a 
synergistic effect in mammary carcinogenesis. Understanding the complex 
signals that hormones convey to the mammary gland could shed light on the 
events that surround breast tumour formation and growth and eventually initiate 
new strategies for treatment. 
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5 DNA METHYLATION IN BREAST CANCER 
 
5.1 Introduction 
Identification of novel molecular markers with the potential for optimal breast 
cancer management and improved survival rates is essential. During the last 
decade a huge emphasis has been given to the identification of genetic changes 
and expression profiles that correlate with clinical characteristics of the disease, 
in an attempt to discover genetic markers predicting prognosis and response to 
treatment. Many of these studies have been based on a single sample from 
within the tumour, assuming that this single region reflects the genetic signature 
of the whole cancer. However, there are increasing reports of the presence of 
intra-tumour heterogeneity and its effect on expression profiling in several cancer 
types 368-374, including breast cancer 375, 376.  
 
Intra-tumour heterogeneity is the result of a multi-factorial microenvironment 
which exhibits a zonal heterogeneity from central to peripheral regions 377 (Figure 
5-1). Studies comparing the central with the peripheral zone have identified 
expression of different molecules within these regions. In the centre, which is 
characterised by hypoxic conditions, genes such as vascular endothelial growth 
factor (VEGF) have been shown to be regulated and molecules such as the 
matrix metalloproteinases (MMPs) are over-expressed. In the tumour periphery, 
which is localised at the stromal border, forming the biologically active invasion 
front and cancer stem cell reservoir, molecules such as E-cadherin have been 
shown to be down-regulated 378, 379.  
 
 
















Even, for ER and PR, which are the most significant markers in breast cancer 
treatment strategies, there is conflicting data with studies also reporting to be 
differently expressed in different regions within the tumour 380-382. This has led to 
an increased emphasis for the need to study more than one part of the tumour to 
ensure the generation of accurate and reproducible data, especially as these 
data are used to guide patient management. Based on these observations it was 
hypothesised that the problem of intra-tumour heterogeneity may be overcome by 
studying DNA based alterations, such as epigenetic changes, specifically DNA 
methylation, which may not be affected by the zonal microenvironment of the 
tumour.  
 
Figure 5-1: Intra-tumour heterogeneity. Intra-tumoural heterogeneity is a result of a multi-
factorial microenvironment which exhibits a zonal separation from central to peripheral regions.  
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In addition, to improve early diagnostic strategies better models are needed to 
investigate early stage disease. Studies have indicated that epigenetic alterations 
may be the initiating events in the expansion of cells in pre-neoplastic lesions 271. 
However, although epigenetic alterations contribute to the pathogenesis of breast 
cancer, the effect of these changes as the initiating event of carcinogenesis has 
been difficult to study. Our group was amongst the first to describe an epigenetic 
field defect, altered DNA methylation in morphological normal breast tissue 
adjacent to tumour, in breast cancer 383, 384 and these findings have been 
confirmed by others 273, 385, 386. If methylation changes arise early in normal 
tissues, leading to regional epigenetic defects, then a comparison between 
histological normal tissues from cancer patients and healthy controls could lead 
to the identification of methylation markers that could be useful in risk 
assessment 387. Since most of the research studies to identify markers for the 
early detection of the disease have been focused on cells within the tumour from 
early stage cases we have hypothesised that by studying morphologically normal 
tissue adjacent to the tumour it could prove a good strategy for the identification 
of risk prediction markers. Such study is important as the identification of patients 
who are at high risk of cancer could benefit from prophylactic treatment.  
 
Multiple genes have been shown to be differently methylated in normal versus 
tumour tissue (discussed in section 2.3.4). Recently, our group and others 
demonstrated that PCGT genes are more likely to have cancer specific promoter 
DNA hypermethylation than non-PCGT genes 279, 280, 388. Furthermore, we 
showed that hypermethylation of NEUROD1, a PCGT gene, within pretreatment 
core biopsies preferentially discriminated between neoplastic and non-neoplastic 
breast tissue samples and was associated with a favourable response to 
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treatment 305. Given the data showing that expression profiles are affected by 
intra-tumour heterogeneity, it is essential to establish that the methylated profile 
of the core biopsy is representative of the entire tumour. PCGT methylation could 
prove a good candidate marker for serum analysis but before analysing serum it 
is important to investigate whether such cancer specific PCGT methylation is 
representative of the entire tumour.  In addition, it is interesting to investigate 
whether PCGT methylation in morphologically normal tissue adjacent to the 
tumour could predict the presence of breast cancer.  
 
For the purposes of this study; 1) initially the expression and DNA methylation 
profile of NEUROD1 in 9 breast cancer cell lines and 63 frozen breast cancer 
tissues were analysed. Based on the results it was postulated that DNA 
methylation signature may carry information independently from the expression 
profile of the tumour. In order to further investigate both 2) the predictive role and 
3) homogeneity of PCGT gene methylation in breast cancer, methylation analysis 
was carried out using MethyLight: a highly sensitive real-time PCR methylation 
assay 250. 55 PCGT genes (6 of which are also known ER targeted genes) were 
analysed in paraffin embedded breast cancer tissue biopsies taken from the 
central and peripheral parts of the tumour and were compared between them and 
with non-neoplastic breast tissue. Finally, 4) comparison of PCGT methylation 
levels between morphologically normal tissue adjacent to the tumour and non-
neoplastic breast tissue was performed.  
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5.2 Materials and Methods 
5.2.1 Subjects 
The samples were collected at the Department of Pathology, Paracelsus Private 
Medical University Salzburg (Salzburg, Austria). Clinical and pathologic data were 
stored in a database in accordance with hospital privacy regulations.  
 
Tissue samples were collected from 50 postmenopausal women undergoing 
surgery for ER positive breast cancer or benign breast changes (the final number 
of the samples used collected from these 50 women reduced after the quality 
control performed of the extracted DNA). Core biopsies were dissected from the 
centre of IDC and from the peripheral cancer stromal border. Relevant tissue 
areas from tumours at least 1cm in diameter were selected on Haematoxylin and 
Eosin (H&E) slides and used to guide dissection from the paraffin block. For DNA 
extraction, 3 mm diameter core punches were used. The samples were a priori 
separated into two sets: training (15 tissues taken from the centre of the tumour 
and 14 from the periphery) and validation (19 tissues taken from the centre of the 
tumour and 20 from the periphery). Both the cores and the slides with the tissue 
of interest were prepared by our collaborators in Salzburg.  
 
A second set of samples for mRNA analysis was obtained from our collaborators. 
Frozen breast tissue samples were collected from 63 patients with breast cancer. 
The breast cancer specimens were obtained immediately after resection of the 
breast or lumpectomy brought to the pathologist and a part of the tissue was 
pulverized under cooling with liquid nitrogen and stored at -70°C.  
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5.2.2 Cell-lines, culture conditions and reagents 
Human breast cancer cell lines BT-20, ZR-75-1, MCF7, MDA-MB-231, T-47D, 
and SK-BR-3 were obtained from the American Type Culture Collection (ATCC) 
and cultured according to their recommendations. The following cell lines were 
generously provided by: HBL-100 from NE Hynes, F Miescher Institute, Basle, 
Switzerland and Hs 578T from GC Buehring, School of Public Health, Berkley, 
CA, USA and were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
(Gibco Invitrogen Corporation, Lofer, Austria) containing 10% foetal bovine serum 
(Biochrom AG, Berlin, Germany). 
 
5.2.3 Gene selection 
Recently our group has provided evidence for a new model of carcinogenesis. 
The predisposition of Polycomb Repressor Complex 2 (PRC2) targets to cancer-
specific DNA hypermethylation suggests a ‘crosstalk ‘between PRC2 and de 
novo DNA methyltransferases in precursor cancer cells with  a PRC2 distribution 
similar to that of ES cells. This ‘crosstalk’ may be initiated and/or facilitated by 
various environmental exposures, transgenerational inheritance, endocrine 
exposure, inflammation and by age. If a cell loses the potential to terminally 
differentiate as a consequence of irreversible CpG methylation, it will undergo 
prolonged exposure to environmental onslaught, and so, more likely to acquire 
those mutations and/or deletions necessary for carcinogenesis. It has also been 
reported that PcG targets are up to 12-fold more likely to demonstrate cancer 
specific promoter methylation than non-targets further supporting the hypothesis 
that cross talk between PcG proteins and DNMTs have the potential to lay 
ground for the development of cancer 280. Based on that observation, polycomb 
group targeted genes (PCGT) were chosen to be analysed. The genes therefore, 
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were occupied at least by two of the three proteins forming the PRC2 complex; 
EZH2, EED and SUZ12. Some of the selected genes also belong to the HOX 
Family Genes (n=12) known to be functionally associated with breast cancer 
biogenesis 389 and some of them to be methylated in breast cancer 390. Finally, 
some of the genes were also oestrogen receptor target genes 391 (n=6) (PITX2, 
ESR1, PGR, CDH13, DCC, FLJ39739). Decreased methylation of ER-targeted 
genes has been shown to be associated with breast cancer risk 307, 391 
hypothesising that as a function of time and dose, cumulative oestrogen 
exposure during lifetime leaves an epigenetic signature in the DNA, which is 
associated with a postmenopausal risk to develop breast cancer 116.   
 
5.2.4 RNA isolation and reverse transcription (RT) - PCR 
Total cellular RNA was extracted by the acid guanidium thiocyanate-phenol-
chloroform method and cDNA was kindly prepared by Heidi Fiegl. Primers and 
probe for RT PCR analysis for NEUROD1 were purchased from Applied 
Biosystems (Applied Biosystems Assay ID: Hs00159598_m1) designed by Heidi 
Fiegl. Primers and probes for the TATA box-binding protein (TBP; a component 
of the DNA-binding protein complex TFIID as endogenous RNA control) were 
used according to Bieche et al 392. Real-time PCR was performed using an ABI 
Prism 7900HT Detection System (Applied Biosystems, Foster City, CA). The 
standard curves were generated using serially diluted solutions of standard cDNA 
derived from the HBL-100 breast carcinoma cell-line. 
 
5.2.5 DNA extraction from paraffin embedded tissue samples 
QIAGEN/QIA-amp Tissue kit was used. The experimental procedure was based 
on the protocol provided with the kit named as ‘‘Purification of Total DNA from 
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Animal Tissue’’. For each DNA extraction approximately 25 mg of tissue were 
used. The samples were transferred into Sarstedt tube where 900 μl xylene was 
added, vortexed vigorously, centrifuged at 13000 rpm for 5 minutes with the 
supernatant being removed at the end of the step. Two rounds of ethanol 
washing (800 μl each time) followed. The supernatant was removed and the 
samples were incubated at 37°C for 15 minutes until all ethanol was evaporated. 
The tissue pellet was re-suspended in 180 μl buffer ATL and 40 μl of proteinase K 
were added. The samples were vortexed and incubated at 55°C (water bath) 
overnight.  
 
The following day (s), 40 μl proteinase K were added till the tissue cores were 
fully digested. 200 μl of Buffer AL were added and they were mixed immediately 
by vortexing and then incubated at 70°C for 10 minutes. 200 μl of ethanol were 
added and mixed thoroughly by vortexing and then centrifuged. The mixture was 
transferred to the DNeasy Mini Spin Column  (DNMSC) placed in a 2 ml collection 
tube and centrifuged at 8000 rpm for 1 minute. The flow–through was pipetted 
again into the spin column and centrifuged. The DNMSC was placed in a new 2 
ml collection tube and two washing steps with 500 µl Buffer AW1 and AW1 were 
carried out. The DNMSC was placed in a clean 1.5 ml microcentrifuge tube 
(eppendorf) where 100 µl Buffer AE were added and incubated for 5 minutes, and 
then centrifuged for 1 minute at 8000 rpm to elute. DNA was transferred tube and 
for long storage they were placed at -80°C. 
 
5.2.6 DNA quantification-NanoDrop 
NanoDrop was used for the quantification of DNA. 1 µl of the buffer that the DNA 
was eluted in (AE buffer for the paraffin embedded tissue samples) was pipetted 
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onto the NanoDrop to blank the device. To check the concentration of the 
samples 1 µl of undiluted DNA was used.  
 
5.2.7 DNA Quality Test 
To check the DNA quality of the paraffin embedded tissue samples, real time 
PCR reaction was carried out using three housekeeping genes collagen 2A1 
(COLA2A1), actin (ACTB) and Glyceraldehyde 3-phosphate dehydrogenase  
(GAPDH). For each reaction 4 ng/µl were used. All the primers used for the 
purposes of the study were provided from (Metabion, International AG, 
Germany). Details regarding the primers are provided in Appendix IX. 
 
5.2.8 M.SssI Modification  
M.SssI is a CpG methylase that methylates cytosines in the context of the CpG 
dinucleotide using SAM as a methyl donor. M.SssI-treated DNA is used as a 
universally methylated reference sample in all MethyLight reactions. Repeated 
rounds of M.SssI treatment are beneficial for methylating the genomic DNA 
sample. After each round of M.SssI treatment, the purified DNA sample was 
bisulphite-converted and tested with a methylation-specific MethyLight reaction 
to determine if the methylation reaches a plateau. This M.SssI-DNA sample was 
also used as a template for the standard curve samples. 
 
Components 
621 µl DNA (0.05 µg/µl final concentration), 100 µl 32 mM SAM (0.16 mM final 
concentration), 200 µl 10 X NEB2 Buffer (1 X final concentration), 50 µl M.SssI 
enzyme (4 units/µl) l (0.05 units/µl final concentration), water: to 2000 µl. The 
reaction components were mixed thoroughly and incubated at 37°C overnight. 
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Next day, to a volume of 2000 µl the following components were added: 28 µl 
SAM (1:10; 3.2 mM), 16 µl M.SssI enzyme (4units/µl) and incubated at 37°C 
overnight. 
 
5.2.9 Bisulphite Modification  
BM is a 3 step process involving:  
1) Sulphonation   2) Hydrolytic Deamination 3) Desulphonation 
BM and recovery of bisulphite-converted DNA steps were performed using the 
Zymo EZ DNA methylation kit (Zymo Research, Orange, CA) according to the 
manufacturer's instructions. M.SssI-modified DNA was also treated for use as a 
methylated reference in MethyLight assays. 40 µl of sample DNA were added 
manually to the Conversion Plate and 130 µl CT conversion reagent was added 
and mixed by pipetting. A foil cover was placed onto the plate and the samples 
were incubated overnight in a thermal cycler under the following conditions: 
Program: 98°C for 10 minutes, 53°C for 30 minutes, 8 cycles: 53 °C for 6 minutes, 
37°C for 30 minutes, 4°C storage for up to 6 hours 
 
Next day, the Zymo Spin I-96 Deep well Filter Plate was placed onto a Collection 
Plate. M-Binding Buffer (600 µl) was added to the Zymo Spin I-96 Deep well Filter 
Plate. The samples were transferred to the Conversion Plate manually and the 
plate was centrifuged at 3000 rpm for 5 minutes. The flow through by the end of 
this step was discarded. The M-Desulphonation Buffer (200 µl) was added and 
the plate was covered and left to incubate for 15 minutes. After incubation a 
centrifugation step was followed at 3000 g for 5 minutes and eventually the flow 
through was discarded.  
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Two steps of washing followed by adding M-Wash Buffer (400 µl). For the first 
washing a centrifugation at 3000 rpm for 5 minutes was carried out and for the 
second washing centrifugation was at 3000 rpm for 10 minutes. Finally the 
collection plate was discarded and the Zymo Spin I-96 Deep well Filter Plate was 
placed onto an Elution Plate where 30µl of M-Elution Buffer were added. The 
samples were incubated for 5 minutes at room temperature and then centrifuged 
at 3000 rpm for 3 minutes to elute the DNA. The plate was stored at 4°C before 
recording eluted volumes and transferring to labelled tubes. The final tubes were 
stored at -80°C until required for MethyLight. The samples are prepared using the 
appropriate concentration by diluting them. Negative controls (water) were 
prepared having the same volume as the samples to be able to check that the 
modification was free of contamination. The positive control was Sss1-treated 
human peripheral blood lymphocyte DNA in order to check if the bisulphite 
modification was successful.  
 
Preparation of solutions 
Proteinase K: 260 μl of Proteinase K Storage Buffer had to be added to the tube 
containing Proteinase K, which was dissolved and then stored at -20°C. 
CT Conversion Reagent: The CT Conversion Reagent was prepared prior to first 
use. 790 μl of M-Solubilisation Buffer and 300 μl of M-Dilution Buffer were added 
to a tube of CT Conversion Reagent that was mixed at room temperature with 
frequent vortexing for 10 minutes. Then 160 μl of M-Reaction Buffer were added 
and mixed for an additional 1 minute. 
M-Wash Buffer: 100% ethanol of 24 ml was added to the 6 ml M-Wash Buffer 
before use. 
DNA methylation in breast cancer   
5-237 
5.2.10 MethyLight Primers and Probes  
All the primers and probes were ordered from (Metabion, International AG, 
Germany). Primers and probes specific for methylated DNA and used for 
MethyLight reactions are listed in the Appendix IX. All primers and probes were 
designed by Heidi Fiegl and Sophia Apostolidou kindly showed me how to design 
them.  
Design 
The following sites were used in order to design the primers and probes for the 
study: 
1) Sequence identification: (http://www.gene.ucl.ac.uk/nomenclature/)  
2) Search of CpG islands in the promoter region: CpGplot software 
(http://www.ebi.ac.uk/emboss/cpgplot/), CpG Island Searcher software 
(http://www.uscnorris.com/cpgisland2/cpg.aspx) 
3) Primer design: ABI Primer expresses software 
 
Requirements 
1) Primers were designed as close as possible to the probe without overlapping 
the probe  (Primers) 
2) The G-C content was kept in the 30 - 80% range (Primers and Probes) 
3) Runs of an identical nucleotide were avoided. This is especially true for 
guanine (Gs), where runs of four or more Gs should be avoided (Primers and 
Probes) 
4) When using Primer Express software, the Tm was 58 - 60 °C (Primers) 
5) The five nucleotides at the 3’ end had no more than two G and/or C bases 
(Primers) 
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6) Gs on the 5’ end were avoided (Probes) 
7) The strand that gives the probe more Cs than Gs was selected (Probes) 
8) Temperature was at 68-70 °C using the Primer Express Software 
 
Preparation 
All primer/probe sets used were diluted to the same stock concentrations to 
standardize the PCR reaction set-up as well as the running of the PCR program. 
The primers and probes, since they are lyophilized after synthesis, need to be 
dissolved in sterile water. The forward and reverse primers were prepared at a 
concentration of 300 µM and the probe at a concentration of 100 µM.  
 
Small aliquots of the primers at these concentrations were made to prevent 
repeated freeze/thaw events. The primers/probe were diluted to a working stock 
of 6 µM (primers) and 2 µM (probe). This is achieved by combining the stock 
solutions of the forward primer, reverse primer and probe in one tube as an Oligo 
Mix: (4 µl of the 300 µM forward primer, 4 µl of the 300 µM reverse primer, and 4 
µl of the 100 µM probe in a 600 µl total volume). For a 15µl MethyLight reaction 
we used 2.25 µl of the Oligo Mix. This 2.25 µl volume represents the combined 
volumes from each of the two individual 6 µM primers and the 2 µM probe. It 
should be noted that the probe for each methylation reaction contains a black 
hole quencher (BHQ-1) at the 3’ end and a 6 FAM fluorophore at the 5’ terminus. 
 
5.2.11 MethyLight 
The technical core of DNA methylation analysis for our group is MethyLight. A 
sensitive, fluorescence-based real-time PCR technique that is capable of 
quantitating DNA methylation at a particular locus by using DNA oligonucleotides 
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that anneal differentially to bisulphite converted DNA according to the methylation 
status in the original genomic DNA. Compared with any other currently available 
technique for CpG methylation analysis (e.g. MSP, pyrosequencing, microarrays, 
etc.), MethyLight offers the unique opportunity to be run as a highly sensitive high 
throughput facility while being able to provide quantitative measures without the 
necessity for manipulation of post-PCR products. A single disadvantage of 
MethyLight is that it cannot detect allele-specific methylation differences (which 
would be possible by BM pyrosequencing), which is not needed for the purpose 
of this project.  
 
The specificity of the reactions for methylated DNA was confirmed separately by 
using in all MethyLight reactions SssI-treated human peripheral blood lymphocyte 
DNA (New England Biolabs, UK) which is prepared in advance and used as a 
universally methylated reference sample. One set of primers and probes for 
COL2A1 was designed specifically for bisulphite-converted DNA and used as 
reference set to normalize for input DNA. The percentage of fully methylated 
molecules at a specific locus was calculated by dividing the GENE: COL2A1 ratio 
of a sample by the GENE: COL2A1 ratio of SssI-treated WBC DNA and 
multiplying by 100. The abbreviation PMR indicates this measurement. A gene 
was deemed methylated if the percentage of fully methylated reference value was 
>0.  
 
Conduction of MethyLight assay 
The MethyLight assay utilises the TaqMan PCR principle which requires forward 
and reverse primers as well as an oligomeric probe which emits fluorescence 
only after it is degraded by the 5’-3’ exonuclease activity of Taq polymerase 
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without uracil DNA glycosylase (Applied Biosystems). Each PCR reaction uses 
the same basic reaction set-up. Uracil DNA glycosylase (AMPerase) was not 
included as a component in the PCR reactions. AMPerase catalyzes the removal 
of uracil, and this is problematic since bisulphite converted DNA is used as a 
DNA template and will therefore contain uracil (from unmethylated cytosines). 
After the primer/probe preparation the MasterMix Reactions were prepared 
mixing the OligoMix (2.25 µl) and TaqMan PCR (7.5 µl) at a final volume of 10µl 
(adding water). Finally, 5 µl of the bisulphite DNA sample were disposed into the 
wells of a 384-well plate and then 10 µl of the MasterMix were added. The plate 
was sealed, mixed and centrifuged at 1500 rpm for 1 minute. Then it was placed 
in real-time PCR instrument. 
 
Program: 
95°C for 10 minutes, then 50 cycles of: 95°C for 15 seconds, 60°C for 1 minute 
 
Bisulphite converted M.SssI-treated DNA was also included in different 
concentrations used as a standard curve for each methylation and control 
reactions (water and OligoMix).   
 
5.2.12 Statistics 
Statistical analysis was carried out using a computer assisted program-SPSS 
version 12.0.1, Chicago, IL. For both training and validation sets for each gene 
the percent of non-zero results, the median and the p-values from the Mann-
Whitney test was calculated. The genes in both training and validation sets were 
also assessed using Receiver Operator Characteristic (ROC) curves and the 
Area under the Curve (AUC) value. When a gene was denoted a ‘reverse 
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decision rule’ was applied if higher methylation values meant it was more likely 
the subject to be a control rather than cancer case. In order to assess if there is a 
difference between the centre and periphery groups, a non-parametric paired test 
(Wilcoxon rank test) was carried out comparing the rank order of values for 
centre versus periphery. Spearman correlation analysis was performed in order 
to examine any association between the two zones.  
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5.3 Results 
5.3.1 Clinicopathological characteristics of the study subjects  
The samples taken from the study women were divided into two sets: training and 
validation. The training set consisted of 25 cases and 25 controls and the 
validation set of 25 cases and 25 controls. The number of cases and controls in 
both sets dropped after the DNA quality test. As it is seen in Table 5-1 there were 
no statistically significant differences (p-value less than 0.05) between the 














Mean Age   60 59.55 0.298 
Histological Type 
IDC 5 8 
0.227 
IDC+DCIS 10 12 
Grading 
I 1 0 
0.073 II 10 17 
III 4 3 
Staging 
1 11 11 
0.096 
2 4 9 
PR 
positive 12 15 
0.237 
negative 3 5 
HER2 positive 
1 7 5 
0.121 2 1 3 
0 7 12 
Sentinel Node 
positive 5 9 
0.072 
negative 15 11 
Table 5-1: Clinicopathological features of the study women for training and 
validation set for the analysis of (A) the tissue taken from the centre and 
periphery and (B) the morphologically normal tissue adjacent to the tumour.  
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periphery and (B) the morphologically normal tissue adjacent to the tumour.  
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Table 5-1: Clinicopathological features of the study women for training and 
validation set for the analysis of (A) the tissue taken from the centre and 








DCIS=ductal carcinoma in situ; IDC=invasive ductal carcinoma; HER2=human 
epidermal growth factor receptor 2; PR=progesterone receptor 
 
 
IDC=invasive ductal carcinoma, DCIS=ductal carcinoma in situ; PR=progesterone 
receptor; HER2+=human epidermal growth factor receptor 2 
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DCIS=ductal carcinoma in situ; IDC=invasive ductal carcinoma; HER2=human 
epidermal growth factor receptor 2; PR=progesterone receptor 
 
 
IDC=invasive ductal carcinoma, DCIS=ductal carcinoma in situ; PR=progesterone 
receptor; HER2+=human epidermal growth factor receptor 2 
 
 
DCIS=ductal carcinoma in situ; IDC=invasive ductal carcinoma; HER2=human 
epidermal growth factor receptor 2; PR=progesterone receptor 
 
 
IDC=invasive ductal carcinoma, DCIS=ductal carcinoma in situ; PR=progesterone 














The control samples were taken from postmenopausal women that were 
undergoing surgery for benign conditions and were age matched to the women 
diagnosed with breast cancer. 
 
5.3.2 DNA quality test  
Specific criteria were s t up to select th  eligible samples to perform the analysis.  
The quality of the genomic DNA was checked by two methods 1) quantification 
(Nano-Drop) and 2) real-time PCR using three housekeeping genes collagen 
(COL2A1), actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The samples that had sufficient DNA for the purposes of the analysis 
and a mid-exponential cycle threshold (Ct) value of <36, were included in the 








Mean Age   60 60.75 0.287 
Histological Type 
IDC 5 9 
0.107 
IDC+DCIS 14 11 
Grading 
I 1 0 
0.132 II 13 17 
III 5 3 
Staging 
1 13 11 
0.243 
2 6 9 
PR 
positive 15 16 
0.803 
negative 4 4 
HER2+ 
1 8 5 
0.121 2 3 2 
0 8 13 
Sentinel Node 
positive 6 6 
0.789 
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5.3.3 NEUROD1 methylation and mRNA expression 
Based on two of our recent studies, we showed that NEUROD1 was one of the 
best discriminators between breast cancer and non neoplastic tissue samples 280 
and that methylated NEUROD1 promoter could be a good predictive marker for 
chemosensitivity in breast cancer 305. Since cancer specific methylation of some 
of the PCGT genes, such as MYOD1 and NEUROG1 has been shown not to be 
associated with expression in epithelial cancers 280 we wanted to investigate the 
association of the methylation and expression profile of NEUROD1 in breast 
cancer. Therefore, we analysed and compared NEUROD1 methylation (a specific 
sequence within CpG island in the promoter region of the gene was chosen 
based on our previous publication to be analysed, details are provided in 
Appendix Table IX.1 and 2) (Figure 5-2) and NEUROD1 mRNA expression (its 
expression was controlled for collagen) (Figure 5-3) in a panel of 9 human breast 
cancer cell lines. As it is illustrated in Figure 5-3, from the 9 tested cell lines only 
one expressed NEUROD1 whereas NEUROD1 methylation was observed in 8 
out of 9 cell lines. In the only cell line that expression was observed was HBL-100 
which is established from human breast milk and possibly not the most 
representative breast cancer cell line. To further examine this observation, we 
analysed NEUROD1 expression and methylation of 63 frozen breast cancer 
tissue samples. The experiments were performed in triplicate and, when at least 
two signals of the analysis had given a negative value, the expression was 
considered as zero. As is seen in Table 5-2, the majority of the cases; 54/63 
(85.7%) did not express NEUROD1 in contrast to NEUROD1 methylation, which 
was detected in all cases with a PMR value ranging from 0.047-632.995.  

























Figure 5-2: NEUROD1 DNA methylation of the different cell lines.  
 
Figure 5-1: NEUROD1 DNA methylation of the different cells line.  
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Figure 5-1: NEUROD1 DNA methylation of the different cells line.  













































































































































Figure 5-3: NEUROD1 mRNA expression of the different cell lines.  
 
Figure 5-2: NEUROD1 mRNA expression of the different cells lines.  
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Figure 5-2: NEUROD1 mRNA expression of the different cells lines.  




















PMR Expression PMR Expression 
1 0.047 0.000 33 25.456 0.000 
2 0.246 0.000 34 29.153 0.000 
3 0.641 0.000 35 29.829 0.000 
4 0.669 2.595 36 30.277 0.000 
5 0.708 0.000 37 32.528 0.000 
6 0.722 0.000 38 34.396 0.000 
7 0.892 93.856 39 34.549 0.302 
8 1.495 0.000 40 36.433 0.000 
9 1.912 0.000 41 36.685 0.000 
10 3.205 0.000 42 39.516 0.000 
11 3.628 0.000 43 46.768 0.000 
12 4.412 0.000 44 46.908 0.000 
13 4.898 0.000 45 47.793 0.000 
14 5.067 0.000 46 52.011 0.000 
15 6.855 0.000 47 56.516 1.064 
16 6.875 0.000 48 59.441 0.416 
17 6.889 0.000 49 61.509 0.000 
18 7.02 0.000 50 63.278 0.000 
19 7.234 0.000 51 71.241 2.882 
20 9.178 0.000 52 75.363 0.000 
21 9.866 0.000 53 75.382 0.000 
22 10.85 0.000 54 75.608 1.959 
23 12.713 0.000 55 79.196 0.000 
24 12.82 0.000 56 79.849 0.000 
25 13.714 0.000 57 84.717 0.000 
26 15.965 0.000 58 85.034 0.000 
27 16.285 0.000 59 86.433 0.000 
28 17.025 0.849 60 86.963 0.000 
29 18.225 0.000 61 95.934 0.000 
30 19.358 0.000 62 202.137 0.000 
31 23.485 1.125 63 482.26 0.000 
32 23.731 0.000    
Table 5-2: NEUROD1 methylation and mRNA expression in 63 breast cancer specimens. 
Table 5-2: NEUROD1 methylation and mRNA expression in 63 breast cancer specimens. 
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Table 5-2: NEUROD1 methylation and mRNA expression in 63 breast cancer specimens. 
 
PMR= percentage of methylated reference 
 
PMR= percentage of methylated reference 
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PMR= percentage of methylated reference 
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5.3.4 DNA methylation of PCGT genes and breast cancer  
In order to further investigate the methylation level changes of the PCGT genes 
in breast cancer the sample sets consisting of tumour taken from the centre and 
from the periphery from the 35 postmenopausal women with ER positive breast 
cancer were compared to these with non neoplastic breast tissue taken from 40 
postmenopausal women who had under gone surgery for benign breast changes. 
These are not the ideal control samples and another possibility would have been 
to have tissue from healthy postmenopausal women undergoing mammoplasty 
reduction–still with this approach though problems arise in getting enough 
progenitor cells for the purposes of the analysis. In the training set, methylation of 
55 PCGT genes in 14 tumour tissues taken from the centre and 15 tumour 
tissues taken from the periphery and 22 controls were analysed. 24% (13 out of 
55) of the genes were cancer specific (p<0.05), being more frequently methylated 
in tumour samples compared to non-neoplastic tissues as illustrated in Table 5-3.  
 
To test the hypothesis that the selected genes are cancer predictors, they were 
assessed by ROC analysis as seen in Table 5-4. In this table for both the tumour 
taken from the centre and periphery groups the p-values given reflect whether the 
AUCs are significantly different from 0.5 (a straight line from bottom left to top 
right corners, implying a decision rule no better than chance). The predictive 
value of the 13 genes tested by ROC analysis showed a range of 0.71-0.95. To 
further validate these findings an independent validation set consisting of 19 
tumour tissues taken from the centre, 20 tumour samples taken from the 
periphery and 18 controls were analysed examining the 13 PCGT genes from the 
training set that had a p<0.05 in the Mann-Whitney analysis for both samples 
taken from the centre and the periphery of the tumour. All 13 genes (Table 5-5) 
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were confirmed and were shown to be statistically significant (p<0.05). We 
calculated the predictive potential of these 13 genes by ROC analysis as 
illustrated in Table 5-6. Interestingly, even though the sample size is low, the 
results were consistent and the same panel of genes that were shown to be 
statistically significant with the Mann-Whitney test also had a statistically 
significant AUC value (p<0.05). 
 
  



















Control  (n = 22) Centre  (n = 15) Periphery  (n = 14) 
% Median % Median p % Median p p-value 
positive PMR * positive PMR value positive PMR value Rank 
HOXD9 77.30% 0.01 100.00% 1.42 0.000 100.00% 2.48 0.000 1 
HOXA7 90.90% 0.28 100.00% 5.39 0.000 100.00% 3.96 0.000 3 
PENK 9.10% 0.00 73.30% 0.09 0.000 78.60% 4.22 0.000 2 
TMEFF2 50.00% 0.00 93.30% 8.96 0.000 92.90% 7.06 0.000 5 
HOXA1  59.10% 0.03 80.00% 11.74 0.002 85.70% 11.31 0.000 6 
MT1A 95.50% 69.92 100.00% 28.72 0.003 100.00% 19.20 0.003 15 
CRABP1 0.00%  - 33.30% 0.00 0.004 42.90% 0.00 0.001 9 
GATA4 22.70% 0.00 60.00% 0.11 0.007 28.60% 0.00 0.609 35 
HOXD11 63.60% 0.75 80.00% 17.53 0.007 92.90% 35.48 0.000 8 
HOXD12 54.50% 0.03 73.30% 10.12 0.010 85.70% 7.75 0.002 12 
NEUROD1 54.50% 0.00 73.30% 0.39 0.020 78.60% 5.19 0.002 13 
GAD1 100.00% 0.72 100.00% 2.57 0.020 100.00% 4.33 0.000 7 
HOXA13 54.50% 1.14 66.70% 177.49 0.021 100.00% 181.40 0.000 4 
PITX2 (II) 72.70% 0.26 73.30% 4.33 0.029 85.70% 10.64 0.001 10 
Table 5-3: Summary statistics of controls versus tumour tissue taken from the centre and periphery from the breast cancer cases analysed in the training 
set. P-value from the Mann-Whitney test for each gene is provided (significant p-value less than 0.05). The genes were ordered according to the rank of the p-value 
for the test of TUC versus control, and a further column for the TUP group gave the rank order value for the TUP versus control group to facilitate comparison 
between tests.  
 
Table 5-3: Summary statistics of controls versus TUC and TUP from the breast cancer cases analysed in the training set. P-value from the Mann-Whitney 
test for each gene is provided (significant p-value less than 0.05). The genes were ordered according to the rank of the p-value for the test of TUC versus 
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Table 5-3: Summary statistics of controls versus TUC and TUP from the breast cancer cases analysed in the training set. P-value from the Mann-Whitney 
test for each gene is provided (significant p-value less than 0.05). The genes were ordered according to the rank of the p-value for the test of TUC versus 
control, and a further column for the TUP group gave the rank order value for the TUP versus control group to facilitate comparison between tests.  
PMR= percentage of methylated reference 
 
 
PMR= percentage of methylated reference; TUC= tumour taken from centre; TUP= tumour taken from periphery 
 
 
PMR= percentage of methylated reference; TUC= tumour taken from centre; TUP= tumour taken from periphery 
  





Control  (n = 22) Centre  (n = 15) Periphery (n = 14) 
% Median  % Median  p % Median  p p-value 
positive PMR *  positive PMR  value  positive PMR  value Rank 
HIC1 63.60% 28.33 100.00% 42.58 0.043 100.00% 31.32 0.054 22 
PGR 23.80% 0.00 0.00%  - 0.045 21.40% 0.00 0.680 39 
HOXD8 63.60% 0.18 80.00% 4.57 0.052 64.30% 7.04 0.111 28 
ITGA4 0.00%  - 13.30% 0.00 0.083 28.60% 0.00 0.009 17 
PITX2 (I) 0.00%  - 13.30% 0.00 0.083 28.60% 0.00 0.009 18 
CACNA1G 0.00%  - 13.30% 0.00 0.083 14.30% 0.00 0.072 24 
TWIST 13.60% 0.00 33.30% 0.00 0.086 14.30% 0.00 0.829 44 
MT3 77.30% 0.07 46.70% 0.00 0.107 57.10% 0.00 0.041 21 
EBF3(DKFZ) 4.50% 0.00 20.00% 0.00 0.121 42.90% 0.00 0.004 16 
GABRA2 4.50% 0.00 20.00% 0.00 0.136 21.40% 0.00 0.115 29 
DLC1 13.60% 0.00 0.00% -  0.142 14.30% 0.00 0.957 50 
GATA5 13.60% 0.00 33.30% 0.00 0.144 50.00% 0.02 0.010 19 
HOXA11 100.00% 26.31 100.00% 19.15 0.146 100.00% 19.77 0.092 27 
CDH13 13.60% 0.00 33.30% 0.00 0.156 14.30% 0.00 1.000 55 
SFRP4 50.00% 0.00 33.30% 0.00 0.171 21.40% 0.00 0.057 23 
NEUROD2 59.10% 0.02 60.00% 2.34 0.189 85.70% 7.14 0.001 11 
ESR1 50.00% 0.00 20.00% 0.00 0.201 14.30% 0.00 0.024 20 
HOXB7 77.30% 0.02 53.30% 0.00 0.202 78.60% 0.02 0.636 37 
NEUROG1 0.00%  - 6.70% 0.00 0.226 14.30% 0.00 0.072 26 




PMR= percentage of methylated reference 
 
 























Control  (n = 22) Centre (n = 15) Periphery (n = 14) 
% Median % Median p % Median p p-value 
positive PMR * positive PMR value positive PMR value Rank 
SLC6A20 9.10% 0.00 0.00%  - 0.236 7.10% 0.00 0.892 47 
SFRP1 45.50% 0.00 26.70% 0.00 0.242 35.70% 0.00 0.885 46 
ZBTB16 54.50% 0.00 33.30% 0.00 0.266 28.60% 0.00 0.269 31 
HOXA10 95.50% 2.91 80.00% 7.13 0.300 85.70% 5.03 0.626 36 
DCC 4.50% 0.00 13.30% 0.00 0.311 7.10% 0.00 0.713 41 
SLIT2 63.60% 0.12 46.70% 0.00 0.317 50.00% 0.02 0.637 38 
IGF2 4.50% 0.00 13.30% 0.00 0.343 7.10% 0.00 0.713 40 
HOXC9 18.20% 0.00 6.70% 0.00 0.376 7.10% 0.00 0.331 32 
GDNF 18.20% 0.00 6.70% 0.00 0.376 14.30% 0.00 0.764 43 
TITF1 18.20% 0.00 6.70% 0.00 0.376 14.30% 0.00 0.920 48 
HOXA9 100.00% 11.88 86.70% 7.74 0.404 100.00% 11.52 1.000 54 
CYP27B1 100.00% 4.86 100.00% 4.65 0.458 0.00% 6.34 0.183 30 
MYOD1 22.70% 0.00 26.70% 0.00 0.498 64.30% 0.21 0.003 14 
SFRP5 81.80% 2.43 60.00% 0.63 0.708 71.40% 1.54 0.744 42 
CYP1B1 4.50% 0.00 6.70% 0.00 0.752 0.00%  - 0.425 34 
CALCA 45.50% 0.00 40.00% 0.00 0.784 35.70% 0.00 0.942 49 
FLJ39739  50.00% 0.00 33.30% 0.00 0.973 35.70% 0.00 0.873 45 
GATA3 0.00% - 0.00% - 1.000 14.30% 0.00 0.072 25 
PYCARD 0.00% - 0.00% - 1.000 0.00%  - 1.000 51 
TP73 0.00% - 0.00% - 1.000 0.00%  - 1.000 52 
BCL22 0.00% - 0.00% - 1.000 0.00%  - 1.000 53 
PMR= percentage of methylated reference 
 
 























Centre  Periphery  
AUC 
95% CI 95% CI p 
AUC 
95% CI 95% CI p p-value 
Rank Lower Upper value Lower Upper value 
HOXD9 0.930 0.852 1.008 0.000 0.955 0.894 1.015 0.000 5 
HOXA7 0.891 0.788 0.993 0.000 0.935 0.859 1.011 0.000 11 
TMEFF2 0.853 0.719 0.987 0.000 0.888 0.767 1.009 0.000 9 
PENK 0.830 0.682 0.979 0.001 0.883 0.745 1.021 0.000 10 
HOXA1 0.792 0.619 0.966 0.003 0.867 0.715 1.019 0.000 1 
*MT1A 0.788 0.051 0.373 0.003 0.795 0.048 0.361 0.003 13 
HOXD11 0.761 0.584 0.937 0.008 0.860 0.726 0.994 0.000 6 
HOXD12 0.745 0.564 0.927 0.012 0.808 0.650 0.967 0.002 12 
GAD1  0.727 0.557 0.897 0.020 0.870 0.733 1.007 0.000 2 
NEUROD1 0.721 0.540 0.902 0.024 0.805 0.633 0.977 0.002 4 
HOXA13 0.718 0.526 0.910 0.026 0.922 0.835 1.009 0.000 3 
PITX2 (II) 0.712 0.513 0.911 0.030 0.825 0.656 0.993 0.001 7 
CRABP1 0.667 0.477 0.856 0.089 0.714 0.526 0.903 0.032 8 
Table 5-4: ROC analysis for both samples taken from the centre and periphery of the tumour in training set. The performance of each gene as a predictor of 
breast cancer was assessed using ROC curves and the AUC value. The genes were ordered according to the rank of the p-value for the test of the tissue samples 
taken from the center and periphery of tumour versus control. Significance required a p-value of less than 0.05. * ‘Reverse decision rule’ applied means that the 
higher the methylation value, the more likely the subject is a control rather than breast cancer case (tumour taken from the center and periphery).  
 
Table 5-4: ROC analysis for both TUC and TUP in training set. The performance of each gene as a predictor of breast cancer was assessed using ROC 
curves and the AUC value. The genes were ordered according to the rank of the p-value for the test of TUC and TUP versus control. Significance required 
a p-value of less than 0.05. * ‘Reverse decision rule’ applied means that the higher the methylation value, the more likely the subject is a control rather 
than TUC or TUP breast cancer case.  
 
Table 5-4: ROC analysis for both TUC and TUP in training set. The performance of each gene as a predictor of breast cancer was assessed using ROC curves 
and the AUC value. The genes were ordered according to the rank of the p-value for the test of TUC and TUP versus control. Significance required a p-value of less 
than 0.05. * ‘Reverse decision rule’ applied means that the higher the methylation value, the more likely the subject is a control rather than TUC or TUP breast cancer 
case.  
 
Table 5-4: ROC analysis for both TUC and TUP in training set. The performance of each gene as a predictor of breast cancer was assessed using ROC 
curves and the AUC value. The genes were ordered according to the rank of the p-value for the test of TUC and TUP versus control. Significance required 
a p-value of less than 0.05. * ‘Reverse decision rule’ applied means that the higher the methylation value, the more likely the subject is a control rather 
than TUC or TUP breast cancer case.  
AUC= Area under the curve; CI= confidence interval 
 
 
AUC= Area under the curve; TUC= tumour taken from centre; TUP= tumour taken from periphery; CI= confidence interval 
 
  



















Controls  (n = 18) Centre  (n = 19) Periphery (n = 20) 
% Median % Median p % Median p p-value 
positive PMR positive PMR value positive PMR value Rank 
HOXA1  44.40% 0 94.70% 26.15 0.000 89.50% 25.54 0.000 3 
GAD1  100.00% 0.78 100.00% 15.00 0.000 94.70% 14.72 0.000 2 
HOXA13 38.90% 0 94.70% 152.61 0.000 84.20% 126.08 0.000 5 
CRABP1 0.00% - 73.70% 5.16 0.000 57.90% 3.12 0.000 7 
NEUROD1 44.40% 0 89.50% 9.73 0.000 89.50% 6.51 0.000 4 
HOXD9 100.00% 0.24 100.00% 8.02 0.000 100.00% 1.84 0.002 10 
PITX2(II) 38.90% 0 84.20% 5.69 0.000 84.20% 4.25 0.000 6 
HOXD11 66.70% 0.1 94.70% 39.07 0.000 84.20% 32.94 0.001 9 
TMEFF2 83.30% 0.15 89.50% 22.34 0.000 100.00% 16.57 0.000 1 
PENK 22.20% 0 68.40% 0.29 0.001 73.70% 0.85 0.000 8 
HOXA7 100.00% 1.86 94.70% 6.22 0.004 100.00% 4.31 0.025 12 
HOXD12 66.70% 0.17 78.90% 4.98 0.006 89.00% 6.97 0.002 11 
MT1A 100.00% 73.06 100.00% 37.55 0.023 100.00% 46.07 0.027 13 
Table 5-5: Percentage of positive cases and distribution of methylation levels of the 13 genes tested in validation set. Controls and breast cancer cases 
(tumour samples taken from the centre and periphery) showing the percentage of positive cases and the median PMR values. P-values are provided from Mann-
Whitney test for each gene. Significance required a p-value of less than 0.05 after Mann-Whitney test.  
 
Table 5-5. Percentage of positive cases and distribution of methylation levels of the 13 genes tested in validation set. Controls and breast cancer cases 
(TUC and TUP) showing the percentage of positive cases and the median PMR values. P-values are provided from Mann-Whitney test for each gene. 
Significance required a p-value of less than 0.05 after Mann-Whitney test.  
PMR= Percentage of Methylated Reference  
 
 
PMR= Percentage of Methylated Reference; TUC= tumour taken from centre; TUP= tumour taken from periphery  
 
  



















Centre Periphery  
AUC 95% CI 95% CI p AUC 95% CI 95% CI p p-value 
  Lower Upper value  Lower Upper value Rank 
HOXD9 0.889 0.787 0.991 0.000 0.801 0.659 0.944 0.002 9 
HOXA7 0.778 0.626 0.93 0.004 0.716 0.551 0.881 0.025 12 
TMEFF2 0.86 0.722 0.997 0.000 0.977 0.936 1.017 0.000 1 
PENK 0.792 0.642 0.943 0.002 0.822 0.68 0.963 0.001 8 
HOXA1 0.950 0.872 1.029 0.000 0.901 0.788 1.014 0.000 3 
*MT1A 0.719 0.111 0.450 0.020 0.713 0.637 0.942 0.027 13 
HOXD11 0.883 0.767 0.999 0.000 0.825 0.679 0.971 0.001 7 
HOXD12 0.76 0.598 0.923 0.007 0.789 0.638 0.941 0.003 11 
GAD1  0.936 0.853 1.018 0.000 0.918 0.810 1.026 0.000 2 
NEUROD1 0.904 0.795 1.012 0.000 0.892 0.78 1.004 0.000 4 
HOXA13 0.925 0.837 1.014 0.000 0.858 0.729 0.987 0.000 5 
PITX2 (II) 0.876 0.752 0.999 0.000 0.852 0.723 0.981 0.000 6 
CRABP1 0.868 0.742 0.994 0.000 0.789 0.637 0.942 0.003 10 
Table 5‑6: ROC analysis for both tumour samples taken from centre and periphery in validation set. The performance of each gene as a predictor of cancer 
was assessed using ROC curves and the AUC value. The significant assessment required a p-value of less than 0.05. The genes were ordered according to the rank 
of the p-value for the test of samples taken from the centre and periphery of the tumour versus control. * ‘Reverse decision rule’ applied means that the higher the 
methylation value, the more likely the subject is a control rather than cancer case. 
 
Table 5‑6: ROC analysis for both TUC and TUP in validation set. The performance of each gene as a predictor of cancer was assessed using ROC curves 
and the AUC value. The significant assessment required a p-value of less than 0.05. The genes were ordered according to th rank of the p-value for the 
test of TUC and TUP versus control. * ‘Reverse decision rule’ applied means that the higher the methylation value, the more likely the subject is a control 
rather than TUC or TUP cancer case. 
AUC= Area under the curve; CI= confidence interval 
 
AUC= area under the curve; TUC= tumour taken from centre; TUP= tumour taken from periphery; CI= confidence interval 
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5.3.5 DNA methylation of PCGT genes and intra-tumour heterogeneity  
Even though we show methylation levels of specific genes to be comparable 
between selected tissue samples that were taken from the center and the 
periphery of the tumour in both the training and validation sets, there were also 
some genes that demonstrated differential methylation levels between the two 
tumour zones. This was true for both cancer specific genes (genes that were 
shown to be specifically methylated in the breast tumour tissue when they were 
compared to the controls) but also for the genes that were shown to be non-
specifically methylated in cancer. In order to verify these results we performed 
non-parametric paired test for the genes one by one. Comparison between the 
two zones within the tumour for cancer specific genes (Table 5-7) and non-
cancer specific genes (Table 5-8) did not show any difference in the methylation 
levels. In order to investigate whether there is any correlation between the two 
different zones we performed Spearman correlation analysis. The analysis 
showed 4 out of the 13 cancer specific genes to be positively correlated in both 
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HOXD9 0.675 0.339 0.054 
HOXA7 0.993 0.120 0.507 
PENK 0.766 0.110 0.544 
TMEFF2 0.280 0.399 0.021 
HOXA1  0.614 0.347 0.048 
MT1A 0.714 0.675 0.000 
CRABP1 0.715 0.567 0.001 
HOXD11 0.822 0.313 0.077 
HOXD12 0.217 0.216 0.227 
NEUROD1 0.814 0.361 0.039 
GAD1  0.526 0.266 0.135 
HOXA13 0.382 -0.035 0.847 
PITX2 (II) 0.829 0.256 0.151 
Table 5-7:  Comparison of DNA methylation changes between the samples that were taken 
from the centre and periphery of the tumour with non-parametric paired test and Spearman 
correlation analysis for the breast cancer specific genes. P-values are given from the 13 
genes that were further confirmed in the validation set.  Non-parametric paired test analysis 
comparing the rank order of values for tissue taken from the centre of the tumour versus tissue 
taken from the periphery of the tumour to assess if there is a difference in their methylation levels 
and correlation coefficient analysis is also demonstrated.  
  
 
 Table 5-7:  Comparison of DNA methylation changes between TUC and TUP with non-
parametric paired test and Spearman correlation analysis for the breast cancer specific 
genes. P-values are given from the 13 genes that were further confirmed in the validation 
set.  Non-parametric paired test analysis comparing the rank order of values for TUC versus 
TUP to assess if there is a difference in their methylation levels and correlation coefficient 
analysis is also demonstrated.  
  


























































Table 5-8: Comparison of DNA methylation changes in non-cancer specific genes 
between tissue taken from the centre of the tumour and tissue taken from the periphery 
of the tumour with non-parametric paired test analysis.  
 









































 Table 5-8: Comparison of DNA methylation changes in non-cancer specific genes 
between TUC and TUP with non-parametric paired test analysis.  
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5.3.6 PCGT gene methylation in the normal tissue adjacent to the tumour 
and breast cancer risk prediction 
In order to investigate DNA methylation changes of the PCGT genes in 
morphologically normal tissue adjacent to the breast tumour a set consisting of 
19 postmenopausal women with ER+ breast cancer (cases) were analysed and 
compared with non neoplastic tissue from 22 postmenopausal women who had 
undergone surgery for benign breast changes (controls). In the training set, 
methylation changes of 55 PCGT genes were examined. 5.5% (3 genes out of 
55; HOXD8, SL6A20 and HOXA9) of the genes analysed showed significant 
(p<0.05) methylation changes in the normal tissue adjacent to the tumour when 
compared with the non neoplastic tissue as it is illustrated in Table 5-9. The 
majority of the genes did not show any methylation changes. 
 
To further validate these findings, we analysed in an independent set consisting 
of 20 cases and 20 controls the identified genes from the training set which had a 
p<0.05. One of the three genes analysed, HOXA9 was confirmed and was shown 
to be statistically significant in the validation set as illustrated in Table 5-10. 
Interestingly, the results for HOXA9 were consistent with the median PMR values 
observed in the training set for both cases and controls being also observed in 
the validation set. In addition, it is worth noting that HOXA9 demonstrated less 
frequent methylation in the normal tissue adjacent to the tumour compared to the 
controls. To test the hypothesis that HOXA9 is a breast cancer predictor, ROC 
analysis for both training and validation set was performed. The predictive value 
of HOXA9 was statistically significant showing an AUC value of 0.677 (p=0.05) 
for the training set and an AUC value of 0.682 (p=0.048) for the validation set.    
  




Training Set  
Genes name 










Minimum Maximum p-value 
HOXD8 63.6% 0.18 0.00 15.60 21.1% 0.00 0.00 7.30 0.01 
SLC6A20 9.1% 0.00 0.00 0.04 31.6% 0.00 0.00 5.15 0.05 
HOXA9 100.0% 11.88 0.01 28.74 100.0% 7.01 1.41 44.32 0.05 
GDNF 18.2% 0.00 0.00 4.64 0.0% 0.00 0.00 0.00 0.06 
HOXA6 59.1% 2.21 0.00 19.21 26.3% 0.00 0.00 23.65 0.06 
CALCA 45.5% 0.00 0.00 2.40 15.8% 0.00 0.00 2.39 0.07 
FLJ39739  50.0% 0.00 0.00 0.01 21.1% 0.00 0.00 0.03 0.11 
HOXA1 59.1% 0.03 0.00 12.49 26.3% 0.00 0.00 11.67 0.12 
GATA3 0.0% 0.00 0.00 0.00 10.5% 0.00 0.00 0.01 0.12 
SLIT2 63.6% 0.12 0.00 4.22 47.4% 0.00 0.00 4.24 0.13 
SFRP5 81.8% 2.43 0.00 16.75 57.9% 0.03 0.00 11.18 0.13 
PITX2 (II) 72.7% 0.26 0.00 10.43 47.4% 0.00 0.00 3.53 0.25 
CYP27B1 100.0% 4.86 1.18 10.65 100.0% 5.87 1.98 12.20 0.26 
PYCARD (ASC) 0.0% 0.00 0.00 0.00 5.3% 0.00 0.00 0.00 0.28 
CACNA1G 0.0% 0.00 0.00 0.00 5.3% 0.00 0.00 3.37 0.28 
CRABP1 0.0% 0.00 0.00 0.00 5.3% 0.00 0.00 0.27 0.28 
Table 5-9: Summary statistics of controls versus normal tissue adjacent to the breast tumour analysed in the training set. P-value from the Mann-Whitney 
test for each gene is provided (significant p-value less than 0.05).  
PMR= percentage of methylated reference 
 
 
Apparent Sensitivity = TP / TP + FNPMR= percentage of methylated reference 
 
  





























Minimum Maximum p-value 
TP73 0.0% 0.00 0.00 0.00 5.3% 0.00 0.00 18.55 0.28 
HOXD12 54.5% 0.03 0.00 10.28 84.2% 0.99 0.00 8.43 0.31 
HOXA10  95.5% 2.91 0.00 28.98 89.5% 4.25 0.00 18.92 0.35 
ZBTB16 54.5% 0.00 0.00 3.30 36.8% 0.00 0.00 0.33 0.35 
IGF2  4.5% 0.00 0.00 0.11 0.0% 0.00 0.00 0.00 0.35 
CYP1B1 4.5% 0.00 0.00 0.11 0.0% 0.00 0.00 0.00 0.35 
GATA5 13.6% 0.00 0.00 1.49 5.3% 0.00 0.00 0.04 0.36 
DLC1 13.6% 0.00 0.00 0.94 5.3% 0.00 0.00 0.79 0.39 
NEUROD1 54.5% 0.00 0.00 5.20 52.6% 0.33 0.00 5.15 0.39 
ESR1 50.0% 0.00 0.00 4.03 31.6% 0.00 0.00 5.73 0.42 
GABRA2 4.5% 0.00 0.00 0.00 10.5% 0.00 0.00 3.78 0.43 
EBF3 (DKFZ) 4.5% 0.00 0.00 0.00 10.5% 0.00 0.00 18.55 0.43 
DCC 4.5% 0.00 0.00 0.01 10.5% 0.00 0.00 1.43 0.43 
GAD1 0.0% 0.72 0.00 28.64 94.7% 0.98 0.00 11.43 0.46 
NEUROD2 59.1% 0.02 0.00 9.29 63.2% 0.17 0.00 10.14 0.53 
HOXD11 63.6% 0.75 0.00 58.02 68.4% 1.26 0.00 33.40 0.54 
PENK 9.1% 0.00 0.00 0.28 15.8% 0.00 0.00 1.54 0.55 
HIC1 63.6% 28.33 0.00 73.74 63.2% 22.13 0.00 60.88 0.59 
MT3 77.3% 0.07 0.00 3.85 73.7% 0.03 0.00 1.78 0.66 
PMR= percentage of methylated reference 
 
 
PMR= percentage of methylated reference 
 
  





























Minimum Maximum p-value 
MYOD1 22.7% 0.00 0.00 2.04 26.3% 0.00 0.00 1.48 0.68 
HOXC9 18.2% 0.00 0.00 0.31 21.1% 0.00 0.00 8.28 0.68 
TWIST 13.6% 0.00 0.00 0.01 15.8% 0.00 0.00 0.30 0.70 
HOXB7 77.3% 0.02 0.00 1.88 63.2% 0.01 0.00 4.58 0.72 
SFRP1 45.5% 0.00 0.00 16.36 42.1% 0.00 0.00 17.09 0.75 
SFRP4 50.0% 0.00 0.00 58.57 47.4% 0.00 0.00 46.14 0.78 
HOXA13 54.5% 1.14 0.00 242.64 47.4% 0.00 0.00 144.87 0.78 
CDH13 13.6% 0.00 0.00 1.87 15.8% 0.00 0.00 0.77 0.86 
HOXA7 90.9% 0.28 0.00 4.22 0.0% 0.34 0.01 5.66 0.90 
TMEFF2 50.0% 0.00 0.00 6.46 47.4% 0.00 0.00 18.07 0.91 
MT1A 95.5% 69.92 0.00 220.33 0.0% 67.83 19.93 129.29 0.92 
HOXA11 100.0% 26.31 1.15 66.64 100.0% 27.53 4.01 71.03 0.92 
GATA4  22.7% 0.00 0.00 3.23 21.1% 0.00 0.00 6.71 0.93 
HOXD9 77.3% 0.01 0.00 1.78 68.4% 0.01 0.00 11.85 0.94 
TITF1 18.2% 0.00 0.00 0.40 15.8% 0.00 0.00 11.67 0.97 
PGR 23.8% 0.00 0.00 2.02 26.3% 0.00 0.00 5.32 0.99 
BCL2 0.0% 0.00 0.00 0.00 0.0% 0.00 0.00 0.00 1.00 
NEUROG1 0.0% 0.00 0.00 0.00 0.0% 0.00 0.00 0.00 1.00 
ITGA4 0.0% 0.00 0.00 0.00 0.0% 0.00 0.00 0.00 1.00 
PITX2 (I) 0.0% 0.00 0.00 0.00 0.0% 0.00 0.00 0.00 1.00 
PMR= percentage of methylated reference 
 
 
PMR= percentage of methylated reference 
 
  




 Validation Set 
Genes name  










Minimum Maximum p-value 
HOXA9 100% 12.59 0.34 19.03 90% 6.51 0.00 21.49 0.05 
HOXD8 50% 0.02 0.00 14.85 35% 0.00 0.00 14.16 0.37 
SLC6A20 0% 0.00 0.00 0.00 0% 0.00 0.00 0.00 1.00 
Table 5-10: Summary statistics of controls versus normal tissue adjacent to the breast tumour analysed in the validation set. P-value from the Mann-
Whitney test for each gene is provided (significant p-value less than 0.05).  
 
Table 5-10: Summary statistics of controls versus normal tissue adjacent to the breast tumour analysed in the validation set. P-value from the Mann-
Whitney test for each gene is provided (significant p-value less than 0.05).  
PMR= percentage of methylated reference 
 
 
PMR= percentage of methylated reference 
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5.3.7 Comparison of DNA methylation changes observed in breast 
tumour and the corresponding normal tissue  
Comparison of DNA methylation changes observed between the two tissues, the 
morphologically normal tissue adjacent to the breast tumour and the breast 
tumour, was taken into account. As it was shown in Table 5-3, 13 genes showed 
to have significant DNA methylation changes in the breast tumour compared to 
controls but none of these were shown to have a significant methylation change 
in the corresponding morphologically normal tissue adjacent to the tumour (Table 
5-9). Significant methylation changes within the corresponding normal tissue 
were observed only for one gene, HOXA9 which was not shown to be one of the 
breast cancer specific genes (Table 5-3). 
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5.4 Discussion 
Over the last few years the role of DNA methylation in cancer has been the 
subject of many studies. Recently our group has provided evidence for a new 
model of carcinogenesis. The predisposition of Polycomb Repressor Complex 2 
(PRC2) targets to cancer-specific DNA hypermethylation suggests a ‘crosstalk 
‘between PRC2 and de novo DNA methyltransferases in precursor cancer cells 
with  a PRC2 distribution similar to that of ES cells. This ‘crosstalk’ may be 
initiated and/or facilitated by various environmental exposures, transgenerational 
inheritance, endocrine exposure, inflammation and by age. If a cell loses the 
potential to terminally differentiate as a consequence of irreversible CpG 
methylation, it will undergo prolonged exposure to environmental onslaught, and 
so, more likely to acquire those mutations and/or deletions necessary for 
carcinogenesis 280. Based on these observations PCGT were chosen to be 
analysed. Additionally, it is generally accepted that methylation of gene 
promoters is associated with gene silencing. However, as accumulating evidence 
suggests that DNA methylation can occur at loci without an effect on gene 
expression we wanted to investigate the correlation between NEUROD1 
methylation and expression. Based on this analysis no association between DNA 
methylation and gene expression was found. These data are in agreement with 
previous reports suggesting that PCGT genes with tumour-specific promoter DNA 
methylation are not normally expressed in the epithelium of the tumour. It also 
provides further evidence on our previous published data that DNA methylation of 
PCGT genes in cancer may result in a residual stem-cell memory rather than a 
selective pressure for silencing these particular genes during carcinogenesis 280.  
Therefore, based on the following three observations: 1) there is not a 
relationship between NEUROD1 methylation and expression levels 2) lack of 
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NEUROD1 expression in the majority of the samples tested and 3) published 
findings that methylation of PCGT genes is a promising target for marker 
identification 305 280 279, 388, we wanted to further examine the predictive role of 
these genes in breast cancer and to examine whether they are affected by intra-
tumour heterogeneity. MethyLight analysis of PCGT genes identified a constant 
panel of genes to be methylated in both central and peripheral tumour samples 
compared to controls, and non-parametric paired analysis indicated that there 
was no statistical significant difference between the methylation levels of the two 
zones within the cancer. This was true for both breast cancer specific genes and 
genes that were not specifically methylated in cancer. In order to investigate 
whether there is an association between the methylation changes observed in the 
two different tumour tissues, we performed correlation analysis showing 4 out of 
13 genes to be positive associated.  
 
NEUROD1 was one of the genes that did not show statistically significant 
differences in the methylation levels between tumour taken from the centre and 
the periphery suggesting it is homogeneously methylated within the tumour. This 
is an important finding as it further supports our previous report that NEUROD1 
methylation could be a good predictive marker in breast cancer as it is not 
affected by intra-tumour heterogeneity 305. Moreover, this study provides further 
evidence for paired-like homeodomain transcription factor 2 (PITX2) which has 
been shown by Harbeck et al, to be a good biomarker for breast cancer hormone 
therapy treatment and, having performed analysis of several different tissue 
sections, has also shown a low variability in methylation measurements 393.  
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Through literature review, no other study was found to have examined breast 
cancer intra-tumour heterogeneity and its effect on DNA methylation changes. In 
contrast, there are two studies analysing expression modifications in correlation 
to intra-tumour heterogeneity. Both were carried on micro-dissected tumour cells 
rather than core biopsies. The first study by Aubele et al confirmed heterogeneity 
by comparative genomic hybridization 375. The second study by Zhu et al 
described expression heterogeneity in sections that were obtained from 
morphologically dissimilar regions, one from the centre containing invasive breast 
tumourigenic cells, and the other from the periphery containing DCIS. The 
differences in the expression profile described in this study could however, be 
attributed to the different type of cells analysed i.e. comparing invasive to non-
invasive cells 376. Our finding that methylated PCGT genes provide reliable data 
irrespective of sampling topography, suggests that methylation analysis of these 
genes could hold great potential for improving breast cancer management. They 
could be useful for the early diagnosis of breast cancer predicting the biology of 
these tumours; refer to epigenetic treatment strategies, and finally provide 
suggestions that could have an important impact on the future of women’s health. 
In addition, we have also demonstrated that the technology for methylation 
analysis can be easily applied in clinical routine as only a core biopsy would be 
required instead of purified cell population of cells.  
 
Our results are in contrast to reports of DNA methylation changes of different 
candidate genes in other cancer types which have been shown to be affected by 
intra-tumour heterogeneity. In melanoma when methylation changes and 
expression status of suppressor genes were analysed, tissue taken from the 
centre of the tumour found to represent the whole tumour more accurately than 
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the tissue from the periphery 394, 395. A more recent study of ovarian cancer 
suggested that both inter- and intra-tumour heterogeneity are allied with NY-
ESO-1 expression, which was correlated with promoter and global DNA-
methylation alterations when micro-dissected cells were analysed 396. Further 
studies are required before it can be determined whether these changes are 
cancer or gene specific.  
 
In this study we have identified and confirmed in the validation set, 13 PCGTs 
that can predict breast cancer. This includes the first report of hypermethylation of 
the trans-membrane protein with EGF-like and two follistatin-like domains 2 
(TEMFF2), the proenkephalin (PENK), glutamate decarboxylase-1 (GAD1) and 
cellular retinoic acid binding protein 1 (GRABP1) genes in breast cancer. Even 
though the role of TMEFF2 gene methylation has been observed in other types of 
cancer such as colorectal, bladder 397, 398 and gastric adenocarcinomas 399 there 
are no reports for breast cancer. PENK gene expression has been shown to be 
down regulated in prostate and bladder cancer using, expression profiling 400. 
Methylation of GAD1 has not been previously shown to be associated with 
cancer and CRABP1 methylation was only reported in association with colon 401 
and ovarian 402 cancer. In contrast, there are reports of an association between 
methylation of PITX2, also an ER-targeted gene - the only ER-targeted gene 
analysed shown to be cancer specific -, and metallothionein 1A (MT1A) with 
breast carcinogenesis, further validating the data presented 393, 403. 
 
Interestingly, 6 of the 13 methylated loci identified are genes belonging to the 
homeobox (HOX) domain. These genes are known to control normal 
development and differentiation of many multi-cellular organisms 404. In humans 
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there are 39 HOX genes organised in four clusters – A, B, C and D being 
localised on chromosome 7, 17, 2 AND 12 respectively 389. The last decade the 
role of the HOX domain in carcinogenesis has also been pointed. An example is 
HOXB7 which has been implicated as an oncogene and is known to increase the 
expression of basic fibroblast growth factor (bFGF) in melanoma 405. Indeed, 
previous data has confirmed that HOX gene cluster methylation is a common 
feature in cancer 390 including breast cancer 406, 407. In the search for more 
specific and sensitive markers a recent study by Fiegl et al, has shown that 
methylation of HOXA11 is strongly associated with the residual tumor after 
cytoreductive surgery and a good marker indicating poor prognosis in ovarian 
cancer 408. A recent study though has suggests that methylation of the HOXA 
cluster may be a normal developmental and cell type specific process rather than 
a cancer specific mechanism 409 but their study subjects are not well 
characterised and the tumour tissue samples analysed with MeDIP should have 
been compared with normal tissue from controls in order to be able to have solid 
conclusions. It is worth mentioning that in this study despite the small sample size 
used the results are consistent and it has identified cancer specific genes 
characterized by high AUC values indicating a high sensitivity and specificity 
compared to studies that have used larger sample sizes 406.  
 
Methylation of HOXA9 was observed in morphological normal tissue adjacent to 
the breast tumour. There could be two possible explanations on why this is 
observed. The first explanation could be based on the theory of a cancer stem 
cell population. As it was discussed in the literature review, the last few years 
there is an increasing body of evidence suggesting that early epigenetic changes 
of stem cells may be the initiating events in carcinogenesis and evolve in normal 
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tissue in advance to tumour formation 115. Methylation changes of non-tumour 
tissue adjacent to the tumour may represent an epigenetic disruption of 
progenitor cells which could lead to tumour formation through a stepwise process 
that could lead to further epigenetic changes. DNA methylation changes may 
lead to a polyclonal population of cells which have the potential for neoplastic 
changes. If this is true then the ideal target for cancer risk assessment and 
treatment would be to detect these pre-neoplastic epigenetic lesions before 
tumour formation. At the moment there are studies trying to identify and isolate 
cancer stem cells 410, 411 but in general these approaches have been hindered by 
technical difficulties. 
 
The second possibility is that the methylation changes observed could represent 
a premalignant epigenetic lesion which is a mediator of a field defect in these 
tissues, although the origin of this field remains unknown 273. Possibly these 
methylation changes around the tumour even though they are not responsible for 
causing transformation on their own, they could be permissive for the acquisition 
of additional epigenetic or genetic changes which could eventually lead to tumour 
formation. The first observation of this phenomenon was made in oral cancer 412. 
This theory has been supported by subsequent studies carried out on colorectal 
cancer 272, head and neck squamous cell carcinoma, lung, esophagus, vulva, 
cervix, bladder, and skin and breast cancer 273. Based on such observations it 
has been suggested that such information could prove valuable for risk 
assessment. The study on breast cancer identified RASSF1A to be methylated in 
four different zones of normal breast tissue in the ipsilateral and contralateral 
breasts of women with breast cancer 273. In contrast to our study, they showed 
RASSF1A methylation to occur in both the tumour and the normal tissue adjacent 
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to the tumour with a higher degree of methylation seen in the tissue closer to the 
tumour 273. 
 
In addition, the results showed HOXA9 to be statistically significant less 
frequently methylated in the morphologically normal tissue adjacent to the tumour 
compared to the controls and the corresponding tumour tissue. This observation 
comes in agreement with another study by our group investigating methylation 
changes in white blood cells and whether they are predictive of breast cancer risk 
163. It has to be pointed that in this study HOXA9 was also shown methylated in 
the tissue analysed from the controls. This could be mainly attributed to aging, in 
a recent study our group showed that stem cell PCGTs are far more likely to 
become methylated with age than non-targets 413. Therefore, to avoid any bias in 
the study our study women were all postmenopausal and aged-matched. It needs 
to be pointed that the control samples used for the purposes of the study is not 
the ideal set of samples, the other option could have been (but not available) to 
use cancer free women undergoing mammoplasty reduction. The problem with 
this sample set though would have been the low number of progenitor cells for 
analysis. 
 
For future work it would be interesting to investigate methylation profiles of 
metastatic specimens compared to matched primary tissues in order to examine 
whether DNA methylation of PCGT genes is homogeneous in breast cancer 
metastases. A recent study by Wu et al demonstrated that samples taken from a 
patient’s primary breast carcinoma and their metastatic breast cancer are 
characterized by extensive expression heterogeneity. The study confirmed that 
ER and/or PR status characterising the primary cancer may be lost in the 
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metastatic carcinoma. This observation is important as the metastasis will not be 
hormone sensitive as its primary carcinoma resulting in resistance to the therapy. 
Interestingly the methylation signature of the primary tumour tissue compared to 
the metastatic specimen was similar, with the latter only exhibiting a higher 
intensity of methylation 414.  
 
In addition, microdissection of epithelial and stromal cells from the morphological 
normal tissue adjacent to the tumour compared to the corresponding tumour and 
controls would be an interesting study to better understand which cells are 
triggering DNA methylation changes in the breast. Preliminary evidence suggests 
that DNA methylation in the epithelial genome could be directed by the 
neighbouring fibroblasts indicating that the breast cancer microenvironment may 
be the one inducing epigenetic changes 415. Genetic changes in the 
morphologically normal cells adjacent to the tumour have been shown to be 
characterised by loss of heterozygosity, microsatellite and chromosome instability 
and gene mutations 416 with these alterations in the stroma not mimicking those 
in the epithelium playing a different and parallel role in carcinogenesis and 
tumor progression, probably by modifying some features specific to breast 
cancer 417. A more recent study though has shown conflicting results 418. 
Finally, it would be ideal to analyse tumour tissue and the corresponding 
plasma/serum from breast cancer patients but also plasma/serum collected 
before diagnosis from women with breast cancer and from controls to better 
understand the role of DNA methylation in breast cancer and their clinical value. 
A recent study has shown that aberrant promoter hypermethylation of RASSFA1 
n serum/plasma DNA may be common among high-risk women and may be 
present years before cancer diagnosis 419. Another study has shown an 
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association between elevated levels of tenascin-W and the presence of cancer 
in both serum samples and the stoma tissue analysed in colorectal cancers 420. 
 
This is a proof of principle study demonstrating for the first time that methylation 
of PCGT genes is unaffected by intra-tumour heterogeneity within a set of breast 
cancer samples. These findings suggest that methylation of specifically identified 
PCGT genes may present a more robust means with which to guide breast 
cancer management, particularly in instances when only small core biopsies are 
available for assessment. Further investigation of epigenetic intra-tumour 
heterogeneity within breast cancer, as well as other cancer types is necessary. In 
addition, more studies are needed in order to better understand field 
cancerisation in breast cancer and its value in risk prediction. Nonetheless 
evidence is beginning to accumulate in recognition of the potential of DNA 
methylation markers in cancer assessment and treatment. 
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6 SUMMARY AND FUTURE WORK  
6.1 Introduction 
The aim of the research presented in this PhD thesis is to identify and validate 
risk factors/biomarkers for breast cancer and add to the ongoing efforts to 
improve risk prediction in the general population. The project is continuing with 
analysis of serum DNA methylation changes using high-throughput technology to 
establish whether DNA methylation profiles will serve as a new tool to predict 
breast cancer risk. The plan is to correlate these changes with serum hormonal 
levels with final goal to build better breast cancer risk prediction models. A 
number of important findings have resulted from the first phase of the work which 
forms the basis of this thesis and are summarised in the following section.   
 
6.2 Summary of the main findings 
6.2.1 Which is the best way to identify breast cancer cases in the general 
population? 
Identification of breast cancer cases within UKCTOCS was a lengthy process. 
When the study started it was decided to use not only notification obtained from 
the cancer registry and UKCTOCS FUQ but to validate this using a specific 
questionnaire on breast cancer (the BCQ) which was send to the treating 
physician of the women. The purpose was to confirm diagnosis and to collect 
further clinicopathological data. Identification of the women with breast cancer 
started in October 2006 and ended in February 2009 with the last up-date from 
ONS. It resulted in the initial identification of 2629 women with possible breast 
cancer. As soon as ethical approval was provided the BCQs were sent to the 
treating physician of the women. 1083 BCQs were returned. By comparing the 
three sources discrepancies were identified and the need to further investigate 
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which source is most accurate for breast cancer diagnosis was born. Literature 
review confirmed the absence of such a study with the majority of previous 
studies reporting on accuracy of cancer data by comparing self-reported data 
collected using questionnaires to CR records. It became apparent that this would 
be the largest study conducted in England and Wales examining the sensitivity of 
both self-reporting and CR to medical confirmation obtained in a form of 
questionnaire completed by the physicians treating the women diagnosed with 
breast cancer.  
Main findings:  
1) Decreased sensitivity of CR compared to FUQ is mostly due to delays in 
cancer registration with higher PPV characterising CR compared to self-
reporting (FUQ).  
2) Researchers could rely on national CR data as it had the lowest 
percentage of misclassifications.  
3) Self-reported data is another good source but accuracy is to a certain 
extent dependent on factors such as age, education and family breast 
cancer history. 
4) Only directly contacting physicians eliminated all discrepancies within our 
cohort which otherwise would have been misclassified.  
5) Confirmation of the cancer diagnosis by checking medical notes as it was 
carried out using a questionnaire provided the most complete data. 
However it needs to be noted that this is labour intensive and 70% of 
responses were received. 
 
Going through the analysis affords the degree of assurance that the suggested 
methodology is sufficiently robust to accurately identify breast cancer cases. This 
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is important as studies investigating cancer risk assessment are completely 
dependent on accurate data about cancer diagnosis.  
 
6.2.2 Shedding light on the role of sex steroid hormones and their 
controllers -gonadotrophins- and examining for the first time serum 
bioactivity of sex steroid receptors in breast cancer  
Sex steroid hormones are known to be involved in breast carcinogenesis. 
However, search of the literature revealed the absence of studies investigating 
sex steroid hormone levels in breast cancer patients at different time intervals 
before diagnosis and their role in risk prediction. The meta-analysis by Key et al 
197 was the first report to examine whether differences exist in breast cancer risk 
less and more than two years before breast cancer diagnosis. Additionally, no 
study was found that had explored the role of gonadotrophins and breast cancer 
risk and there was only one study with adequate sample size that had 
investigated progesterone and breast cancer risk 202.  No reports were found 
investigating SB of steroid receptors in relation to breast cancer. With the recent 
report by our group demonstrating a 10 fold increase of breast cancer risk in 
women with ER-α and ER-β SB in the top quintile at the time of diagnosis 162, it 
was of great interest to investigate their value in samples collected up to five 
years before diagnosis both to asses them as markers and better understand 
their role in breast carcinogenesis. Finally, literature search showed the absence 
of studies investigating the joint effect of hormones in predicting breast cancer 
risk with all studies examining the effect of single hormones. The only study that 
had explored the combined effect of oestrogens and androgens had shown to 
increase breast cancer risk prediction but women had provided serum samples at 
the time of breast cancer diagnosis 201 and not prior to diagnosis years in 
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advance as in this study. Therefore, using nested case control study in 
UKCTOCS eligible cases and controls were identified to investigate and cover all 
the above missing links with the aim to better understand the role of sex steroid 
hormones and gonadotrophins in breast cancer risk prediction.   
Main findings: 
1) Less than 2 years before diagnosis, the main oestrogen associated with 
breast cancer risk is oestrone with increased levels being significantly 
associated with breast cancer risk. 
2) The main androgen associated with breast cancer risk is testosterone with 
increased levels independent of time prior to diagnosis being associated 
with increased risk.  
3) ER-α and ER-β SBs more than 2 years before diagnosis are associated 
with breast cancer with women having ER-α SB in top quintile 2 years 
before diagnosis having a two fold increased breast cancer risk.  
4) Combination of hormones has a better breast cancer risk prediction power 
in comparison to single hormones.  
5) Testosterone and FSH were shown to have a possible synergistic effect in 
breast carcinogenesis with a high risk predictive power independent of 
time to diagnosis. 
6) SHBG and ER-β SB was demonstrated to have a possible synergistic 
effect in breast carcinogenesis but also to predict breast cancer more than 
2 years before diagnosis with high significance.  
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6.2.3 What does the future hold of DNA methylation changes in breast 
cancer?  
Epigenetics and especially DNA methylation changes hold a great promise in the 
future for clinical assessment of breast cancer. Researching the literature it was 
clear that other methods to assess the disease were lacking due to intra-tumour 
heterogeneity 375, 376. Additionally, there was a huge interest in the environment 
around the tumour, with the majority of the studies on colon and breast cancer 
showing methylation changes in premalignant colorectal and breast tissue 
representing a field defect, perpetuating further neoplastic changes 272, 273. In the 
meantime, our group among others was the first to provide evidence that stem 
cell PCGT genes are more likely to have cancer specific promoter DNA 
hypermethylation than non-PCGT genes 279, 280, 388. Therefore, investigation of the 
role of PCGT methylation in breast cancer examining intra-tumour heterogeneity 
and epigenetic field defect was raised. With this study, it was shown for the first 
time that PCGT methylation changes were predictive of breast cancer and 
homogeneous across the tumour. This is an important finding as PCGT 
methylation changes could prove good candidate markers for serum analysis but 
before analysing serum it was fundamental to investigate whether such changes 
are representative of the entire tumour. The discovery of a cancer marker that is 
detected in both the serum and tumour tissue would be ideal – therefore, by 
looking into whether this marker is affected by intra-tumour heterogeneity is the 
first step towards further analysis.  
Main findings: 
1) Methylation of specific PCGT loci predicts the presence of breast cancer in 
core biopsy specimens. 
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2) 13/55 PCGT genes were shown to be cancer specific (p\0.05) with a ROC 
AUC of 0.7 (range 0.71–0.95) and with DNA methylation changes 
investigated predicting the presence of cancer in both tissues taken from 
the center and the periphery of the tumour. 
3) Methylation of specific PCGT loci is unaffected by tumour-heterogeneity. 
4) DNA methylation analysis of PCGT genes carries information independent 
from expression and could be used to assess core breast biopsies and 
ultimately guide patient management.  
 
6.3 Future work 
For future work we are planning to work on the following aspects (some of the 
suggested future work is already underway):  
 
 Apart from the main role of oestrogens and androgens in breast cancer risk, 
it is of great interest to better understand the role progesterone in breast 
carcinogenesis. Previous studies have shown HRT use (synthetic progesterone 
derivatives are used) to be associated with an increased risk of breast cancer. In 
a recent study it has been demonstrated that in vivo administration of 
medroxyprogesterone acetate triggers massive induction of the key osteoclast 
differentiation factor Receptor Activator of NF-κB Ligand (RANKL) in mammary 
gland epithelial cells (data to be published in Nature by collaborators). RANKL is 
essential for the development and activation of osteoclasts. RANKL and its 
receptor RANK also control lymph node organogenesis, development of thymic 
medullary epithelial cells and, importantly, formation of a lactating mammary 
gland during pregnancy. Both RANKL and RANK expression have been 
observed in primary breast cancers in humans and breast cancer cells lines and 
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it has been proposed that the RANKL/RANK system can regulate bone 
metastases of epithelial tumours 421, 422. Based on these observations, in a 
collaboration set up between Professor Martin Widschwendter with Professor 
Georg Schett and Professor Josef M. Penninger further studies are underway to 
investigate the role of RANK and RANKL and correlate it with progesterone levels 
in women described in chapter 4. Furthermore, PR SB will be investigated to 
better understand its association with breast cancer. Our collaborators in Bonn 
are trying to establish the assay. During my stay in Bonn, different clones 
produced by Guido Hasenbrink were tried under different conditions (this data 
was not shown) to check functionality of the assay but unfortunately the assay did 
not work. Once the PR SB assay is perfected the plan is to analyse PR SB in our 
cohort.  
 
 To better understand the synergistic effect of FSH and testosterone in 
breast carcinogenesis further experiments will be carried out. Collaboration has 
already been set up with Professor Louis Dubeau to investigate the possible 
synergist effect of FSH and testosterone in mammary tissue in a mouse model. 
This will involve crossing two transgenic mouse lines expressing Cre 
recombinase under the control of a truncated form of the FSHR with a ROSA26R 
Cre reporter mouse and investigating the expression of FSHR in the breast tissue 
(stroma, epithelium and fat). If expression is confirmed mammary cells will be 
treated with FSH and IGF1 alone and in combination to investigate whether 
increased aromatization (CYP11A1, HSD3B1 and CYP19A1 mRNA levels 
measured) occurs by comparing them to cells that have not been treated.  
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 After investigating the homogeneity of PCGT methylation changes in breast 
tumour, it would be interesting to examine methylation profiles of metastatic 
specimens compared to matched primary tissues to study whether DNA 
methylation of PCGT genes are homogeneous in breast cancer metastases. 
Additionally, microdissected epithelial and stromal cells from the morphological 
normal tissue adjacent to the tumour compared to the corresponding tumour and 
controls would be an interesting study to better understand which cells are 
triggering DNA methylation changes in the breast.  
 
 Analyses of tumour tissue and the corresponding plasma/serum from breast 
cancer patients but also plasma/serum collected before diagnosis from women 
with breast cancer and from controls to better understand the role of DNA 
methylation in breast cancer and their clinical value are essential. Over the last 
decade it has become clear that hypermethylation can be detected in tumour-
derived DNA found in the serum and plasma of cancer patients. The far majority 
of studies have analysed serum/plasma in diseased individuals to either use this 
as an early detection marker or as a prognostic/predictive marker. None of the 
studies so far have addressed the question whether DNA in serum/plasma is able 
to predict predisposition to develop cancer years before onset of disease. A 
method to detect pre-neoplastic and/or early neoplastic change prior to tumour 
mass formation is needed to allow us to catch tumours early. Such an approach 
would also offer invaluable knowledge to add to current theories of 
carcinogenesis. During the PhD study new techniques were discovered for 
epigenome analysis caughting up with the demands of modern epigenetics. 
Further work will be carried out to using whole epigenome analysis to investigate 
whether serum DNA methylation changes could prove useful markers for risk 
Summary and future work  
6-281 
assessment. Our group has already started epigenotyping the 200 cases and 400 
controls used to examine hormonal changes along with more cases that were 
further identified through the process described in chapter 3 using high-
throughput technology (Illumina) to discover markers for breast cancer risk 
prediction. The work includes optimising DNA extraction from serum, analysing 
DNA methylation changes for more than 27,000 genes using Illumina technology 
in 350 cases and 400 controls, solving the statistical issues in the analysis of 
high-throughput DNA methylation data. 
 
 Animal models have provided a lot of information linking the effects of 
steroid hormones on epigenome to cancer. Much less is available in human 
beings. Our group was one of the first to find in breast cancer, target genes of 
ER-α to be less methylated in ER positive cancers in comparison to ER negative 
ones 163. One of the main questions to be answered through the planned work is 
whether long-term hormonal exposure alters the epigenome in non-neoplastic 
cells in human beings. In order to answer this question DNA methylation changes 
in serum samples described in chapter 4 will be correlated with the already 
measured sex steroid hormones and sex steroid receptor SB to better 
understand their effect on the epigenome and in breast carcinogenesis.  
 
 Eventually combination of all the data will show whether a better risk 
prediction could be obtained that will eventually have an impact in women’s life. 
 
6.4 Conclusion  
This thesis reported on all the important incremental steps made in achieving the 
aims described in chapter 1 within the timeframe of the three-year PhD. Briefly, 
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the aims of this project were to: 1) examine which is the best source of identifying 
breast cancer cases in the general population 2) investigate the association of 
sex steroids, gonadotrophins and novel assays of sex steroid hormone receptor 
SB in breast cancer 3) examine whether they can be combined to improve breast 
cancer risk assessment and investigate their synergistic effect 4) identify new 
DNA methylation markers that might add to such a strategy in the future, with an 
overall goal to improve breast cancer risk prediction. The findings of this research 
have shown that the most accurate source of information for breast cancer 
diagnosis involves combining CR and self-reporting data using the rule that both 
must concur if breast cancer is to be confirmed. The research has demonstrated 
that oestrone and testosterone are the most strongly associated oestrogens and 
androgens, respectively, with breast cancer risk along with SB of their receptors 
which proved to be an attractive alternative marker for risk assessment in 
postmenopausal women. By examining the best combination of hormones/SB for 
breast cancer risk prediction, testosterone and FSH were shown to have 
significant predictive power and a possible synergistic effect in breast 
carcinogenesis. Furthermore, DNA methylation changes were shown to be 
associated with breast cancer and most importantly to be homogeneous. This is 
important for future studies trying to identify markers for risk assessment. Further 
studies are required to assess the role of serum DNA methylation changes and 
breast cancer risk. Examining the effect of sex steroid hormones into the 
epigenome and combination of hormones and breast cancer specific genes in a 
model to better predict breast cancer risk requires exploration. 
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Appendix VI:  Statistically non-significant joint associations of high levels of 




Joint association of oestrogens 
Oestradiol 
Oestrone 
  OR* (95% CI) 
 Not adjusted 
2.016 (1.017-4.668) 
p=0.072 












































Supplemental Table VI-1: Joint association of high levels of oestrogens (top quantiles) 
with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of oestrogens and androgens 
Oestradiol  Oestrone 
DHEAS Androstenedione DHEAS 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.090 (0.499-2.148) 1.853 (1.037-4.487) 1.274 (0.595-2.848) 
p=0.817 p=0.094 p=0.545 









  1.768 (0.828-3.739) 1.106 (0.476-2.439) 
 p=0.135 p=0.807 
Oestrone 
1.060 (0.495-2.174)   
p=0.877   
Androstenedione 
0.880 (0.397-1.868)  0.925 (0.389-2.083) 
p=0.743  p=0.854 
Testosterone 
0.642 (0.286-1.379) 1.369 (0.616-3.015) 0.750 (0.312-1.709) 
p=0.266 p=0.434 p=0.503 
DHEAS 
 1.857 (0.880-3.561)  
 p=0.100  
SHBG 
1.101 (0.512-2.265) 1.719 (0.823-4.282) 1.149 (0.507-2.496) 
p=0.798 p=0.144 p=0.730 
Progesterone  
1.034 (0.465-2.207) 1.977 (0.913-3.691) 1.138 (0.486-2.566) 
p=0.932 p=0.081 p=0.759 
LH 
1.074 (0.501-2.199) 1.784 (0.855-3.691) 1.274 (0.564-2.764) 
p=0.849 p=0.118 p=0.547 
FSH 
1.106 (0.515-2.227) 1.852 (0.890-3.822) 1.287 (0.570-2.789) 
p=0.789 p=0.094 p=0.529 
ER-α SB 
1.106 (0.517-2.262) 1.721 (0.812-3.591) 1.283 (0.568-2.778) 
p=0.788 p=0.149 p=0.534 
ER-β SB 
1.095 (0.511-2.241) 1.727 (0.972-3.606) 1.402 (0.637-2.988) 
p=0.809 p=0.146 p=0.388 
AR SB 
0.988 (0.500-2.054) 1.715 (0.917-3.577) 1.251 (0.554-2.710) 
p=0.974 p=0.151 p=0.577 
Supplemental Table VI-2: Joint association of high levels of oestrogens and androgens 
(top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of oestrogens and progesterone  
Oestradiol  Oestrone  
Progesterone  
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.125 (0.547-2.280) 1.670 (0.803-3.712) 
p=0.745 p=0.187 




















































1.020 (0.476-2.086) 1.509 (0.768-3.277) 
 p=0.959 p=0.301 
Supplemental Table VI-3: Joint association of high levels of oestrogens and 
progesterone (top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of oestrogens and gonadotrophins  
Oestradiol Oestrone 
LH FSH LH FSH 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.711 (0.209-2.140) 0.714 (0.199-2.930) 1.066 (0.405-2.678) 1.468 (0.655-3.912) 
p=0.565 p=0.622 p=0.894 p=0.394 









  1.052 (0.389-2.671) 1.288 (0.496-3.171) 
  p=0.915 p=0.587 
Oestrone 
0.776 (0.210-2.366) 0.795 (0.170-2.903)   
p=0.673 p=0.742   
Androstenedione 
0.646 (0.175-1.945) 0.687 (0.148-2.437) 0.935 (0.322-2.428) 1.201 (0.462-3.006) 
p=0.464 p=0.586 p=0.895 p=0.686 
Testosterone 
0.556 (0.149-1.693) 0.679 (0.145-2.430) 0.945 (0.343-1.398) 1.247 (0.475-3.107) 
p=0.331 p=0.576 p=0.908 p=0.640 
DHEAS 
0.704 (0.192-2.098) 0.717 (0.155-2.515) 1.056 (0.390-2.633) 1.469 (0.590-3.537) 
p=0.553 p=0.626 p=0.910 p=0.393 
SHBG 
0.757 (0.205-2.285) 0.672 (0.145-2.374) 1.014 (0.373-2.541) 1.589 (0.630-3.886) 
p=0.641 p=0.562 p=0.978 p=0.312 
Progesterone  
0.696 (0.191-2.073) 0.712 (0.154-2.498) 1.046 (0.387-2.608) 1.469 (0.589-3.538) 
p=0.541 p=0.619 p=0.925 p=0.394 
LH 
 0.871 (0.185-3.150)  1.661 (0.658-4.067) 
 p=0.843  p=0.268 
FSH 
0.697 (0.190-2.087)  1.047 (0.385-2.622)  
p=0.544  p=0.925  
ER-α SB 
0.714 (0.195-2.127) 0.718 (0.155-2.522) 1.024 (0.377-2.557) 1.455 (0.583-3.510) 
p=0.570 p=0.628 p=0.961 p=0.406  
ER-β SB 
0.708 (0.194-2.108) 0.715 (0.155-2.508) 1.065 (0.394-2.652) 1.472 (0.590-3.544) 
p=0.561 p=0.624 p=0.895 p=0.391 
AR SB 
0.705 (0.193-2.099) 0.724 (0.156-2.542) 1.081 (0.399-2.695) 1.490 (0.598-3.590) 
p=0.555 p=0.637 p=0.871 p=0.376 
Supplemental Table VI-4: Joint association of high levels of oestrogens and gonadotrophins (top 
quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. **OR 
values for SB adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds ratio; 
SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of oestrogens and SHBG 
Oestradiol Oestrone  
SHBG 
  OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.417 (0.077-1.172) 0.468 (0.1404-0.910) 
p=0.175 p=0.180 









 0.498 (0.084-1.398) 
 p=0.222 
Oestrone 
0.424 (0.096-1.329)  
p=0.184  
Androstenedione 
0.388 (0.088-1.230) 0.537 (0.150-1.519) 
p=0.146 p=0.279 
Testosterone 
0.319 (0.071-1.027) 0.586 (0.164-1.657) 
p=0.082 p=0.352 
DHEAS 






0.392 (0.089-1.242) 0.589 (0.190-1.532) 
p=0.150 p=0.309 
LH 
0.416 (0.095-1.305) 0.454 (0.128-1.260) 
p=0.175 p=0.163 
FSH 
0.419 (0.095-1.315) 0.465 (0.132-1.292) 
p=0.179 p=0.177 
ER-α SB 
0.398 (0.090-1.249) 0.461 (0.130-1.280) 
p=0.154 p=0.172 
ER-β SB 
0.418 (0.095-1.307) 0.500 (0.141-1.404) 
p=0.176 p=0.225 
AR SB 
0.274 (0.043-1.004) 0.503 (0.142-1.410) 
p=0.091 p=0.228 
Supplemental Table VI-5: Joint association of high levels of oestrogens and 
gonadotrophins (top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Appendices 
- 358 - 
 
Hormones 
Joint association of androgens and progesterone 
DHEAS  
Progesterone  
















































Supplemental Table VI-6: Joint association of high levels of androgens and progesterone 
(top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of androgens and gonadotrophins  
Andorestenedione DHEAS 
FSH LH FSH 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) 
 Not adjusted 
2.266 (0.957-5.423) 0.991 (0.410-1.832) 1.501 (0.501-3.631) 
p=0.085 p=0.982 p=0.424 









2.371 (0.773-4.610) 1.012 (0.458-2.122) 1.699 (0.629-4.456) 
p=0.154 p=0.976 p=0.281 
Oestrone 
2.748 (0.925-5.578) 1.206 (0.553-2.526) 1.620 (0.640-3.065) 
p=0.072 p=0.625 p=0.293 
Androstenedione 
 0.707 (0.304-1.541) 1.306 (0.453-3.570) 
 p=0.398 p=0.606 
Testosterone 
1.760 (0.588-3.663) 0.676 (0.297-1.457) 1.170 (0.403-3.226) 
p=0.398 p=0.330 p=0.764 
DHEAS 
2.341 (0.887-5.100)   
p=0.087   
SHBG 
2.172 (0.952-5.595) 0.888 (0.401-1.859) 1.457 (0.511-3.948) 
p=0.061 p=0.759 p=0.463 
Progesterone  
2.368 (0.654-4.113) 0.908 (0.398-1.966) 1.336 (0.431-3.871) 
p=0.273 p=0.810 p=0.597 
LH 
6.975 (1.141-7.092)  1.986 (0.675-5.611) 
p=0.024  p=0.197 
FSH 
 0.994 (0.450-2.081)  
 p=0.989  
ER-α SB 
2.227 (0.929-5.345) 1.000 (0.453-2.089) 1.504 (0.490-4.308) 
p=0.069 p=0.999 p=0.453 
ER-β SB 
2.131 (0.892-5.096) 1.093 (0.508-2.248) 1.342 (0.482-3.509) 
p=0.085 p=0.812 p=0.554 
AR SB 
2.193 (0.915-5.258) 0.993 (0.450-2.073) 1.149 (0.387-3.110) 









Supplemental Table VI-7: Joint association of high levels of androgens and 
gonadotrophins (top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SHBG and androgens 
Androstenedione Testosterone DHEAS  
SHBG 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.552 (0.083-1.578) 1.085 (0.462-3.475) 0.909 (0.278-2.782) 
p=0.301 p=0.875 p=0.862 









0.399 (0.091-1.246) 1.237 (0.444-3.228) 0.967 (0.296-2.775) 
p=0.154 p=0.669 p=0.952 
Oestrone 
0.448 (0.101-1.419) 1.128 (0.382-3.028) 0.950 (0.295-2.670) 
p=0.121 p=0.816 p=0.926 
Androstenedione 
 0.737 (0.225-2.889) 0.772 (0.236-2.199) 
 p=0.585 p=0.642 
Testosterone 
0.310 (0.069-0.992)  0.656 (0.199-1.891) 
p=0.074  p=0.454 
DHEAS 
0.541 (0.151-1.546) 1.064 (0.365-2.824)  
p=0.288 p=0.906  
SHBG 
   
   
Progesterone  
0.518 (0.144-1.478) 1.040 (0.349-2.824) 0.832 (0.253-2.399) 
p=0.257 p=0.940 p=0.744 
LH 
0.549 (0.153-1.561) 1.104 (0.374-2.963) 0.857 (0.266-2.404) 
p=0.297 p=0.848 p=0.788 
FSH 
0.552 (0.154-1.565) 1.086 (0.369-2.904) 0.907 (0.282-2.540) 
p=0.301 p=0.873 p=0.859 
ER-α SB 
0.557 (0.156-1.583) 1.057 (0.358-2.833) 0.917 (0.285-2.571) 
p=0.309 p=0.915 p=0.875 
ER-β SB 
0.411 (0.094-1.282) 1.091 (0.370-2.924) 0.910 (0.283-2.549) 
p=0.167 p=0.866 p=0.864 
AR SB 
0.279 (0.044-1.015) 0.901 (0.280-2.521) 0.734 (0.201-2.188) 
p=0.094 p=0.849 p=0.602 
Supplemental Table VI-8: Joint association of high levels of androgens and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of progesterone and gonadotrophins  
Progesterone  
LH FSH 
  OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.903 (0.0365-1.859) 1.133 (0.353-3.277) 
p=0.806 p=0.826 









0.886 (0.374-1.950) 1.433 (0.508-3.839) 
p=0.771 p=0.478 
Oestrone 
1.277 (0.565-2.769) 1.690 (0.628-4.412) 
p=0.543 p=0.283 
Androstenedione 
0.650 (0.257-1.498) 0.677 (0.179-2.117) 
p=0.331 p=0.524 
Testosterone 
0.614 (0.251-1.397) 0.888 (0.262-2.698) 
p=0.260 0.838 
DHEAS 
0.863 (0.347-2.014) 1.116 (0.331-3.372) 
p=0.740 p=0.849 
SHBG 






 1.323 (0.393-4.004) 
 p=0.629 
FSH 
0.908 (0.383-1.998)  
p=0.816  
ER-α SB 
1.145 (0.514-2.431) 1.480 (0.483-4.232) 
p=0.730 p=0.470 
ER-β SB 
0.903 (0.381-1.989) 1.134 (0.342-3.362) 
p=0.807 p=0.825 
AR SB 
1.128 (0.506-2.391) 1.251 (0.416-3.357) 
p=0.759 p=0.673 
Supplemental Table VI-9: Joint association of high levels of progesterone and 
gonadotrophins (top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of gonadotrophins  
LH 
FSH 
















































*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Supplemental Table VI-10: Joint association of high levels of gonadotrophins (top 
quantiles) with risk of breast cancer – all cases.    
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Joint association of SHBG and progesterone 
SHBG 
Progesterone 
















































Supplemental Table VI-11: Joint association of high levels of sex hormone-binding 
globulin and progesterone (top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SHBG and gonadotrophins  
SHBG 
LH FSH 
  OR* (95% CI) OR* (95% CI) 
 Not adjusted 
0.229 (0.052-0.892) 0.580 (0.278-1.785) 
p=0.051 p=0.250 









0.224 (0.035-0.796) 0.716 (0.275-1.668) 
p=0.047 p=0.460 
Oestrone 
0.235 (0.037-0.835) 0.601 (0.215-1.453) 
p=0.055 p=0.287 
Androstenedione 
0.120 (0.007-0.597) 0.596 (0.213-1.438) 
p=0.041 p=0.278 
Testosterone 
0.246 (0.038-0.894) 0.535 (0.174-1.370) 
p=0.066 p=0.225 
DHEAS 






0.229 (0.036-0.815) 0.457 (0.150-1.148) 
p=0.051 p=0.123 
LH 
 0.664 (0.236-1.625) 
 p=0.397 
FSH 
0.217 (0.043-0.790)  
p=0.046  
ER-α SB 
0.243 (0.038-0.871) 0.493 (0.162-1.243) 
p=0.062 p=0.165 
ER-β SB 
0.229 (0.036-0.814) 0.479 (0.157-1.210) 
p=0.051 p=0.149 
AR SB 
0.230 (0.036-0.815) 0.487 (0.160-1.225) 
p=0.051 p=0.157 
Supplemental Table VI-12: Joint association of high levels of sex hormone-binding 
globulin and gonadotrophins (top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of oestrogens and androgens  
Oestradiol Oestrone 
Androstenedione Testosterone DHEAS DHEAS 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.701 (0.818-4.014) 1.594 (0.872-3.527) 0.870 (0.303-2.266) 1.578 (0.696-4.398) 
p=0.179 p=0.199 p=0.786 p=0.330 









   1.324 (0.463-3.322) 
   p=0.570 
Oestrone 1.618 (0.710-3.446) 1.514 (0.715-3.032) 0.834 (0.270-2.137)  
p=0.227 p=0.256 p=0.726  
Androstenedione  1.287 (0.581-2.706) 0.731 (0.231-1.933) 1.078 (0.367-2.792) 
 p=0.517 p=0.556 p=0.882 
Testosterone 1.086 (0.448-2.483)  0.518 (0.162-1.385) 0.903 (0.305-2.353) 
p=0.850  p=0.220 p=0.843 
DHEAS 1.680 (0.730-3.626) 1.582 (0.736-3.229)   
p=0.200 p=0.220   
SHBG 1.662 (0.705-3.689) 1.503 (0.700-3.062) 0.740 (0.233-1.977) 1.437 (0.515-3.660) 
p=0.224 p=0.275 p=0.575 p=0.463 
Progesterone  
1.669 (0.731-3.657) 1.592 (0.751-3.196) 0.875 (0.284-2.236) 1.395 (0.519-3.390) 
p=0.201 p=0.204 p=0.795 p=0.480 
LH 1.671 (0.737-3.544) 1.579 (0.749-3.146) 0.859 (0.280-2.183) 1.574 (0.588-3.803) 
p=0.195 p=0.208 p=0.768 p=0.334 
FSH 
1.709 (0.753-3.631) 1.639 (0.774-3.284) 0.894 (0.290-2.283) 1.621 (0.605-3.929) 
p=0.177 p=0.177 p=0.828 p=0.304 
ER-α SB 
1.592 (0.676-3.464) 1.449 (0.671-2.934) 0.868 (0.283-2.205) 1.579 (0.591-3.812) 
p=0.259 p=0.32 p=0.875 p=0.330 
ER-β SB 
1.528 (0.650-3.315) 1.446 (0.668-2.934) 0.795 (0.284-2.231) 1.854 (0.728-4.362) 
p=0.302 p=0.324 p=0.784 p=0.171 
AR SB 
1.531 (0.652-3.314) 1.452 (0.672-2.940) 0.871 (0.672-2.211) 1.581 (0.590-3.824) 
p=0.299 p=0.317 p=0.788 p=0.330 
Supplemental Table VI-13: Joint association of high levels of oestrogens and androgens (top 
quantiles) with risk of breast cancer – cases that gave a sample less than 2 years before 
diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. **OR 
values for SB adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds ratio; 
SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of oestrogens and progesterone  
Progesterone  
Oestradiol  Oestrone  
  OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.181 (0.475-2.813) 2.015 (0.897-5.412) 
p=0.714 p=0.123 









 2.161 (0.838-5.212) 
 p=0.094 
Oestrone 
1.156 (0.440-2.702)  
p=0.751  
Androstenedione 
0.939 (0.344-2.306) 1.576 (0.591-3.921) 
p=0.896 p=0.341 
Testosterone 
0.802 (0.294-1.963) 1.465 (0.554-3.605) 
p=0.645 p=0.419 
DHEAS 






1.334 (0.506-3.153) 1.948 (0.756-4.678) 
p=0.531 p=0.146 
LH 
1.158 (0.443-2.691) 1.979 (0.773-4.713) 
p=0.747 p=0.134 
FSH 
1.217 (0.464-2.848) 2.090 (0.814-5.000) 
p=0.667 p=0.107 
ER-α SB 
1.001 (0.358-2.419) 1.752 (0.650-4.296) 
p=0.999 p=0.237 
ER-β SB 
1.010 (0.361-2.442) 1.857 (0.685-4.591) 
p=0.983 p=0.195 
AR SB 
0.998 (0.357-2.412) 1.744 (0.646-4.278) 
p=0.999 p=0.242 
Supplemental Table VI-14: Joint association of high levels of oestrogens and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of oestrogens and gonadotrophins 
Oestradiol Oestrone  
LH FSH LH FSH 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.047 (0.258-3.504) 1.422 (0.365-5.493) 1.488 (0.541-4.603) 2.273 (0.980-6.940) 
p=0.945 p=0.609 p=0.461 p=0.095 









  1.465 (0.060-3.998) 1.898 (0.645-5.035) 
  p=0.480 p=0.213 
Oestrone 1.134 (0.249-3.386) 1.556 (0.328-5.757)   
p=0.851 p=0.530   
Androstenedione 0.997 (0.220-3.315) 1.396 (0.298-4.995) 1.260 (0.470-3.687) 1.837 (0.619-4.920) 
p=0.996 p=0.630 p=0.694 p=0.242 
Testosterone 0.837 (0.183-2.817) 1.352 (0.287-4.884) 1.315 (0.347-3.660) 1.858 (0.624-4.990) 
p=0.792 p=0.665 p=0.619 p=0.234 
DHEAS 1.031 (0.229-3.397) 1.434 (0.309-5.081) 1.464 (0.421-4.002) 2.286 (0.829-5.854) 
p=0.963 p=0.601 p=0.481 p=0.092 
SHBG 1.003 (0.223-3.307) 1.436 (0.309-5.097) 1.467 (0.041-4.008) 2.295 (0.832-5.890) 
p=0.996 p=0.599 p=0.477 p=0.091 
Progesterone  
1.150 (0.253-3.876) 1.327 (0.284-4.750) 1.412 (0.441-3.895) 2.590 (0.920-6.866) 
p=0.835 p=0.683 p=0.526 p=0.059 
LH  1.635 (0.344-6.036)  2.427 (0.874-6.292) 
 p=0.486  p=0.074 
FSH 
1.002 (0.221-3.333)  1.444 (0.451-3.960)  
p=0.998  p=0.498  
ER-α SB 
1.049 (0.234-3.446) 1.425 (0.307-5.045) 1.504 (0.471-4.117) 2.281 (0.828-5.841) 
p=0.942 p=0.607 p=0.451 p=0.093 
ER-β SB 
1.062 (0.236-3.501) 1.427 (0.307-5.070) 1.522 (0.469-4.168) 2.265 (0.820-5.814) 
p=0.928 p=0.606 p=0.437 p=0.096 
AR SB 
1.050 (0.234-3.447) 1.434 (0.309-5.076) 1.495 ().469-4.085) 2.289 (0.831-5.865) 
p=0.942 p=0.601 p=0.456 p=0.091 
Supplemental Table VI-15: Joint association of high levels of oestrogens and 
gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis. 
  
*OR values for top-bottom classification were based on controls only and were age adjusted. **OR 
values for SB adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SHBG and oestrogens  
Oestradiol Oestrone 
SHBG 
  OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.267 (0.033-1.457) 0.456 (0.039-1.978) 
p=0.206 p=0.301 









 0.477 (0.074-1.732) 
 p=0.331 
Oestrone 
0.275 (0.014-1.603)  
p=0.217  
Androstenedione 
0.257 (0.015-1.569) 0.526 (0.081-1.929) 
p=0.196 p=0.402 
Testosterone 
0.213 (0.012-1.485) 0.565 (0.088-2.069) 
p=0.142 p=0.455 
DHEAS 






0.237 (0.013-1.523) 0.690 (0.158-2.126) 
p=0.171 p=0.562 
LH 
0.268 (0.015-1.492) 0.448 (0.070-1.613) 
p=0.207 p=0.290 
FSH 
0.272 (0.015-1.504) 0.448 (0.070-1.615) 
p=0.213 p=0.290 
ER-α SB 
0.268 (0.015-1.587) 0.456 (0.071-1.642) 
p=0.207 p=0.301 
ER-β SB 
0.261 (0.014-1.511) 0.452 (0.070-1.648) 
p=0.199 p=0.298 
AR SB 
0.267 (0.015-1.563) 0.490 (0.076-1.779) 
p=0.206 p=0.349 
Supplemental Table VI-16: Joint association of high levels of oestrogens and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer – cases that gave a 
sample less than 2 years before diagnosis. 
  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of androgens  
Testosterone  
DHEAS 
















































Supplemental Table VI-17: Joint association of high levels of androgens (top quantiles) 
with risk of breast cancer – cases that gave a sample less than 2 years before diagnosis. 
  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of androgens and progesterone  
DHEAS 
Progesterone  
















































Supplemental Table VI-18: Joint association of high levels of androgens and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis. 
  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of androgens and gonadotrophins 
Androstenedione DHEAS  
LH FSH LH FSH 
 OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
 Not adjusted 
2.429 (0.854-5.197) 1.890 (0.703-6.343) 1.234 (0.455-2.679) 1.634 (0.472-5.124) 
p=0.057 p=0.250 p=0.646 p=0.421 








Oestradiol 2.583 (0.981-6.410) 1.473 (0.400-4.442) 1.269 (0.481-2.993) 2.013 (0.606-5.926) 
p=0.045 p=0.517 p=0.604 p=0.219 
Oestrone 3.059 (1.139-7.816) 1.336 (0.560-5.529) 1.604 (0.632-3.746) 2.158 (0.720-5.862) 
p=0.021 p=0.273 p=0.292 p=0.143 
Androstenedione 
  0.859 (0.296-2.164) 1.470 (0.385-4.679) 
  p=0.760 p=0.535 
Testosterone 1.917 (0.702-4.940) 1.146 (0.304-3.548) 0.879 (0.324-2.138) 1.349 (0.352-4.323) 
p=0.186 p=0.824 p=0.787 p=0.631 
DHEAS 2.492 (0.916-6.428) 1.864 (0.570-5.327)   
p=0.063 p=0.264   
Progesterone  
2.242 (0.854-5.536) 2.079 (0.628-6.081) 1.083 (0.410-2.553) 1.594 (0.421-5.038) 
p=0.086 p=0.197 p=0.863 p=0.450 
SHBG 2.441 (0.907-6.214) 1.036 (0.229-3.432) 1.078 (0.391-3.684) 1.203 (0.257-4.272) 
p=0.066 p=0.958 p=0.877 p=0.789 
LH 
 2.291 (0.687-6.791)  1.985 (0.507-6.607) 
 p=0.147  p=0.283 
FSH 
2.429 (0.926-5.979)  1.224 (0.464-2.884)  
p=0.059  p=0.661  
ER-α SB 
2.617 (0.996-6.487) 1.881 (0.575-5.382) 1.235 (0.470-2.898) 1.344 (0.291-5.038) 
p=0.041 p=0.257 p=0.645 p=0.665 
ER-β SB 
2.390 (0.914-5.864) 1.855 (0.569-5.284) 1.408 (0.563-3.216) 1.441 (0.388-4.384) 
p=0.063 p=0.266 p=0.436 p=0.544 
AR SB 
2.449 (0.937-6.006) 1.928 (0.590-5.512) 1.234 (0.469-2.898) 1.080 (0.239-3.582) 
p=0.056 p=0.239 p=0.647 p=0.908 
Supplemental Table VI-19: Joint association of high levels of androgens and gonadotrophins 
(top quantiles) with risk of breast cancer – cases that gave a sample less than 2 years before 
diagnosis. 
  
*OR values for top-bottom classification were based on controls only and were age adjusted. **OR 
values for SB adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds ratio; 
SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SHBG and androgens 
Androstenedione Testosterone DHEAS 
SHBG 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.276 (0.028-) 0.703 (0.054-2.873) 0.709 (0.277-3.091) 
p=0.217 p=0.650 p=0.659 








Oestradiol  not enough points 
0.716 (0.108-2.781) 0.787 (0.166-2.961) 
p=0.670 p=0.761 
Oestrone not enough points 
0.755 (0.115-2.930) 0.766 (0.096-2.481) 
p=0.719 p=0.733 
Androstenedione 
 0.300 (0.016-1.609) 0.635 (0.077-2.032) 
 p=0.256 p=0.564 
Testosterone not enough points 
 0.513 (0.093-2.632) 
 p=0.400 
DHEAS 
0.269 (0.008-1.373) 0.666 (0.101-2.594)  
p=0.209 p=0.606  
SHBG 
   
   
Progesterone  
0.251 (0.014-1.289) 0.625 (0.094-2.439) 0.604 (0.090-2.406) 
p=0.187 p=0.551 p=0.527 
LH 
0.267 (0.015-1.357) 0.703 (0.107-2.687) 0.677 (0.103-2.609) 
p=0.205 p=0.651 p=0.618 
FSH 
0.275 (0.015-1.396) 0.703 (0.107-2.686) 0.712 (0.108-2.734) 
p=0.215 p=0.651 p=0.663 
ER-α SB 
0.275 (0.015-1.398) 0.705 (0.108-2.698) 0.710 (0.108-2.728) 
p=0.216 p=0.654 p=0.661 
ER-β SB not enough points 
0.654 (0.100-2.508) 0.679 (0.103-2.613) 
p=0.587 p=0.621 
AR SB not enough points 
0.703 (0.107-2.686) 0.708 (0.108-2.723) 
p=0.651 p=0.659 
Supplemental Table VI-20: Joint association of high levels of androgens and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer – cases that gave a 
sample less than 2 years before diagnosis. 
9  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of progesterone and gonadotrophins  
Progesterone  
LH FSH 













1.380 (0.522-3.274) 1.964 (0.593-5.751) 
p=0.486 p=0.234 
Oestrone 
1.628 (0.606-3.967) 2.120 (0.639-6.229) 
p=0.302 p=0.186 
Androstenedione 
1.012 (0.350-2.557) 0.678 (0.101-2.716) 
p=0.980 p=0.626 
Testosterone 
0.980 (0.358-2.414) 1.064 (0.227-3.784) 
p=0.967 p=0.920 
SHBG 
1.236 (0.466-2.943) 1.206 (0.261-4.206) 
p=0.648 p=0.784 
DHEAS 






 1.444 (0.310-5.115) 
 p=0.595 
FSH 
1.402 (0.530-3.324)  
p=0.464  
ER-α 
1.397 (0.528-3.311) 1.295 (0.281-4.505) 
p=0.469 p=0.705 
ER-β 
1.381 (0.521-3.279) 1.255 (0.2.72-4.348) 
p=0.486 p=0.739 
AR 
1.400 (0.529-3.322) 1.167 (0.256-3.941) 
p=0.467 p=0.818 
Supplemental Table VI-21: Joint association of high levels of gonadotrophins and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of gonadotrophins  
LH 
FSH 




















































Supplemental Table VI-22: Joint association of high levels of gonadotrophins (top 
quantiles) with risk of breast cancer – cases that gave a sample less than 2 years before 
diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SHBG and progesterone 
SHBG 
Progesterone 
















































Supplemental Table VI-23: Joint association of high levels of progesterone and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer – cases that gave a 
sample less than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SHBG and gonadotrophins  
SHBG 
LH FSH 
  OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.221 (0.013-1.121) 0.565 (0.142-1.590) 
p=0.145 p=0.364 









0.218 (0.012-1.089) 0.777 (0.221-2.135) 
p=0.142 p=0.655 
Oestrone 
0.232 (0.013-1.163) 0.577 (0.133-1.749) 
p=0.159 p=0.386 




0.250 (0.014-1.273) 0.440 (0.069-1.570) 
p=0.184 p=0.278 
DHEAS 






0.226 (0.027-1.136) 0.362 (0.140-1.268) 
p=0.153 p=0.175 
LH 
 0.611 (0.103-1.881) 
 p=0.442 
FSH 
0.200 (0.012-1.032)  
p=0.125  
ER-α SB 
0.236 (0.013-1.182) 0.373 (0.059-1.309) 
p=0.164 p=0.189 
ER-β SB 
0.209 (0.011-1.047) 0.344 (0.054-1.211) 
p=0.132 p=0.156 
AR SB 
0.221 (0.012-1.103) 0.373 (0.059-1.310) 
p=0.146 p=0.189 
Supplemental Table VI-24: Joint association of high levels of sex hormone-binding 
globulin and gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a 
sample less than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Hormones          
Joint association of oestrogens 
Oestradiol 
Oestrone 
















































*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Supplemental Table VI-25: Joint association of high levels of oestrogens (top quantiles) 
with risk of breast cancer – cases that gave a sample more than 2 years before diagnosis.  
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Joint association of oestrogens and androgens   
Oestradiol Oestrone 
DHEAS Androstenedione Testosterone DHEAS 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
 Not adjusted 
1.331 (0.515-3.069) 1.202 (0.502-4.037) 1.669 (0.773-4.910) 0.942 (0.294-2.757) 
p=0.528 p=0.725 p=0.272 p=0.917 








Oestradiol  1.221 (0.389-3.232) 1.680 (0.626-4.085) 0.890 (0.249-2.503) 
 p=0.706 p=0.271 p=0.839 
Oestrone 1.318 (0.504-3.075)    
p=0.543    
Androstenedione 1.079 (0.400-2.610)  1.471 (0.602-3.637) 0.750 (0.214-2.175) 
p=0.873  p=0.422 p=0.622 
Testosterone 0.810 (0.295-2.005) 1.002 (0.310-2.757)  0.602 (0.164-1.762) 
p=0.663 p=0.997  p=0.391 
DHEAS 
 1.208 (0.382-3.236) 1.740 (0.634-4.352)  
 p=0.723 p=0.253  
Progesterone  
1.351 (0.516-3.153) 1.149 (0.368-3.021) 1.543 (0.578-3.726) 0.873 (0.244-2.461) 
p=0.508 p=0.791 p=0.354 p=0.813 
SHBG 1.425 (0.522-3.525) 1.254 (0.388-3.465) 1.681 (0.622-4.118) 0.829 (0.225-2.455) 
p=0.461 p=0.679 p=0.275 p=0.753 
LH 
1.300 (0.496-3.037) 1.124 (0.359-2.957) 1.609 (0.601-3.885) 0.929 (0.260-2.623) 
p=0.564 p=0.824 p=0.311 p=0.898 
FSH 
1.328 (0.506-3.111) 1.203 (0.386-3.152) 1.667 (0.623-4.027) 0.937 (0.263-2.636) 
p=0.535 p=0.725 p=0.276 p=0.910 
ER-α SB 
1.385 (0.528-3.243) 1.201 (0.384-3.165) 1.710 (0.638-4.138) 0.944 (0.264-2.666) 
p=0.475 p=0.728 p=0.254 p=0.920 
ER-β SB 
1.347 (0.513-3.54) 1.172 (0.375-3.078) 1.648 (0.617-3.971) 0.932 (0.261-2.626) 
p=0.514 p=0.763 p=0.286 p=0.903 
AR SB 
1.122 (0.400-2.717) 1.222 (0.391-3.207) 1.676 (0.629-4.034) 0.910 (0.255-2.559) 
p=0.811 p=0.703 p=0.269 p=0.869 
Supplemental Table VI-26: Joint association of high levels of oestrogens and androgens (top 
quantiles) with risk of breast cancer – cases that gave a sample more than 2 years before 
diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. **OR 
values for SB adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Appendices 





Joint association of oestrogens and progesterone 
Oestradiol Oestrone  
Progesterone  
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.067 (0.418-2.753) 1.297 (0.451-3.644) 
p=0.893 p=0.624 









 1.073 (0.298-3.074) 
 p=0.903 
Oestrone 
1.254 (0.480-2.921)  
p=0.618  
Androstenedione 
0.787 (0.271-1.999) 0.986 (0.355-2.697) 
p=0.635 p=0.979 
Testosterone 
0.718 (0.245-1.834) 0.506 (0.113-1.635) 
p=0.512 p=0.303 
DHEAS 
1.090 (0.376-2.767) 1.353 (0.409-3.876) 
p=0.863 p=0.591 
SHBG 






1.009 (0.360-2.445) 1.274 (0.404-3.397) 
p=0.985 p=0.649 
FSH 
1.057 (0.376-2.116) 1.292 (0.411-4.33) 
p=0.908 p=0.629 
ER-α 
1.290 (0.492-3.020) 1.290 (0.409-3.444) 
p=0.576 p=0.632 
ER-β 
1.069 (0.381-2.584) 1.233 (0.391-3.288) 
p=0.890 p=0.694 
AR 
1.053 (0.375-2.551) 1.274 (0.405-3.386) 
p=0.914 p=0.647 
 
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Supplemental Table VI-27: Joint association of high levels of oestrogens and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample more 
than 2 years before diagnosis.  
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Joint association of oestrogens and gonadotrophins  
Oestradiol Oestrone  
LH FSH LH FSH 
 OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.363 (0.044-2.788) 
Not enough points 
0.617 (0.124-2.560) 0.650 (0.148-3.127) 
p=0.335 p=0.530 p=0.577 










Not enough points 
0.618 (0.095-2.296) 0.657 (0.101-2.470) 
 p=0.531 p=0.587 
Oestrone 
0.396 (0.021-2.118)   
p=0.381   
Androstenedione 
0.329 (0.018-1.750) 0.648 (0.078-2.422) 0.579 (0.088-2.205) 
p=0.293 p=0.574 p=0.484 
Testosterone 
0.284 (0.015-1.529) 0.593 (0.091-2.239) 0.706 (0.108-2.674) 
p=0.235 p=0.501 p=0.654 
DHEAS 
0.362 (0.020-1.909) 0.617 (0.095-2.296) 0.650 (0.100-2.441) 
p=0.334 p=0.531 p=0.577 
SHBG 
0.363 (0.021-2.043) 0.617 (0.092-2.236) 0.650 (0.111-2.764) 
p=0.366 p=0.507 p=0.681 
Progesterone  
0.361 (0.020-1.900) 0.603 (0.093-2.241) 0.642 (0.099-2.409) 
p=0.333 p=0.511 p=0.566 
LH 
  0.747 (0.114-2.865) 
  p=0.708 
FSH 
0.363 (0.020-2.568) 0.620 (0.096-2.316)  
p=0.336 p=0.536  
ER-α 
0.354 (0.019-1.872) 0.548 (0.084-2.059) 0.615 (0.094-2.331) 
p=0.324 p=0.438 p=0.532 
ER-β 
0.340 (0.018-1.798) 0.616 (0.095-2.296) 0.667 (0.102-2.515) 
p=0.306 p=0.529 p=0.602 
AR 
0.350 (0.019-1.842) 0.639 (0.099-2.380) 0.678 (1.04-2.555) 
p=0.318 p=0.561 p=0.616 
 
Supplemental Table VI-28: Joint association of high levels of oestrogens and 
gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a sample 
more than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of oestrogens and SHBG 
Oestradiol Oestrone 
SHBG 
  OR* (95% CI) OR* (95% CI) 
 Not adjusted 
0.267 (0.033-1.457) 0.456 (0.039-1.978) 
p=0.206 p=0.301 









 0.477 (0.074-1.732) 
 p=0.331 
Oestrone 
0.275 (0.014-1.498)  
p=0.217  
Androstenedione 
0.257 (0.015-1.465) 0.526 (0.081-1.929) 
p=0.196 p=0.402 
Testosterone 
0.213 (0.012-1.758) 0.565 (0.088-2.069) 
p=0.142 p=0.455 
DHEAS 






0.237 (0.013-1.432) 0.690 (0.158-2.126) 
p=0.171 p=0.562 
LH 
0.268 (0.015-1.785) 0.448 (0.070-1.613) 
p=0.207 p=0.290 
FSH 
0.272 (0.015-1.432) 0.448 (0.070-1.615) 
p=0.213 p=0.290 
ER-α SB 
0.268 (0.015-1.527) 0.456 (0.071-1.642) 
p=0.207 p=0.301 
ER-β SB 
0.261 (0.014-1.791) 0.452 (0.070-1.648) 
p=0.199 p=0.298 
AR SB 
0.267 (0.015-1.451) 0.490 (0.076-1.779) 
p=0.206 p=0.349 
Supplemental Table VI-29: Joint association of high levels of oestrogens and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer – cases that gave a 
sample more than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of androgens  
Androstenedione Testosterone 
DHEAS DHEAS 
  OR* (95% CI) OR* (95% CI) 
 Not adjusted 
1.897 (0.884-3.458) 1.611 (0.870-3.108) 
p=0.067 p=0.141 









1.888 (0.917-3.735) 1.552 (0.794-2.923) 
p=0.074 p=0.184 
Oestrone 
2.000 (0.976-3.942) 1.630 (0.840-3.048) 
p=0.050 p=0.135 
Androstenedione 
 1.207 (0.575-2.447) 
 p=0.609 
Testosterone 






1.897 (0.929-3.720) 1.587 (0.819-2.960) 
p=0.068 p=0.156 
SHBG 
2.801 (1.141-7.047) 1.920 (0.847-4.315) 
p=0.025 p=0.114 
LH 
1.993 (0.974-3.924) 1.662 (0.857-3.106) 
p=0.051 p=0.120 
FSH 
1.895 (0.929-3.707) 1.598 (0.824-2.983) 
p=0.068 p=0.151 
ER-α SB 
1.967 (0.960-3.868) 1.647 (0.848-3.079) 
p=0.055 p=0.127 
ER-β SB 
1.925 (0.939-3.792) 1.611 (0.830-3.010) 
p=0.064 p=0.145 
AR SB 
1.718 (0.826-3.410) 1.437 (0.731-2.704) 
p=0.132 p=0.274 
Supplemental Table VI-30: Joint association of high levels of androgens (top quantiles) 
with risk of breast cancer – cases that gave a sample more than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Hormones         
Joint association of androgens and progesterone 
Androstenedione Testosterone DHEAS 
Progesterone  
 OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.535 (0.751-2.988) 1.618  (0.827-3.052) 1.038 (0.497-1.857) 
p=0.224 p=0.148 p=0.915 









1.470 (0.706-2.912) 1.569 (0.788-2.996) 0.994 (0.486-1.920) 
p=0.283 p=0.183 p=0.987 
Oestrone 
1.646 (0.814-3.186) 1.884 (0.965-3.555) 1.384 (0.714-2.580) 
p=0.149 p=0.055 p=0.319 
Androstenedione  
 1.148 (0.531-2.394) 0.749 (0.346-1.531) 
 p=0.719 p=0.443 
Testosterone 
0.893 (0.394-1.943)  0.597 (0.270-1.254) 
p=0.780  p=0.186 
DHEAS 
1.869 (0.795-4.337) 2.191 (0.932-5.198)  
p=0.145 p=0.071  
SHBG 
1.554 (0.752-3.055) 1.613 (0.817-3.054) 1.033 (0.507-2.560) 
p=0.215 p=0.153 p=0.926 
Progesterone  
      
      
LH 
1.515 (0.733-2.973) 1.638 (0.829-3.104) 1.065 (0.522-2.052) 
p=0.242 p=0.140 p=0.856 
FSH 
1.522 (0.738-2.981) 1.605 (0.813-3.040) 1.023 (0.502-1.969) 
p=0.235 p=0.157 p=0.948 
ER-α 
1.624 (0.803-3.142) 1.640 (0.828-3.115) 1.375 (0.710-2.560) 
p=0.161 p=0.141 p=0.328 
ER-β 
1.515 (0.735-2.969) 1.634 (0.827-3.097) 1.021 (0.501-1.962) 
p=0.240 p=0.143 p=0.952 
AR 
1.513 (0.733-2.969) 1.695 (0.855-3.226) 1.223 (0.622-2.298) 
p=0.242 p=0.117 p=0.543 
Supplemental Table VI-31: Joint association of high levels of androgens and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample more 
than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of androgens and gonadotrophins  
Androstenedione Testosterone DHEAS 
LH FSH LH LH FSH 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) OR* (95% CI) 
 Not adjusted 
2.127 (0.720-4.720) 2.320 (0.863-6.889) 2.248 (0.673-4.961) 0.739 (0.211-1.885) 1.350 (0.307-4.294) 
p=0.119 p=0.108 p=0.095 p=0.592 p=0.661 








Oestradiol 2.208 (0.802-5.605) 2.334 (0.782-6.357) 2.160 (0.786-5.464) 0.744 (0.211-2.050) 1.332 (0.289-4.592) 
p=0.105 p=0.106 p=0.114 p=0.601 p=0.673 
Oestrone 
2.529 (0.906-6.559) 2.523 (0.833-7.048) 2.658 (0.947-6.977) 0.813 (0.228-2.272) 1.093 (0.242-3.614) 
p=0.062 p=0.083 p=0.051 p=0.717 p=0.894 
Androstenedione 
  1.796 (0.638-4.658) 0.588 (0.164-1.650) 1.095 (0.234-3.843) 
  p=0.241 p=0.355 p=0.896 
Testosterone 1.694 (0.598-4.424) 1.853 (0.607-5.153)  0.518 (0.144-1.468) 1.041 (0.222-3.676) 
p=0.295 p=0.250  p=0.256 p=0.953 
DHEAS 2.228 (0.795-5.780) 2.346 (0.783-6.417) 2.466 (0.855-6.667)   
p=0.108 p=0.105 p=0.081   
Progesterone  
2.092 (0.762-5.263) 2.438 (0.813-6.688) 2.218 (0.806-5.626) 0.677 (0.192-1.866) 1.276 (0.277-4.402) 
p=0.129 p=0.091 p=0.103 p=0.491 p=0.720 
SHBG 2.283 (0.822-5.858) 2.311 (0.771-6.324) 2.008 (0.677-5.456) 0.712 (0.197-2.033) 1.489 (0.316-5.364) 
p=0.094 p=0.112 p=0.186 p=0.559 p=0.568 
LH 
 3.002 (0.974-8.630)   1.973 (0.409-7.413) 
 p=0.044   p=0.342 
FSH 
2.169 (0.789-5.479)  2.288 (0.832-5.797) 0.751 (0.212-2.070)  
p=0.112  p=0.090 p=0.612  
ER-α SB 
2.303 (0.832-5.875) 2.508 (0.836-6.878) 2.335 (0.846-5.938) 0.743 (0.210-2.054) 1.667 (0.357-5.909) 
p=0.090 p=0.081 p=0.083 p=0.601 p=0.460 
ER-β SB 
2.165 (0.790-5.444) 2.302 (0.770-6.272) 2.188 (0.795-5.539) 0.747 (0.211-2.058) 1.190 (0.262-3.992) 
p=0.111 p=0.112 p=0.108 p=0.606 p=0.795 
AR SB 
2.140 (0.782-5.370) 2.426 (0.811-6.622) 2.261 (0.824-5.715) 0.736 0.209-2.022) 1.216 (0.268-4.070) 
p=0.116 p=0.092 p=0.094 p=0.587 p=0.771 
Supplemental Table VI-32: Joint association of high levels of androgens and gonadotrophins (top 
quantiles) with risk of breast cancer – cases that gave a sample more than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. **OR values for SB 
adjusted for other hormones or SB treated as categorical variable, using top bottom classification and age 
adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; ER=oestrogen 
receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds ratio; SB=serum bioactivity; 
SHBG=sex hormone-binding globulin 
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Joint association of androgens and SHBG 
Androstenedione Testosterone DHEAS 
SHBG 
  OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted  
0.276 (0.028-) 0.703 (0.054-2.873) 0.709 (0.277-3.091) 
p=0.217 p=0.650 p=0.659 








Oestradiol not enough points 
0.716 (0.108-2.781) 0.787 (0.166-2.961) 
p=0.670 p=0.761 
Oestrone not enough points 
0.755 (0.115-2.930) 0.766 (0.096-2.481) 
p=0.719 p=0.733 
Androstenedione 
 0.300 (0.016-1.609) 0.635 (0.077-2.032) 
 p=0.256 p=0.564 
Testosterone not enough points 
 0.513 (0.093-2.632) 
 p=0.400 
DHEAS 
0.269 (0.008-1.373) 0.666 (0.101-2.594)  
p=0.209 p=0.606  
Progesterone  
   
   
SHBG 
0.251 (0.014-1.289) 0.625 (0.094-2.439) 0.604 (0.090-2.406) 
p=0.187 p=0.551 p=0.527 
LH 
0.267 (0.015-1.357) 0.703 (0.107-2.687) 0.677 (0.103-2.609) 
p=0.205 p=0.651 p=0.618 
FSH 
0.275 (0.015-1.396) 0.703 (0.107-2.686) 0.712 (0.108-2.734) 
p=0.215 p=0.651 p=0.663 
ER-α SB 
0.275 (0.015-1.398) 0.705 (0.108-2.698) 0.710 (0.108-2.728) 
p=0.216 p=0.654 p=0.661 
ER-β SB not enough points 
0.654 (0.100-2.508) 0.679 (0.103-2.613) 
p=0.587 p=0.621 
AR SB not enough points 
0.703 (0.107-2.686) 0.708 (0.108-2.723) 
p=0.651 p=0.659 
Supplemental Table VI-33: Joint association of high levels of androgens and 
gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a sample 
more than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. **OR 
values for SB adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of progesterone and gonadotrophins  
Progesterone  
LH FSH 
  OR* (95% CI) OR** (95% CI) 
 Not adjusted 
0.403 (0.083-1.605) 0.944 (0.179-4.049) 
p=0.229 p=0.942 









0.393 (0.062-1.396) 0.846 (0.127-3.344) 
p=0.216 p=0.832 
Oestrone 
0.933 (0.261-2.631) 1.279 (0.279-4.362) 
p=0.904 p=0.716 
Androstenedione 
0.338 (0.053-1.220) 0.675 (0.100-2.724) 
p=0.154 p=0.623 
Testosterone 
0.286 (0.044-1.045) 0.730 (0.107-3.012) 
p=0.102 p=0.697 
DHEAS 
0.377 (0.058-1.421) 0.949 (0.140-3.934) 
p=0.210 p=0.948 
Progesterone  






 1.140 (0.169-4.738) 
 p=0.871 
FSH 
0.406 (0.064-1.442)  
p=0.232  
ER-α SB 
0.871 (0.245-2.427) 1.708 (0.367-6.033) 
p=0.809 p=0.440 
ER-β SB 
0.407 (0.064-1.449) 0.959 (0.143-3.866) 
p=0.234 p=0.958 
AR SB 
0.833 (0.235-2.309) 1.339 (0.293-4.560) 
p=0.748 p=0.666 
Supplemental Table VI-34: Joint association of high levels of progesterone and 
gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a sample 
more than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Appendices 




Hormones       
Joint association of gonadotrophins  
LH 
FSH 

















































Supplemental Table VI-35: Joint association of high levels of androgens and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample more 
than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SHBG and progesterone 
SHBG 
Progesterone 
  OR* (95% CI) 
Not adjusted  
0.539 (0.082-1.916) 
p=0.420 












































Supplemental Table VI-36: Joint association of high levels of androgens and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample more 
than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SHBG and gonadotrophins  
SHBG 
LH FSH 
  OR* (95% CI) OR* (95% CI) 
Not adjusted  
0.221 (0.013-1.121) 0.565 (0.142-1.590) 
p=0.145 p=0.364 









0.218 (0.012-1.089) 0.777 (0.221-2.135) 
p=0.142 p=0.655 
Oestrone 
0.232 (0.013-1.163) 0.577 (0.133-1.749) 
p=0.159 p=0.386 




0.250 (0.014-1.273) 0.440 (0.069-1.570) 
p=0.184 p=0.278 
DHEAS 






0.226 (0.027-1.136) 0.362 (0.140-1.268) 
p=0.153 p=0.175 
LH 
 0.611 (0.103-1.881) 
 p=0.442 
FSH 
0.200 (0.012-1.032)  
p=0.125  
ER-α SB 
0.236 (0.013-1.182) 0.373 (0.059-1.309) 
p=0.164 p=0.189 
ER-β SB 
0.209 (0.011-1.047) 0.344 (0.054-1.211) 
p=0.132 p=0.156 
AR SB 







Supplemental Table VI-37: Joint association of high levels of sex hormone bidning 
globulin and gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a 
sample more than 2 years before diagnosis.  
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Appendix VII:  Statistically non-significant joint associations of high levels of sex 
steroid receptor serum bioactivities with breast cancer risk 
 
 
Joint association of high SB of sex steroid receptors - all cases 
SB 
ER-α and ER-β SB ER-α and AR SB ER-β and AR SB  
OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.399 (0.833-2.338) 1.428 (0.833-2.338) 1.713 (0.867-2.739) 
p=0.202 p=0.199 p=0.065 









1.421 (0.840-2.377) 1.411 (0.840-2.423) 1.698 (0.952-3.030) 
p=0.184 p=0.216 p=0.070 
Oestrone 
1.323 (0.781-2.213) 1.396 (0.781-2.407) 1.597 (0.891-2.839) 
p=0.291 p=0.234 p=0.111 
Androstenedione 
1.231 (0.745-2.144) 1.416 (0.745-2.449) 1.586 (0.882-2.827) 
p=0.370 p=0.217 p=0.119 
Testosterone  
1.360 (0.799-2.286) 1.324 (0.799-2.290) 1.622 (0.755-2.290) 
p=0.250 p=0.320 p=0.106 
DHEAS 
1.399 (0.767-2.177) 1.427 (0.829-2.446) 1.715 (0.924-2.937) 
p=0.201 p=0.200 p=0.066 
SHBG 
1.300 (0.767-2.177) 1.415 (0.767-2.440) 1.624 (0.906-2.888) 
p=0.322 p=0.214 p=0.099 
Progesterone 
1.386 (0.821-2.313) 1.397 (0.804-2.395) 1.743 (0.973-3.100) 
p=0.215 p=0.228 p=0.059 
LH 
1.388 (0.821-2.317) 1.388 (0.798-2.383) 1.676 (0.939-2.970) 
p=0.214 p=0.238 p=0.077 
FSH 
1.393 (0.824-2.325) 1.420 (0.816-2.439) 1.708 (0.958-3.023) 
p=0.208 p=0.207 p=0.066 
ER-α SB 
  1.420 (0.744-2.693) 
  p=0.284 
ER-β SB 
 1.516 (0.905-2.795)  
 p=0.183  
AR SB 
1.345 (0.764-2.346)   
p=0.298     
Supplemental Table VII-1: Joint association of high sex steroid receptor serum 
bioactivity (top quantiles) with risk of breast cancer – all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of high SB of sex steroid receptors –  
less than 2 years before diagnosis 
SB 
ER-α and ER-β SB ER-α and AR SB ER-β and AR SB 
OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.931 (0.454-1.877) 0.956 (0.436-2.057) 1.060 (0.407-2.104) 
p=0.847 p=0.908 p=0.888 









0.941 (0.430-1.888) 0.962 0.421-1.995) 1.048 (0.434-2.273) 
p=0.871 p=0.921 p=0.910 
Oestrone 
0.869 (0.396-1.748) 0.922 (0.401-1.921) 0.954 (0.391-2.087) 
p=0.708 p=0.836 p=0.910 
Androstenedione 
0.792 (0.347-1.635) 0.964 (0.419-2.013) 1.003 (0.412-2.196) 
p=0.551 p=0.925 p=0.994 
Testosterone  
0.891 (0.405-1.799) 0.863 (0.374-1.807) 0.991 (0.405-2.186) 
p=0.759 p=0.710 p=0.984 
DHEAS 
0.932 (0.427-1.866) 0.951 (0.417-1.967) 1.046 (0.432-2.274) 
p=0.851 p=0.898 p=0.915 
SHBG 
0.793 (0.362-1.597) 0.882 (0.38-1.834) 0.901 (0.372-1.961) 
p=0.537 p=0.751 p=0.802 
Progesterone 
0.920 (0.421-1.841) 0.932 (0.408-1.929) 1.076 (0.444-2.342) 
p=0.822 p=0.857 p=0.862 
LH 
0.931 (0.426-1.846) 0.946 (0.415-1.959) 1.049 (0.434-2.275) 
p=0.848 p=0.888 p=0.909 
FSH 
0.928 (0.425-1.858) 0.951 (0.417-1.971) 1.060 (0.439-2.298) 
p=0.840 p=0.899 p=0.889 
ER-α SB 
  1.014 (0.388-2.439) 
  p=0.976 
ER-β SB 
 1.243 (0.509-2.829)  
 p=0.615  
AR SB 
0.890 (0.392-1.869)   
p=0.768     
Supplemental Table VII-2: Joint association of high sex steroid receptor serum bioactivity 
(top quantiles) with risk of breast cancer - cases that gave a sample less than 2 years 
before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Appendix VIII: Statistically non-significant joint associations of high levels of sex 










SB - Hormones 
Joint association of SB and oestrogens  
ER-α SB 
Oestradiol Oestrone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.412 (0.672-3.144) 1.573 (0.872-3.632) 
p=0.375 p=0.333 









  1.634 (0.775-3.394) 
  p=0.341 
Oestrone 
1.540 (0.691-3.365)   
p=0.280   
Androstenedione 
1.531 (0.682-3.366) 1.738 (0.819-3.634) 
p=0.291 p=0.325 
Testosterone 
1.194 (0.529-2.619) 1.664 (0.779-3.501) 
p=0.661 p=0.552 
DHEAS 
1.414 (0.645-3.007) 1.581 (0.754-3.250) 
p=0.373 p=0.332 
SHBG 
1.463 (0.662-3.144) 1.579 (0.748-3.274) 
p=0.333 p=0.439 
Progesterone  
1.475 (0.668-3.176) 1.658 (0.758-3.449) 
p=0.323 p=0.287 
LH 
1.360 (0.619-2.899) 1.590 (0.757-3.276) 
p=0.431 p=0.420 
FSH 
1.428 (0.650-3.047) 1.583 (0.755-3.257) 
p=0.361 p=0.315 
ER-α SB 
    
    
ER-β SB 
1.404 (0.637-3.005) 1.615 (0.744-3.451) 
p=0.387 p=0.217 
AR SB 
1.374 (0.612-2.996) 1.533 (0.716-3.223) 
p=0.428 p=0.262 
Supplemental Table VIII-1: Joint association of high ER-α serum bioactivity and 
oestrogens (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SB and androgens 
ER-α SB 
Androstenedione DHEAS 
  OR* (95% CI) OR* (95% CI) 
Not adjusted  
1.882 (1.09-4.638) 0.976 (0.425-2.421) 
p=0.077 p=0.956 









2.083 (1.007-4.312) 0.946 (0.375-2.204) 
p=0.046 p=0.901 
Oestrone 
1.872 (0.918-3.787) 0.956 (0.378-2.230) 
p=0.080 p=0.919 
Androstenedione 
 0.817 (0.318-1.938) 
 p=0.658 
Testosterone 
1.391 (0.652-2.945) 0.706 (0.270-1.711) 
p=0.388 p=0.454 
DHEAS 
1.877 (0.917-3.811)  
p=0.081  
SHBG 
1.785 (0.873-3.620) 0.943 (0.372-2.209) 
p=0.108 p=0.895 
Progesterone  
1.950 (0.944-4.017) 0.936 (0.361-2.254) 
p=0.068 p=0.885 
LH 
1.866 (0.914-3.783) 0.989 (0.391-2.311) 
p=0.083 p=0.981 
FSH 






1.969 (0.963-4.119) 0.960 (0.375-2.274) 
p=0.071 p=0.929 
AR SB 
1.834 (0.884-3.777) 0.911 (0.353-2.169) 
p=0.099 p=0.838 
Supplemental Table VIII-2: Joint association of high ER-α serum bioactivity and 
androgens (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Appendices 



























SB - Hormones 
Joint association of SB and progesterone  
ER-α SB 
Progesterone  
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Supplemental Table VIII-3: Joint association of high ER-α serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SB and SHBG  
ER-α SB  
SHBG 
















































Supplemental Table VIII-4: Joint association of high ER-α serum bioactivity and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and gonadotrophins 
ER-α SB 
LH FSH 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.669 (0.257-1.74) 1.168 (0.465-3.159) 
p=0.405 p=0.748 









0.540 (0.175-1.391) 0.983 (0.337-2.577) 
p=0.234 0.973 
Oestrone 
0.524 (0.170-1.353) 0.954 (0.326-2.509) 
p=0.213 p=0.926 
Androstenedione 0.556 (0.179-1.438) 1.084 (0.370-2.862) 
 p=0.258 p=0.874 
Testosterone 
0.550 (0.176-1.433) 1.124 (0.381-2.988) 
p=0.253 p=0.820 
DHEAS 
0.668 (0.237-1.637) 1.183 (0.432-3.005) 
p=0.404 p=0.730 
SHBG 
0.664 (0.235-1.640) 1.162 (0.511-2.973) 
p=0.401 p=0.759 
Progesterone  
0.547 (0.177-1.408) 1.020 (0.349-2.689) 
p=0.244 p=0.969 
LH 
  1.433 (0.511-3.761) 
  p=0.473 
FSH 
0.678 (0.239-1.680)   
p=0.427   
ER-α SB 
    
    
ER-β SB 
0.540 (0.181-1.401) 0.978 (0.587-2.589) 
p=0.237 p=0.966 
AR SB 
0.540 (0.190-1.392) 0.976 (0.414-2.563) 
p=0.235 p=0.962 
Supplemental Table VIII-5: Joint association of ER-α serum bioactivity and 
gonadotrophins (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and oestrogens  
ER-β SB 
Oestradiol Oestrone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.752 (0.445-2.056) 1.154 (0.610-2.571) 
p=0.530 p=0.648 









  1.197 (0.571-2.419) 
  p=0.573 
Oestrone 
0.728 (0.278-1.708)   
p=0.486   
Androstenedione 
0.729 (0.275-1.742) 1.210 (0.574-2.461) 
p=0.496 p=0.541 
Testosterone 
0.608 (0.228-1.453) 1.174 (0.554-2.402) 
p=0.284 p=0.350 
DHEAS 
0.749 (0.286-1.754) 1.160 
p=0.524 p=0.644 
SHBG 
0.702 (0.268-1.652) 1.057 (0.505-2.131) 
p=0.439 p=0.486 
Progesterone  
0.783 (0.298-1.853) 1.195 (0.570-2.416) 
p=0.594 p=0.710 
LH 
0.742 (0.283-1.741) 1.124 (0.538-2.259) 
p=0.512 p=0.612 
FSH 
0.757 (0.289-1.776) 1.169 (0.560-2.351) 
p=0.541 p=0.663 
ER-α SB 
0.684 (0.259-1.731) 1.017 (0.476-2.093) 
p=0.410 p=0.965 
ER-β SB 
    
    
AR SB 
0.763 (0.287-1.824) 1.112 (0.524-2.270) 
p=0.561  p=0.774 
Supplemental Table VIII-6: Joint association of high ER-β serum and oestrogens (top 
quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and androgens 
ER-β SB 
Androstenedione Testosterone DHEAS 
 OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.604 (0.760-3.395) 1.856 (1.053-4.377) 1.108 (0.438-2.574) 
p=0.200 p=0.084 p=0.820 









1.665 (0.789-3.461) 1.932 (0.940-3.995) 1.263 (0.484-3.110) 
p=0.172 p=0.070 p=0.617 
Oestrone 
1.504 (0.699-3.165) 1.753 (0.842-3.616) 1.159 (0.450-2.800) 
p=0.285 p=0.128 p=0.748 
Androstenedione 
  1.429 (0.664-) 0.927 (0.351-2.290) 
  p=0.354 p=0.872 
Testosterone 
1.044 (0.467-2.278)   0.820 (0.310-2.034) 
p=0.914   p=0.675 
DHEAS 
1.597 (0.756-3.316) 1.859 (0.906-3.787)   
p=0.211 p=0.087   
SHBG 
1.442 (0.686-2.974) 1.672 (0.819-3.386) 1.044 (0.408-2.491) 
p=0.324 p=0.153 p=0.925 
Progesterone  
1.521 (0.702-3.225) 1.829 (0.891-3.727) 1.144 (0.430-2.869) 
p=0.276 p=0.096 p=0.778 
LH 
1.557 (0.742-3.207) 1.863 (0.914-3.768) 1.097 (0.430-2.611) 
p=0.232 p=0.083 p=0.838 
FSH 
1.596 (0.761-3.281) 1.851 (0.910-3.736) 1.099 (0.431-2.611) 
p=0.206 p=0.085 p=0.835 
ER-α SB 
1.432  (0.669-
3.035) 1.693 (0.816-3.483) 1.061 (0.405-2.606) 
p=0.351 p=0.152 p=0.900 
ER-β SB 
      
      
AR SB 
1.649 (0.764-3.509) 1.953 (0.933-4.073) 1.025 (0.393-2.500) 
p=0.195 p=0.073 p=0.958 
Supplemental Table VIII-7: Joint association of high ER-β serum bioactivity and 
androgens (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using 
top bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and progesterone  
ER-β SB 
Progesterone  
























































Supplemental Table VIII-8: Joint association of high ER-β serum bioctivity and 
progesterone (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and gonadotrophins 
ER-β SB 
LH FSH 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.615 (0.207-1.612) 1.637 (0.621-3.813) 
p=0.350 p=0.282 









0.605 (0.195-1.575) 1.631 (0.646-4.017) 
p=0.335 p=0.287 
Oestrone 
0.609 (0.196-1.589) 1.654 (0.654-4.082) 
p=0.342 p=0.274 
Androstenedione 
0.641 (0.206-1.677) 1.695 (0.668-4.195) 
p=0.395 p=0.254 
Testosterone 
0.570 (0.182-1.505) 1.588 (0.621-3.956) 
p=0.287 p=0.321 
DHEAS 
0.616 (0.198-1.599) 1.645 (0.652-4.048) 
p=0.350 p=0.278 
SHBG 
0.559 (0.180-1.461) 1.445 (0.413-3.565) 
p=0.266 p=0.423 
Progesterone  
0.607 (0.196-1.579) 1.629 (0.645-4.012) 
p=0.338 p=0.288 
LH 
  1.828 (0.717-4.562) 
  p=0.195 
FSH 
0.623 (0.200-1.626)   
p=0.365   
ER-α SB 
0.551 (0.195-1.454) 1.528 (0.334-3.785) 
p=0.258 p=0.359 
ER-β SB 
    
    
AR SB 
0.606 (0.202-1.577) 1.600 (0.371-3.953) 
p=0.336 p=0.308 
Supplemental Table VIII-9: Joint association of high ER-β serum bioactivity and 
gonadotrophins (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SB and SHBG  
SHBG 
ER-β SB 
















































Supplemental Table VIII-10: Joint association of high ER-β serum bioactivity and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint assocation of SB and oestrogens  
AR SB 
Oestradiol 

























































Supplemental Table VIII-11: Joint association of high AR serum bioactivity and 
oestrogens (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SB and androgens 
AR SB 
DHEAS 
















































Supplemental Table VIII-12: Joint association of high AR serum bioactivity and 
androgens (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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 Joint association of SB and SHBG 
AR SB 
SHBG 
















































Supplemental Table VIII-13: Joint association of high AR serum bioactivity and 
androgens (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and progesterone  
AR SB 
Progesterone  
















































Supplemental Table VIII-14: Joint association of high AR serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and gonadotrophins 
AR SB 
LH FSH 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.594 (0.153-2.096) 0.892 (0.343-2.499) 
p=0.434 p=0.821 









0.583 (0.133-1.937) 0.894 (0.341-2.308) 
p=0.418 p=0.824 
Oestrone 
0.597 (0.132-1.989) 0.899 (0.310-2.326) 
p=0.439 p=0.833 
Androstenedione 
0.601 (0.123-2.011) 0.991 (0.339-2.574) 
p=0.447 p=0.986 
Testosterone 
0.562 (0.129-1.899) 0.988 (0.311-2.577) 
p=0.392 p=0.981 
DHEAS 
0.594 (0.134-1.971) 0.893 (0.307-2.306) 
p=0.433 p=0.822 
SHBG 
0.618 (0.136-2.085) 0.884 (0.572-2.306) 
p=0.473 p=0.808 
Progesterone  
0.580 (0.132-1.924) 0.903 (0.308-2.338) 
p=0.412 p=0.839 
LH 
  0.980 (0.295-2.557) 
  p=0.968 
FSH 
0.607 (0.129-2.036)   
p=0.456   
ER-α SB 
0.490 (0.110-1.609) 0.856 (0.632-2.215) 
p=0.282 p=0.758 
ER-β SB 
0.583 (0.130-1.946) 0.878 (0.660-2.277) 
p=0.419 p=0.656 
AR SB 
    
    
Supplemental Table VIII-15: Joint association of high AR serum bioactivity and 
gonadotrophins (top quantiles) with risk of breast cancer - all cases.    
*OR values for top-bottom classification were based on controls only and were age adjusted. **OR 
values for SB adjusted for other hormones or SB treated as categorical variable, using top bottom 
classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 








SB - Hormones 
Joint association of SB and oestrogens 
ER-α SB 
Oestradiol Oestrone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.895 (0.275-2.600) 1.293 (0.643-3.995) 
p=0.845 p=0.597 









  1.368 (0.481-3.407) 
 p=0.523 
Oestrone 
0.946 (0.263-2.697)  
p=0.923  
Androstenedione 
0.982 (0.273-2.808) 1.455 (0.509-3.653) 
p=0.975 p=0.448 
Testosterone 
0.780 (0.216-2.233) 1.319 (0.458-3.335) 
p=0.669 p=0.578 
DHEAS 
0.898 (0.254-2.497) 1.301 (0.460-3.211) 
p=0.850 p=0.589 
SHBG 
0.941 (0.264-2.656) 1.239 (0.435-3.085) 
p=0.916 p=0.663 
Progesterone  
0.925 (0.260-2.597) 1.353 (0.476-3.374) 
p=0.891 p=0.538 
LH 
0.881 (0.249-2.453) 1.306 (0.462-3.227) 
p=0.824 p=0.584 
FSH 






0.988 (0.277-2.791) 1.626 (0.554-4.253) 
p=0.983 p=0.342 
AR SB 
0.883 (0.244-535) 1.306 (0.453-3.302) 
p=0.831 p=0.592 
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Supplemental Table VIII-16: Joint association of high ER-α serum bioactivity and 
oestrogens (top quantiles) with risk of breast cancer – cases that gave a sample less than 
2 years before diagnosis.    
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SB - Hormones 
Joint association of SB and androgens 
ER-α SB 
Androstenedione Testosterone DHEAS 
 OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 1.617 (0.706-4.505) 
1.704 (10.806-
4.663) 0.686 (0.202-2.506) 
p=0.300 p=0.226 p=0.558 









1.825 (0.680-4.447) 1.829 (0.725-4.259) 0.674 (0.153-2.100) 
p=0.202 p=0.175 p=0.541 
Oestrone 
1.627 (0.612-3.901) 1.645 (0.655-3.794) 0.661 (0.150-2.071) 
p=0.296 p=0.260 p=0.523 
Androstenedione 
 1.383 (0.532-3.312) 0.582 (0.130-1.858) 
 p=0.482 p=0.409 
Testosterone 
1.207 (0.434-3.054)  0.498 (0.110-1.619) 
p=0.702  p=0.294 
DHEAS 
1.588 (0.595-3.820) 1.668 (0.660-3.879)  
p=0.322 p=0.251  
SHBG 
1.491 (0.560-3.583) 1.679 (0.666-3.896) 0.636 (0.144-1.994) 
p=0.392 p=0.244 p=0.485 
Progesterone  
1.640 (0.608-4.009) 1.628 (0.644-3.783) 0.656 (0.146-2.112) 
p=0.297 p=0.274 p=0.522 
LH 
1.608 (0.606-3.846) 1.707 (0.682-3.919) 0.701 (0.159-2.186) 
p=0.306 p=0.224 p=0.582 
FSH 
1.608 (0.603-3.874) 1.705 (0.679-3.937) 0.679 (0.154-2.122) 
p=0.309 p=0.228 p=0.549 
ER-α SB 
   
   
ER-β SB 
2.164 (0.778-5.574) 2.034 (0.792-4.858) 0.780 (0.176-2.482) 
p=0.119 p=0.120 p=0.704 
AR SB 
1.617 (0.599-3.950) 1.742 (0.680-4.126) 0.673 (0.151-2.146) 
p=0.310 p=0.222 p=0.545 
Supplemental Table VIII-17: Joint association of high ER-α serum bioactivity and 
androgens (top quantiles) with risk of breast cancer – cases that gave a sample less than 
2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SB and SHBG 
ER-α SB 
SHBG 
  OR* (95% CI) 
 Not adjusted 
0.484 (0.062-2.710) 
p=0.496 












































Supplemental Table VIII-18: Joint association of high ER-α serum bioactivity and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer – cases that gave a 
sample less than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and progesterone 
ER-α SB 
Progesterone  
















































Supplemental Table VIII-19: Joint association of high ER-α serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and gonadotrophins 
ER-α SB 
LH FSH 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.872 (0.268-2.502) 0.972 (0262-3.492) 
p=0.811 p=0.965 









0.626 (0.143-1.927) 0.625 (0.096-2.347) 
p=0.465 p=0.543 
Oestrone 
0.604 (0.138-1.870) 0.599 (0.092-2.268) 
p=0.433 p=0.509 
Androstenedione 
0.672 (0.153-2.083) 0.763 (0.117-2.895) 
p=0.536 p=0.728 
Testosterone 
0.625 (0.142-1.948) 0.737 (0.113-2.809) 
p=0.466 p=0.695 
DHEAS 
0.869 (0.992-2.433) 0.992 (0.222-3.220) 
p=0.806 p=0.990 
SHBG 
0.870 (0.243-2.458) 0.989 (0.220-3.239) 
p=0.809 p=0.985 
Progesterone  
0.636 (0.654-1.956) 0.654 (0.100-2.472) 
p=0.479 p=0.584 
LH 
 1.093 (0.240-3.677) 
 p=0.895 
FSH 






0.724 (0.164-2.271) 0.723 (0.110-2.766) 
p=0.618 p=0.677 
AR SB 
0.639 (0.146-1.973) 0.636 (0.098-2.349) 
p=0.486 p=0.559 
Supplemental Table VIII-20: Joint association of high ER-α serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and oestrogens 
ER-β SB 
Oestradiol Oestrone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.205 (0.027-1.089) 0.854 (0.333-2.516) 
p=0.125 p=0.756 









  0.878 (0.287-2.221) 
 p=0.797 
Oestrone 
0.200 (0.009-0.991)  
p=0.120  
Androstenedione 
0.206 (0.011-1.033) 0.878 (0.285-2.240) 
p=0.129 p=0.800 
Testosterone 
0.177 (0.010-0.888) 0.831 (0.269-2.137) 
p=0.096 p=0.722 
DHEAS 
0.204 (0.011-1.006) 0.859 (0.282-2.163) 
p=0.124 p=0.765 
SHBG 
0.190 (0.011-0.945) 0.726 (0.238-1.835) 
p=0.109 p=0.531 
Progesterone  
0.209 (0.012-1.040) 0.877 (0.287-2.222) 
p=0.131 p=0.798 
LH 
0.202 (0.011-0.998) 0.845 (0.277-2.127) 
p=0.122 p=0.74 
FSH 
0.208 (0.011-1.026) 0.871 (0.285-2.198) 
p=0.128 p=0.787 
ER-α SB 






0.213 (0.012-1.065) 0.847 (0.275-2.167) 
p=0.136 p=0.748 
Supplemental Table VIII-21: Joint association of high ER-β serum bioactivity and 
oestrogen (top quantiles) with risk of breast cancer – cases that gave a sample less than 
2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and androgens 
ER-β SB 
Androstenedione Testosterone DHEAS 
 OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.118 (0.402-3.150) 1.088 (0.438-3.462) 0.514 (0.111-2.235) 
p=0.830 p=0.871 p=0.384 









1.180 (0.379-3.086) 1.161 (0.372-3.042) 0.603 (0.092-2.286) 
p=0.752 p=0.776 p=0.515 
Oestrone 
1.071 (0.341-2.820) 1.044 (0.333-2.750) 0.511 (0.078-1.914) 
p=0.897 p=0.936 p=0.385 
Androstenedione 
 0.887 (0.275-2.429) 0.426 (0.064-1.638) 
 p=0.827 p=0.277 
Testosterone 
0.807 (0.250-2.203)  0.380 (0.057-1.459) 
p=0.694  p=0.217 
DHEAS 
1.084 (0.347-2.843) 1.058 (0.339-2.772)  
p=0.878 p=0.915  
SHBG 
0.945 (0.305-2.456) 0.927 (0.298-2.410) 0.460 (0.071-1.697) 
p=0.914 p=0.884 p=0.312 
Progesterone  
1.105 (0.351-2.926) 1.014 (0.323-2.669) 0.470 (0.071-1.839) 
p=0.851 p=0.979 p=0.340 
LH 
1.084 (0.349-2.813) 1.088 (0.351-2.821) 0.511 (0.079-1.875) 
p=0.877 p=0.871 p=0.380 
FSH 
1.111 (0.358-2.883) 1.085 (0.350-2.814) 0.510 (0.079-1.874) 
p=0.840 p=0.875 p=0.380 
ER-α SB 
1.166 (0.363-3.184) 1.106 (0.349-2.963) 0.553 (0.084-2.108) 
p=0.777 p=0.851 p=0.448 
ER-β SB 
   
   
AR SB 
1.170 (0.370-3.130) 1.151 (0.363-3.082) 0.490 (0.075-1.862) 
p=0.768 p=0.793 p=0.361 
Supplemental Table VIII-22: Joint association of high ER-β serum bioactivity and androgens 
(top quantiles) with risk of breast cancer – cases that gave a sample less than 2 years before 
diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and progesterone 
ER-β SB 
Progesterone  
















































*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Supplemental Table VIII-23: Joint association of high ER-β serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis.    
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Joint association of SB and SHBG 
ER-β SB 
SHBG 
  OR* (95% CI) 
 Not adjusted not enough points 





















Supplemental Table VIII-24: Joint association of high ER-β serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of SB and gonadotrophins 
ER-β SB 
LH FSH 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.476 (0.096-1.912) 1.408 (0.261-3.492) 
p=0.328 p=0.566 









0.467 (0.073-1.682) 1.380 (0.375-4.147) 
p=0.316 p=0.589 
Oestrone 
0.463 (0.072-1.678) 1.402 (0.379-4.421) 
p=0.312 p=0.573 
Androstenedione 
0.510 (0.079-1.849) 1.521 (0.412-4.600) 
p=0.377 p=0.484 
Testosterone 
0.456 (0.071-1.665) 1.433 (0.385-4.370) 
p=0.304 p=0.551 
DHEAS 
0.477 (0.075-1.718) 1.419 (0.386-4.264) 
p=0.330 p=0.557 
SHBG 
0.427 (0.067-1.545) 1.219 (0.331-3.671) 
p=0.264 p=0.740 
Progesterone  
0.469 (0.073-1.689) 1.420 (0.386-4.273) 
p=0.319 p=0.557 
LH 
 1.503 (0.406-4.566) 
 p=0.498 
FSH 
0.478 (0.075-1.726)  
p=0.332  
ER-α SB 






0.473 (0.074-1.704) 1.402 (0.378-4.254) 
p=0.324 p=0.574 
Supplemental Table VIII-25: Joint association of high ER-β serum bioactivity and 
gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a sample 
less than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SB and oestrogens 
AR SB 
Oestradiol 
  OR* (95% CI) 
Not adjusted  
1.129 (0.379-2,997) 
p=0.816 












































Supplemental Table VIII-26: Joint association of high AR serum bioactivity and 
oestrogens (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of AR SB and androgens 
AR SB 
Androstenedione Testosterone DHEAS 
 OR* (95% CI) OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.881 (1.685-5.052) 2.322 (1.056-6.640) 0.724 
p=0.214 p=0.067 p=0.614 









1.880 (0.644-4.912) 2.387 (0.922-5.810) 0.776 (0.176-2.435) 
p=0.215 p=0.060 p=0.699 
Oestrone 
1.710 (0.582-4.498) 2.080 (0.800-5.067) 0.613 (0.140-1.900) 
p=0.295 p=0.115 p=0.447 
Androstenedione 
 2.008 (0.760-4.987) 0.679 (0.152-2.166) 
 p=0.141 p=0.554 
Testosterone 
1.367 (0.453-3.704).  0.569 (0.127-1.836) 
p=0.553  p=0.393 
DHEAS 
1.844 (0.626-4.877) 2.300 (0.882-5.643)  
p=0.234 p=0.075  
SHBG 
1.690 (0.577-4.436) 2.276 (0.876-5.565) 0.648 (0.148-2.013) 
p=0.304 p=0.077 p=0.500 
Progesterone  
1.784 (0.603-4.742) 2.233 (0.856-5.472) 0.660 (0.148-2.092) 
p=0.263 p=0.085 p=0.524 
LH 
1.821 (0.624-4.760) 2.288 (0.888-5.524) 0.710 (0.162-2.198) 
p=0.239 p=0.072 p=0.594 
FSH 
1.873 (0.639-4.922) 2.323 (0.899-5.631) 0.716 (0.163-2.221) 
p=0.220 p=0.068 p=0.603 
ER-α SB 
2.039 (0.673-5.607) 2.552 (0.949-6.523) 0.783 (0.175-2.516) 
p=0.180 p=0.054 p=0.710 
ER-β SB 
2.472 (0.812-6.915) 2.865 (0.997-7.269) 0.847 (0.190-2.707) 
p=0.092 p=0.028 p=0.799 
AR SB 
   
      
Supplemental Table VIII-27: Joint association of high AR serum bioactivity and androgens 
(top quantiles) with risk of breast cancer – cases that gave a sample less than 2 years 
before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of AR SB and progesterone 
AR SB 
Progesterone  
















































Supplemental Table VIII-28: Joint association of high AR serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample less 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Appendices 






















Joint association of SB and SHBG 
AR SB 
SHBG 
  OR* (95% CI) 
Not adjusted  
0.377 (0.048-2.019) 
p=0.355 












































Supplemental Table VIII-29: Joint association of high AR serum bioactivity and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer – cases that gave a 
sample less than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of AR SB and gonadotrophins 
AR SB 
LH FSH 
 OR* (95% CI) OR* (95% CI) 
Not adjusted  
0.773 (0.156-3.425) 1.492 (0.491-4.145) 
p=0.742 p=0.459 









0.770 (0.117-2.990) 1.462 (0.459-3.999) 
p=0.739 p=0.482 
Oestrone 
0.781 (0.118-3.055) 1.522 (0.475-4.189) 
p=0.754 p=0.440 
Androstenedione 
0.829 (0.125-3.238) 1.762 (0.547-4.883) 
p=0.811 p=0.300 
Testosterone 
0.762 (0.115-3.007) 1.728 (0.536-4.796) 
p=0.731 p=0.317 
DHEAS 
0.771 (0.117-2.989) 1.510 (0.473-4.142) 
p=0.740 p=0.447 
SHBG 
0.816 (0.123-3.233) 1.493 (0.464-4.143) 
p=0.798 p=0.464 
Progesterone  
0.759 (0.115-2.944) 1.522 (0.475-4.189) 
p=0.725 p=0.440 
LH 
 1.599 (0.497-4.435) 
 p=0.390 
FSH 
0.786 (0.188-3.108)  
p=0.761  
ER-α SB 
0.706 (0.107-2.731) 1.488 (0.466-4.079) 
p=0.657 p=0.463 
ER-β SB 




    
Supplemental Table VIII-30: Joint association of high AR serum bioctivity and 
gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a sample 
less than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of ER-α SB and oestrogens  
ER-α SB 
Oestradiol Oestrone 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
1.954 (0.930-5.545) 1.868 (0.819-4.739) 
p=0.133 p=0.158 









  1.945 (0.770-4.543) 
 p=0.136 
Oestrone 
2.173 (0.850-5.175)  
p=0.088  
Androstenedione 
2.071 (0.803-4.976) 2.035 (0.801-4.789) 
p=0.113 p=0.114 
Testosterone 
1.670 (0.644-4.017) 2.110 (0.826-4.995) 
p=0.266 p=0.099 
DHEAS 
1.953 (0.775-4.550) 1.868 (0.744-4.323) 
p=0.133 p=0.158 
SHBG 
1.974 (0.780-4.623) 1.850 (0.734-4.299) 
p=0.129 p=0.167 
Progesterone  
2.054 (0.809-4.836) 1.987 (0.785-4.651) 
p=0.110 p=0.125 
LH 
1.887 (0.746-4.411) 1.910 (0.757-4.448) 
p=0.156 p=0.147 
FSH 






1.783 (0.699-4.204) 1.580 (0.604-3.825) 
p=0.201 p=0.326 
AR SB 
1.881 (0.725-4.526) 1.762 (0.687-4.170) 
p=0.171 p=0.212 
Supplemental Table VIII-29: Joint association of high ER-α serum bioactivity and 
oestrogens (top quantiles) with risk of breast cancer – cases that gave a sample more 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SB and androgens 
ER-α SB 
Androstenedione DHEAS 
  OR* (95% CI) OR* (95% CI) 
Not adjusted  
2.146 (1.194-6.765) 1.295 (0.482-3.864) 
p=0.074 p=0.627 









2.335 (0.954-5.401) 1.238 (0.392-3.303) 
p=0.052 p=0.688 
Oestrone 
2.120 (0.878-4.798) 1.273 (0.404-3.391) 
p=0.079 p=0.650 
Androstenedione 
 1.084 (0.338-2.939) 
 p=0.882 
Testosterone 
1.571 (0.618-3.767) 0.946 (0.290-2.629) 
p=0.322 p=0.920 
DHEAS 
2.173 (0.894-4.259)  
p=0.072  
SHBG 
2.076 (0.858-4.712) 1.271 (0.402-3.402) 
p=0.089 p=0.653 
Progesterone  
2.277 (0.927-5.279) 1.261 (0.389-3.492) 
p=0.061 p=0.673 
LH 
2.128 (0.879-4.838) 1.317 (0.416-3.530) 
p=0.079 p=0.607 
FSH 






1.855 (0.740-4.375) 1.120 (0.349-3.049) 
p=0.168 p=0.835 
AR SB 
2.035 (0.824-4.726) 1.159 (0.359-3.183) 
p=0.107 p=0.787 
Supplemental Table VIII-30: Joint association of high ER-α serum bioactivity and 
androgens (top quantiles) with risk of breast cancer – cases that gave a sample more than 
2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of ER-α SB and progesterone 
ER-α SB 
Progesterone  
















































Supplemental Table VIII-31: Joint association of high ER-α serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample more 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Appendices 






















Joint association of SB and SHBG 
ER-α SB 
SHBG 
  OR* (95% CI) 
Not adjusted   
2.650 (1.012-8.210) 
p=0.095 












































Supplemental Table VIII-32: Joint association of high ER-α serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer – cases that gave a sample more 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of ER-α SB and gonadotrophins 
ER-α SB 
LH FSH 
 OR* (95% CI) OR* (95% CI) 
Not adjusted 
0.459 (0.108-2.134) 1.386 (0.470-4.884) 
p=0.305 p=0.580 









0.448 (0.070-1.614) 1.392 (0.381-4.123) 
p=0.291 p=0.576 
Oestrone 
0.445 (0.069-1.604) 1.354 (0.371-4.003) 
p=0.287 p=0.608 
Androstenedione 
0.447 (0.070-1.619) 1.464 (0.399-4.362) 
p=0.291 p=0.521 
Testosterone 
0.472 (0.073-1.720) 1.642 (0.445-4.929) 
p=0.326 p=0.407 
DHEAS 
0.458 (0.072-1.649) 1.389 (0.379-4.123) 
p=0.304 p=0.580 
SHBG 
0.462 (0.072-1.667) 1.388 (0.379-4.135) 
p=0.310 p=0.581 
Progesterone  
0.456 (0.071-1.642) 1.434 (0.390-4.283) 
p=0.301 p=0.544 
LH 
 1.768 (0.472-5.492) 
 p=0.350 
FSH 






0.404 (0.063-1.471) 1.254 (0.340-3.753) 
p=0.236 p=0.705 
AR SB 
0.441 (0.069-1.590) 1.351 (0.369-4.044) 
p=0.282 p=0.612 
Supplemental Table VIII-33: Joint association of high ER-α serum bioactivity and 
gonadotrophins (top quantiles) with risk of breast cancer – cases that gave a sample 
more than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of ER-β SB and oestrogens  
ER-β SB 
Oestradiol Oestrone 
 OR* (95% CI) OR* (95% CI) 
 Not adjusted 
1.351 (0.630-4.455) 1.482 (0.687-3.834) 
p=0.536 p=0.360 









  1.551 (0.626-3.502) 
 p=0.311 
Oestrone 
1.315 (0.465-3.243)  
p=0.573  
Androstenedione 
1.291 (0.450-3.248) 1.580 (0.635-3.588) 
p=0.606 p=0.294 
Testosterone 
1.109 (0.385-2.793) 1.623 (0.650-3.704) 
p=0.835 p=0.269 
DHEAS 
1.352 (0.479-3.335) 1.483 (0.602-3.325) 
p=0.535 p=0.360 
SHBG 
1.282 (0.452-3.172) 1.386 (0.560-3.119) 
p=0.611 p=0.451 
Progesterone  
1.424 (0.501-3.546) 1.537 (0.621-3.470) 
p=0.471 p=0.321 
LH 
1.338 (0.472-3.313) 1.417 (0.573-3.185) 
p=0.550 p=0.420 
FSH 
1.346 (0.476-3.328) 1.480 (0.599-3.333) 
p=0.542 p=0.364 
ER-α SB 






1.366 (0.475-3.448) 1.400 (0.559-3.199) 
p=0.530 p=0.444 
 
Supplemental Table VIII-34: Joint association of high ER-β serum bioactivity and 
oestrogens (top quantiles) with risk of breast cancer - cases that gave a sample more 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB/Hormones 
Joint association of SB and androgens 
ER-β SB 
Androstenedione DHEAS 
  OR* (95% CI) OR* (95% CI) 
 Not adjusted 
2.133 (0.905-5.328) 1.786 (0.633-4.588) 
p=0.076 p=0.251 









2.164 (0.891-4.942) 1.997 (0.670-5.361) 
p=0.074 p=0.185 
Oestrone 
1.944 (0.770-4.540) 1.898 (0.647-4.978) 
p=0.136 p=0.210 
Androstenedione 
 1.481 (0.491-4.000) 
 p=0.456 
Testosterone 
1.307 (0.494-3.211) 1.346 (0.444-3.654) 
p=0.570 p=0.574 
DHEAS 
2.189 (0.895-5.039)  
p=0.072  
SHBG 
1.973 (0.816-4.477) 1.709 (0.586-4.429) 
p=0.113 p=0.291 
Progesterone  
1.995 (0.779-4.741) 2.088 (0.675-5.901) 
p=0.129 p=0.176 
LH 
2.079 (0.860-4.714) 1.791 (0.613-4.655) 
p=0.088 p=0.251 
FSH 
2.122 (0.880-4.797) 1.770 (0.609-4.576) 
p=0.079 p=0.259 
ER-α SB 






2.159 (0.872-5.041) 1.608 (0.537-4.302) 
p=0.082 p=0.363 
Supplemental Table VIII-35: Joint association of high ER-β serum bioactivity and 
androgens (top quantiles) with risk of breast cancer - cases that gave a sample more than 
2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of  ER-β SB and progesterone 
ER-β SB 
Progesterone  












Oestradiol 1.143 (0.313-3.344) 
p=0.821 
Oestrone 1.397 (0.438-3.801) 
p=0.535 
Androstenedione 0.922 (0.247-2.779) 
p=0.893 
Testosterone 0.740 (0.198-2.225) 
p=0.617 
DHEAS 1.083 (0.289-3.289) 
p=0.896 





LH 1.034 (0.286-2.974) 
p=0.955 
FSH 1.045 (0.290-2.995) 
p=0.940 
ER-α SB 1.129 (0.351-3.090) 
p=0.823 





*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
Supplemental Table VIII-36: Joint association of high ER-β serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer - cases that gave a sample more 
than 2 years before diagnosis.    
Appendices 




SB - Hormones 
Joint association of  ER-β SB and gonadotrophins 
ER-β SB 
LH FSH 
  OR* (95% CI) OR* (95% CI) 
Not adjusted 0.769 (0.211-2.656) 1.894 (0.637-5.702) 
p=0.681 p=0.248 








Oestradiol 0.751 (0.172-2.325) 1.915 (0.589-5.430) 
p=0.656 p=0.241 
Oestrone 0.759 (0.174-2.349) 1.880 (0.579-5.328) 
p=0.668 p=0.254 
Androstenedione 0.770 (0.175-2.397) 1.850 (0.567-5.278) 
p=0.685 p=0.269 
Testosterone 0.718 (0.163-2.250) 1.796 (0.547-5.151) 
p=0.609 p=0.296 
DHEAS 
0.769 (0.176-2.378) 1.893 (0.584-5.356) 
p=0.682 p=0.248 
SHBG 
0.712 (0.163-2.211) 1.709 (0.525-4.855) 
p=0.598 p=0.334 
Progesterone  
0.756 (0.173-2.339) 1.865 (0.574-5.281) 
p=0.663 p=0.260 
LH 
 2.153 (0.655-6.232) 
 p=0.172 
FSH 0.779 (0.178-2.415) 
  
p=0.697   
ER-α SB 0.648 (0.146-2.040) 1.663 (0.505-4.855) 
p=0.504 p=0.365 
ER-β SB    
   
AR SB 
0.755 (0.172-2.340) 1.822 (0.559-5.184) 
p=0.662 p=0.280 
Supplemental Table VIII-37: Joint association of high ER-β serum bioactivity and 
gonadotrophins (top quantiles) with risk of breast cancer - cases that gave a sample more 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; 
OR=odds ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of AR SB and oestrogens  
AR SB 
Oestradiol Oestrone 
  OR* (95% CI) OR* (95% CI) 
Not adjusted 1.969 (0.825-4.877) 2.388 (0.955-5.951) 
p=0.129 p=0.058 








Oestradiol  2.066 (0.762-5.132) 
 p=0.130 
Oestrone 
2.209 (0.864-5.264)   
p=0.081   
Androstenedione 
1.979 (0.774-4.696) 2.520 (0.972-6.135) 
p=0.133 p=0.046 
Testosterone 
1.775 (0.694-4.191) 2.368 (0.858-6.042) 
p=0.205 p=0.079 
DHEAS 
1.983 (0.785-4.626) 2.411 (0.935-5.831) 
p=0.125 p=0.056 
SHBG 1.862 (0.736-4.255) 2.336 (0.903-5.672) 
p=0.165 p=0.066 
Progesterone  1.944 (0.769-4.537) 2.547 (0.980-6.245) 
p=0.137 p=0.045 
LH 1.964 (0.776-4.597) 2.233 (0.865-5.408) 
p=0.132 p=0.082 
FSH 1.968 (0.778-4.598) 2.395 (0.927-5.808) 
p=0.130 p=0.059 
ER-α SB 1.673 (0.639-4.064) 1.914 (0.722-4.761) 
p=0.27 p=0.172 
ER-β SB 1.792 (0.702-4.223) 2.040 (0.765-5.121) 
p=0.197 p=0.137 
AR SB 
   
    
Supplemental Table VIII-38: Joint association of high AR serum bioactivity and 
oestrogens (top quantiles) with risk of breast cancer - cases that gave a sample more 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of  SB and androgens 
AR SB 
DHEAS 
  OR* (95% CI) 
Not adjusted  
1.607 (0.572-4.062) 
p=0.338 












































Supplemental Table VIII-39: Joint association of high AR serum bioactivity and 
androgenss (top quantiles) with risk of breast cancer - cases that gave a sample more 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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Joint association of SB and SHBG 
AR SB 
SHBG 
  OR* (95% CI) 
Not adjusted  
2.650 (1.012-8.210) 
p=0.095 












































Supplemental Table VIII-40: Joint association of high AR serum bioactivity and sex 
hormone-binding globulin (top quantiles) with risk of breast cancer - cases that gave a 
sample more than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of AR SB and progesterone 
AR SB 
Progesterone  
  OR* (95% CI) 
Not adjusted 2.305 (0.847-5.809) 
p=0.085 











































Supplemental Table VIII-41: Joint association of high AR serum bioactivity and 
progesterone (top quantiles) with risk of breast cancer - cases that gave a sample more 
than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydro- epiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
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SB - Hormones 
Joint association of AR SB and gonadotrophins 
AR SB 
LH FSH 
  OR* (95% CI) OR* (95% CI) 
Not adjusted 0.412 (0.048-3.107) 0.300 (0.043-2.631) 
p=0.401 p=0.249 









0.385 (0.021-2.069) 0.305 (0.017-1.562) 
p=0.368 p=0.255 
Oestrone 
0.411 (0.022-2.200) 0.302 (0.016-1.550) 
p=0.400 p=0.252 
Androstenedione 
0.394 (0.021-2.123) 0.321 (0.018-1.657) 
p=0.379 p=0.278 
Testosterone 
0.396 (0.021-2.150) 0.339 (0.018-1.753) 
p=0.383 p=0.302 
DHEAS 
0.416  (0.022-2.226) 0.297 (0.016-1.522) 
p=0.406 p=0.245 
SHBG 0.433 (0.023-2.340) 0.302 (0.016-1.561) 
p=0.429 p=0.253 
Progesterone  
0.399  (0.022-2.139) 0.301 (0.016-1.547) 
p=0.385 p=0.251 
LH 
 0.332 (0.018-1.718) 
 p=0.292 
FSH 
0.422  (0.023-2.270)   
p=0.415   
ER-α SB 
0.309 (0.017-1.661) 0.268 (0.015-1.387) 
p=0.268 p=0.209 
ER-β SB 
0.364 (0.020-1.972) 0.266 (0.014-1.379 
p=0.341 p=0.207 
AR SB 
   
    
Supplemental Table VIII-42: Joint association of high AR serum bioactivity and 
gonadotrophins (top quantiles) with risk of breast cancer - cases that gave a sample 
more than 2 years before diagnosis.    
*OR values for top-bottom classification were based on controls only and were age adjusted. 
**OR values for SB adjusted for other hormones or SB treated as categorical variable, using top 
bottom classification and age adjusted. OR with p-values ≤0.05 marked with bold.  
AR=androgen receptor; CI=confidence interval; DHEAS=dehydroepiandrosterone sulphate; 
ER=oestrogen receptor; FSH=follicular stimulating hormone; LH=luteinising hormone; OR=odds 
ratio; SB=serum bioactivity; SHBG=sex hormone-binding globulin 
 
